-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HugaZ4EXvK3Z3ui2Da2m+DkCcMFoJvfVaETuGwd2v56FvGId/huDu6U7uP56jVeh
 i8ue45GisrV6K+0htWyltQ==

<SEC-DOCUMENT>0000950123-10-086417.txt : 20100915
<SEC-HEADER>0000950123-10-086417.hdr.sgml : 20100915
<ACCEPTANCE-DATETIME>20100915172000
ACCESSION NUMBER:		0000950123-10-086417
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20100630
FILED AS OF DATE:		20100915
DATE AS OF CHANGE:		20100915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		101074485

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>a57251e10vk.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e10vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 10pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 10pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 10pt"><B>FORM 10-K</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(Mark One)</B>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</b></TD>
</TR>
</TABLE>
</DIV>


<!-- xbrl,dc -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 12%"><B>For the fiscal year ended June&nbsp;30, 2010</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</b></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 12%"><B>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>
Commission file number: 000-30489</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 10pt"><B>LIFEVANTAGE CORPORATION</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Colorado</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>90-0224471</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>11545 W. Bernardo Court, Suite&nbsp;301</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>San Diego, California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>92127</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">Registrant&#146;s telephone number: <B>(858)&nbsp;312-8000</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">Securities registered pursuant to Section&nbsp;12(b) of the Act: <B>None</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">Securities registered pursuant to Section&nbsp;12(g) of the Act:<BR>
Common Stock, $0.001 par value per share<BR>
(Title of Class)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of
the Securities Act. Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or
Section 15(d) of the Act. Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for
such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90&nbsp;days. Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period
that the registrant was required to submit and post such files). Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K is
not contained herein, and will not be contained, to the best of registrant&#146;s knowledge, in
definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form 10-K
or any amendment to this Form 10-K. <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.
(Check one):
</DIV>



<DIV align=center>
<TABLE style="FONT-SIZE: 10pt" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR style="FONT-SIZE: 6pt">
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD></TR>

  <TR vAlign=top>
    <TD vAlign=top noWrap align=left>Large accelerated filer <FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD vAlign=top noWrap align=center>Accelerated filer
<FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD align=center>&nbsp;</TD>
    <TD noWrap align=center>Non-accelerated filer <FONT face="Wingdings">&#111;</FONT><BR>(Do not check if a smaller reporting
company)</TD>
    <TD align=center>&nbsp;</TD>
    <TD vAlign=top noWrap align=center>Smaller reporting company
<FONT face="Wingdings">&#254;</FONT></TD></TR>
</TABLE></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Act). Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The aggregate market value of the registrant&#146;s common stock (par value $0.001) held by
non-affiliates as of the end of the registrant&#146;s second fiscal quarter, December&nbsp;31, 2009, was
$13,364,857&nbsp;million. Shares of the registrant&#146;s common stock held by each current
executive officer and director and by each shareholder who is known by the registrant to own 10% or
more of the outstanding common stock have been excluded from this computation in that such persons
may be deemed to be affiliates of the registrant. Share ownership information of certain persons
known by the registrant to own greater than 10% of the outstanding common stock for purposes of the
preceding calculation is based solely on information on Schedules 13D and 13G, if any, filed with
the Commission. This determination of affiliate status is not necessarily a conclusive
determination for other purposes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The number of shares of common stock (par value $0.001) outstanding as of August&nbsp;31, 2010, was
63,742,673 shares.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>DOCUMENTS INCORPORATED BY REFERENCE</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Portions of the registrant&#146;s definitive Proxy Statement for the 2011 Annual Meeting of
Shareholders, to be filed within 120&nbsp;days after the end of the registrant&#146;s fiscal year ended June
30, 2010, are incorporated by reference into Part&nbsp;III of this Annual Report on Form 10-K, to the
extent stated therein.
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain statements contained in this report and the information incorporated by reference
herein may contain &#147;forward-looking statements&#148; (as such term is defined in Section&nbsp;27A of the
Securities Act of 1933, as amended and Section&nbsp;21E of the Securities Exchange Act of 1934, as
amended). These statements, which involve risks and uncertainties, reflect our current
expectations, intentions, or strategies regarding our possible future results of operations,
performance, and achievements. Forward-looking statements include, without limitation: statements
regarding future products or product development; statements regarding future selling, general and
administrative costs and research and development spending; statements regarding our product
development strategy; statements regarding the future performance of our network marketing sales
channel; and statements regarding future financial performance, results of operations, capital
expenditures and sufficiency of capital resources to fund our operating requirements. These
forward-looking statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and applicable rules of the Securities and Exchange
Commission and common law.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These forward-looking statements may be identified in this report and the information
incorporated by reference by words such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;could&#148;, &#147;estimate&#148;, &#147;expect&#148;,
&#147;intend&#148;, &#147;plan&#148;, &#147;predict&#148;, &#147;project&#148;, &#147;should&#148; and similar terms and expressions, including
references to assumptions and strategies. These statements reflect our current beliefs and are
based on information currently available to us. Accordingly, these statements are subject to
certain risks, uncertainties, and contingencies, which could cause our actual results, performance,
or achievements to differ materially from those expressed in, or implied by, such statements.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following factors are among those that may cause actual results to differ materially from
our forward-looking statements:</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Limited operating history and lack of significant revenues from operations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our ability to successfully expand our operations and manage our future growth;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Difficulty in managing growth and expansion;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dilutive effects of any potential need to raise additional capital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The deterioration of global economic conditions and the decline of consumer confidence and
spending;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We reported material weaknesses in our internal control over financial reporting, and if we
are unable to improve our internal control over financial reporting, our financial results
may not be accurately reported;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Environmental liabilities stemming from past operations and property ownership;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Significant dependence upon a single product;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Competition in the dietary supplement market;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The potential failure or unintended negative consequences of our network marketing sales
channel;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our ability to retain independent distributors or to hire new independent distributors on
an ongoing basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The potential for government or third party actions against us resulting from independent
distributor activities that violate applicable laws or regulations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The potential for third party and governmental actions involving our network marketing
sales channel;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our ability to protect our intellectual property rights and the value of our product;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our ability to continue to innovate and provide products that are useful to consumers;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The effect of current and future government regulations of the network marketing and
dietary supplement industries on our business;

</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The effect of unfavorable publicity on our business;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The potential for product liability claims against us;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our dependence on third party manufacturers to manufacture our product;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The ability to obtain raw material for our product;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our common stock is currently classified as a penny stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our stock price may experience future volatility;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The illiquidity of our common stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Substantial sales of shares of our common stock;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other factors not specifically described above, including the other risks, uncertainties,
and contingencies described under &#147;Description of Business&#148;, &#147;Risk Factors&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operation&#148; in Items 1 and 7 of
this report.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>When considering these forward-looking statements, you should keep in mind the cautionary
statements in this report and the documents incorporated by reference. We have no obligation
and do not undertake to update or revise any such forward-looking statements to reflect events
or circumstances after the date of this report.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><A href="#101"><B>PART I</B> </A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">Item&nbsp;1. Business</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#103">Item&nbsp;1A. Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#104">Item&nbsp;1B. Unresolved Staff Comments</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#105">Item&nbsp;2. Properties</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#106">Item&nbsp;3. Legal Proceedings</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#107">Item&nbsp;4. (Removed and Reserved)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><A href="#108"><B>PART II</B></A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#109">Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#110">Item&nbsp;6. Selected Financial Data</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#111">Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#112">Item&nbsp;7A Quantitative and Qualitative Disclosures About Market Risk</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#113">Item&nbsp;8 Financial Statements and Supplementary Data</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#114">Item&nbsp;9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#115">Item&nbsp;9A Controls and Procedures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#116">Item&nbsp;9B Other Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><A href="#117"><B>PART III</B></A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#118">Item&nbsp;10. Directors, Executive Officers and Corporate Governance</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#119">Item&nbsp;11. Executive Compensation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#120">Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#121">Item&nbsp;13. Certain Relationships and Related Transactions, and Director Independence</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#122">Item&nbsp;14. Principal Accountant Fees and Services</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><A href="#123"><B>PART IV</B></A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#124">Item&nbsp;15. Exhibits, Financial Statement Schedules</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#125">Signatures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="a57251exv10w14.htm">EX-10.14</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="a57251exv23w1.htm">EX-23.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="a57251exv31w1.htm">EX-31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="a57251exv31w2.htm">EX-31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="a57251exv32w1.htm">EX-32.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="a57251exv32w2.htm">EX-32.2</A></FONT></TD></TR>
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART I</B>
</DIV>

<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 1  &#151; BUSINESS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Overview</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our company was incorporated in Colorado in June&nbsp;1988 under the name Andraplex
Corporation. We changed our corporate name to Yaak River Resources, Inc. in January&nbsp;1992, and
subsequently changed it again in October&nbsp;2004 to Lifeline Therapeutics, Inc., and in November&nbsp;2006
to LifeVantage Corporation. In October&nbsp;2004 and March&nbsp;2005, we acquired all of the outstanding
common stock of Lifeline Nutraceuticals Corporation, our wholly-owned subsidiary through which we
hold the patent rights in Protandim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LifeVantage Corporation, the LifeVantage Corporation logo, LifeVantage<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, and
Protandim<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> are trademarks of LifeVantage Corporation in the United States and in other selected
countries. All other brand names or trademarks appearing in this report are the property of their
respective holders. Unless otherwise noted, the terms &#147;we&#148;, &#147;our&#148;, &#147;us&#148;, &#147;Company&#148; and
&#147;LifeVantage&#148; refer to LifeVantage Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>General</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LifeVantage is a dietary supplement company which markets and sells its products through the
network marketing, or multi-level marketing industry and seeks to enhance life through anti-aging
and wellness products while creating business opportunities. We pursue our mission of &#147;helping
people reach their health and wellness goals through science-based solutions to oxidative stress&#148;
by providing a financially rewarding business opportunity to distributors and quality products to
distributors and customers who seek a healthy lifestyle. We sell our products in the United States,
Japan and Mexico, through a network of independent distributors, preferred customers and direct
customers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We offer only what we refer to as &#147;true&#148; products, which are products backed by science in two
principal categories: a dietary supplement that combats oxidative stress, and anti-aging skincare.
Currently, we manufacture, market, distribute and sell two products, our centerpiece product,
Protandim&#174;, a dietary supplement which has been clinically proven to reduce the effects of
oxidative stress as well as the progressive rate of cellular aging; and our LifeVantage
TrueScience&#153; Anti-Aging Cream, a scientifically-based, groundbreaking and unique skin care product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended June&nbsp;30, 2009, we began selling our products through the network
marketing or multi-level marketing distribution channel, which we believe is the most effective and
scaleable way to market and sell our products. As part of that change in business model, we added a
team that includes some of the most sought-after and highest-producing independent distributors in
the network marketing industry, which we believe will continue to significantly impact our ability
to grow sales through the network marketing sales channel. Our move into the network marketing
sales channel is responsible for the significant increase in revenue as well as associated expenses
that occurred during the year ended June&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the network marketing channel is well suited to marketing our products because
sales of nutritional and personal care products are strengthened by ongoing personal contact
between consumers and distributors. This personal contact enhances consumers&#146; nutritional and
health education and motivates consumers to begin and maintain wellness programs. Our products are
backed by facts and science which serve as powerful sales tools, and our distributors use our
products themselves.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LifeVantage is focused on building and maintaining our distributor network by offering
financially rewarding and flexible career opportunities through sales of quality, innovative and
efficacious products to health conscious consumers. We believe the income opportunity provided by
our network marketing program appeals to a broad cross-section of people, particularly those
seeking to supplement family income, start a home-based business or pursue entrepreneurial full and
part-time opportunities. Our independent distributors profit from selling our products and can also
earn commissions and bonuses on sales made by other distributors who join their sales
organizations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We enable distributors to maximize their potential by providing a broad array of motivational,
educational and support services. We motivate our distributors through our performance-based
compensation plan, individual recognition, reward programs and promotions, and participation in
local and national Company-sponsored sales events. We provide professionally designed training
materials that our distributors use to enhance recruitment and maximize their sales. We and/or our
distributor leadership conduct thousands of training sessions each year to educate and motivate our
distributors. These training events teach our distributors how to develop business-building and
leadership skills and how to differentiate our products to consumers. Our corporate-sponsored
training events provide a forum for distributors, who otherwise operate independently, to share
ideas with us and each other. We believe that our efficient and effective distribution, logistics
and customer care support systems assist our distributors by providing same day or next-day sales
capabilities and support services. We may further aid our distributors by generating additional
publicity and demand for our products through traditional marketing and public relations
activities, such as media coverage and endorsements.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We sell our products in the United States, Japan and Mexico. While sales within our local
markets may fluctuate due to economic, market and regulatory conditions, competitive pressures,
political and social instability or for Company-specific reasons, we believe that geographic
diversity will help to mitigate our financial exposure as we continue to grow and expand into new
markets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Market</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dietary Supplements Market
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">According to the <I>Nutritional Business Journal, Direct-to-Consumer Selling in the Nutrition Industry
Report </I>2010, in 2009, more than $15&nbsp;billion in U.S. nutrition industry sales were generated from
non-retail channels, including the Internet, network or multi-level marketers (MLMs), healthcare
practitioners, direct response TV, direct response radio, and mail-order catalogs/direct mail.
This report further suggests that each direct sales channel faces its own set of opportunities and
challenges. On the one hand, both healthcare practitioner and network-marketing supplement firms
benefited in 2009 from consumer trends that increased the year-over-year sales of dietary
supplements. Many consumers turned to vitamins and other nutrition products as a cost-effective
method to protect their health. On the other hand, competition from online and brick-and-mortar
retailers&#151; both of which engaged in deep discounting last year&#151;and consumers&#146; general lack of
disposable income, eroded U.S. supplement sales growth in the MLM channel in 2009.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><IMG src="a57251a5725101.gif" alt="(PIE CHART)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><IMG src="a57251a5725102.gif" alt="(PIE CHART)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Although the network-marketing channel was affected the most, overall nutrition product sales
growth within the U.S. direct-to-consumer channels was suppressed last year. According to <I>NBJ</I>
estimates, U.S. consumer sales of nutrition products via direct channels grew only 4% in 2009. This
was down from the 7% compound annual growth rate posted by the direct channels from 1997-2009. The
majority of U.S. nutrition industry sales continue to be sold at brick-and-mortar retail locations,
but the direct-to-consumer sales channels remain important to the industry&#146;s growth and continue to
play an important role in building brand awareness and driving sales for nutrition products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Source: <I>Nutritional Business Journal, Direct-to-Consumer Selling in the Nutrition Industry Report</I>
2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Anticipated Industry Growth</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to a recent report by the Mercanti Group, an investment banking firm that closely
follows the health and wellness industry, the nutritional supplements industry is expected to grow
as a result of a number of factors, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>consumers increasingly moving toward alternative solutions for general wellness issues;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the changing lifestyles of consumers;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a growing elderly population;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>aging Baby Boomers and their &#147;better off&#148; financial status;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the fact that nutritional supplements can complement or be used as an alternative
to traditional pharmaceutical treatments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>recently gained credibility of nutritional supplements as a result of the Food and
Drug Administration&#146;s (&#147;FDA&#146;s&#148;) insistence on stringent product quality and testing
procedures;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>newly implemented federal Good Manufacturing Practices (GMP);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>increasing research by federal agencies;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a steady stream of innovative new products that target an expanding range of increasingly specific conditions; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the increasing growth of the direct sales industry, with specific product growth
especially pronounced among products that are not available in retail stores.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>The Anti-Aging Market</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports published by Global Industry Analysts, Inc. (&#147;GIA&#148;), publishers of off-the-shelf
market research, indicate that demand for products in the worldwide anti-aging products market is
increasing as a result of a several factors, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>lifestyle changes effected by consumers to increase their chance of longevity;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changing practices in personal grooming which have resulted in more time and money
being directed to external grooming efforts to minimize the visible effects of aging;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>increased demand for skin lotions, toners, wrinkle-removal creams, skin whiteners,
luxury topical skin care products, concealers and cover-ups;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>increasing number of younger age anti-aging consumers becoming more proactive about
their skin maintenance routine; and,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the growing acceptance of vitamins and antioxidants as effective anti-aging
nutrients.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The GIA report also states that growing wariness of harsh chemicals is expected to lead to
increased demand for anti-aging products with organic, natural, herbal and botanical extracts as
active ingredients. Anti-aging products which include chamomile, copper, gold, minerals, and amino
acids are expected to make large gains in the marketplace in coming years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Marketing and Direct Selling Opportunity</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We develop and market branded dietary supplement and skin care products that we believe are
well suited for network marketing. Our distributors sell our products by educating consumers about
the benefits and distinguishing characteristics of our products and by offering personalized
customer service. We attempt to attract and motivate high-caliber, independent distributors with
our focus on product innovation, a competitive compensation plan and distributor support programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Direct selling through the network marketing sales channel has proven to be an effective
method of marketing our high-quality products because our distributors can personally educate
consumers on the quality and benefits of our products, differentiating them from our competitors&#146;
offerings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We target our products to several growing market segments:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Anti-Aging market;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Baby Boomer market, interested in anti-aging through cosmetics, dietary supplements,
and supplemental business opportunities; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the market created by the current economic crisis, those seeking to supplement income or
replace lost income.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are focused on building and maintaining our distributor network by offering financially
rewarding career opportunities through the sale of unique, category-creating products that are
backed by science, to health conscious consumers concerned about the effects of aging. We believe
the income potential provided by our business opportunity appeals to a broad cross-section of the
population, particularly those seeking part-time and full-time income due to the global economic
crisis and job loss, those seeking home-based business opportunities, and those seeking
entrepreneurial business income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the network marketing industry, we believe we are currently at an advantage as distributors
generally view companies which provide newer opportunities as more attractive than companies who
have been in the industry for a longer period of time. In addition,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">we believe we are attractive to distributors because we offer highly consumable products
backed by science, with third-party substantiation and celebrity and scientific endorsement, and
offer distributors the opportunity to be a part of a publicly traded company. We believe that all
of these factors increase the attractiveness of our products and product sales opportunity to our
distributors and consumers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the
&#147;DSA Fact Sheet for 2009&#148; published  by the Direct Selling Association, the direct sales market
is a multi-billion dollar market enjoying steady growth in both sales and in the distributor
salesforce. The Direct Selling Association reports that, although sales dropped slightly from
$29.50&nbsp;billion to $28.33&nbsp;billion between 2008 and 2009, the five-year trend is up 1.5% annually.
At the same time, the distributor salesforce increased from 15.1&nbsp;million people to 16.1 people with
the 5-year trend up 3.5% annually. Our strategy for expanding our distributor network is to
attract established distributors to our products while maintaining our appeal to industry newcomers
who bring their own credibility and energy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe our commitment to developing and manufacturing science-based products will enhance
our ability to attract new consumers and new distributors, to retain distributors, and will help to
increase sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Background</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Oxidative Stress</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oxidative stress refers to the cellular and tissue damage caused by chemically reactive oxygen
radicals formed as a natural consequence of cellular metabolism and results from utilizing oxygen to generate energy. A small percentage of the oxygen we utilize
generates toxic oxygen free radicals that damage the cells and tissues of the human body and
consequently negatively impact our general health. These reactive oxygen species (&#147;ROS&#148;) and free
radicals can be elevated under a wide variety of conditions, including radiation, UV light,
smoking, excessive alcohol consumption, certain medical conditions such as neurodegenerative
diseases and diabetes, and advancing age.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elevated ROS levels inflict structural damage to nucleic acid, lipid, carbohydrate and protein
components of cells, thereby directly contributing to or exacerbating tissue dysfunction, disease,
and age-related debilitation. Normally, cellular antioxidant enzymes serve to inactivate ROS and
maintain their levels at those compatible with normal cell function. Important among these enzymes
are superoxide dismutase (&#147;SOD&#148;) and catalase (&#147;CAT&#148;). However, the levels of these protective
antioxidant enzymes decrease with age and also decrease in a number of disease conditions, while
ROS levels may increase.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SOD is the body&#146;s most effective natural antioxidant. SOD works in conjunction with CAT, and
under some circumstances, the balance may be important. A by-product of SOD&#146;s potent antioxidant
activity is hydrogen peroxide, a dangerous substance that subsequently needs to be converted into
water and oxygen by CAT. Together, these two enzymes constitute the first line of defense for the
body. Scientists have long believed that increasing levels of SOD and CAT is an important means of
fighting oxidative stress,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">disease, and the effects of aging; however, SOD and CAT oral supplements by
themselves have not been shown either to  be absorbed or work in conjunction with each other by oral administration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oxidative stress is the result of the metabolic
process and may promote the undesirable effects of aging. As the body
ages, oxidative stress levels increase significantly, as the body is
unable to
 maintain equilibrium relative to the free radicals produced through the metabolic process.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oxidative stress is widely believed to be a
key factor in the aging process by triggering premature cell death. The body&#146;s defenses against oxidative stress and free radicals
decrease with age. Oxidative stress has also been linked as a
causative or associated factor in over 100 diseases, while lowering
oxidative stress levels is known to improve health.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Product Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Protandim&#174;</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Protandim product is a patented dietary
supplement that has been shown in a clinical trial to reduce the
age-dependent increase in markers of oxidative stress, and has also been shown to
provide substantial benefits to combat the variety of negative health effects caused by oxidative stress.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Protandim supplement combats oxidative stress by
increasing the body&#146;s natural antioxidant protection at the genetic level, inducing the production of naturally occurring protective
antioxidant enzymes including SOD, CAT, and glutathione synthase. The unique blend of phytonutrients in the Protandim product signals
the body&#146;s genes to produce antioxidant enzymes. These enzymes are &#147;catalytic,&#148; which means that enzymes such as SOD and CAT are not
consumed when they neutralize free radicals.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protandim has also been associated with Nrf2
activation in animal and cell models. Nrf2 is a protein messenger that sends information to the cell&#146;s DNA,
which, in the human body,  consists of approximately 25,000
genes. Several hundred of these genes,  collectively known as
&#147;survival genes,&#148; are activated by the Protandim product.
These gene products enable cells to survive in conditions of oxidative
stress, caused by due to the imbalance of free radicals and other oxidants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nrf2 also affects approximately one hundred
additional genes by decreasing their production. Included in these down-regulated genes are pro-inflammatory and pro-fibrotic genes.
Inflammation accompanies many diseases including arthritis, but inflammation also occurs with traumatic injuries, such as cuts, sprains or
bruises. The process of inflammation is designed, in part, to prevent infection by killing foreign microorganisms by creating toxic free
radicals. Thus the pain, redness and swelling associated with a
disease or injury are largely due to inflammation as the body responds
to the threat of infection. With many diseases or traumatic injuries, inflammation is followed by scar tissue formation, referred to as
&#147;fibrosis.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2009, we announced that we had been
granted a third patent for the Protandim product. The patent, &#147;Methods for Enhancing <I>Antioxidant Enzyme Activity and Reducing
C-Reactive Protein Levels</I>,&#148; was issued on August 25, 2009. This patent (U.S. Patent No. 7,579,026) claims a method for increasing
antioxidant enzyme activity using compositions, such as Protandim, by reducing plaque formation in the vasculature of a subject,
thereby reducing excessive atherosclerosis or hypertension.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The newest Protandim patent supplements the coverage of rights previously obtained, which
included exclusive rights to the Protandim composition and methods of manufacture of the Protandim
product and further separates Protandim from other dietary supplements. Additionally, the claims of
the patent are written broadly, and include additional ingredients that may also work but were not
selected for use in the  Protandim supplement. Thus, we believe the patent protects the original
formula as well as other formulas we could create to develop a Protandim product line extension.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Clinical Studies</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A peer-reviewed human clinical study that we conducted in 2004 and 2005 showed that after
the Protandim supplement was taken for 30 consecutive days, the level of circulating TBARS, the
laboratory markers for oxidative stress in the human body, decreased by an average of 40&nbsp;percent.,
to levels typical to a 20&nbsp;year old. When taken for 120
consecutive days, the Protandim supplement
increased the activity of SOD and CAT antioxidant enzymes by up to 54&nbsp;percent, substantially
increasing the body&#146;s antioxidant defenses. This study was published in the journal <I>Free Radical
Biology and Medicine, vol. 40, pp. 341-7 (2006).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Published and Independent Preclinical Studies</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since the initial clinical studies completed in 2004 and 2005,
Protandim has been, or currently is, the subject of more than 20 studies being conducted at academic medical centers. Five
of the pre-clinical studies have been published in peer-reviewed scientific journals, including: a
Company-funded study exploring the mechanism of action of the Protandim supplement;
an animal study
using mice to examine the tumor prevention capabilities of Protandim conducted at Louisiana State
University; an animal study exploring pulmonary hypertension and subsequent right heart failure
conducted at Virginia Commonwealth University; an animal study examining the effects of Protandim
in mice with induced Duchenne Muscular Dystrophy conducted at Massachusetts General Hospital,
Harvard Medical School, and at the University of Colorado; and, the most recent study conducted at
Louisiana State University probing Protandim&#146;s ability to modulate the relationship between
superoxide dismutase and tumor suppressor p53.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One possible mechanism of action for the Protandim supplement was discovered to be activation
of the transcription factor Nrf2 in a Company-funded study published in February&nbsp;2009. This study
also demonstrated synergy among the Protandim supplement&#146;s five active ingredients which would
enable them to be effective while being administered at lower concentrations of each. This
peer-reviewed study was published in <I>Free Radical Biology and Medicine, vol. 46, pp. 430-40 (2009).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The study completed at Louisiana State University (LSU)&nbsp;and sponsored by the Skin Cancer
Foundation was published in the journal PloS ONE, an international, peer-reviewed, open access
journal published by the Public Library of Science. This study, entitled &#147;<I>Protandim, a
Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis
as a Model</I>,&#148; investigated whether Protandim could suppress tumor formation in mice through a
dietary approach. At the end of a two-stage skin carcinogenesis, the mice on the
Protandim-containing basal diet showed a reduction in both skin tumor incidence and multiplicity by
33% and 57% respectively, compared to those on a basal diet.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Virginia Commonwealth University study was published in <I>Circulation, </I>a journal published
by the American Heart Association. This study, entitled &#147;<I>Chronic Pulmonary Artery Pressure
Elevation Is Insufficient to Explain Right Heart Failure</I>,&#148; investigated the ability of Protandim to
protect the heart in a laboratory model of pulmonary hypertension in rats. The researchers
concluded that Protandim prevented the death of heart cells in rats and significantly lowered
osteopontin (OPN-1) levels by more than 50%, and that Protandim effectively activated the
transcription factor Nrf2, a signal to the cell&#146;s DNA to increase expression of a network of
antioxidants, anti-inflammatory, and anti-fibrotic genes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The  study, <I>The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves
Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice</I>, was published in the Journal of Dietary
Supplements and concluded that Protandim caused a decrease in the body&#146;s production of harmful gene
products such as osteopontin. This study also found that Protandim caused an increase in
production of the body&#146;s Nrf2-regulated protective genes, sometimes referred to as &#147;survival
genes.&#148; It also concluded that Protandim improves markers of fibrosis in a model of Duchenne
Muscular Dystrophy (DMD). The study was performed by Dr.&nbsp;Brian Tseng and his colleagues at
Massachusetts General Hospital, Harvard Medical School, and the University of Colorado Denver.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The most recent study, titled &#147;The Chemopreventive Effects of Protandim: Modulation of p53
Mitochondrial Translocation and Apoptosis during Skin Carcinogenesis,&#148; was conducted by researchers
at Louisiana State University and published in the scientific journal PloS ONE. This study further
investigated Protandim&#146;s ability to increase production of the body&#146;s Nrf2-regulated protective
genes, sometime referred to as &#147;survival genes.&#148; This study examined the biochemical mechanisms that
underlie the ability of Protandim to suppress tumors in mice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>LifeVantage TrueScience&#153; Anti-Aging Cream</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2009, we launched our LifeVantage TrueScience<I>&#153; </I>Anti-Aging Cream, a
scientifically-based, groundbreaking and unique skin care product which includes natural and effective
ingredients. This new, proprietary skin care formula was developed in association
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with Kimberly Stone, M.D., a Denver-based board certified dermatologist, and was formulated to
protect the skin from a variety of factors that contribute to aging and the symptoms of unhealthy
skin.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The LifeVantage TrueScience<I>&#153; </I>Anti-Aging Cream contains
a number of ingredients including those found in the Protandim supplement, and it has been formulated with the intention to improve skin tone and even skin
coloring, diminish the appearance of fine lines and wrinkles, and provide a vibrant, healthy and
glowing appearance. LifeVantage TrueScience<I>&#153; </I>Anti-Aging Cream is also designed to improve skin
smoothness and pigmentation, while increasing skin moisture.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The LifeVantage TrueScience proprietary skin care formula offers:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Hydration/Moisturizing: </B>LifeVantage TrueScience<I>&#153; </I>Anti-Aging Cream features a
Lamellar Phase Emulsion System that forms a liquid emulsion barrier for superior
moisturizing. This is accomplished by delivering exotic fatty acids to retain the body&#146;s
natural moisture and produce a moisturizing effect. It also features sodium
hyaluronate, a superior moisture-binding agent that can balance moisture levels at the
surface of the skin.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Toning/Brightening: </B>The turmeric extract in LifeVantage TrueScience<I>&#153; </I>Anti-Aging
Cream is specially modified to remove the majority of yellow compounds without reducing
the effectiveness of its potent curcuminoids. Curcuminoids have been shown to produce
skin lightening that evens dispigmentation. Additionally, the leucojum aestivum
bulb extract slows the spread of melanocytes, which contributes to uneven skin coloring.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Wrinkles/Fine Lines: </B>The palm peptides and leucojum aestivum bulb extract in
LifeVantage TrueScience<I>&#153; </I>Anti-Aging Cream have been shown to visibly reduce signs of
wrinkles and fine lines. They also promote improved skin tone and texture.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Lipid Rejuvenation: </B>LifeVantage TrueScience<I>&#153; </I>Anti-Aging Cream delivers multiple
ingredients intended to mimic the naturally occurring lipid structure in the skin and
retain the body&#146;s own moisturizing lipids.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Our Business Strategy</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Network Marketing Model</I></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foundation of our distribution system and sales philosophy is network marketing, which we
believe is the most effective and scaleable way to sell our products. We sell our products in the
United States, Japan and Mexico through a network of independent distributors, preferred
customers and direct customers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to helping our distributors achieve physical health and wellness through use of
our products, we offer our distributors, who are independent contractors, attractive income
opportunities. Distributors may earn income on their own sales and can also earn commissions and
bonuses on sales made by the distributors in their sales organizations. We believe that our
products are particularly well-suited to the network marketing distribution channel because of
their strong scientific backing. Additionally, sales of dietary supplements have historically been
very strong in this channel through ongoing personal contact and coaching between consumers and
distributors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that this business model will enable us to grow our business with only moderate
investment in our infrastructure and other fixed costs. In addition, our distributors coordinate a
large share of distributor recruiting and training initiatives. Furthermore, based on increasing
demand, we can readily increase production and distribution of our products as a result of our
third party manufacturing relationships.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We develop and market branded dietary supplement and skin care products that we believe are
well suited for network marketing. We attract and motivate high-caliber, independent distributors because
of our focus on product innovation, a competitive compensation plan and our distributor support
programs. Direct selling through the network marketing sales channel has proven to be an effective
method of marketing our high-quality products because our distributors can personally educate
consumers on the quality and benefits of our products, differentiating them from our competitors&#146;
offerings.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As we work to grow our business, we are focused on the following key strategies:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>offering compelling and innovative products backed by science;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>offering rewarding and motivating distributor incentives, training, events, and loyalty / recognition programs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continuing to support clinical studies to demonstrate the effectiveness of our products; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>combining traditional public relations and marketing strategies with the viral marketing power of network marketing.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Distributor Network</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To become a distributor in most markets, a person must be enrolled by an existing distributor
and may purchase a business pack. The product and literature contents in the kits vary commensurate
with the size and cost of each kit. Our plan does not require the purchase of product to join, only
to participate in the compensation plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Active distributors under our compensation plan are defined as those distributors who have
purchased products for resale or personal consumption during the previous six months and have
enrolled at least one other distributor. In addition, we have implemented a &#147;preferred customer&#148;
program which allows customers to purchase products directly from us, on a recurring monthly
product subscription basis. We include preferred customers who have purchased products during the
previous six months in our &#147;active distributor&#148; numbers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on our distributors to recruit and sponsor new distributors of our products. While we
provide Internet support, product samples, brochures, magazines, and other sales and marketing
materials, distributors are primarily responsible for recruiting and educating new distributors
with respect to products, our compensation plan, and how to build a successful distributorship.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The sponsoring of new distributors creates multiple levels in a network marketing structure.
Individuals that a distributor sponsors are referred to as &#147;downline&#148; or &#147;sponsored&#148; distributors.
If downline distributors also sponsor new distributors, they create additional levels in the
structure, but their downline distributors remain in the same downline network as their original
sponsoring distributor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sponsoring activities are not required of distributors and we do not pay any commissions for
sponsoring new distributors, unless the new distributors purchase products. However, because of the
financial incentives provided to those who succeed in building and mentoring a distributor network
that resells and consumes products, many of our distributors attempt, with varying degrees of
effort and success, to sponsor additional distributors. People often become distributors after
using our products as regular customers. Once a person becomes a distributor, he or she is able to
purchase products directly from us at wholesale prices. The distributor is also entitled to sponsor
other distributors in order to build a network of distributors and product users. A new distributor
must enter into our standard distributor agreement, which among other things, obligates the
distributor to abide by our policies and procedures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Distributor Earnings</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distributor earnings are derived from several sources. First, distributors may earn profits by
purchasing our products at wholesale prices, and selling the products to retail customers. Second,
distributors who sponsor other distributors and establish their own sales organizations may earn
commissions on the product purchased by distributors and customers within their own organization.
Each distributor&#146;s success is dependent on two primary factors: 1) the time, effort and commitment
a distributor puts into his or her LifeVantage business and 2) the product sales made by a
distributor and his or her sales organization.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Distributor Motivation and Training</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that motivation and training are essential elements in distributor success and that
we and our distributor supervisors have established a consistent schedule of events to support
these needs. We are also committed to providing professionally-designed training materials
distributors can utilize in their sales and recruiting efforts. During the past year, we and our
distributors have conducted thousands of training sessions to educate and motivate our
distributors, and plan to continue to do so. These training events not only teach our distributors
leadership skills and how to build successful organizations utilizing industry-proven techniques,
but also how to teach the science behind our products to differentiate our products to consumers.
In addition, we sponsor our corporate broadcast network TrueTV, which delivers educational,
motivational, and inspirational content from our executive officers, Scientific Advisory Board,
celebrities, and field leaders.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe our commitment to developing and manufacturing science-based products will enhance
our ability to attract new consumers and new distributors, to continue to retain distributors, and
will help to increase our market share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Competitive Advantages</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that we are competitive within the network marketing industry as a result of
several key factors, including:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to offer our distributors a compelling business opportunity to market
and sell highly consumable products backed by science;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our experienced executive and network distribution team, comprised of some of the
most sought after and high-producing independent distributors in the industry;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>providing a broad array of motivational, educational, and support services;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>third-party substantiation and celebrity and scientific endorsement for our company and products; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to motivate our distributors through a performance-based compensation
plan, individual recognition, reward programs and incentives, and participation in local
and national corporate events.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We enable distributors to succeed by providing a broad array of motivational, educational, and
support services, including ongoing efforts to secure independent coverage of our science and
products. We have received coverage from, among others, ABC &#147;Primetime,&#148; NBC &#147;Today,&#148; PBS &#147;Healing
Quest,&#148; September&nbsp;2009 &#147;Delicious Living&#148; magazine, and the September/October&nbsp;2009 issue of &#147;AARP
Magazine&#148;.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Product Portfolio</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that we offer our distributors a compelling business opportunity to market and sell
highly consumable products backed by facts and science. We are committed to building distributor,
customer and brand loyalty by providing targeted products for the nutrition and health and wellness
industry.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Compensation Plan</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of our competitive advantages is our sales compensation plan. Our distributors can profit
from selling our products and can also earn royalties and bonuses on sales made by other
distributors who join their sales organizations. Under our compensation plan, a distributor is paid
monthly commissions in the distributor&#146;s home country, in local currency, for the distributor&#146;s own
product sales and for product sales in that distributor&#146;s downline distributor network across all
geographic markets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe the income potential provided by our business opportunity appeals to a broad
cross-section of the population, particularly those seeking part-time and full-time income due to
the global economic crisis and job loss, those seeking home-based business opportunities, and those
seeking entrepreneurial business income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July&nbsp;2009, our Board of Directors approved a Distributor Stock Option Pool totaling 300,000
shares of Common Stock under our 2007 Long Term Incentive Plan, out of which stock option grants
may be granted to distributors as incentives for achieving top distributor levels within our
distributor compensation plan. This has been greeted with great enthusiasm by our distributors and
has been an effective retention tool.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that these programs, along with an increased level of distributor recognition, goal
setting and accountability, will continue to motivate our distributors to drive revenue growth.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Distributor Regulation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We monitor regulations and distributor activity in each market to ensure our independent
distributors comply with federal, state and local laws. Our published independent distributor
policies and procedures establish the rules that distributors must follow. We require our
independent distributors to present products and business opportunities ethically and
professionally. Independent distributors further agree that their presentations to customers must
be consistent with, and limited to, the product claims and representations made in our literature.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independent distributors must represent to us that their receipt of commissions is based on
retail sales and substantial personal sales efforts. We must produce or pre-approve all sales aids
used by distributors such as brochures and online materials. Products may
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be promoted only by personal contact or by collateral materials produced or approved by us.
Independent distributors may not use our trademarks or other intellectual property without our
consent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We systematically review reports of alleged independent distributor misbehavior. If we
determine one of our independent distributors has violated any of our policies or procedures, we
may terminate the distributor&#146;s rights completely. Alternatively, we may impose sanctions, such as
warnings, probation, withdrawal or denial of an award, suspension of privileges of a
distributorship, fines and/or withholding of commissions until specified conditions are satisfied,
or other appropriate injunctive relief.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Manufacturing</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We outsource the primary manufacturing, fulfillment, and shipping components of our business
to companies we believe possess a high degree of expertise. Outsourcing allows us to avoid the
relatively high fixed costs of building our own infrastructure to accomplish these same tasks,
while gaining access to advanced manufacturing process capabilities and expertise. Outsourcing also
allows us to minimize our commitment of resources to human capital required to manage these
operational components successfully. Finally, outsourcing provides us with access to additional
inventory without significant advance notice and often at an incremental price lower than the unit
prices for the base service.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In July&nbsp;2008, we entered into a contract manufacturing agreement with Cornerstone Research &#038;
Development, Inc. (&#147;Cornerstone&#148;) under which Cornerstone
manufactures and packages the Protandim
supplement.
Cornerstone, as the contract manufacturer of Protandim, has a legal obligation to comply with the
Current Good Manufacturing Practices regulations that are applicable to those who manufacture,
package, label and hold dietary supplements. Additionally,
we are subject to regulations that, among other things, obligate us
to know what and how manufacturing activities are performed so that we
can make decisions related to whether the packaged and labeled
product conforms to our established
specifications and whether to approve and release product for distribution.
We maintain and qualify other manufacturing options in order to keep our
costs low, maintain the quality of our products, and to be prepared for unanticipated demand spikes
or manufacturing failure. Cornerstone delivers product to our fulfillment center based on our
purchase orders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We outsourced the manufacturing of LifeVantage TrueScience&#153; Anti-Aging Cream to Wasatch
Product Development, LLC, (&#147;Wasatch&#148;). Wasatch&#146;s core competency is sourcing and manufacturing
cosmetics for both U.S. and international customers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Marketing</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In fiscal 2009, we launched our network marketing sales channel. We have a sales, marketing,
public relations and customer service group consisting of 13 full-time equivalent employees. We
utilize our network of independent distributors located throughout the United States and in Mexico
and Japan to market and sell our products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Sales of our Products</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We accept orders for our products through independent distributor websites (&#147;Virtual Offices&#148;)
that we provide to our independent distributors as part of our network marketing program. We also
accept orders for our products through our website at www.lifevantage.com. Orders placed through
Virtual Offices and through our website are forwarded daily to our contract fulfillment center
where orders are processed and shipped to the consumer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We offer a toll-free number to our distributors and other customers to order product or ask
questions. Our customer service representatives answer customer calls and place orders in the
Company&#146;s web order processing system, as well as answer questions, track packages, and provide
refunds to customers. The customer service representatives receive extensive training and are
particularly knowledgeable about our products and adept at &#147;up-selling&#148; customers to our auto-ship
purchasing option, which allows us to realize recurring revenue on a monthly basis with no further
action required by the customer. We use InfoTrax System&#146;s DataTrax software for orders through
Virtual Offices and tracking independent distributor commissions. DataTrax is widely-used by
network marketing and direct selling companies and incorporates order entry, inventory shipment,
distributor management and commission generation. The DataTrax software accepts and authorizes
credit card submissions for independent distributor orders placed through our website as well as
Virtual Offices. On a daily basis, the DataTrax software charges credit cards and notifies the
fulfillment center of sales shipping needs through a web-enabled application. The operational
system at the fulfillment center responds back to DataTrax when the product has been shipped and we
can recognize revenue. Independent distributors generally pay for products by credit card, prior to
shipment, and we typically carry minimal accounts receivable.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Research and Development</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We continue to spend time, effort, and financial resources on the research and development of
our products. In fiscal years ended 2010 and 2009, we spent $392,691 and $224,366, respectively,
on Company-sponsored research and development.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Protandim product is currently the subject of approximately 20 independent scientific
studies at various universities and research facilities. The nature and stages of the studies vary,
as some are still in planning stages, while other studies are currently in progress. Universities
and institutions conducting research include the University of Colorado; Colorado State University;
Denver Health Medical Center; Children&#146;s Hospital, Denver; the University of Florida; the
University of Kentucky; the University of Michigan; Louisiana State University; Ohio State
University; Vanderbilt University; Glamorgan University, Wales; Sahlgrenska University Hospital,
Sweden; Harvard University; and the Mexican Institute of Social Security, Mexico City. The various
studies deal with the alleviation of oxidative stress under the following conditions: altitude
sickness, non-alcoholic steatohepatitis, lung antioxidant status in withdrawing alcoholics,
autonomic physiology and aging, skin cancer, photoaging of the skin, osteoarthritis,
HIV/AIDS-associated lipodystrophy, pulmonary hypertension, periodontal disease, heart disease,
coronary artery bypass graft failure, asthma, Duchenne muscular dystrophy, metabolic syndrome, and
optic neuropathy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Competition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Direct Antioxidants</I></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vitamin C, Vitamin E, Coenzyme Q-10, and other sources of exogenous antioxidants are
competitors of the Protandim supplement. However, they are non-enzymatic oxygen radical scavengers and
do not increase the body&#146;s enzymatic elimination of oxidants.
Our research indicates that the Protandim
supplement increases production of natural antioxidant enzymes, such as SOD and CAT, within the
cells of the body. Oxygen is consumed by mitochondria in the body, which is where oxidative stress
is at its worst. We believe that the body&#146;s internal antioxidant enzymes, produced at homeostatic
levels, provide a better defense against oxidative stress than exogenous sources of antioxidants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Oral SOD and CAT</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are many companies performing research into antioxidants, and these companies are
intensely competitive. There are some companies that sell oral forms of SOD and CAT, which make
claims that compete with the Protandim supplement. However, due to research which indicates the lack
of bioavailability and efficacy of such oral delivery, we believe the Protandim supplement to be
superior. It is highly likely that one or more additional entities will develop, purchase or
license from a third party, products which may be competitive with the Protandim supplement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Network Marketing Companies</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We compete with other network marketing companies, many of which have a longer operating
history and greater visibility, name recognition and financial resources than we do. We compete for
new independent distributors on the strength of our business opportunities, product offerings,
compensation plan, management, and our operations. In order to successfully compete in the network
marketing industry and attract and retain independent distributors, we must maintain the
attractiveness of our business opportunities to our distributors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Product Liability and Other Insurance</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have product liability insurance coverage for the Protandim product that we believe is
adequate for our needs. We have also obtained commercial property and liability coverage, as well
as directors&#146; and officers&#146; liability insurance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Intellectual Property</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Protandim product is a proprietary, patented dietary supplement formulation for enhancing
antioxidant enzymes including SOD and CAT. The patents and patent applications protecting this
formulation are held by our wholly-owned subsidiary, Lifeline Nutraceuticals Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We use commercially reasonable efforts to protect our intellectual property and license rights
through patent protection, trade secrets, and contractual protections, and intend to continue to
develop a strong brand identity in the Protandim&#174; trademark.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our intellectual property is covered, in part, by three U.S. patents issued on July&nbsp;10, 2007,
June&nbsp;10, 2008 and August&nbsp;25, 2009. An additional U.S. Utility Patent application is pending in the
U.S. Patent and Trademark Office and additional filings are anticipated. Corresponding applications
directed to the Protandim formulation are pending in Australia, Canada, China, Europe, India and
Japan. Our patents and patent applications claim the benefit of priority of seven U.S. provisional
patent applications, the earliest of which was filed on March&nbsp;23, 2004, and relate to compositions,
methods, and methods of manufacture of various compositions, including those embodied by the
Protandim product. The expected duration of our patent applications is through March&nbsp;23, 2025.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protandim&#174; is a registered trademark in the United States, Canada, China, the European
Community, Japan and Taiwan. We have applied for protection of the Protandim mark in China, and
Mexico.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied for registration of the trademark LifeVantage in Canada and through the World
Intellectual Property Organization (WIPO). We have registered the mark LifeVantage&#174; in the United
States and Mexico and through WIPO in Australia, China, Japan and the European Community. We also
have pending applications for the mark LifeVantage TrueScience&#153; in the United States, Mexico,
Australia, China, Japan, the European Community, and Switzerland. The LifeVantage TrueScience&#174;
mark is registered in Norway and Singapore.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not know with reasonable certainty the timing of the final grant or denial of the
applications for registration of these marks in these countries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to protect the confidentiality of our intellectual property, including trade secrets
and know-how and other proprietary technical and business information, it is our policy to limit
access to such information to those who require access in order to perform their functions and to
enter into agreements with employees, consultants and vendors to contractually protect such
information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Governmental Regulations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>FDA Regulations</I></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The formulation, manufacturing, packaging, labeling, and advertising of Protandim and the
Company&#146;s personal care line of products are subject to regulation by the Food and Drug
Administration (&#147;FDA&#148;). The Company is not required to obtain FDA pre-market approval to sell
the Protandim supplement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Protandim product is marketed as a &#147;dietary supplement&#148; as defined in the Dietary
Supplement Health and Education Act of 1994 (&#147;DSHEA&#148;). DSHEA is intended to promote access to safe,
quality dietary supplements, and information about dietary supplements. In 1994, DSHEA established
a new framework governing the composition and labeling of dietary supplements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DSHEA permits statements of nutritional support to be included in labeling for dietary
supplements without FDA pre-or-post-marketing approval. Such statements may describe how a
particular dietary ingredient may affect the structure, function, or general well-being of the body
or the mechanism of action by which dietary ingredients affect the foregoing. Such statements may
not state or imply that a dietary supplement is intended to diagnose, cure, mitigate, treat, or
prevent a disease unless such claim has been reviewed and approved by the FDA, as a &#147;health claim&#148;
or qualified health claim. A company that uses a statement of nutritional support in labeling must
possess evidence substantiating that the statement is truthful and not misleading. The FDA may
assert that a particular statement of nutritional support that a company is using is an illegal
claim; that assertion, normally, is in the form of a Warning Letter to which company may respond.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DSHEA also permits certain scientific literature, for example a reprint of a peer-reviewed
scientific publication, to be used &#147;in connection with the sale of a dietary supplement to
consumers&#148; without the literature being subject to regulation as labeling. However, such literature
must not be false or misleading, the literature may not promote a particular manufacturer, or brand
of dietary supplement and it must include a balanced view of the available scientific information
on the subject matter, among other requirements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we exercise care in our formulation, manufacturing, packaging, labeling, and advertising
of the  Protandim supplement, we cannot guarantee that the FDA will never inform the Company that the
FDA believes some violation of law has occurred. Any allegations of our non-compliance may result
in time-consuming and expensive defense of our activities. An enforcement action could include a
warning letter that informs us of alleged violations. Although we would be entitled to take
corrective action in response to any such warning letter, the issuance of a warning letter will be
public information. That information could affect our relationships
with our investors, vendors, and consumers. The FDA could also initiate other types of
enforcement actions, including actions for product seizure, inspection, and/or criminal
prosecution.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>FTC Regulations</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advertising and marketing of our products are also subject to regulation by the Federal Trade
Commission (&#147;FTC&#148;) under the Federal Trade Commission Act (&#147;FTC Act&#148;). Section&nbsp;5 of the FTC Act
prohibits unfair methods of competition and unfair or deceptive acts or practices in or affecting
commerce. Section&nbsp;12 of the FTC Act provides that disseminating any false advertisement pertaining
to drugs or foods, which would include dietary supplements, is an unfair or deceptive act or
practice. Under the FTC&#146;s Substantiation Doctrine, an advertiser is required to have competent and
reliable scientific evidence for all express and implied health-related product claims before the
claims are made. Failure to substantiate product claims may be considered deceptive or unfair.
Pursuant to this FTC requirement, we are required to have adequate substantiation for all material
advertising claims made for our products. The FTC routinely reviews advertising and websites to
identify questionable advertising claims and practices, and competitors may inform the FTC when
they believe other competitors are violating the FTC Act. The FTC may decide to initiate an
investigation into a company&#146;s advertising practices, which may initially involve non-public
pre-lawsuit discovery. Such an investigation may (i)&nbsp;be very expensive to defend, (ii)&nbsp;be lengthy,
and (iii)&nbsp;result in one or more adverse rulings by a court, administrative law judge, or in a
publicly disclosed consent decree.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally, any telemarketing activities we may engage in must comply with the FTC&#146;s
Telemarketing Sales Rule, 16 CFR Part&nbsp;310, and additional telemarketing and marketing statutes and
regulations of the FTC and of various states. Because these activities, in general, are in the
public eye and because it may be difficult to ensure compliance with these laws and regulations by
the individuals who actually make and receive such calls, there is a risk that we could be the
subject of investigation and other enforcement activities that may be brought by the FTC and state
agencies. We regularly train and educate telemarketing representatives to correctly and
appropriately represent our product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Network marketing activities are regulated by the FTC, as well as various federal, state and
local governmental agencies in the United States and foreign countries. These laws and regulations
are generally intended to prevent fraudulent or deceptive schemes, often referred to as &#147;pyramid&#148;
schemes, that compensate participants for recruiting additional participants irrespective of
product sales, use high-pressure recruiting methods and/or do not involve legitimate products. The
laws and regulations often:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>impose cancellation/product return, inventory buy-backs and cooling-off rights for
consumers and distributors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>require us or our distributors to register with governmental agencies;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>impose caps on the amount of commission we can pay;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>impose reporting requirements; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>impose upon us requirements, such as requiring distributors to maintain
levels of retail sales to qualify to receive commissions, to ensure that distributors
are being compensated for sales of products and not for recruiting new distributors.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The laws and regulations governing network marketing are modified from time to time, and, like
other network marketing companies, we may be subject from time to time to government investigations
related to our network marketing activities. This may require us to make changes to our business
model and aspects of our compensation plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>State Regulations</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to U.S. federal regulation, each state has enacted its own food and drug laws. We
may receive requests to supply information regarding our sales or advertising to state regulatory
agencies. We remain subject to the risk that, in one or more of our present or future markets, our
products, sales, and advertising could be found non-compliant with state laws and regulations. If
we fail to comply with these laws and regulations, it could have a material adverse effect on our
business in a particular market or in general. In addition, these laws and regulations could affect
our ability to enter new markets.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>The Bioterrorism Act</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2002, Congress enacted the Public Health Security and Bioterrorism Preparedness and
Response Act of 2002 (the &#147;Bioterrorism Act&#148;). The Bioterrorism Act contained new requirements with
regard to the sale and importation of food products in the United States:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Mandatory registration with the FDA of all food manufacturers.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior notice to regulators of inbound food shipments.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Recordkeeping requirements, and grant of access to the FDA of applicable
records.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Grant of detention authority to the FDA of food products in certain
circumstances.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the record keeping requirements, LifeVantage is considered to be a &#147;nontransporter&#148; of
Protandim&#174; products and must maintain certain records required of nontransporters. We are in the
process of ensuring that we keep all appropriate records required by the Bioterrorism Act.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Potential FDA and Other Regulation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We could become subject to additional laws or regulations administered by the FDA, FTC, or by
other federal, state, or local regulatory authorities, to the repeal of laws or regulations that we
consider favorable, such as DSHEA, or to more stringent interpretations of current laws or
regulations. For example, the FDA is currently developing a written guidance for New Dietary Ingredients (&#147;NDI&#148;)
which will clarify the FDA&#146;s interpretation of the new dietary ingredient statute. Increased FDA
enforcement could lead the FDA to challenge dietary supplements already being sold in the United
States and is likely to make the introduction and use of novel (new) dietary ingredients in dietary
supplements more difficult.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Dietary Supplement and Nonprescription Drug Consumer Protection Act, Public Law 109-462,
became effective on December 22, 2007. The law requires us to report
to the FDA  all serious
adverse events and to maintain for six years  records of all adverse events, whether or not
serious. An adverse event is defined as any health-related event associated with the use of a dietary supplement
that is adverse. In addition, this law requires the label of each dietary supplement, including Protandim,
to include a domestic address or telephone number by which the
company selling the product may receive a report
of a serious adverse event with such product. The label of Protandim complies with that statutory
provision. </DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><b>Results of Operations</b></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We commenced sales of Protandim in February&nbsp;2005. For the fiscal years ended June&nbsp;30,  2010 and 2009, we generated revenues of  $11,478,460 and $4,141,304, respectively, and
incurred net losses of  $11,048,328 and $9,114,634, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our expenditures have consisted primarily of marketing expenses, operating expenses, payroll
and professional fees, customer service, research and development and product manufacturing for the
marketing and sale of the Protandim supplement. In the third and fourth quarters of our 2009 fiscal
year, we assumed substantial overhead costs as we entered the network marketing sales channel,
including expenses related to the addition of new personnel, legal and marketing expenses necessary
to launch the sales channel. In addition, legal expenses related to the complaint filed, and since
settled, by Zrii were unanticipated and costly. See &#147;Legal Proceedings&#148; for more information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Employees</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010, we had approximately 33 full time employees, including three officers.
We outsource our manufacturing and distribution operations to minimize the number of our employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Available Information</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our principal place of business is at 11545 West Bernardo Court, Suite&nbsp;301, San Diego, CA
92127. Our telephone number is (858)&nbsp;312-8000 and our fax number is (858)&nbsp;312-8001. Our website
address is <U>www.lifevantage.com</U>; however, information found on our website is not
incorporated by reference into this report. Our web site address is included in this report as an
inactive textual reference only.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The reports filed with the Securities and Exchange Commission (&#147;SEC&#148;) by us and by our
officers, directors, and significant shareholders are available for review on the SEC&#146;s website at
www.sec.gov. You may also read and copy materials that we file with the SEC at the SEC&#146;s Public
Reference Room at 100 F Street, NE, Washington, DC 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="103"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 1A  &#151; RISK FACTORS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Because of the following risks, as well as other risks affecting our financial condition and
operating results, past financial performance should not be considered to be a reliable indicator
of future performance, and investors should not use historical trends to anticipate results or
trends in future periods. The risks described below are those we currently believe could materially
affect us. The following risk are not necessarily all of the important factors that could cause our
actual results of operations to differ materially from those expressed in the forward-looking
statements in this report.</I></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risk Factors Relating to Our Company</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>We have a limited operating history and lack of sufficient revenues from operations.</I></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We did not generate any significant revenues from the sale of Protandim until the last six
months of fiscal 2005. For the fiscal years ended June&nbsp;30,  2010 and 2009, we generated revenues of
$4,141,304 and $11,478,460, respectively. For  fiscal year ended June&nbsp;30, 2010, we incurred a net loss of
$11,048,328 and for our fiscal year ended June&nbsp;30, 2009, we incurred a
net loss of $9,114,619. We may not be successful in continuing to increase revenues or in achieving or
sustaining profitability.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>We may not be successful in expanding our operations.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to finance future operations will depend on our ability to generate additional
revenues and profits from operations. Management has projected that existing cash on hand will be
sufficient to allow us to continue operations through June&nbsp;30, 2011. A shortfall from projected
sales levels would likely result in expense reductions, which could have a material adverse effect
on our ability to continue operations at current levels.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>If we are able to expand our operations, we may be unable to successfully manage our future growth</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since we initiated our network marketing sales channel in fiscal 2009, our business has grown
significantly. This growth has placed substantial strain on our management, operational, financial
and other resources. If we are able to continue to expand our operations, we may experience
periods of rapid growth, including increased resource requirements. Any such growth could place
increased strain on our management, operational, financial and other resources, and we may need to
train, motivate, and manage employees, as well as attract management, sales, finance and
accounting, international, technical, and other professionals. Any failure to expand these areas
and implement appropriate procedures and controls in an efficient manner and at a pace consistent
with our business objectives could have a material adverse effect on our business and results of
operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>We have identified material weaknesses in our internal control over financial reporting which, if
not remediated, could cause us to fail to timely and accurately report our financial results or
prevent fraud, or result in restatements of our financial statements. As a consequence,
shareholders could lose confidence in our financial reporting and our stock price could suffer.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the preparation of our financial statements included in this report, as
well as certain previously issued financial statements, we concluded that there were material
weaknesses in our internal control over financial reporting as described in &#147;Item&nbsp;9A. Controls and
Procedures.&#148; We restated our interim condensed consolidated financial statements for the quarter
ended September&nbsp;30, 2009, in large part due to these inadequate internal control over financial
reporting. These material weaknesses, or difficulties encountered in implementing new or improved
controls or remediation, could prevent us from accurately reporting our financial results, result
in material misstatements in our financial statements or cause us to fail to meet our reporting
obligations. Failure to comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 could negatively
affect our business, the price of our common stock and market confidence in our reported financial
information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we have begun implementing processes intended to remediate the material weaknesses we
have identified, no assurances can be given when we will remediate all of the material weaknesses
we identified or that we will be successful. Further, if we do not successfully remediate any known
material weaknesses in a timely manner, we could be subject to sanctions by regulatory authorities
such as the SEC or investor perceptions could be negatively affected, each of which could have an
adverse effect on our business, financial condition or results of operations.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>We may need to raise additional capital.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If cash generated from operations is insufficient to satisfy our liquidity requirements, we
may need to raise additional capital, which may be dilutive to our existing shareholders. The
amount of dilution could be increased by the issuance of securities with dilutive characteristics,
such as anti-dilution clauses or price resets. In addition, if we raise additional funds by issuing
securities, the market price of our common stock may decline. If we are unable to raise additional
capital in a timely manner, we would be forced to liquidate some or all of our assets, or to
curtail, suspend, or cease all or certain of our operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, our ability to raise debt financing is limited. The terms of our outstanding
convertible debentures due November&nbsp;2011 generally prohibit us from incurring any indebtedness for
borrowed money of any kind without the consent of the holders of at least a majority of the
principal amount of the then outstanding debentures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Economic conditions, including the current financial crisis and declining consumer confidence and
spending, could harm our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global economic conditions have deteriorated significantly over the past several years.
Consumer confidence and spending have declined drastically and the global credit crisis has limited
access to capital for many companies. The economic downturn could adversely impact our business in
the future by causing a decline in demand for our products, particularly if the economic conditions
continue to worsen. In addition, such economic conditions may adversely impact access to capital
for us and our suppliers, may decrease our independent distributors&#146; ability to obtain or maintain
credit cards, and may otherwise adversely impact our operations and overall financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Our failure to comply with certain covenants contained in our convertible debentures due November
2011 could require us to redeem such debentures at a premium.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our convertible debentures due between November&nbsp;2011 and February 2012 provide that if (i)&nbsp;our company is a party to any
change of control transaction; (ii)&nbsp;our reporting requirements under the Exchange Act are suspended
or terminated; (iii)&nbsp;we fail for any reason to satisfy the current public information requirement
under Rule&nbsp;144; or (iv)&nbsp;our common stock is not listed or quoted on a national securities exchange
or the OTC Bulletin Board, the holders of such debentures may elect to have us redeem their
debentures at an amount equal to the sum of 130% of the then outstanding principal amount and 100%
of accrued and unpaid interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to comply with these covenants may be affected by changes in our business
condition or results of our operations, or other events beyond our control. If we were to breach
any of these covenants and the holders elected to have us redeem their debentures, we may not have
the cash on hand to effect the required redemption and may not be able to raise it, thereby
impairing our ability to operate our business or forcing us to seek bankruptcy protection. Even we
did have the cash on hand, the use of such cash to redeem the debentures would impair our ability
to fund ongoing operations, and if we were able raise additional capital to redeem the debentures,
we may be required to issue securities that would be dilutive to our stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>We could be exposed to certain environmental liabilities due to our past operations and property
ownership.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the 1990s, we owned mining properties in the Yaak River mining district of Montana. We
never conducted any mining operations or ore processing on these properties, nor have we performed
on-site environmental studies on these properties. The State of Montana Department of Environmental
Quality believed that the properties may contain residues from past mining. We may be liable for
material environmental liabilities associated with these properties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, until November&nbsp;2004, we owned land in Lawrence, Colorado. We are not aware of any
environmental liabilities with respect to this land. The party that acquired the land from us
assumed any environmental liability related to the land. Nonetheless, a governmental agency or a
private party could seek to hold us accountable for such environmental liabilities, if any.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risk Factors Relating to our Business and Industry</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>We primarily depend on a single product for our revenue.</I></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we have introduced new products, we primarily sell Protandim. We cannot rely on a
broad portfolio of other products to support our operations in the event we experience any
difficulty with the manufacture, marketing, sale, or distribution of Protandim. We may be unable
to sustain or increase the price or sales levels for Protandim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>The dietary supplement market is highly competitive.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The dietary supplements retail market is large and highly competitive and fragmented.
Participants include specialty retailers, supermarkets, drugstores, mass merchants, multi-level
marketing organizations, on-line merchants, mail-order companies, and a variety of other smaller
participants. Many of our competitors have greater financial and other resources available to them
and possess better manufacturing, distribution and marketing capabilities. We believe that the
market is also highly sensitive to the introduction of new products, including various prescription
drugs, which may rapidly capture a significant share of the market. In the United States, we also
compete for sales with heavily advertised national brands manufactured by large pharmaceutical and
food companies, as well as other retailers. In addition, as some products become more mainstream,
we experience increased competition for those products as more participants enter the market. Our
international competitors include large international pharmacy chains, major international
supermarket chains, and other large U.S.-based companies with international operations. We may not
be able to compete effectively and our attempt to do so may result in increased pricing pressure,
which may result in lower margins and have a material adverse effect on our results of operations
and financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Our network marketing sales channel may not be successful.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In fiscal 2009, we initiated a network marketing sales channel through which independent
distributors enter into agreements with us to sell Protandim&#174; and other products that we may
introduce in the market. Our independent distributors may terminate their services at any time,
and, like most network marketing companies, we have experienced and are likely to continue to
experience turnover among independent distributors. Independent distributors who join our company
to purchase our products for personal consumption or for short-term income goals may only stay with
us for a short time. While we take steps to help train, motivate, and retain independent
distributors, we cannot accurately predict the number or productivity of our independent
distributors. We may change the manner in which we use our networking sales channel or discontinue
it completely if its benefits do not outweigh its expenses and risks.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>The loss of key high-level distributors could negatively impact the growth of our network marketing
sales channel.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our independent distributors, together with their extensive networks of downline distributors,
currently account for substantially all of our sales. We compete with other network marketing
companies to attract and retain productive independent distributors. The loss of a high-level
independent distributor or a group of leading distributors in the independent distributor&#146;s network
of downline distributors, whether by choice or through disciplinary actions for violations of our
policies and procedures, could negatively impact the growth of our network marketing sales channel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Independent distributor activities that violate laws could result in governmental actions against
us and could otherwise harm our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our independent distributors are independent contractors. They are not employees and they act
independently of us. The network marketing industry is subject to governmental regulation. We
implement strict policies and procedures to try to ensure that our independent distributors comply
with laws. Any determination by the Federal Trade Commission or other governmental agency that we
or our distributors are not in compliance with laws could potentially harm our business. Even if
governmental actions do not result in rulings or orders against us, they could create negative
publicity that could detrimentally affect our efforts to recruit or motivate independent
distributors and attract customers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Network marketing is heavily regulated.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Various government agencies throughout the world regulate network marketing practices. These
laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often
referred to as &#147;pyramid&#148; schemes, which compensate participants
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">for recruiting additional participants irrespective of product sales, use high pressure
recruiting methods and/or do not involve legitimate products. Complying with these rules and
regulations can be difficult and requires the devotion of significant resources on our part. We
may not be able to continue business in existing markets or commence operations in new markets
because of these laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Our business is subject to strict government regulations.</I></B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The processing, formulation, manufacturing, packaging, labeling, advertising, and distribution
of our products are subject to federal laws and regulation by one or more federal agencies,
including the FDA, the FTC, the Consumer Product Safety Commission, the United States Department of
Agriculture, and the Environmental Protection Agency. These activities are also regulated by
various state, local, and international laws and agencies of the states and localities in which our
products are sold. Government regulations may prevent or delay the introduction, or require the
reformulation, of our products, which could result in lost revenues and increased costs to us. For
instance, the FDA regulates, among other things, the composition, safety, labeling, and marketing
of dietary supplements (including vitamins, minerals, herbs, and other dietary ingredients for
human use). The FDA may not accept the evidence of safety for any new dietary ingredient that we
may wish to market, may determine that a particular dietary supplement or ingredient presents an
unacceptable health risk, and may determine that a particular claim or statement of nutritional
value that we use to support the marketing of a dietary supplement is an impermissible drug claim,
is not substantiated, or is an unauthorized version of a &#147;health claim.&#148; Any of these actions could
prevent us from marketing particular dietary supplement products or making certain claims or
statements of nutritional support for them. The FDA could also require us to remove a particular
product from the market. Any future recall or removal would result in additional costs to us,
including lost revenues from any additional products that we are required to remove from the
market, any of which could be material. Any product recalls or removals could also lead to
liability, substantial costs, and reduced growth prospects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional or more stringent regulations of dietary supplements and other products have been
considered from time to time. These developments could require reformulation of some products to
meet new standards, recalls or discontinuance of some products not able to be reformulated,
additional record-keeping requirements, increased documentation of the properties of some products,
additional or different labeling, additional scientific substantiation, adverse event reporting, or
other new requirements. Any of these developments could increase our costs significantly. For
example, the Dietary Supplement and Nonprescription Drug Consumer Protection Act (S3546) which was
passed by Congress in December&nbsp;2006, imposes significant regulatory requirements on dietary
supplements including reporting of &#147;serious adverse events&#148; to FDA and recordkeeping requirements.
This legislation could raise our costs and negatively impact our business. In June&nbsp;2007, the FDA
adopted final regulations on GMPs in manufacturing, packaging, or holding dietary ingredients and
dietary supplements, which apply to the products we manufacture and sell. These regulations require
dietary supplements to be prepared, packaged, and held in compliance with certain rules. These
regulations could raise our costs and negatively impact our business. Additionally, our third-party
suppliers or vendors may not be able to comply with these rules without incurring substantial
expenses. If our third-party suppliers or vendors are not able to timely comply with these new
rules, we may experience increased cost or delays in obtaining certain raw materials and
third-party products. Also, the FDA has announced that it plans to publish guidance governing the
notification of new dietary ingredients. Although FDA guidance is not mandatory, it is a strong
indication of the FDA&#146;s current views on the topic discussed in the guidance, including its
position on enforcement. Depending on its recommendations, particularly those relating to animal or
human testing, such guidance could also raise our costs and negatively impact our business. We may
not be able to comply with new rules without incurring additional expenses, which could be
significant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Future laws may hinder or prohibit the production or sale of our existing products and any future
products.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may be subject to additional laws in the future. See &#147;Business&#151;Government Regulations.&#148; In
addition, laws with which we currently comply may be amended or interpreted more stringently. New
laws or new interpretations of current laws could require us to reformulate our products to meet
new standards, impose additional ingredient restrictions or impose additional claim restrictions.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-24-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Our intellectual property rights are valuable, and any inability to protect them could reduce the
value of our products and brand.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loss of our intellectual property rights in our products could permit our competitors to
manufacture their own version of our products. We have attempted to protect our intellectual
property rights in our products through a combination of patents, patent applications,
confidentiality agreements, non-compete agreements and other contractual protection mechanisms, and
we will continue to do so. While we intend to defend against any threats to our intellectual
property, there can be no assurance that our patents or other agreements will adequately protect
our intellectual property. In addition, we could be required to expend significant amounts to
defend our rights to proprietary information, and may not be successful in such defense. There can
also be no assurance that pending patent applications owned by us will result in patents being
issued to us, that patents issued to or licensed by us in the past or in the future will not be
challenged or circumvented by competitors or that such patents will be found to be valid or
sufficiently broad to protect our products or to provide us with any competitive advantage. Third
parties could also obtain patents that may require us to negotiate licenses to conduct our
business, and there can be no assurance that the required licenses would be available on reasonable
terms or at all. We also rely on confidentiality and non-compete agreements with &#091;certain
employees, consultants and other parties&#093; to protect, in part, trade secrets and other proprietary
rights. There can be no assurance that these agreements will not be breached, that we will have
adequate remedies for any breach, that others will not independently develop substantially
equivalent proprietary information or that third parties will not otherwise gain access to our
trade secrets or proprietary knowledge.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Other parties might claim that we infringe on their intellectual property rights.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although the dietary supplement industry has historically been characterized by products with
naturally occurring ingredients, recently it is becoming more common for suppliers and competitors
to apply for patents or develop proprietary technologies and processes. Third parties may assert
intellectual property infringement claims against us despite our efforts to avoid such
infringement. Such claims could prevent us from offering competitive products or result in
litigation or threatened litigation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Unfavorable publicity could materially hurt our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent upon consumers&#146; perceptions of the safety, quality, and efficacy of
our products, as well as products distributed by other companies. Future scientific research or
publicity may not be favorable to our industry or any particular product. Because of our dependence
upon consumer perceptions, adverse publicity associated with illness or other adverse effects
resulting from the consumption of our product or any similar products distributed by other
companies could have a material adverse impact on us. Such adverse publicity could arise even if
the adverse effects associated with such products resulted from failure to consume such products as
directed. Adverse publicity could also increase our product liability exposure, result in increased
regulatory scrutiny and lead to the initiation of private lawsuits.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>We are subject to the risk of investigatory and enforcement action by the FTC.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will always be subject to the risk of investigatory and enforcement action by the FTC based
on our advertising claims and marketing practices. The FTC routinely reviews product advertising,
including websites, to identify significant questionable advertising claims and practices. The FTC
has brought many actions against dietary supplement companies based upon allegations that
applicable advertising claims or practices were deceptive or not substantiated. If the FTC
initiates an investigation, the FTC can initiate pre-complaint discovery that may be nonpublic in
nature. Any investigation may be very expensive to defend and may result in an adverse ruling or in
a consent decree.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Challenges by regulatory authorities or private parties to the form of our network marketing system
or other regulatory compliance issues could harm our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Both regulatory authorities and private parties, including our independent distributors, may
challenge the form of our network marketing system or elements of our network marketing system.
Adverse rulings in any case filed against a network marketing company, even if it is not against
us, could negatively impact our business if they create adverse publicity, modify current
regulatory requirements in a manner that is inconsistent with our current business practices, or
impose fines or other penalties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Our business is susceptible to product liability claims.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The manufacture and sale of any product for human consumption raises the risk of product
liability claims. These claims may derive from the product itself or a contaminant found in the
product from the manufacturing, packaging, sales process or even due to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-25-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">tampering
by unauthorized third parties. Our products consist of vitamins, minerals, herbs, and other ingredients that are classified
as foods or dietary supplements and are not subject to pre-market regulatory approval in the United
States. Our products could contain contaminated substances, and some of our products contain
ingredients that do not have long histories of human consumption. Previously unknown adverse
reactions resulting from human consumption of these ingredients could occur. In addition,
third-party manufacturers produce many of the products we sell. As a distributor of products
manufactured by third parties, we may also be liable for various product liability claims for
products we do not manufacture. We  may be subject to various product liability
claims, including, among others, that our products include inadequate instructions for use or
inadequate warnings concerning possible side effects and interactions with other substances. Any
product liability claim against us could result in increased costs and could adversely affect our
reputation with our customers, which in turn could adversely affect our revenues and operating
income.
Even with the insurance we have obtained, there is a
risk that our insurance will not cover our potential exposure completely or would fail to cover a
particular claim, in which case we may not have the financial resources to satisfy such claim. In
addition, certain types of damages, such as punitive damages, are not covered by our insurance
policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>We are dependent upon third parties to manufacture our product.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently only use one manufacturer for each of our products. We are dependent on the
uninterrupted and efficient operation of these manufacturers&#146; facilities. If any of our current
manufacturers are unable to fulfill our manufacturing requirements or seek to impose unfavorable
terms, we will have to seek out other manufacturers, which could disrupt our operations and we may
not be successful in finding alternative manufacturing resources. In addition, competitors who
perform their own manufacturing may have an advantage over us with respect to pricing, availability
of product, and in other areas through their control of the manufacturing process.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Raw material for our product may be difficult to obtain or expensive.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raw materials account for a significant portion of our manufacturing costs. Suppliers may be
unable or unwilling to provide the raw materials our manufacturers need in the quantities
requested, at a price we are willing to pay, or that meet our quality standards. We are also
subject to potential delays in the delivery of raw materials caused by events beyond our control,
including labor disputes, transportation interruptions and changes in government regulations. Any
significant delay in or disruption of the supply of raw materials could, among other things,
substantially increase the cost of such materials, require reformulation or repackaging of
products, require the qualification of new suppliers, or result in our inability to meet customer
demands.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Product returns may adversely affect our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Returns are part of our business. We offer a 30-day, money back unconditional guarantee to all
customers. Our return rate since the inception of selling activities is 1% to 4% of sales. We
replace returned product damaged during shipment wholly at our cost, which historically has been
negligible. Future return rates or costs associated with returns may increase. In addition, to
date, product expiration dates have not played any role in product returns; however, it is possible
they will increase in the future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>The loss of key personnel could negatively impact our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future performance will depend upon our ability to attract, retain, and motivate our executive
and senior management team, as well as, scientific staff. Our success depends to a significant
extent both upon the continued services of our current executive and senior management team and
scientific staff, as well as our ability to attract, hire, motivate, and retain additional
qualified management and scientific staff in the future. In addition, competition for executive and
senior staff in the dietary supplement market is intense, and our operations could be adversely
affected if we cannot attract and retain qualified personnel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our employees
are &#147;at will&#148; employees, which means that any employee may
quit at any time and we may terminate any employee at any time. We do not carry &#147;key person&#148;
insurance covering members of senior management or scientific staff.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-26-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Economic, political, and other risks associated with our international operations could adversely
affect our revenues and international growth prospects.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In fiscal year 2010 we launched international operations in Mexico and Japan. During such year
we derived less than 10% of our revenues from our international operations. As part of our business
strategy, we intend to expand our international presence. Our international operations are subject
to a number of risks inherent to operating in foreign countries, and any expansion of our
international operations will increase the effects of these risks. These risks include, among
others:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>political and economic instability of foreign markets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>foreign governments&#146; restrictive trade policies;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inconsistent product regulation or sudden policy changes by foreign agencies or
governments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the imposition of, or increase in, duties, taxes, government royalties, or non-tariff
trade barriers;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>difficulty in collecting international accounts receivable and potentially longer
payment cycles;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>increased costs in maintaining international marketing efforts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>problems entering international markets with different cultural bases and consumer
preferences; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fluctuations in foreign currency exchange rates.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any of these risks could have a material adverse effect on our international operations and
our growth strategy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Risks Related to Ownership of Our Common Stock</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Our common stock is currently classified as penny stock.</I></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase and sale transactions involving penny stocks are subject to additional requirements.
Under Rule&nbsp;15g-9 promulgated under the Exchange Act, broker-dealers who sell or effect the purchase
of penny stock to persons other than established customers or in certain exempted transactions,
must make a special written disclosure to, and suitability determination for, the purchaser and
receive the purchaser&#146;s written agreement to a transaction prior to sale. The regulations on penny
stocks limit the ability of broker-dealers to sell our common stock and thus may limit the ability
of our shareholders to sell their shares of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>If we need additional financing in the future and are required to issue securities that are priced
at less than the conversion price of our convertible debentures or the exercise price of warrants,
it will result in additional dilution.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the debentures and warrants we have outstanding contain provisions that will require us
to reduce, respectively, the conversion price and exercise price thereof if we issue additional
securities while such debentures and warrants are outstanding which contain purchase prices,
conversion prices or exercise prices less than the conversion price of the debentures or the
exercise price of the warrants currently outstanding. If this were to occur, our stockholders
would sustain material dilution in their ownership interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>If the holders of our outstanding convertible debentures, warrants and options convert and exercise
their securities into common stock, we will issue up to 74,967,425 shares, which will materially dilute
the voting power of our currently outstanding common stock and could cause our stock price to
decline.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010, we had 61,494,849 shares of common stock outstanding.
 In
addition, we may elect to pay all principal and accrued interest on our convertible debentures that
mature on September&nbsp;26, 2010 and October&nbsp;31, 2010 in shares of common stock. If we were to pay all
such principal in shares of common stock we would issue an aggregate of 4,625,000 shares.
We also have
outstanding convertible debentures  that convert into an additional
aggregate of 23,226,400 shares of common
stock (assuming conversion at the current conversion price and assuming payment of all accrued
interest in cash), warrants that are exercisable for an aggregate of 38,580,294 shares of common
stock and stock options outstanding for an aggregate of 8,535,731 shares of common stock. The
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-27-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">issuance of these shares will dilute the voting power of our currently outstanding common
stock and could cause our stock price to decline.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>The market price of our securities could be adversely affected by sales of restricted securities.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actual sales or the prospect of future sales of shares of our common stock under Rule&nbsp;144 may
have a depressive effect upon the price of, and market for, our common stock. In addition, the
shares of common stock we may issue upon conversion of debentures or the cashless exercise of
warrants described above may also be sold in compliance with Rule&nbsp;144. We cannot predict what
effect, if any, that sales of shares of common stock, or the availability of these shares for sale,
will have on the market prices prevailing from time to time. Historically, the trading volume of
our common stock has been low and the market may not be able to absorb the sale of a substantial
number of shares. In addition, the possibility that substantial amounts of common stock may be sold
in the public market may adversely affect prevailing prices for our common stock and could impair
our ability to raise capital in the future through the sale of equity securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Our stock price may experience future volatility.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading price of our common stock has historically been subject to wide fluctuations. The
price of our common stock may fluctuate in the future in response to quarter-to-quarter variations
in operating results, material announcements by us or competitors, governmental regulatory action,
conditions in the dietary supplement industry, or other events or factors, many of which are beyond
our control, and some of which do not have a strong correlation to our operating performance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Our common stock has historically been illiquid.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The average daily trading volume of our common stock on the over-the-counter market was
approximately 125,000 shares per day over the fiscal year ended June&nbsp;30, 2010. If limited trading
in our stock continues, it may be difficult for investors to sell their shares in the public market
at any given time at prevailing prices.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Substantial sales of shares may impact the market price of our common stock</I></B><I>.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our shareholders sell substantial amounts of our common stock, the market price of our
common stock may decline. These sales also might make it more difficult for us to sell equity or
equity-related securities in the future at a time and price that we consider appropriate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>We have never paid dividends on our capital stock, and we do not anticipate paying any cash
dividends in the foreseeable future.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have paid no cash dividends on any of our classes of capital stock to date. In addition,
we are currently restricted from paying any dividends on our common stock under the terms of our
outstanding convertible debentures due November&nbsp;2011. Even absent such restriction, we currently
intend to retain our future earnings, if any, to fund the development and growth of our business.
In addition, the terms of any future debt or credit facility, if any, may preclude us from paying
dividends. As a result, capital appreciation, if any, of our common stock will be your sole source
of gain for the foreseeable future.
</DIV>
<DIV align="left">
<A name="104"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 1B  &#151; UNRESOLVED STAFF COMMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.
</DIV>
<DIV align="left">
<A name="105"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 2  &#151; PROPERTIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Corporate Offices</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The lease for our corporate headquarters in South Jordan, Utah is a thirty nine (39)&nbsp;month
sublease for approximately 9,600 rentable square feet of office space. The lease term began in
February&nbsp;2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our San Diego office is approximately 3,200 square feet of office space which we lease under a
5-year lease that began in November&nbsp;2008.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-28-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, in June&nbsp;2009 we entered into a recurring three (3)&nbsp;month lease agreement for
office space in Mexico City, Mexico for approximately 150 square feet.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Warehouse Facilities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2009 we entered into an arrangement with Integracore Fulfillment in Salt Lake
City, Utah for assembling distributor kits and fulfillment related to our network marketing sales
channel. There is no long term agreement related to this arrangement.
</DIV>
<DIV align="left">
<A name="106"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 3  &#151; LEGAL PROCEEDINGS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;27, 2009, Zrii, LLC filed a complaint against the Company and two former Zrii
independent contractors in the United States District Court for the Southern District of
California. This lawsuit was completely and permanently settled on December&nbsp;18, 2009. On that day,
the Company and Zrii executed a Settlement Agreement which, among other things, (1)&nbsp;released all
claims that each party, including their respective associated individuals, had against one another,
(2)&nbsp;provided for the dismissal with prejudice of the lawsuit and (3)&nbsp;called for the payment of
$400,000 by the Company to Zrii. That payment was timely made on December&nbsp;18, 2009. The Stipulation
of Dismissal of the lawsuit was filed with the Court on December&nbsp;18, 2009. The Order of Dismissal
with Prejudice was entered on December&nbsp;21, 2009.
</DIV>
<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 4  &#151; (REMOVED AND RESERVED)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</DIV>
<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART II</B>
</DIV>

<DIV align="left">
<A name="109"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 5  &#151; MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Market Information and Holders</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since February&nbsp;2, 2007, our common stock has been quoted on the OTC Bulletin Board under the
symbol &#147;LFVN.&#148; From October&nbsp;5, 2004 to February&nbsp;1, 2007, our common stock was quoted on the OTC
Bulletin Board under the symbol &#147;LFLT.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below sets forth for the fiscal quarters indicated the reported high and low bid
prices of our common stock, as quoted on the OTC Bulletin Board. These prices were reported by an
online service, reflect inter-dealer prices, without retail mark-up, mark-down or commission and
may not represent actual transactions. Our fiscal year-end is June&nbsp;30.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>High</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Low</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>High</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Low</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">First Quarter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.71</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.33</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Second Quarter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.44</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.07</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Third Quarter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.47</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.26</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.78</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Fourth Quarter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.38</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.94</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.45</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is issued in registered form and the following information is taken from
the records of our current transfer agent, Computershare Trust Company, Inc., located in Golden,
Colorado. As of June&nbsp;30, 2010, we had 290 shareholders of record and 61,494,849 shares of common
stock outstanding. This does not include an unknown number of persons who hold shares through
brokers and dealers in street name and who are not listed on our shareholder records.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-29-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Dividends</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not declared any dividends on any class of our equity securities since incorporation
and we do not anticipate that we will declare any dividends in the foreseeable future. In addition,
the terms of our outstanding convertible debentures due November&nbsp;2011 prohibit us from paying cash
dividends or distributions on our common stock as long as any portion of such debentures remain
outstanding without the consent of the holders of at least a majority of the principal amount of
the then outstanding debentures. Even
absent such restriction, we currently intend to retain our future earnings, if any, for use in
our operations and the expansion of our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Securities Authorized for Issuance under Equity Compensation Plans</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>

    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>

    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>

    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">

    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(c) Number of securities</B></TD>
     <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">

    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(b) Weighted-</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>remaining available for</B></TD>
     <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD nowrap align="center" colspan="2"><B>(a) Number of</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>average exercise</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>future issuance under</B></TD>
     <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">

    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>securities to be issued</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>price of</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>equity compensation</B></TD>
     <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD nowrap align="center" colspan="2"><B>upon exercise of</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>outstanding</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>plans (excluding</B></TD>
     <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD nowrap align="center" colspan="2"><B>outstanding options,</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>options, warrants</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>securities reflected in</B></TD>
     <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Plan Category</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>warrants and rights</B></TD>
     <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>and rights</B></TD>
    <TD>&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>column (a))</B></TD>
     <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equity
compensation plans
approved by
security holders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,535,731</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">304,269</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s board of directors approved an increase to the shares reserved for issuance
under the Company&#146;s 2007 Long-Term Incentive Plan from 6,000,000 shares to 10,000,000 shares and
this increase was approved by the Company&#146;s shareholders at the 2009 Annual Meeting. In June&nbsp;2010
we issued 1,160,000 shares of restricted stock to distributors under our equity compensation plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Unregistered Sales of Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective June&nbsp;30, 2009 and August&nbsp;5, 2009, the Company sold 6,869,369 unregistered shares of
common stock at a price of $0.35 per share. In connection with these issuances, the Company also
issued warrants exercisable for 1,373,852 shares of its common stock. The warrants have an exercise
price of $0.50 per share and may be exercised at any time following issuance during the three-year
exercise period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective November&nbsp;18, 2009, December&nbsp;11, 2009, December&nbsp;31, 2009, January&nbsp;20, 2010, February
4, 2010 and February&nbsp;26, 2010, the Company entered into securities purchase agreements with
accredited investors pursuant to which the Company sold an aggregate of $5,000,000 of 8%
convertible debentures and warrants to purchase shares of the Company&#146;s common stock with an
exercise price of $0.50 per share. Each investor received a debenture in the principal amount
equal to such investor&#146;s aggregate subscription amount less the amount equal to the quotient
obtained by dividing such aggregate subscription amount by $1,000. The debenture is convertible
into shares of the Company&#146;s common stock at any time at the discretion of the holder at a
conversion price per share of $0.20, subject to adjustment including anti-dilution protection.
Each investor also received a warrant to purchase that number of shares of the Company&#146;s common
stock that equals 50% of the quotient obtained by dividing such investor&#146;s aggregate subscription
amount by $0.20. The Company issued debentures in the aggregate principal amount of $4,995,000 and
warrants to purchase an aggregate of 12,499,999 shares of the Company&#146;s common stock. The Company also issued warrants to purchase an aggregate of 2,497,500 shares of the Company&#146;s common stock to placement agents in conjunction with this offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of common stock issuable upon conversion of the debentures and
upon exercise of the warrants the Company issued in this offering is, respectively, 24,974,999 and
 14,997,499, assuming the conversion price and exercise price is the initial conversion price and
exercise price at the time of conversion and/or exercise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issuances described above were exempt from registration under the Securities Act of 1933,
as amended, pursuant to Section&nbsp;4(2) thereof and/or Rule&nbsp;506 promulgated thereunder. The
transaction was not conducted in connection with a public offering, and no public solicitation or
advertisement was made or relied upon by the investors in connection with the offering.
</DIV>
<DIV align="left">
<A name="110"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 6  &#151; SELECTED FINANCIAL DATA</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.
</DIV>
<DIV align="left">
<A name="111"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 7  &#151; MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>You should read the following discussion and analysis in connection with our financial statements
and related notes beginning on page F-1 following Part III of this report.</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-30-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a dietary supplement company that manufactures, markets, distributes, and sells
Protandim, a patented dietary supplement intended to increase the body&#146;s natural antioxidant
protection by inducing multiple protective enzymes including superoxide dismustase (SOD)&nbsp;and
catalase (CAT)&nbsp;through network marketing and direct-to-consumer sales channels. We also sell our
LifeVantage TrueScience Anti-Aging Cream, a skin care product, through the same channel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our revenue depends significantly upon the number and productivity of our independent
distributors. Independent distributors market and sell our products and recruit new distributors
based on the distinguishing benefits and innovative characteristics of our products. We have
developed a distributor compensation plan and other incentives designed to motivate our independent
distributors to market and sell our products and to build sales organizations. If we experience
delays or difficulties in introducing compelling products or attractive initiatives to independent
distributors, this can have a negative impact on our revenue and harm our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Our Products</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We primarily sell a single product, Protandim, and in June&nbsp;2009 we began selling our
LifeVantage TrueScience<I>&#153; </I>Anti-Aging Cream (&#147;LifeVantage TrueScience&#148;) which incorporates the
ingredients in Protandim and other proprietary ingredients. We developed Protandim, a proprietary
blend of ingredients that combats oxidative stress by increasing the body&#146;s natural antioxidant
protection at the genetic level, inducing the production of naturally occurring protective
antioxidant enzymes including SOD, CAT, and glutathione synthase.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We sell Protandim and LifeVantage TrueScience through our network marketing sales channel
utilizing independent distributors and directly to individuals through our preferred customer
program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have focused our research efforts on investigating various aspects and
consequences of the imbalance of oxidants and antioxidants, an abnormality, which is a central
underlying feature in many disorders. We intend to continue our research, development, and
documentation of the efficacy of Protandim to provide credibility to the market. We also anticipate
undertaking research, development, testing, and licensing efforts to be able to introduce
additional products in the future, although we may not be successful in this endeavor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ongoing research and development projects involving Protandim are currently in various stages
of completion with several institutions including the University of Colorado at Denver Health
Science Center, University of Minnesota&#146;s Masonic Cancer Center, Ohio State University, University
Hospital in Brno, Czech Republic, University of Michigan and Louisiana State University. The
studies relate to various conditions including pulmonary hypertension, non-alcoholic fatty liver
disease, Duchenne muscular dystrophy, coronary artery bypass graft failure, renal failure,
diabetes, and photoaging of the skin. The recently completed and published peer-reviewed mouse
study at Louisiana State University found a significant increase in the expression levels of SOD
and catalase enzymes and tumor incidence and multiplicity were reduced in mice fed a Protandim&#174;
diet by 33% and 57%, respectively, compared with mice on a basal diet. Another study, conducted by
a prominent dermatologist using Protandim&#174;, is examining the relationship between anti-aging and
the skin&#146;s natural ability to rejuvenate at the cellular level.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We commenced sales of Protandim in February&nbsp;2005. For the fiscal years ended June&nbsp;30, 2010 and 2009, we generated net revenues of,   $11,478,460 and $4,141,304, respectively,
and incurred net losses of $11,048,328 and  $9,114,634, respectively. Beginning in
fiscal year 2009, we began sales of kits, marketing materials and other sales aides to distributors
in addition to the sales of Protandim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our expenditures have consisted primarily of marketing expenses, operating expenses, payroll
and professional fees, customer service, research and development and product manufacturing for the
marketing and sale of Protandim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To meet our increased expense requirements and achieve profitability, our sales must continue
to increase. Our revenue is highly dependent upon the number and productivity of our independent
distributors. Growth in our sales volume requires an increase in the productivity and/or growth in
the total number of our independent distributors.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-31-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If cash generated from operations is insufficient to satisfy our liquidity requirements, we
may need to raise additional financing. Additional financing may be dilutive to our existing
shareholders. If we are unable to obtain sufficient financing, or increase our
revenues, we will be required to reduce the scope of our existing and\or planned operations,
which could harm our business, financial condition and operating results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Comparison of Years Ended June&nbsp;30, 2010 and 2009</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Sales. </I>We generated net sales of $11,478,460 during the year ended June&nbsp;30, 2010 and
$4,141,304 during the year ended June&nbsp;30, 2009 primarily from the sale of Protandim and
TrueScience. The increase in sales of $7,337,156 was due to significant growth in our network
marketing channel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Gross Margin. </I>Cost of sales were $1,905,992 for the year ended June&nbsp;30, 2010, and $852,804 for
the year ended June&nbsp;30, 2009, resulting in a gross margin of $9,572,468, or 83%, and $3,288,500, or
79%, respectively. The increase in margin of $6,283,968 is due to the increase in sales as well as
a slight increase in margin percentage due to cost savings realized from our new contract
manufacturer during the year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Operating Expenses. </I>Total operating expenses for the fiscal year ended June&nbsp;30, 2010 were
$16,894,420 as compared to operating expenses of $11,093,578 for the fiscal year ended June&nbsp;30,
2009. Operating expenses consist of sales and marketing expenses, general and administrative,
research and development, and depreciation and amortization. Our launch of our network marketing
sales channel contributed to the increase in operating expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Sales and Marketing. </I>Sales and marketing expense for the fiscal year ended June&nbsp;30, 2010 was
$8,481,496 compared to $4,107,768 in fiscal year 2009 representing an increase of $4,373,728 in
fiscal year 2010. This increase was due primarily to commissions incurred on increased sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>General and Administrative. </I>Our general and administrative expense for the fiscal year ended
June&nbsp;30, 2010 was $7,765,331 compared to $6,588,414 in fiscal year 2009. The increase of $1,176,917
was primarily due to an increase in stock-based compensation expense and costs associated with
increased headcount.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Research and Development. </I>Our research and development expense for the fiscal year ended June
30, 2010 was $392,691 compared to $224,366 in fiscal year 2009. The increase of $168,325 was due
to increased fees for our Scientific Advisory Board and research contracts with the University of
Colorado.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Depreciation and Amortization. </I>Depreciation and amortization for the fiscal year ended June
30, 2010 was $254,902 compared to $173,030 in fiscal year 2009. The increase of $81,872 is
primarily due to amortization of intangible assets acquired during the year ended June&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Net Other Expense. </I>We recognized net other expense for the fiscal year ended June&nbsp;30, 2010 of
$3,726,376 as compared to $1,309,556 in fiscal year 2009. The increase in other expense of
$2,416,820 is largely the result of increased interest expense related to our private placements
and convertible debentures that we sold in private placement transactions which closed in fiscal
2010 and the fair market valuation of our related derivative warrant and conversion liabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Net Loss. </I>Our net loss for the fiscal year ended June&nbsp;30, 2010 was $11,048,328 as compared to
the net loss of $9,114,634 for the fiscal year ended June&nbsp;30, 2009. This represents an increase in
net loss of $1,933,694.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Liquidity and Capital Resources</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our primary liquidity and capital resource requirements are to finance the cost of our planned
sales and marketing efforts, the manufacture and sale of Protandim and our LifeVantage TrueScience
Anti-Aging Skin Cream, and to pay our general and administrative expenses. Our primary sources of
liquidity are cash flow from the sales of our products and funds raised from our 2009 private
placement financing transactions which closed in 2009 and 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August&nbsp;2009, we completed a sale of shares of common stock and warrants to purchase Common
Stock. We sold 2,583,668 shares of common stock at a purchase price of $0.35 per share and issued
warrants exercisable for 516,724 shares of Common Stock, for gross proceeds of $904,283. The
warrants sold in the Offering have an exercise price of $0.50 per share and may be exercised at any
time during the three-year period following the issuance.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-32-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Between November&nbsp;2009 and February&nbsp;2010, the Company issued convertible debentures in
aggregate principal amount of $4,995,000 that bear interest at 8&nbsp;percent per annum and have a term
of two years. The Company received aggregate net cash proceeds of $4,035,687, after deducting
placement fees $464,313 and taking into account the conversion of an outstanding note payable as
described below. The convertible debentures are convertible into the Company&#146;s common stock at
$0.20 per share during their term. In conjunction with these convertible debentures the Company
issued warrants to purchase an aggregate of 14,997,499 shares of the Company&#146;s common stock with an
exercise price of $0.50 per share and warrants to purchase an aggregate of 2,035,866 shares of
common stock with an exercise price of $0.20 per share. In addition, a note payable to a related
party in the amount of $500,000 was converted to a convertible debenture.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At June&nbsp;30, 2010, our available liquidity was $1,637,676 including available cash and cash
equivalents. This represented an increase of $1,028,881 from the $608,795 in cash, cash equivalents
and marketable securities as of June&nbsp;30, 2009. During the fiscal year ended June&nbsp;30, 2010, our net
cash used by operating activities was $4,499,483 as compared to net cash used by operating
activities of $5,206,904 during the fiscal year ended June&nbsp;30, 2009. Our cash used by operating
activities during the fiscal year ended June&nbsp;30, 2010 decreased primarily as a result of a decrease
in our operating loss as compared to the prior year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the fiscal year ended June&nbsp;30, 2010, our net cash provided by investing activities was
$178,296 primarily due to the redemption of available-for-sale marketable securities offset by
purchases of equipment and intangible assets. During the fiscal year ended June&nbsp;30, 2009, our net
cash provided by investing activities was $204,492, primarily due to the redemption of
available-for-sale marketable securities offset by purchases of equipment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by financing activities during the fiscal year ended June&nbsp;30, 2010 was
$5,381,845, compared to cash provided by financing activities of $5,414,324 during the fiscal year
ended June&nbsp;30, 2009. Cash provided by financing activities during the fiscal year ended June&nbsp;30,
2010 was primarily from proceeds from our convertible debenture offerings in 2010. Cash provided by
financing activities during the fiscal year ended June&nbsp;30, 2009 was primarily from proceeds from
our private placement offerings in 2009 and proceeds from a revolving line of credit borrowed
against our marketable securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain an investment portfolio of marketable securities that is managed by a professional
financial institution. This portfolio of auction rate preferred securities (&#147;ARPS&#148;) of AA and AAA
rated closed-end funds, which historically have been extremely liquid, has been adversely affected
by the broader national liquidity crisis. We have negotiated a repurchase plan with the financial
institution holding these securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have a line of credit, secured by our marketable securities, which allows us to borrow up
to 80% of the value of the marketable securities. Based upon that line of credit, our management
has classified 80% or $340,000 of our marketable securities as short term. The remaining 20% or
$85,000 of our marketable securities that may not be available in the current year is classified as
long term. However, future economic events could change the portions of these classified as short
term and long term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At June&nbsp;30, 2010, we had working capital (current assets minus current liabilities) of
$(2,103,899) compared to working capital of ($748,353) at June&nbsp;30, 2009. The decrease in working
capital was due primarily to $(1,444,331) of short-term derivative conversion liability related to
our 2007 debenture financing and $(702,361) of short-term convertible debt from our 2007 debenture
financing.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to convert our short-term debentures and related derivative liabilities into
4,625,000 shares of our common stock during the first half of our fiscal 2011. The conversions
should bring our negative working capital to zero or slightly positive. Based on our forecasted
cash flow for fiscal 2011 we have determined that cash on hand will be sufficient to fund our
operations through June&nbsp;30, 2011 and the foreseeable future thereafter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Off-Balance Sheet Arrangements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We did not have any off-balance sheet arrangements as of the period ended June&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Critical Accounting Policies</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We prepare our financial statements in conformity with accounting principles generally
accepted in the United States of America. As such, we are required to make certain estimates,
judgments, and assumptions that we believe are reasonable based upon the information available.
These estimates and assumptions affect the reported amounts of assets and liabilities at the date
of the financial statements and the reported amounts of revenues and expenses during the periods
presented. Actual results could differ from these estimates. Our significant accounting policies
are described in Note 2 to our financial statements. Certain of these significant accounting
policies require us to make difficult, subjective, or complex judgments or estimates. We consider
an accounting estimate to be critical if (1)&nbsp;the accounting estimate requires us to make
assumptions about matters that were highly uncertain at the time the accounting estimate was made,
and (2)&nbsp;changes in the estimate that are reasonably likely to occur from period to period, or use
of different estimates that we reasonably could have used in the current period, would have a
material impact on our financial condition or results of operations.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-33-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are other items within our financial statements that require estimation, but are not
deemed critical as defined above. Changes in estimates used in these and other items could have a
material impact on our financial statements. Management has discussed the development and selection
of these critical accounting estimates with our board of directors, and the audit committee has
reviewed the following disclosures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Allowances for Product Returns</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We record allowances for product returns at the time we ship the product based on estimated
return rates of 1% to 4%. We offer a 30-day, money back unconditional guarantee to all customers.
In addition, up to 30% of a distributer&#146;s orders in the prior 12&nbsp;months may be eligible for a
return and refund subject to certain limitations. As of June&nbsp;30, 2010, our shipments of
approximately $1,830,840 were subject to the money back guarantee. In addition, we allow
terminating distributors to return 30% of unopened unexpired product that they purchased within the
prior twelve months, subject to certain consumption limitations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We monitor our return estimate on an ongoing basis and revise the allowances to reflect our
experience. Our allowance for product returns was $343,900 on June&nbsp;30, 2010, compared with $68,500
on June&nbsp;30, 2009. To date, product expiration dates have not played any role in product returns,
and we do not expect they will in the future because it is unlikely that we will ship product with
an expiration date earlier than the latest allowable product return date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Inventory Valuation</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We state inventories at the lower of cost or market on a first-in first-out basis. From time
to time, we maintain a reserve for inventory obsolescence and we base this reserve on assumptions
about current and future product demand, inventory whose shelf life has expired, and market
conditions. From time to time, we may be required to make additional reserves in the event there is
a change in any of these variables. We recorded no reserves for obsolete inventory as of June&nbsp;30,
2010 because our product has a shelf life of at least 3&nbsp;years based upon testing performed
quarterly in an accelerated aging chamber at our manufacturer&#146;s facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Revenue Recognition</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We ship the majority of our product directly to the consumer through the direct to consumer
and network marketing sales channels via UPS and we receive substantially all payment for these
sales in the form of credit card charges. We recognize revenue from direct product sales to
customers upon passage of title and risk of loss to customers when product ships from the
fulfillment facility. Sales revenue and estimated returns are recorded when product is shipped.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Derivative Instruments</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the sale of debt or equity instruments, we may sell options or warrants to
purchase our common stock. In certain circumstances, these options or warrants may be classified as
derivative liabilities, rather than as equity. Additionally, the debt or equity instruments may
contain embedded derivative instruments, such as conversion options, which in certain circumstances
may be required to be bifurcated from the associated host instrument and accounted for separately
as a derivative instrument liability.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate fair values of derivative financial instruments using various techniques that are
considered to be consistent with the objective measurement of fair values. In selecting the
appropriate technique, we consider, among other factors, the nature of the instrument, the market
risks that it embodies and the expected means of settlement. For less complex derivative
instruments, such as freestanding warrants, we generally use the Black Scholes Merton option
valuation technique, adjusted for the effect of dilution, because it embodies all of the requisite
assumptions (including trading volatility, estimated terms, and risk free rates) necessary to fair
value these instruments. For embedded conversion features we generally use a lattice technique
because it contains all the requisite assumptions to value these features. Estimating fair values
of derivative financial instruments requires the development of significant and subjective
estimates that may, and are likely to, change over the duration of the instrument with related
changes in internal and external market factors. In addition, option-based techniques are highly
volatile and sensitive to changes in the trading market price of our common stock. Since derivative
financial instruments are initially and subsequently carried at fair values, our income or loss
will reflect the volatility in changes to these estimates and assumptions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Intangible Assets &#151; Patent Costs</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We review the carrying value of our patent costs and compare to fair value at least annually
to determine whether the patents have continuing value. In determining fair value, we consider
undiscounted future cash flows and market capitalization.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-34-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Stock-Based Compensation</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We use the fair value approach to account for stock-based compensation in accordance with
current accounting guidance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Research and Development Costs</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have expensed all of our payments related to research and development activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Commitments and Obligations</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 1px solid #000000"><B>Payments due by period</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 0px solid #000000"><B>Less than</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Contractual Obligations</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Total</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>1 year</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>1-3 years</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>3-5 years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Convertible Debt Obligations (subject to conversion to
common stock)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,570,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">925,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,645,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating Lease Obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">730,221</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">316,318</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">305,809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,094</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revolving
line of Credit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">433,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">433,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,734,486</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,675,303</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,951,089</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,094</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-35-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Recently Issued Accounting Standards</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2009, the Financial Accounting Standards Board (&#147;FASB&#148;) issued guidance which
established the FASB Accounting Standards Codification (the Codification) as the single source of
authoritative accounting principles in the preparation of financial statements in conformity with
GAAP. This guidance also explicitly recognized rules and interpretive releases of the SEC under
federal securities laws as authoritative GAAP for SEC registrants. This guidance was effective for
financial statements issued for periods ending after September&nbsp;15, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Standards Implemented</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective January&nbsp;1, 2009, the Company adopted the fair value measurement provisions as
required by the Fair Value Measurements and Disclosure Topic of the Codification, as it relates to
the measurement of nonfinancial assets and liabilities on a non-recurring basis. The adoption of
these provisions did not have an impact on our Consolidated Financial Statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective January&nbsp;1, 2009, the Company adopted enhanced disclosures about how and why we use
derivative instruments, how they are accounted for, and how they affect our financial performance
as required by the Derivatives and Hedging Topic of the Codification.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective June&nbsp;30, 2009, the Company adopted the subsequent event provisions of the
Codification. These provisions provide guidance on management&#146;s assessment of subsequent events.
The adoption of these provisions did not have an impact on the Company&#146;s Consolidated Financial
Statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective January&nbsp;1, 2010, the Company adopted Accounting Standards Update (&#147;ASU&#148;) 2010-06,
<I>Improving Disclosures about Fair Value Measurements. </I>The ASU amends FASB Codification Topic 820,
Fair Value Measurements and Disclosures, and requires additional disclosures regarding fair value
measurements.
</DIV>
<DIV align="left">
<A name="112"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 7A  &#151; QUANTITATIVE AND QUALITATIVE DISCLOURES ABOUT MARKET RISK</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.
</DIV>
<DIV align="left">
<A name="113"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 8  &#151; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;8 is set forth in the financial statements included in
Item&nbsp;15 of this report and is incorporated into this Item&nbsp;8 by reference.
</DIV>
<DIV align="left">
<A name="114"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 9  &#151; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</DIV>
<DIV align="left">
<A name="115"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 9A  &#151; CONTROLS AND PROCEDURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted an evaluation under the supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the
design and operation of our disclosure controls and procedures. The term disclosure controls and
procedures, as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Securities and Exchange Act of
1934, as amended (&#147;Exchange Act&#148;), means controls and other procedures of a company that are
designed to ensure that information required to be disclosed by the company in the reports it files
or submits under the Exchange Act is recorded, processed, summarized and reported, within the time
periods specified in the SEC&#146;s rules and forms. Disclosure controls and procedures also include,
without limitation, controls and procedures designed to ensure that information required to be
disclosed by a company in the reports that it files or submits under the Exchange Act is
accumulated and communicated to the company&#146;s management, including its principal executive and
principal financial officers, or persons performing similar functions, as appropriate, to allow
timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive
Officer and Chief Financial Officer have concluded that our
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-36-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">disclosure controls and procedures were not effective as of June&nbsp;30, 2010 at the reasonable
assurance level due to the material weaknesses in our internal control over financial reporting
discussed immediately below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Management&#146;s Report on Internal Control Over Financial Reporting</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is responsible for establishing and maintaining adequate internal control over
financial reporting as defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act. Our
internal control over financial reporting is designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles. Our internal control over
financial reporting includes those policies and procedures that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pertain to the maintenance of records that in reasonable detail accurately and fairly
reflect the transactions and dispositions of our assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with GAAP, and that our receipts and
expenditures are being made only in accordance with the authorization of our management and
directors; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use or disposition of our assets that could have a material effect on the
financial statements.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management assessed the effectiveness of our internal control over financial reporting as of
June&nbsp;30, 2010. In making this assessment, management used the framework set forth in the report
entitled <I>Internal Control&#151;Integrated Framework </I>issued by the Committee of Sponsoring Organizations
of the Treadway Commission, or COSO. The COSO framework summarizes each of the components of a
company&#146;s internal control system, including (i)&nbsp;the control environment, (ii)&nbsp;risk assessment,
(iii)&nbsp;control activities, (iv)&nbsp;information and communication, and (v)&nbsp;monitoring.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Identified Material Weaknesses</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A material weakness is a control deficiency, or combination of control deficiencies, that
results in more than a remote likelihood that a material misstatement of our financial statements
would not be prevented or detected on a timely basis by our employees in the normal course of
performing their assigned functions. Management identified material weaknesses during our
assessment of our internal control over financial reporting as of June&nbsp;30, 2010. In particular, we
concluded that we did not maintain:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sufficient personnel with an appropriate level of accounting knowledge, experience and
training in the selection and application of technical accounting principles in accordance
with GAAP to support our financial accounting and reporting functions;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Adequate oversight of certain accounting functions and did not maintain adequate
documentation of management review and approval of accounting transactions and financial
reporting processes;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Formal policies governing certain accounting transactions and financial reporting
processes; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A whistleblower hotline.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An independent consulting firm assisted management with its assessment of the effectiveness of
our internal control over financial reporting, including scope determination, planning, staffing,
documentation, testing, remediation and retesting and overall program management of the assessment
project. In conclusion, our Chief Executive Officer and Chief Financial Officer determined that we
did not maintain effective internal control over financial reporting as of June&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Management&#146;s Remediation Initiatives</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are in the process of evaluating our material weaknesses. We have already begun to
remediate many of the material weaknesses. In an effort to remediate the identified material
weaknesses and other deficiencies and to enhance our internal control over financial reporting, we
have initiated, or plan to initiate, the following series of measures:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-37-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Hire staff with experience managing and working in the corporate accounting department
of a publicly traded company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Implement appropriate management oversight and approval activities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Establish comprehensive formal general accounting policies and procedures and require
employees to sign off such policies and procedures as documentation of their understanding
of and compliance with company policies; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Establish a whistleblower hotline and communicate it to appropriate Company
stakeholders.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We anticipate that the above four initiatives will be at least partially, if not fully,
implemented by March&nbsp;31, 2011. Additionally, we plan to test our updated controls and remediate our
material weaknesses by June&nbsp;30, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Conclusion</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The above identified material weaknesses resulted in material audit adjustments to our 2010
financial statements. If the identified material weaknesses are not remediated, one or more of the
identified material weaknesses noted above could result in a material misstatement in our reported
financial statements in a future interim or annual period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In light of the identified material weaknesses, management performed (1)&nbsp;significant
additional substantive review of those areas described above, and (2)&nbsp;additional analyses,
including but not limited to a detailed balance sheet and statement of operations analytical review
that compared changes from the prior period&#146;s financial statements and analyzed all significant
differences. These procedures were completed so management could gain assurance that the financial
statements and schedules included in this report fairly present in all material respects our
financial position, results of operations and cash flows for the periods presented.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Changes in Internal Control over Financial Reporting</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We made no changes during our most recently completed fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control over financial
reporting, as defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act.
</DIV>
<DIV align="left">
<A name="116"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 9B  &#151; OTHER INFORMATION</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.</DIV>

<DIV align="left">
<A name="117"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART III</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by Part&nbsp;III is incorporated by reference to the information to be set
forth in our definitive Proxy Statement for the 2010 Annual Meeting of Shareholders (the &#147;Proxy
Statement&#148;). The Proxy Statement is to be filed with the SEC pursuant to Regulation&nbsp;14A of the
Exchange Act, no later than 120&nbsp;days after the end of the fiscal year covered by this report.
</DIV>
<DIV align="left">
<A name="118"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 10  &#151; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated herein by reference to the information to be set forth in the Proxy Statement.
</DIV>
<DIV align="left">
<A name="119"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 11  &#151; EXECUTIVE COMPENSATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated herein by reference to the information to be set forth in the Proxy Statement.
</DIV>
<DIV align="left">
<A name="120"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 12  &#151; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated herein by reference to the information to be set forth in the Proxy Statement.
</DIV>
<DIV align="left">
<A name="121"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 13  &#151; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated herein by reference to the information to be set forth in the Proxy Statement.
</DIV>
<DIV align="left">
<A name="122"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 14  &#151; PRINCIPAL ACCOUNTANT FEES AND SERVICES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated herein by reference to the information to be set forth in the Proxy Statement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-38-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="123"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART IV</B>
</DIV>

<DIV align="left">
<A name="124"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 15  &#151; EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following documents are being filed as part of this report:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Financial Statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">See the information beginning on page F-1 of this report.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See the Exhibit&nbsp;Index following the signature page of this report.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-39-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="125"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the
registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">LifeVantage Corporation.<BR>
a Colorado corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David W. Brown
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">David W. Brown&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>Its:</TD>
    <TD colspan="2" align="left"> Chief Executive Officer
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>Date:&nbsp;</TD>
    <TD colspan="2" align="left">September 15, 2010&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the capacities and on the
dates indicated.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Title</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ David W. Brown
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
David W. Brown
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chief Executive Officer; Director
<Br>(Principal Executive Officer)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Carrie E. Carlander
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Carrie E. Carlander
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chief Financial Officer
<Br>(Principal Financial Officer and
Principal <Br>Accounting Officer)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Garry Mauro
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Garry Mauro
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chairman of the Board&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ James D. Crapo
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
James D. Crapo
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chairman of the Audit Committee&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Joe M. McCord
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Joe M. McCord
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Richard D. Jones
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Richard D. Jones
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Doug Robinson
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Doug Robinson
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ C. Mike Lu
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
C. Mike Lu
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Kay Stout Manovich
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Kay Stout Manovich
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">September 15, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-40-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Document Description</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Incorporation by Reference</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amended and Restated Articles of
Incorporation.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-KSB (file No.
000-30489), filed on
September&nbsp;28, 2006, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amended and Restated Bylaws.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-KSB (file No.
000-30489), filed on
September&nbsp;28, 2006, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Warrant.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-148119), filed
December&nbsp;17, 2007, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Convertible Debenture.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-148119), filed
December&nbsp;17, 2007, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of 2009 Private Placement Warrant.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-K (File No.
000-30489), filed
September&nbsp;28, 2009, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of 2009 Unit Subscription Agreement.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-K (File No.
000-30489), filed
September&nbsp;28, 2009, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Debenture issued in connection with
November&nbsp;2009 Financing.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on November&nbsp;18,
2009, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Warrant issued in connection with
November&nbsp;2009 Financing.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on November&nbsp;18,
2009, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment to Debentures and Warrants, dated
as of December&nbsp;11, 2009.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Restated Debenture issued pursuant
to Amended and Restated Securities Purchase
Agreement dated December&nbsp;11, 2009.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Restated Warrant issued pursuant to
Amended and Restated Securities Purchase
Agreement dated December&nbsp;11, 2009.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of 8% Convertible Debentures issued on
each of December&nbsp;31, 2009, January&nbsp;20,
2010, February&nbsp;4, 2010 and February&nbsp;26,
2010.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on May&nbsp;14, 2010,
and incorporated herein
by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.11
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Common Stock Purchase Warrant
issued on each of December&nbsp;31, 2009,
January&nbsp;20, 2010, February&nbsp;4, 2010 and
February&nbsp;26, 2010.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on May&nbsp;14, 2010,
and incorporated herein
by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Unit Warrant Certificate.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-126288), filed on
June&nbsp;30, 2005, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Bridge Warrant Certificate.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-126288), filed on
June&nbsp;30, 2005, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Placement Agent Warrant Certificate.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-126288), filed on
June&nbsp;30, 2005, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Placement Agent Warrant Certificate.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2/A (File No.
333-126288), filed on
February&nbsp;6, 2006, and
incorporated herein by
reference.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-41-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Document Description</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Incorporation by Reference</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.5#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LifeVantage Corporation 2007 Long-Term
Incentive Plan.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed with the
LifeVantage Proxy on Form
14-A (File No.&nbsp;000-30489)
dated October&nbsp;20, 2006,
and incorporated herein
by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lease dated July&nbsp;1, 2008 between Bernardo
Regency, L.L.C. and LifeVantage
Corporation.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-KSB (file No.
000-30489), filed on
September&nbsp;23, 2008, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sublease dated March&nbsp;1, 2009 between
Broadweave Networks Inc. and LifeVantage
Corporation.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-K (File No.
000-30489), filed
September&nbsp;28, 2009, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreement between Cornerstone Research and
Development and LifeVantage Corporation.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-K (File No.
000-30489), filed
September&nbsp;28, 2009, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Confidential Termination Agreement and
General Release of Claims dated February
14, 2007 between Gerald J. Houston and the
Company.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Quarterly Report on Form
10-QSB (file No.
000-30489), filed on May
14, 2007, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Letter Agreement dated June&nbsp;1, 2007 between
Aspenwood Capital and LifeVantage
Corporation.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-148119), filed
December&nbsp;17, 2007, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.11
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Letter Agreement dated September&nbsp;28, 2007
between Bolder Venture Partners and
LifeVantage Corporation.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-148119), filed
December&nbsp;17, 2007, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.12
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchase Agreement between General
Nutrition Distribution, LP and LifeVantage
Corporation, dated June&nbsp;21, 2006.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Registration Statement on
Form&nbsp;SB-2 (File No.
333-126288), filed on
June&nbsp;30, 2005, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.13#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Agreement, dated January&nbsp;10,
2008, between LifeVantage Corporation and
David W. Brown.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Current Report on Form
8-K (File No.&nbsp;000-
30489), filed on January
16, 2008, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.14#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LifeVantage Compensation Plan.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed herewith.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.15#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Scientific Advisory Board Agreement
effective as of October&nbsp;1, 2009 by and
between the LifeVantage Corporation and Joe
McCord, Ph.D.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.16
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Securities Purchase Agreement
entered into in connection with November
2009 Financing.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on November&nbsp;18,
2009, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.17
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Amended and Restated Securities
Purchase Agreement originally dated
December&nbsp;11, 2009.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.18#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">First Amendment to Chief Executive Officer
Employment Agreement dated December&nbsp;15,
2009 between the LifeVantage Corporation
and David W. Brown.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.19
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Settlement Agreement dated December&nbsp;18,
2009 by and between Zrii, LLC and William
F. Farley, on the one hand, and the
LifeVantage Corporation, Wellness
Acquisition Group, and the other parties
thereto, on the other hand.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.20
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment to and Acknowledgement of
Cancellation of Promissory Note Agreement
dated February&nbsp;4, 2010 by and between the
LifeVantage Corporation and C. Mike Lu.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on February&nbsp;16,
2010, and incorporated
herein by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.21
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Securities Purchase Agreement dated
December&nbsp;31, 2009, among the LifeVantage
Corporation and the purchaser parties
thereto.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on May&nbsp;14, 2010,
and incorporated herein
by reference.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-42-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Document Description</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Incorporation by Reference</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.22
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Securities Purchase Agreement dated January
20, 2010, among the LifeVantage Corporation
and the purchaser parties thereto.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on May&nbsp;14, 2010,
and incorporated herein
by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.23
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Securities Purchase Agreement dated
February&nbsp;4, 2010, among the LifeVantage
Corporation and the purchaser parties
thereto.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on May&nbsp;14, 2010,
and incorporated herein
by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.24
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Securities Purchase Agreement dated
February&nbsp;26, 2010, among the LifeVantage
Corporation and the purchaser parties
thereto.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incorporated by reference
to LifeVantage
Corporation&#146;s Form&nbsp;8-K
(File No.&nbsp;000-30489),
filed on May&nbsp;14, 2010,
and incorporated herein
by reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">21.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">List of Subsidiaries.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed as an exhibit to
LifeVantage Corporation&#146;s
Annual Report on Form
10-KSB (File No.
000-30489), filed on
October&nbsp;13, 2005, and
incorporated herein by
reference.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Ehrhardt Keefe Steiner &#038; Hottman
PC.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed herewith.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Chief Executive Officer
pursuant to Section&nbsp;302 of the
Sarbanes-Oxley Act of 2002.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed herewith.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Chief Financial Officer
pursuant to Section&nbsp;302 of the
Sarbanes-Oxley Act of 2002.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Filed herewith.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">32.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Chief Executive Officer
pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Furnished herewith.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">32.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Chief Financial Officer
pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Furnished herewith.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-43-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIFEVANTAGE CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Index to Consolidated Financial Statements</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#300">Report of Independent Registered Public Accounting Firm</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">F-2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#306">Consolidated Financial Statements:</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#301">Consolidated Balance Sheets as of June&nbsp;30, 2010 and 2009</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">F-3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#302">Consolidated Statements of Operations for the years ended June&nbsp;30, 2010 and 2009</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">F-4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#303">Consolidated Statements of Stockholders&#146; Deficit and Comprehensive Income for the years ended June&nbsp;30, 2010 and 2009</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">F-5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#304">Consolidated Statements of Cash Flows for the years ended June&nbsp;30, 2010 and 2009</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">F-6&#150;F-7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#305">Notes to Consolidated Financial Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">F-8</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->F-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="300"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the Board of Directors<BR>
LifeVantage Corporation<BR>
San Diego, California

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have audited the accompanying consolidated balance sheets of LifeVantage Corporation and
subsidiary as of June&nbsp;30, 2010 and 2009 and the related consolidated statements of operations,
stockholders&#146; deficit and comprehensive income, and cash flows for the years then ended. These
financial statements are the responsibility of the Company&#146;s management. Our responsibility is to
express an opinion on these financial statements based on our audit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We conducted our audits in accordance with standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. Our audit included consideration of internal control over financial
reporting as a basis for designing audit procedures that are appropriate in the circumstances, but
not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control
over financial reporting. Accordingly, we express no opinion. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that
our audits provide a reasonable basis for our opinion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In our opinion, the consolidated financial statements referred to above present fairly, in all
material respects, the consolidated financial position of LifeVantage Corporation and subsidiary as
of June&nbsp;30, 2010 and 2009, and the results of their operations and their cash flows for the years
then ended in conformity with accounting principles generally accepted in the United States of
America.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">/s/ Ehrhardt Keefe Steiner &#038; Hottman PC

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">September&nbsp;15, 2010<BR>
Denver, Colorado
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="306"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">LIFEVANTAGE CORPORATION AND SUBSIDIARIES
</DIV>

<DIV align="left">
<A name="301"></A>
</DIV>
<!-- xbrl,bs -->
<DIV align="center" style="font-size: 10pt">CONSOLIDATED BALANCE SHEETS</DIV>
<!-- xbrl,body -->

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>As of,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ASSETS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,637,676</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">608,795</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restricted Cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">259,937</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Marketable securities, available for sale</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">340,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">520,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts receivable, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">401,597</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">648,116</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Equity raise receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119,750</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">493,858</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">740,014</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">153,864</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89,220</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,026,995</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,985,832</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Marketable securities, available for sale</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">130,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">196,353</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">274,741</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Intangible assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,045,471</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,175,281</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred debt offering costs, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">844,792</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83,023</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28,613</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66,795</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL ASSETS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,227,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,715,672</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">770,941</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,029,290</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Commissions payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">591,035</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">121,635</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Reserve for sales returns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">343,937</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68,542</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">809,507</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">631,847</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Customer deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34,797</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Escrow for equity offering</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">259,937</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Revolving line of credit and accrued interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">433,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">581,444</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Short-term derivative liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,444,331</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Short-term convertible debt, net of discount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">702,361</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Capital lease obligations, current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41,490</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,130,894</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,734,185</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred rent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,191</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,677</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Derivative liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,123,119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,429,710</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Convertible debt, net of discount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">121,014</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">382,194</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,402,218</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,569,766</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Preferred stock &#151; par value $0.001, 50,000,000
shares authorized, no shares issued or outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock &#151; par value $0.001, 250,000,000
shares authorized and 61,494,849 and 53,968,628
issued and outstanding as of June&nbsp;30, 2010 and
2009, respectively</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61,495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53,969</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,457,145</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,964,927</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(37,661,857</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(23,872,990</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated other comprehensive income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(31,777</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total stockholders&#146; deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,174,994</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,854,094</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,227,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,715,672</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>
<!-- /xbrl,bs -->


<P align="center" style="font-size: 10pt"><!-- Folio -->F-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">LIFEVANTAGE CORPORATION AND SUBSIDIARIES
</DIV>

<DIV align="left">
<A name="302"></A>
</DIV>
<!-- xbrl,op -->
<DIV align="center" style="font-size: 10pt">CONSOLIDATED STATEMENTS OF OPERATIONS</DIV>
<!-- xbrl,body -->

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>For the years ended,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sales, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">11,478,460</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,141,304</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,905,992</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">852,804</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Gross profit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,572,468</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,288,500</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Sales and marketing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,481,496</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,107,768</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,765,331</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,588,414</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">392,691</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">224,366</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">254,902</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">173,030</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,894,420</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,093,578</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Operating loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,321,952</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,805,078</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income and (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest expense, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,828,049</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,309,556</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in fair value of derivative liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,101,673</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,726,376</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,309,556</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(11,048,328</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,114,634</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per share, basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.19</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.23</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average shares outstanding, basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57,373,483</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,360,592</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>
<!-- /xbrl,op -->


<P align="center" style="font-size: 10pt"><!-- Folio -->F-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">LIFEVANTAGE CORPORATION AND SUBSIDIARIES
</DIV>

<DIV align="left">
<A name="303"></A>
</DIV>
<!-- xbrl,ci -->
<DIV align="center" style="font-size: 10pt">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT AND COMPREHENSIVE INCOME</DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt">For the years ended June&nbsp;30, 2010 and 2009</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Accumulated</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Other</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>Common Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Additional</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 0px solid #000000"><B>Accumulated</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Comprehensive</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Amount</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Paid In Capital</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Deficit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Income</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Total</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Balances, July&nbsp;1, 2008</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>24,766,117</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>24,766</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>17,902,840</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><B>$</B></TD>
    <TD align="right"><B>(14,758,356</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>&#151;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>3,169,250</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options/Warrants issued for
services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,454,249</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,454,249</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options and warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,426,810</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,427</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">525,403</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">531,830</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shares and warrants issued
pursuant to private placement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,785,701</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,786</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,978,214</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,000,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Private placement fees and
shares issued for services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">65,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">65</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(402,815</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(402,750</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Reclassification of warrant as
derivative warrant liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(7,652,023</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(7,652,023</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Conversion of debt to equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">925,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">925</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">159,059</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">159,984</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(9,114,634</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(9,114,634</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="24" nowrap align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Balances, June&nbsp;30, 2009</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>53,968,628</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>53,969</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>16,964,927</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><B>$</B></TD>
    <TD align="right"><B>(23,872,990</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>&#151;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><B>$</B></TD>
    <TD align="right"><B>(6,854,094</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cumulative effect of change in accounting principle</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">(448,619</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(2,740,539</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(3,189,158</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shares issued for services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,284,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">343,556</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">344,841</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options/Warrants issued for
services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,315,074</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,315,074</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options and warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">809,453</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,168</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,977</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Conversion of debt to equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,848,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,848</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,369,335</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,372,183</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shares and warrants issued
pursuant to private placement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,583,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,584</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">901,704</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">904,288</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Currency translation adjustment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(31,777</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(31,777</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(11,048,328</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(11,048,328</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="20" nowrap align="left" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD colspan="4" nowrap align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other comprehensive loss </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">(11,080,105</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="24" nowrap align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Balances, June&nbsp;30, 2010</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>61,494,849</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>61,495</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>21,457,145</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><B>$</B></TD>
    <TD align="right"><B>(37,661,857</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><B>$</B></TD>
    <TD align="right"><B>(31,777</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right"><B>$</B></TD>
    <TD align="right"><B>(16,174,994</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="24" nowrap align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,ci -->


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->F-5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">LIFEVANTAGE CORPORATION AND SUBSIDIARIES
</DIV>

<DIV align="left">
<A name="304"></A>
</DIV>
<!-- xbrl,cf -->
<DIV align="center" style="font-size: 10pt">CONSOLIDATED STATEMENTS OF CASH FLOWS</DIV>
<!-- xbrl,body -->

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>For the years ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash Flows from Operating Activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(11,048,328</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,114,634</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Adjustments to reconcile net loss to net cash used by operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">254,902</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">173,030</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Loss on disposition of equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,652</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Stock based compensation to employees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,131,657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">824,974</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Stock based compensation to non-employees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,528,258</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">629,275</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Non-cash interest expense from convertible debentures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,190,180</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">343,710</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Non-cash interest expense from amortization of deferred offering costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">376,891</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,445</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Change in fair value of derivative liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,101,673</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">777,687</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Changes in operating assets and liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">(Increase)/decrease in accounts receivable, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">246,519</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(550,108</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Decrease/(increase) in inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">246,156</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(635,599</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Decrease in deposits to manufacturer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">271,497</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">(Increase)/ decrease in prepaid expenses and deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(64,644</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51,311</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Decrease/(increase) in deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38,182</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(18,348</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">(Decrease)/increase in accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,258,349</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,889,487</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Increase in customer deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34,797</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Increase in accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">925,969</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">507,433</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">(Decrease) in deferred revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(510,765</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Decrease in deferred expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62,049</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net Cash Used by Operating Activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(4,499,483</B></TD>
    <TD nowrap><B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right"><B>(5,206,904</B></TD>
    <TD nowrap><B>)</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash Flows Provided by Investing Activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Redemption of marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">225,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">450,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">(Purchase) of equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,075</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(226,701</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">(Purchase) of intangible assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(40,629</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(18,807</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net Cash Provided by Investing Activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>178,296</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>204,492</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash Flows from Financing Activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net proceeds <BR>
(payments)&nbsp;from revolving line of credit and accrued interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(148,367</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">414,824</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Principal payments under capital lease obligation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(41,490</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,830</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Issuance of
common stock and warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">916,265</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,531,830</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Receivable from equity raise</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119,750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(119,750</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Private placement fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(464,313</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(402,750</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from issuance of private placement of convertible debentures &#038; warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net Cash Provided by Financing Activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>5,381,845</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>5,414,324</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Foreign Currency Effect on cash</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(31,777</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Increase in cash and cash equivalents</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>1,028,881</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>411,912</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and Cash Equivalents &#151; beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">608,795</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">196,883</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash and Cash Equivalents &#151; end of period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>1,637,676</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>608,795</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->F-6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">LIFEVANTAGE CORPORATION AND SUBSIDIARIES<BR>

CONSOLIDATED STATEMENTS OF CASH FLOWS
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>For the years ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Conversion of long-term debt to common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">914,720</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">185,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Conversion
of derivative to common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">457,463</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Warrants issued for private placement fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">674,347</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">689,385</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Equipment acquired through a capital lease</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">51,319</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Write down of deferred offering costs related to conversion of debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">25,016</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Cash paid for interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">165,943</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">104,222</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Cash paid for income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For the year ended June 30, 2010 the Company issued 694,811 shares of common stock
for a total exercise price of $286,700 through non-cash exercises of 1,099,286 warrants.
</DIV>
<!-- /xbrl,cf -->


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->F-7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl,ns -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIFEVANTAGE CORPORATION AND SUBSIDIARIES</B>
</DIV>

<DIV align="left">
<A name="305"></A>
</DIV>
<DIV align="center" style="font-size: 10pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 1 &#151; Organization and Basis of Presentation:</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LifeVantage Corporation (&#147;LifeVantage&#148; or the &#147;Company&#148;) was formed under Colorado law in June
1988, under the name Andraplex Corporation. The Company amended its name to Yaak River Resources,
Inc. in January&nbsp;1992, to Lifeline Therapeutics, Inc. in October&nbsp;2004 and to LifeVantage Corporation
in November&nbsp;2006. The Company is in the business of marketing and selling its proprietary products,
primarily Protandim&#174;, to individuals throughout the United States and in Japan and Mexico. The
Company began selling to individuals during the fiscal year ended June&nbsp;30, 2005 and to retail
stores beginning in fiscal year 2006. The Company&#146;s headquarters are in San Diego, California and
its principal operations are located in South Jordan, Utah.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July&nbsp;2009 the Company formed the wholly owned subsidiaries LifeVantage de M&#233;xico, S. de
R.L. de C.V. (Limited Liability Company), Importadora LifeVantage, S. de R.L. de C.V. (Limited
Liability Company), and Servicios Administrativos para la Importaci&#243;n de Productos Body &#038; Skin,
S.C. to conduct business in Mexico.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;26, 2004, the Company consummated an Agreement and Plan of Reorganization with
Lifeline Nutraceuticals Corporation (&#147;LNC&#148;), a privately held Colorado corporation, formed on July
1, 2003. In October 2004 and March 2005 the shareholders of LNC exchanged 81% of their outstanding shares of common stock for
15,385,110 shares of common stock of the Company, which represented 94% of the then issued and
outstanding shares of the Company. The Company assumed the obligations of LNC note holders as part
of the transaction.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 2 &#151; Summary of Significant Accounting Policies</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Consolidation</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying financial statements include the accounts of the Company and its wholly-owned
subsidiaries LNC, LifeVantage de M&#233;xico, S. de R.L. de C.V.
(Limited Liability Company), Importadora LifeVantage, S. de R.L. de C.V. (Limited Liability
Company), and Servicios Administrativos para la Importaci&#243;n de Productos Body &#038; Skin, S.C. All
inter-company accounts and transactions between the entities have been eliminated in consolidation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Use of Estimates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We prepare our consolidated financial statements and related disclosures in conformity with
accounting principles generally accepted in the United States of
America (GAAP). In preparing
these statements, we are required to use estimates and assumptions that affect the reported amounts
of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the reporting period.
Actual results could differ materially from those estimates and assumptions. On an ongoing basis,
we review our estimates, including those related to allowances for sales returns, income taxes and
tax valuation reserves, share-based compensation, derivative liabilities and loss contingencies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Fair Value of Financial Instruments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounting guidance on fair value measurements and disclosures requires disclosures about the
fair value for all financial instruments, whether or not recognized, for financial statement
purposes. Disclosures about fair value of financial instruments are based on pertinent information
available to management as of June&nbsp;30, 2010 and 2009. Accordingly, the estimates presented in these
consolidated financial statements are not necessarily indicative of the amounts that could be
realized on disposition of the financial instruments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management has estimated the fair values of cash, marketable securities, accounts receivable,
accounts payable, and accrued expenses to be approximately their respective carrying values
reported in these consolidated financial statements because of their short maturities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Fair Value Measurements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value measurement requirements are embodied in certain accounting standards applied in
the preparation of our financial statements. Significant fair value measurements resulted from the
application of guidance on fair value measurements and disclosures to our common stock and warrant
financing arrangements and to our share-based payment arrangements. Accounting guidance on fair
value measurements and disclosures establishes a framework and hierarchy for measuring fair value
in generally accepted accounting principles, and expands disclosures about fair value measurements.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fair value hierarchy:</TD>
</TR>

</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 1 inputs are quoted prices in active markets for identical assets and
liabilities.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 2 inputs are inputs which include quoted prices for similar assets and
liabilities in active markets and inputs that are observable for the assets or liabilities,
either directly or indirectly, for substantially the full term of the financial instrument.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 3 inputs are unobservable inputs and significant to the fair value
measurement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounting guidance on fair value measurement and disclosures permits entities to choose to
measure many financial instruments and certain other items at fair value. It was effective for our
year beginning July&nbsp;1, 2008. Upon its adoption and at this time, we do not intend to reflect any of
our current financial instruments at fair value (except that we are required to carry our
derivative financial instruments at fair value). However, we will consider the appropriateness of
recognizing financial instruments at fair value on a case by case basis in future periods.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The summary of fair values of financial instruments as of June&nbsp;30, 2010 and 2009 are as
follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" colspan="17" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Instrument</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Fair Value</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Carrying Value</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Level</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Valuation Methodology</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">425,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">425,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Market Price</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Derivative warrant liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">10,573,084</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">10,573,084</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Black-Scholes</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Embedded conversion liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">7,994,366</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">7,994,366</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Lattice model</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" colspan="17" style="border-bottom: 1px solid #000000"><B>June 30, 2009</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Instrument</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Fair Value</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Carrying Value</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Level</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Valuation Methodology</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Market Price</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Derivative warrant liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,429,710</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,429,710</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Black-Scholes</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following represents a reconciliation of the changes in fair value of financial
instruments measured at fair value on a recurring basis using significant unobservable inputs
(Level 3) for the years ended June&nbsp;30, 2010 and 2009:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Beginning balance: Derivative liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8,429,710</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total (gains)&nbsp;losses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,101,673</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">777,687</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Adoption of change in accounting principle</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,267,253</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchases, sales, issuances and settlements, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,972,160</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,652,023</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ending balance: Derivative liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">18,567,450</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8,429,710</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Cash and Cash Equivalents</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers only its monetary liquid assets with original maturities of three months
or less as cash and cash equivalents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Restricted Cash</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010 the Company had no restricted cash. As of June&nbsp;30, 2009, the Company
collected  $259,937 of receipts related to an equity offering that closed in August
2009. These funds were held as restricted cash in escrow until the closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Marketable Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has invested, from time to time, in marketable securities, including auction rate
preferred securities of closed-end funds (&#147;ARPS&#148;) to maximize interest income. The Company
considered its investment in these instruments as marketable securities available for sale in
accordance with relevant accounting guidance.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These marketable securities which historically had been liquid have been adversely affected by
the broader national liquidity crisis. The Company entered into an agreement with its investment
advisor, Stifel Nicolaus, to repurchase 100% of the ARPS at par on or prior to June&nbsp;30, 2012. The
schedule for repurchase over the next three years is as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The greater of 10&nbsp;percent or $25,000 to be completed by June&nbsp;30, 2010;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The greater of 10&nbsp;percent or $25,000 to be completed by June&nbsp;30, 2011;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The balance of outstanding ARPS to be repurchased by June&nbsp;30, 2012.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has entered into a line of credit with Stifel Nicolaus to borrow up to 80% of the
par value of the Company&#146;s marketable securities, collateralized solely by the ARPS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon the agreement to expand the line of credit to 80%, management has access to 80% of
its ARPS through borrowing in the current year. Accordingly, management classified 80% or $340,000
of the Company&#146;s marketable securities as short term. The remaining 20% or $85,000 of the Company&#146;s
marketable securities that may not be available in the current year is classified as long-term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010, in light of the plan for repurchase and the repurchases made during the
year, management has determined that there has not been a change in the fair value of the
securities owned. The Company has not recorded any impairment related to these investments, as
management does not believe that the underlying credit quality of the assets has been impacted by
the reduced liquidity of these investments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Accounts Receivable</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s accounts receivable for the year ended June&nbsp;30, 2010 consist primarily of credit
card receivables including a percentage holdback by the credit card processor. The Company&#146;s
accounts receivable for the year ended June&nbsp;30, 2009 primarily consisted of receivables from retail
distributors. Based on the Company&#146;s verification process for customer credit cards and historical
information available, management has determined that an allowance for doubtful accounts on credit
card sales related to its direct and independent distributor sales as of June&nbsp;30, 2010 is not
necessary. No bad debt expense has been recorded for the years ended June&nbsp;30, 2010 and 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Inventory</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory is stated at the lower of cost or market value. Cost is determined using the
first-in, first-out method. The Company has capitalized payments to its contract manufacturer for
the acquisition of raw materials and commencement of the manufacturing, bottling and labeling of
the Company&#146;s product. As of June&nbsp;30, 2010 and June&nbsp;30, 2009, inventory consisted of:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Finished goods</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">326,095</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">522,599</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Raw materials</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">167,763</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">217,415</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">493,858</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">740,014</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->F-10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Property and Equipment</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are recorded at cost. Depreciation of property and equipment is
expensed in amounts sufficient to relate the expiring costs of depreciable assets to operations
over estimated service lives, principally using the straight-line method. Estimated service lives
range from three to seven years. When such assets are sold or otherwise disposed of, the cost and
accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected
in operations in the period of disposal. The cost of normal maintenance and repairs is charged to
expense as incurred. Significant expenditures that increase the useful life of an asset are
capitalized and depreciated over the estimated useful life of the asset. Property and equipment
consist of:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">360,699</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">357,135</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Software</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,463</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82,952</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accumulated depreciation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(249,809</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(165,346</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">196,353</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">274,741</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
expense totaled $84,463 and $59,340 for the years ended June&nbsp;30, 2010 and 2009,
respectively.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Intangible Assets</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has adopted accounting guidance on goodwill and other intangible assets which
establishes standards for accounting for goodwill and other intangibles acquired in business
combinations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As of June&nbsp;30, 2010 and June&nbsp;30, 2009, intangible assets consisted of:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Patent costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,278,953</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,255,696</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Trademark costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">132,712</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accumulated amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(383,543</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(213,127</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intangible assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,045,471</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,175,281</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization
expense totaled $170,439 and $113,690 for the years ended June&nbsp;30, 2010 and 2009,
respectively.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Patents</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The costs of applying for patents are capitalized and, once the patent is granted, will be
amortized on a straight-line basis over the lesser of the patent&#146;s economic or legal life.
Capitalized costs will be expensed if patents are not granted or it is determined that the patent
is impaired. The Company reviews the carrying value of its patent costs periodically to determine
whether the patents have continuing value and such reviews could result in impairment of the
recorded amounts. As of June&nbsp;30, 2010, three U.S. patents have been granted, which are being
amortized upon the date of the grant and continuing over their remaining legal lives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Impairment of Long-Lived Assets</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to guidance established for impairment or disposal of assets the Company assesses
impairment whenever events or changes in circumstances indicate that the carrying amount of a
long-lived asset may not be recoverable. When an assessment for impairment of long-lived assets,
long-lived assets to be disposed of, and certain identifiable intangibles related to those assets
is performed, the Company is required to compare the net carrying value of long-lived assets on the
lowest level at which cash flows can be determined on a consistent basis to the related estimates
of future undiscounted net cash flows for such properties. If the net carrying value exceeds the
net cash flows, then impairment is recognized to reduce the carrying value to the estimated fair
value, generally equal to the future discounted net cash flow.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The recurring losses experienced by the Company have resulted in management&#146;s assessment of
impairment with respect to the capitalized patent costs. Analysis generated for this assessment
concluded that sales volumes, less the cost of manufacturing the product sold, less the sales and
marketing and general and administrative cost of generating the revenues, support management&#146;s
conclusion that no impairment to the capitalized patent costs has occurred as of June&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Concentration of Credit Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounting guidance for financial instruments, requires disclosure of significant
concentrations of credit risk regardless of the degree of such risk. Financial instruments with
significant credit risk include cash and marketable securities. At June&nbsp;30, 2010, the Company had
$1,424,984 in cash accounts at one financial institution, $58,914 in foreign banks for our Mexico
and Japan subsidiaries and $153,778 in an investment management account at another financial
institution.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Derivative Financial Instruments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not use derivative instruments to hedge exposures to cash flow, market, or foreign
currency risks. However, we have entered into certain other financial instruments and contracts,
such as freestanding warrants and embedded conversion features on convertible debt instruments that
are not afforded equity classification. These instruments are required to be carried as derivative
liabilities, at fair value, in our consolidated financial statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative financial instruments consist of financial instruments or other contracts that
contain a notional amount and one or more underlying variables (e.g. interest rate, security price
or other variable), require no initial net investment and permit net settlement. Derivative
financial instruments may be free-standing or embedded in other financial instruments. Further,
derivative financial instruments are initially, and subsequently, measured at fair value and
recorded as liabilities or, in rare instances, assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate fair values of derivative financial instruments using various techniques that are
considered to be consistent with the objective measurement of fair values. In selecting the
appropriate technique, we consider, among other factors, the nature of the instrument, the market
risks that it embodies and the expected means of settlement. For less complex derivative
instruments, such as freestanding warrants, we generally use the Black Scholes Merton option
valuation technique, adjusted for the effect of dilution, because it embodies all of the requisite
assumptions (including trading volatility, estimated terms, and risk free rates) necessary to fair
value these instruments. For embedded conversion features we generally use a lattice technique
because it contains all the requisite assumptions to value these features. Estimating fair values
of derivative financial instruments requires the development of significant and subjective
estimates that may, and are likely to, change over the duration of the instrument with related
changes in internal and external market factors. In addition, option-based techniques are highly
volatile and sensitive to changes in the trading market price of our common stock. Since derivative
financial instruments are initially and subsequently carried at fair values, our income or loss
will reflect the volatility in changes to these estimates and assumptions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our derivative liabilities are significant to our financial statements for the year ended June
30, 2010. The magnitude of derivative income (expense)&nbsp;reflects the following:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The market price of our common stock, which significantly affects the fair
value of our derivative financial instruments, experienced material price fluctuations. To
illustrate, the closing price of our common stock decreased from $0.67 on June&nbsp;30, 2009 to
$0.39 on September&nbsp;30, 2009 and then to $0.25 on December&nbsp;31, 2009. The closing price of
our common stock then increased to $0.39 on March&nbsp;31, 2010 and increased further to $0.51
at June&nbsp;30, 2010.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Convertible Debt Instruments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We issued convertible debt in September and October&nbsp;2007, November and December&nbsp;2009 and
January and February&nbsp;2010. We review the terms of convertible debt and equity instruments that we
issue to determine whether there are embedded derivative instruments, including the embedded
conversion options that are required to be bifurcated and accounted for separately as derivative
instrument liabilities. Also, in connection with the sale of convertible debt and equity
instruments, we may issue freestanding options or warrants that may, depending on their terms, be
accounted for as derivative instrument liabilities, rather than as equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When the embedded conversion option in a convertible debt instrument is not required to be
bifurcated and accounted for separately as a derivative instrument, we review the terms of the
instrument to determine whether it is necessary to record a beneficial conversion feature. When
the effective conversion rate of the instrument at the time it is issued is less than the fair
value of the common stock into which it is convertible, we recognize a beneficial conversion
feature, which is credited to equity and reduces the initial carrying value of the instrument.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When convertible debt is initially recorded at less than its face value as a result of
allocating some or all of the proceeds received to derivative instrument liabilities, to a
beneficial conversion feature or to other instruments, the discount from the face amount, together
with the stated interest on the convertible debt, is amortized over the life of the instrument
through periodic charges to income, using the effective interest method.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Revenue Recognition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We ship the majority of our product directly to the consumer via UPS and receive substantially
all payment for these sales in the form of credit card charges. Revenue from direct product sales
to customers is recognized upon passage of title and risk of loss to customers when product is
shipped from the fulfillment facility. Sales revenue and estimated returns are recorded when
product is shipped. The Company&#146;s return policy is to provide a 30-day money back guarantee on
orders placed by customers. After 30&nbsp;days, the Company does not issue refunds to direct sales
customers for returned product. In the network marketing sales channel, the Company allows
terminating distributors to return unopened unexpired product that they have purchased within the
prior twelve months, subject to certain consumption limitations. To date, returns from terminating
distributors have been negligible. The Company has experienced overall monthly returns of
approximately 3% of sales. Our return rate for sales directly to consumers, which excludes sales
through our network marketing channel is approximately 1% of sales based on historical experience
and our return rate for sales through our network marketing channel is approximately 4% of sales
based upon the Company&#146;s historical experience and network marketing
industry  experience. As of June&nbsp;30, 2010
and June&nbsp;30, 2009, the Company&#146;s reserve balance for returns and allowances was approximately
$343,900 and $68,500, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Shipping and Handling</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shipping and handling costs associated with inbound freight and freight out to customers
including independent distributors are included in cost of sales. Shipping and handling fees
charged to all customers are included in sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Research and Development Costs</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company expenses all costs related to research and development activities as incurred.
Research and development expenses for the years ended June&nbsp;30, 2010 and 2009 were $392,691 and
$224,366, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Advertising Costs</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company expenses advertising costs as incurred. The Company expensed the cost of producing
commercials when the first commercial ran. Advertising expense for the years ended June&nbsp;30, 2010
and 2009 were $21,982 and $573,145, respectively. The significantly lower advertising costs in
fiscal year 2010 were a result of the change in marketing strategy and sales channel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Stock-Based Compensation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company began using the fair value approach, effective beginning in the first quarter of
fiscal 2007, to account for stock-based compensation, in accordance with the modified version of
prospective application as prescribed by accounting guidance on stock compensation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company adopted and the shareholders approved the Company&#146;s 2007 Long-Term Incentive Plan
(the &#147;Plan&#148;), effective November&nbsp;21, 2006, to provide incentives to certain employees, officers,
directors and consultants who contribute to the strategic and long-term performance objectives and
growth of the Company. A maximum of 10,000,000 shares of the Company&#146;s common stock can be issued
under the Plan in connection with the grant of awards. Awards to purchase common stock have been
granted pursuant to the Plan and are outstanding to various employees, officers, directors,
Scientific Advisory Board (&#147;SAB&#148;) members and independent distributors at prices between $0.21 and
$0.76 per share, vesting over one- to three-year periods. Awards expire in accordance with the
terms of each award and the shares subject to the award are added back to the Plan upon expiration
of the award. As of June&nbsp;30, 2010 there were awards outstanding, net of awards expired, for the
purchase in aggregate of 8,535,731 shares of the Company&#146;s common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In certain circumstances, the Company issued common stock for invoiced services, to pay
contractors and vendors and in other similar situations. In accordance with accounting guidance on
stock compensation, payments in equity instruments to non-employees for goods or services are
accounted for by the fair value method, which relies on the valuation of the service at the date of
the transaction.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->F-13<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- xbrl -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation expense was calculated using the fair value method during the fiscal years
ended June&nbsp;30, 2010 and 2009 using the Black-Scholes option pricing model. The following
assumptions were used for options and warrants granted during the years ended June&nbsp;30, 2010 and
2009:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>risk-free interest rate of between 2.01 and 3.52&nbsp;percent in fiscal 2010, and between 1.15
and 3.86&nbsp;percent in fiscal 2009;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dividend yield of -0- percent in fiscal 2010 and 2009;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>expected life of 3 to 6&nbsp;years in fiscal 2010 and 2009;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a volatility factor of the expected market price of the Company&#146;s common stock of between
130 and 337&nbsp;percent in fiscal 2010 and 334&nbsp;percent in fiscal 2009.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company uses Staff Accounting Bulletin (&#147;SAB&#148;) 107 guidance to estimate the expected life of
the options. The guidance provides a simplified method for estimating the expected life of the
options. The Company uses this method because it believes that it provides a better estimate than
the Company&#146;s historical data
as post vesting exercises have been limited.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Income Taxes</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes are accounted for under the asset and liability method. Deferred tax assets and
liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax
bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are
measured using statutory tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets
and liabilities from a change in tax rates is recognized in income in the period that includes the
effective date of the change.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;1, 2007, the Company adopted accounting guidance related to accounting for uncertainty
in income taxes, which creates a single model to address uncertainty in income tax positions and
prescribes the minimum recognition threshold a tax position is required to meet before being
recognized in financial statements. The Company recognizes tax benefits from an uncertain
position only if it is more likely than not that the position will be sustained upon examination by
taxing authorities based on the technical merits of the issue. The amount recognized is the
largest benefit that the Company believes has greater than a 50% likelihood of being realized upon
settlement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Loss Per Share</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic loss per share is computed by dividing the net income or loss by the weighted average
number of common shares outstanding during the period. Diluted loss per common share is computed by
dividing net loss by the weighted average common shares and potentially dilutive common share
equivalents. The effects of approximately 75&nbsp;million common shares issuable pursuant to the
convertible debentures and warrants issued in the Company&#146;s private placement offerings,
compensation based warrants issued by the Company and the Company&#146;s 2007 Long-Term Incentive Plan
are not included in computations when their effect is antidilutive. Because of the net loss for
years ended June&nbsp;30, 2010 and 2009, the basic and diluted average outstanding shares are the same,
as including the additional potential common share equivalents would have an antidilutive effect on
the loss per share calculation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Segment Information</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s operations are aggregated into a single reportable operating segment based upon
similar economic and operating characteristics as well as similar markets. The Company&#146;s operations
are also subject to similar regulatory environments. The Company conducts its operations in the
U.S., Mexico and Japan. Substantially all long-lived assets are in the U.S. Revenues by
geographic area are as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000"><B>Years ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues from unaffiliated customers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">U.S. operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,886,008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,141,304</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td></tr>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Japan operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">436,637</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Mexico operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">155,815</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt"><td>&nbsp;</td></tr>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">11,478,460</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,141,304</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->F-14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Comprehensive Income</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income is defined as all changes in equity from &#147;non-owner&#148; sources. The
components of comprehensive income include the total of net income and currency translation
adjustments. The change in other comprehensive income for the year ended June&nbsp;30, 2010 was $31,777
from the change in currency translation adjustments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>New Accounting Pronouncements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2009, the Financial Accounting Standards Board (&#147;FASB&#148;) issued guidance which
established the FASB Accounting Standards Codification (the Codification) as the single source of
authoritative accounting principles in the preparation of financial statements in conformity with
GAAP. This guidance also explicitly recognized rules and interpretive releases of the Securities
and Exchange Commission (&#147;SEC&#148;) under federal securities laws as authoritative GAAP for SEC
registrants. This guidance was effective for financial statements issued for periods ending after
September&nbsp;15, 2009
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Standards Implemented</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective January&nbsp;1, 2009, the Company adopted the fair value measurement provisions as
required by the Fair Value Measurements and Disclosure Topic of the Codification, as it relates to
the measurement of nonfinancial assets and liabilities on a non-recurring basis. The adoption of
these provisions did not have an impact on our Consolidated Financial Statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective January&nbsp;1, 2009, the Company adopted enhanced disclosures about how and why we use
derivative instruments, how they are accounted for, and how they affect our financial performance
as required by the Derivatives and Hedging Topic of the Codification.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective June&nbsp;30, 2009, the Company adopted the subsequent event provisions of the
Codification. These provisions provide guidance on management&#146;s assessment of subsequent events.
The adoption of these provisions did not have an impact on the Company&#146;s Consolidated Financial
Statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective January&nbsp;1, 2010 the Company adopted Accounting Standards Update (&#147;ASU&#148;) 2010-06,
<I>Improving Disclosures about Fair Value Measurements. </I>The ASU amends FASB Codification Topic 820,
Fair Value Measurements and Disclosures, and requires additional disclosures regarding fair value
measurements.
</DIV>
<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 3 &#151; Convertible Debentures</B>
</DIV>
<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>2007</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;26, 2007 and October&nbsp;31, 2007, the Company issued convertible debentures in a
private placement offering that bear interest at 8&nbsp;percent per annum and have a term of three
years. The convertible debentures are convertible into the Company&#146;s common stock at $0.20 per
share during their term and at maturity, at the Company&#146;s option, may be repaid in full or
converted into common stock at the lower of $0.20 per share or the average trading price for the 10
days immediately prior to the maturity date on September&nbsp;26, 2010 and October&nbsp;31, 2010. The
Company intends to convert the remaining debentures upon maturity. The Company also issued warrants
to purchase shares of the Company&#146;s common stock at $0.30 per share in the private placement
offering.
All warrants issued in the offering were subsequently redeemed by the Company in fiscal 2009.
As of June&nbsp;30, 2010 all amounts are classified as current and all amounts are due in
fiscal 2011. Details of the issuances are in the table below:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Discount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Face</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortized at</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Net Value at</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Debt</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Face Value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Discount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Date Issued</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Issued</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Discount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Converted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Converted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">September&nbsp;26, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,075,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(937,510</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(400,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">231,415</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">566,332</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">535,237</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">October&nbsp;31, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">415,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(378,235</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(165,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">129,078</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">166,281</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">167,124</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Totals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,490,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,315,745</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(565,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">360,493</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">732,613</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">702,361</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010 the convertible debentures are convertible into 4,625,000 shares with a
value as of June&nbsp;30, 2010 of $2,358,750 which exceeds the principal value by $1,433,750. Prior to
conversion or repayment of the convertible debentures, if (i)&nbsp;the Company fails to remain subject
to the reporting requirements under the Exchange Act for a period of at least 45 consecutive days,
(ii)&nbsp;the Company fails to materially comply with the reporting requirements under the Exchange Act
for a period of 45 consecutive days, (iii)&nbsp;the Company&#146;s common stock is no longer quoted on the
Over the Counter Bulletin Board or listed or quoted on a securities exchange, or (iv)&nbsp;a Change of
Control (as defined in the convertible debentures) is consummated, the Company will be required
upon the election of the holder to redeem the convertible debentures in an amount equal to 150
percent of the principal amount of the convertible debenture plus any accrued or unpaid interest.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company determined that the conversion option in the convertible debentures did not
satisfy the definition of being indexed to its own stock, as an anti-dilution provision in the
convertible debentures reduces the conversion price dollar for dollar if the Company issues common
stock with a price lower than the conversion price of the convertible debentures. Based on
authoritative guidance effective on July&nbsp;1, 2009 the embedded conversion option in the convertible
debentures was a liability as of July&nbsp;1, 2009. The Company has bifurcated the embedded conversion
option from the host contract and accounted for this feature as a separate derivative liability.
The cumulative effect of the change in accounting principle was recognized as an adjustment to
accumulated deficit of $2,728,146.
In addition, $448,619 was reclassified from additional paid-in
capital to derivative liabilities.
As of June&nbsp;30, 2010 the embedded conversion option estimated to be
$1,444,331 is reflected in short-term derivative liabilities on the accompanying consolidated
balance sheet.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the Company has reviewed the terms of the convertible debentures to determine
whether there are any other embedded derivative instruments that may be required to be bifurcated
and accounted for separately as derivative instrument liabilities. Certain events of default
associated with the convertible debentures, including the holder&#146;s right to demand redemption in
certain circumstances, have risks and rewards that are not clearly and closely associated with the
risks and rewards of the debt instruments in which they are embedded. The Company has reviewed
these embedded derivative instruments to determine whether they should be separated from the
convertible debentures. However, at this time, the Company has determined that the value of these
derivative instrument liabilities is not material.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company allocated the proceeds received in the private placement to the convertible
debentures and warrants to purchase common stock based on their relative estimated fair values. The
Company allocated $661,629 to the embedded derivative, which was recorded as a liability, and
$578,185 to the common stock warrants, which were recorded in additional paid-in-capital. The
discount from the face amount of the convertible debentures represented by the value initially
assigned to any associated warrants is amortized over the period to the due date of each
convertible debenture, using the effective interest method.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
interest associated with the convertible debentures totaled $717,370 and $447,932
for the fiscal years ended June&nbsp;30, 2010 and 2009, respectively. Effective interest is accreted to
the balance of convertible debt until maturity. Simple interest paid totaled $86,437 and $104,222
for the fiscal years ended June&nbsp;30, 2010 and 2009, respectively. A total of $256,568 was paid for
commissions and expenses incurred in the 2007 private placement offering which is being amortized
into interest expenses over the term of the convertible debentures on a straight-line basis. As of
June&nbsp;30, 2010 the Company has recorded accumulated amortization of 2007 deferred offering costs of
$214,186.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>2009</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Between November&nbsp;2009 and February&nbsp;2010, the Company issued convertible debentures with an
aggregate principal amount of $4,995,000 that bear interest at 8&nbsp;percent per annum and have a term
of two years. Accordingly, as of June&nbsp;30, 2010, these amounts are recorded as long-term convertible
debt on the accompanying balance sheet. The Company received aggregate net cash proceeds of
$4,035,687,after deducting placement fees of $464,313 and taking into account the conversion of an
outstanding note payable as described below. The convertible debentures are convertible into the
Company&#146;s common stock at $0.20 per share during their term. Subject to meeting certain equity
conditions, the Company has the option to redeem the outstanding principal plus accrued interest
for cash at any time during the term of the debentures. In conjunction with these convertible
debentures the Company issued warrants to purchase an aggregate of 14,997,449 shares of the
Company&#146;s common stock with an exercise price of $0.50 per share and warrants to purchase an
aggregate of 2,035,860 shares of the Company&#146;s common stock with an exercise price of $0.20 per
share. In addition, a note payable to a related party in the amount of $500,000 was converted to a
convertible debenture. Details of the issuances are in the table below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Discount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Face</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortized at</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Net Value at</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Debt</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Face Value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Discount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Date Issued</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Issued</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Discount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Converted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Converted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">November&nbsp;18, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">246,896</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(246,896</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(79,940</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">74,374</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(762</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">December&nbsp;11, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">874,125</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(874,125</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(149,900</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">148,704</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,188</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,992</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">December&nbsp;31, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">254,745</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(254,745</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,799</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,799</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;20, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,255,743</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,255,743</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,380</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,380</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;4, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,849,149</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,849,149</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(119,880</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119,232</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,183</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44,535</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;25, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">514,342</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(514,342</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,070</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,070</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Totals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,995,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(4,995,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(349,720</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">342,310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">128,424</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">121,014</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->F-17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010 the convertible debentures are convertible into an aggregate of 23,226,400
shares with a value as of June&nbsp;30, 2010 of $11,845,464 which exceeds the principal value by
$7,200,184. Prior to conversion or repayment of the convertible debentures, if (i)&nbsp;the Company&#146;s
reporting requirements under the Exchange Act are suspended or terminated, (ii)&nbsp;the Company&#146;s
common stock is no longer quoted on the Over the Counter Bulletin Board or listed or quoted on a
securities exchange, (iii)&nbsp;at any time during the period commencing from the six month anniversary
of the date the debenture was issued and ending at such time that all of the shares of common stock
issuable upon conversion of that debenture may be sold without the requirement for the Company to
be in compliance with Rule&nbsp;144(c)(1) and otherwise without restriction or limitation pursuant to
Rule&nbsp;144, if the Company shall fail for any reason to satisfy the current public information
requirement under Rule 144(c) or (iv)&nbsp;a change of control is consummated, the Company will be
required upon the election of the holder to redeem that holder&#146;s convertible debenture in an amount
equal to 130&nbsp;percent of the principal amount of the convertible debenture plus any accrued or
unpaid interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company determined that the convertible debentures did not satisfy the definition of a
conventional convertible instrument, as an anti-dilution provision in the convertible debentures
reduces the conversion price dollar for dollar if the Company issues common stock with a price
lower than the conversion price of the convertible debentures, subject to specified exceptions.
Based on authoritative guidance effective on July&nbsp;1, 2009 the Company has concluded that the
embedded conversion option in the convertible debentures is required to be bifurcated from the host
contract and accounted for this feature as a separate derivative liability, at fair value, in its
financial statements. In addition, the Company has determined that the warrants issued in
conjunction with the convertible debentures are required to be carried as derivative liabilities,
at fair value, in its financial statements, due to certain anti-dilution provisions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the Company has reviewed the terms of the convertible debentures to determine
whether there are any other embedded derivative instruments that may be required to be bifurcated
and accounted for separately as derivative instrument liabilities. Certain events of default
associated with the convertible debentures, including the holder&#146;s right to demand redemption in
certain circumstances, have risks and rewards that are not clearly and closely associated with the
risks and rewards of the debt instruments in which they are embedded. The Company has reviewed
these embedded derivative instruments to determine whether they should be separated from the
convertible debentures. However, at this time, the Company has determined that the value of these
derivative instrument liabilities is not material.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company allocated the proceeds received in the private placements to the embedded
derivative and warrants based on their estimated fair values. As a result, the Company recorded
$6,022,300 to the embedded derivative and $4,752,789 to the warrants, which were recorded as
liabilities. The discount from the face amount of the convertible debentures represented by the
value initially assigned to any associated warrants and embedded derivative is amortized over the
period from the date of issuance to the due date of each convertible debenture, using the effective
interest method. As the total discount exceeded the face value of the
debt by $5,105,742 the
Company recorded interest expense of $5,105,742 and recorded deferred offering costs related to placement
agent warrants of $674,347.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The warrants were valued using the Black-Scholes Merton valuation technique, adjusted for the
effects of dilution using trading market values of between $0.21 and $0.38, a term of 5&nbsp;years,
volatility of between 146% and 161%, risk free rates of between 2.21% and 2.69% and a dividend
yield of zero. The embedded derivatives were valued using a Lattice model using trading market
values of between $0.21 and $0.38, a term of 2&nbsp;years, volatility of between 159% and 162%, risk
free rates of between .77% and 1.14% and a dividend yield of zero. In addition, the Company
estimated the probability of new issuances below $0.20 using the Black-Scholes Merton model. As
of June&nbsp;30, 2010, the embedded conversion option is estimated to be $6,550,035 and is recorded in
long-term liabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
interest associated with the convertible debentures totaled $470,734 for the year
ended June&nbsp;30, 2010. In addition, the Company recorded $5,094,905 of interest expense for the year
ended June&nbsp;30, 2010 due to excess fair value of the derivative liabilities in excess of proceeds
received. Effective interest is accreted to the balance of convertible debt until maturity. Simple
interest paid was $78,908 for the year ended June&nbsp;30, 2010. The Company incurred an aggregate of
$1,138,660 in commissions and expenses in connection with the 2009 private placement offerings,
$464,313 of which was paid in cash and the balance of which was reflected in the issuance of
warrants with a fair market value of $674,347. The $1,138,660 in commissions and expenses is being
amortized into interest expense over the term of the convertible debentures. As of June&nbsp;30, 2010
the Company has recorded accumulated amortization of deferred offering costs of $311,235.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->

<!-- xbrl,n --><DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 4 &#151; Capital Leases</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010 the Company purchased the assets acquired under a capital lease. As of
June&nbsp;30, 2009 the present value of net minimum lease payments under the capital lease was $41,490.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 5 &#151; Line of Credit</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company established a line of credit to borrow up to 80% of cash and marketable securities
up to $580,000. The line is collateralized by the Company&#146;s cash and marketable securities. The
interest rate charged through June&nbsp;30, 2010, 3.00&nbsp;percent, is 0.25&nbsp;percentage points below the
published Wall Street Journal Prime Rate, which was 3.25&nbsp;percent as of June&nbsp;30, 2010. As of June
30, 2010, the Company has borrowed $433,985 including accrued interest from the line.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 6 &#151; Stockholders&#146; Equity</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended June&nbsp;30, 2010, the Company issued common stock and warrants in a private
offering, resulting in gross proceeds to the Company of $904,283. The Company sold
to participants in the offering an aggregate of 2,583,668 shares of common stock and warrants to
purchase an aggregate of 516,724 shares of common stock. These warrants are exercisable for a
period of five years from the date of issuance at an exercise price of $0.50 per share. During the
year ended June&nbsp;30, 2010 the Company issued 2,848,600 shares of common stock as a result of
conversions of convertible debentures, 809,453 shares of common stock as a result of the exercise
of options and warrants and 1,284,500 shares of common stock for services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company granted to certain of its distributors 1,160,000 shares of restricted stock that
are subject to vesting based on continuing service for the Company. The shares of restricted stock
are also subject to restrictions on assignment and transfer. The share grants were in payment for
commitments made in fiscal 2009. The Company recorded an expense of $320,000 associated with this
issuance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March and April of 2009 the Company issued and sold to accredited investors an aggregate of
17,500,000 shares of common stock and warrants to purchase the same number of shares of common
stock. The offering occurred in three closings:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>March&nbsp;16, 2009</U>: The issuance of 3,925,000 shares of common stock of the Company at
a purchase price of $0.20 per share and warrants exercisable for 3,925,000 shares of common
stock with an exercise price of $0.50 per share. Gross proceeds received amounted to
$785,000. Total cash fees for this offering were $78,500.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>March&nbsp;26, 2009</U>: The issuance of 9,115,000 shares of common stock of the Company at
a purchase price of $0.20 per share and warrants exercisable for 9,115,000 shares of common
stock with an exercise price of $0.50 per share. Gross proceeds received amounted to
$1,823,000. Total cash fees for this offering were $182,300.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>April&nbsp;6, 2009</U>: The issuance of 4,460,000 shares of common stock of the Company at a
purchase price of $0.20 per share and warrants exercisable for 4,460,000 shares of common
stock with an exercise price of $0.50 per share. Gross proceeds received amounted to
$892,000. Total cash fees for this offering were $39,200.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s Articles of Incorporation authorize the issuance of preferred shares. However,
as of June&nbsp;30, 2010, none have been issued nor have any rights or preferences been assigned to the
preferred shares by the Company&#146;s Board of Directors.
</DIV>

<!-- xbrl,n --><DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 7 &#151; Stock Option Grants and Warrants</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Option Grants</U> &#151; In accordance with accounting guidance on stock based
compensation, payments in equity instruments for goods or services are accounted for by the fair
value method. For the fiscal years ended June&nbsp;30, 2010 and 2009, stock based compensation of
$2,659,915 and $1,454,249 respectively, was reflected as an increase to additional paid in capital.
Of the $2,659,915 stock based compensation for the fiscal year ended June&nbsp;30, 2010, $1,131,657 was
employee related and $1,528,258 was non-employee related. Of the $1,454,249 stock based
compensation for the fiscal year ended June&nbsp;30, 2009, $824,974 was employee related and $629,275
was non-employee related. As of June&nbsp;30, 2010 the unrecognized expense for the options and warrants
outstanding is $148,233.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the fiscal year ended June&nbsp;30, 2009, the Company granted warrants and options to
consultants for services rendered, In accordance with accounting guidance on stock compensation,
payments in equity instruments to non-employees for goods or services are accounted for by the fair
value method, which relies on the valuation of the service at the date of the transaction, or
public stock sales price, whichever is more reliable as a measurement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company granted stock options to various employees, directors and independent distributors
of the Company during the year ended June&nbsp;30, 2010. The options granted the right to purchase
shares of the Company&#146;s common stock at prices between $0.25 and $0.70 per share. The Company
granted options to purchase shares of the Company&#146;s common stock during the year ended June&nbsp;30,
2009 at prices between $0.21 and $0.75 per share. The options are not transferable and expire on
various dates through June&nbsp;9, 2020.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following is a summary of stock option activity for the years ended June&nbsp;30, 2010 and 2009:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average Remaining</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Exercise Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Contractual Term</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding and exercisable, June&nbsp;30, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,397,116</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.45</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9.22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Granted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,652,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.62</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9.73</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercised</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(15,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8.37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Forfeited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(601,693</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.57</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired or Cancelled</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(24,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3.37</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding and exercisable, June&nbsp;30, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,408,423</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.55</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9.23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Granted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,840,001</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.42</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9.34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercised</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(35,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Forfeited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,517,693</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.65</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired or Cancelled</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(160,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8.85</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding and exercisable, June&nbsp;30, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,535,731</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8.39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->F-20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrants</U> &#151; At June&nbsp;30, 2010, warrants to purchase an aggregate of 38,580,294 shares
of the Company&#146;s common stock were outstanding. The warrants granted during year ended June&nbsp;30,
2010 are at exercise prices ranging between $0.20 and $0.50 with a weighted average exercise price
of $0.46 and expiration dates ranging from March&nbsp;31, 2012 to February&nbsp;4, 2015.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At June&nbsp;30, 2009, warrants to purchase an aggregate of 22,452,644 shares of the Company&#146;s
common stock were outstanding. The warrants granted during year ended June&nbsp;30, 2009 are at exercise
prices ranging between $0.11 and $0.50 with a weighted average exercise price of $0.49 and
expiration dates ranging from September&nbsp;19, 2011 to June&nbsp;30, 2012.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants to purchase 820,000 shares of the Company&#146;s common stock were granted to various
consultants for science, public relations, network marketing and advertising services rendered to
the Company during the fiscal year ended June&nbsp;30, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following is a summary of the warrants granted for the years ended June&nbsp;30, 2010 and 2009:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Warrants</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding and exercisable, June&nbsp;30, 2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,275,080</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Granted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,790,128</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cancelled</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercised</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,128,564</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(484,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding and exercisable, June&nbsp;30, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,452,644</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Granted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,961,602</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cancelled</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,537,858</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercised</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(832,864</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(463,230</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding and exercisable, June&nbsp;30, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38,580,294</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As of June&nbsp;30, 2010 the Company has classified 17,500,000 warrants issued in conjunction with the
2009 private placement of common stock as a long-term derivative liability. The Company has
estimated the fair value of the liability at June&nbsp;30, 2010 as $3,888,890 using the Black-Scholes
Merton model with the following assumptions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>risk free rate of 0.61&nbsp;percent;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dividend yield of -0- percent in fiscal;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>expected life of 1.74 to 1.79&nbsp;years;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a volatility factor of the expected market price of the Company&#146;s common stock of
between 150 and 155&nbsp;percent.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As of June&nbsp;30, 2010 the Company has classified 17,010,862 warrants issued in conjunction with the
2009 and 2010 convertible debentures as a long-term derivative liability. The Company has
estimated the fair value of the liability at June&nbsp;30, 2010 as $6,684,195 using the Black-Scholes
Merton model with the following assumptions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>risk free rate of 1.79&nbsp;percent;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dividend yield of -0- percent in fiscal;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>expected life of 4.44 to 4.73&nbsp;years;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a volatility factor of the expected market price of the Company&#146;s common stock of 144
percent.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">




</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->F-21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 9 &#151; Income Taxes</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2010, the Company had a net operating loss (&#147;NOL&#148;) carry-forward of
approximately $14,900,000. As of June&nbsp;30, 2009, the Company had a net operating loss (&#147;NOL&#148;)
carry-forward of approximately $14,500,000. The NOL may be offset against future taxable income, if
any, through the year ended June&nbsp;30, 2030. A portion of the net operating loss carryforward begins
to expire in 2011, is subject to review by the Internal Revenue Service, and may be subject to U.S.
Internal Revenue Code Section&nbsp;382 limitations. The income tax expense (benefit)&nbsp;for the years ended
June&nbsp;30 consists of the following:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(965,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,444,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Less: valuation allowance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">965,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,444,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income tax provision (benefit)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The effective income tax rate for the years ended June&nbsp;30, 2010 and 2009 differs from the U.S.
Federal statutory income tax rate due to the following:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Federal statutory income tax rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(34.00</TD>
    <TD nowrap>%)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(34.00</TD>
    <TD nowrap>%)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">State income taxes, net of federal benefit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(3.41</TD>
    <TD nowrap>%)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(3.06</TD>
    <TD nowrap>%)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax return to provision true-up</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(0.26</TD>
    <TD nowrap>%)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">1.97</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Permanent differences:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&#151; interest on convertible debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">19.60</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">1.46</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&#151; change in derivative liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.86</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.30</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&#151; stock option compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.59</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.50</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&#151; other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">0.18</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">0.20</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Increase/(Decrease) in valuation allowance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">9.44</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">26.63</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income tax provision (benefit)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of the deferred tax assets and liabilities as of June&nbsp;30, 2010 and 2009 are as
follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred tax assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Federal and state net operating loss carryovers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,677,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,366,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and Development Tax Credits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Contribution carryover</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,400</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred debt offering costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">300</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stock option compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">849,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">381,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property &#038; Equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued vacation &#038; allowance for returns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">175,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred tax asset</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,799,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,819,700</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,700</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Patents and trademarks</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(637,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(685,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in tax accounting methods</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">(54,000</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD nowrap></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property &#038; equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(38,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total deferred liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(691,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(726,700</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net deferred tax asset</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,108,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,093,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Less: valuation allowance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,108,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,093,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred tax liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has provided a valuation allowance for the deferred tax asset at June&nbsp;30, 2010, as
it is unlikely that the realization of the tax benefit of the net operating loss carryforward will
be utilized in the foreseeable future. The valuation allowance increased by
approximately
$1,015,000 for the year ended June&nbsp;30, 2010 and the valuation allowance increased by approximately
$2,444,000 for the year ended June&nbsp;30, 2009.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has adopted accounting guidance for uncertain tax positions which provides that in
order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of
sustaining the position, and the measurement of the benefit is calculated as the largest amount
that is more than 50% likely to be realized upon recognition of the benefit. We believe the Company
has no material uncertain tax positions and have fully reserved against the Company&#146;s future tax
benefit with a valuation allowance and do not expect significant changes in the amount of
unrecognized tax benefits that may occur within the next twelve months. Accordingly, we have not
reserved for interest or penalties. The tax years open for examination by the Internal Revenue
Service include returns for fiscal years June&nbsp;30, 2006, 2007 and 2008 and the open tax years by
state tax authorities include returns for fiscal years June&nbsp;30, 2005, 2006, 2007 and 2008.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 10- Related Parties</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended June&nbsp;30, 2010 one of the Company&#146;s board members earned $224,192 under a
consulting agreement which expired in June&nbsp;2010. The Company paid the board member $150,778 during
the year and as of June&nbsp;30, 2010 owed the remaining $73,414. During the year ended June&nbsp;30, 2009
the Company paid the board member $90,000 under a consulting agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended June&nbsp;30, 2010 one of the Company&#146;s investors made a bridge loan to the
Company for $500,000 at 3% per month interest. Subsequent to making the loan the investor became a
board member and the principal was converted to convertible debt as part of and under the same
terms as the debenture issuance which closed in February&nbsp;2010. The accrued interest was repaid in
cash at that time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended June&nbsp;30, 2010 two of the Company&#146;s board members each made a bridge loan
to the Company for $100,000 plus 10% interest per annum. The loans were repaid in February&nbsp;2010.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 11 &#151; Commitments </B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Corporate Office</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;31, 2008 the Company entered a five (5)&nbsp;year lease in San Diego, California. Pursuant
to the agreement regarding the San Diego lease, we prepaid rent of $7,850. Monthly rent payments
began July&nbsp;1, 2008 and are as follows: $7,850 for July&nbsp;2008; rent is abated during the months of
August, September and October&nbsp;2008, $7,850 per month from November&nbsp;2008 through June&nbsp;2009; $8,125
per month from July&nbsp;2009 through June&nbsp;2010; $8,409 per month from July&nbsp;2010 through June&nbsp;2011;
$8,703 per month from July&nbsp;2011 through June&nbsp;2012; and $9,008 per month from July&nbsp;2012 through June
2013.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March&nbsp;2009 the Company entered into a thirty nine (39)&nbsp;month sublease in South Jordan,
Utah. Pursuant to the agreement, we prepaid rent of $17,256. Monthly rent payments of $17,256 began
March&nbsp;1, 2009 and are as follows: $17,256 per month from March&nbsp;2009 through February&nbsp;2010; $17,773
per month from March&nbsp;2010 through February&nbsp;2011; $18,306 per month from March&nbsp;2011 through February
2012; and $18,855 per month from March&nbsp;2012 through May&nbsp;31, 2012.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent expense totaled $333,220 and $203,693 for the years ended June&nbsp;30, 2010 and 2009
respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future minimum lease payments under the non-cancelable leases are as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year ending June&nbsp;30,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">316,318</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">305,809</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2013</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,094</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total future minimum Lease payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">730,221</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->F-23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- xbrl -->


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Commitments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has made commitments to pay legal fees for several distributors and employees
involved in the Zrii lawsuit. As of June&nbsp;30, 2009, the legal fees incurred on behalf of
distributors and employees were approximately $1,305,569, $786,154 for distributors and $519,415
for employees. In June&nbsp;2010 final payments were made to the law firms owed from the commitments
made in connection with the Zrii lawsuit.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 1px solid #000000"><B>Payments due by period</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15"><B>Less than</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Contractual Obligations</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Total</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>1 year</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>1-3 years</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>3-5 years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Convertible Debt Obligations (subject to conversion to
common stock)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,570,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">925,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,645,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating Lease Obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">730,221</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">316,318</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">305,809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,094</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revolving
line of Credit </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">433,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">433,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,734,486</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,675,303</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,951,089</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,094</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 12 &#151; Interim Financial Results (Unaudited)</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summarizes selected quarterly financial information for quarterly periods during
the years ended June&nbsp;30, 2010 and 2009:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">LIFEVANTAGE CORPORATION AND SUBSIDIARY<BR>
CONDENSED CONSOLIDATED QUARTERLY RESULTS<BR>
(in &#145;000&#146;s except per share data)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Year</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 1px solid #000000"><B>Quarter</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>ended</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Year ended June 30, 2010</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>First</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Second</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Third</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Fourth</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sales, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,858</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,456</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,441</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">11,479</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gross profit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,545</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,044</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,707</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,572</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income (loss)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,865</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(681</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(8,249</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(4,983</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(11,048</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Per common share:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Loss per share, basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.01</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.14</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.08</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.19</TD>
    <TD nowrap>)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Year</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 1px solid #000000"><B>Quarter</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>ended</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Year ended June 30, 2009</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>First</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Second</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Third</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Fourth</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>June 30, 2009</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sales, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,274</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">578</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">655</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,634</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,141</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gross profit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,038</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">451</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">530</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,270</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,289</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income (loss)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(131</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(566</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(3,100</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(5,317</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(9,114</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Per common share:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Loss per share, basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.01</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.02</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.12</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.11</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.23</TD>
    <TD nowrap>)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 13 &#151; Subsequent Events</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has issued 2,247,825 shares of common stock between July&nbsp;1, 2010 and August&nbsp;31,
2010 due to conversions of convertible debentures.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Note 14 &#151; Litigation</B>
</DIV>
<!-- xbrl,body -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;27, 2009, Zrii, LLC (&#147;Zrii&#148;) filed a complaint against the Company and two former
Zrii independent contractors in the United States District Court for the Southern District of
California. The Company&#146;s Lawsuit with Zrii, LLC was completely and permanently settled on December
18, 2009. On that day, the Company and Zrii, LLC executed a Settlement Agreement which, among other
things, (1)&nbsp;released all claims which each party, including associated individuals, of each, had
against one another (2)&nbsp;provided for the dismissal with prejudice of the Lawsuit and (3)&nbsp;called for
the payment of $400,000 by the Company to Zrii, LLC. That
payment was timely made on December&nbsp;18, 2009. The Stipulation of Dismissal of the Lawsuit was
filed with the Court on December&nbsp;18, 2009. The Order of Dismissal with Prejudice was entered on
December&nbsp;21, 2009.
</DIV>
<!-- /xbrl,ns -->

<P align="center" style="font-size: 10pt"><!-- Folio -->F-24<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>a57251exv10w14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w14</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit 10.14
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a57251a5725103.gif" alt="(PAGE 49)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Infinite Fast Start Bonus</B>
<SUP style="FONT-size: 85%; vertical-align: text-top">Personally Enrolled </SUP>: 1-3rd 4th 5th
Also earn $50, and $35 bonuses infinitely deep on qualified Vantage Pack purchases in your
organization.
Purchase a Vantage Pack &#038; qualify to earn an overide on all qualified Vantage Packs within your
organization</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Fast Start Bonus</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>30% to Enroller w/PV between 100-199
40% to Enroller w/ Business Pack and 200 PV
minimum AutoShip*</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Receive 1 share for every 5 personal enrollments at 100 PV.
Royalty Commission / dynamically compressed</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Paid As Rank&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distributor&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro 1 Pro 2 Pro 3 Pro 4 Pro 5 Pro 6 Pro 7 Pro 8 Pro 9 Pro 10</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Minimum Monthly PV** 100 100 100 100 200 200 200 200 200 200 200</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Minimum Monthly OV&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N/A 1,000 2,500 5,000 10,000 20,000 50,000 100,000 200,000 500,000 1,000,000</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Minimum Leg Req. N/A 1 1 2 2 2 2 3 3 3 3</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Maximum % per Leg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N/A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N/A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N/A 80% 80% 70% 70% 60/30*** 60/30*** 60/30*** 40%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>1st 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>2nd 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Level 3rd 9% 9% 9% 9% 9% 9% 9% 9% 9% 9%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>4th 5% 5% 5% 5% 5% 5% 5% 5% 5%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Placement</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>5th 5% 5% 5% 5% 5% 5% 5% 5%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>6th 5% 5% 5% 5% 5% 5% 5%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>7th 5% 5% 5% 5% 5% 5%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>8th 5% 5% 5% 5% 5%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>9th 2% 2% 2% 2%</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Enroller&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gen
1 Gen 2 Gen 3 Gen 4 Gen 5</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>30% Generational&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;you</B>you <B>you&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;you&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;you</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Matching Bonus**** YOU</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><SUP style="FONT-size: 85%; vertical-align: text-top"><B>earn </B></SUP><B>10%</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>earn </B></SUP><B>5% </B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>earn </B></SUP><B>5% </B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>earn </B></SUP><B>5% </B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>earn </B></SUP><B>5%
Earn 10% match on the Unilevel Check of your personal enrollments. Earn additional 5% down 4</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>enrollment generations of personal enrollments. You must enroll 1 person per month with 100 PV in
order to earn the Matching Bonus, through Pro 6.</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>4% of total commissionable sales paid to</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>4% Elite Pool&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;qualified Pro 7 through Pro 10 Distributors.</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">*In order to qualify for the 40% Fast Start Bonus, you must purchase the Vantage Pack. This can be
done at the time of enrollment or via upgrade at a later date.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">**At least 30 PV must be Personal Volume. The remaining can come from your personally enrolled
Preferred Customer&#146;s volume.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">***10% of the OV requirement must come from the equivalent of a third leg.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">****In order to earn a full generational match, you must maintain a minimum autoship of 200 PV. At
least 30 PV must be Personal Volume. The remaining can come from your personally enrolled Preferred
Customer&#146;s volume. If your AutoShip is less than 200 PV, you will earn half of the Matching Bonus.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>The LifeVantage Compensation Plan is new and unique. Any charts, illustrations and stated examples</B></TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>of income under the plan are potential in nature and not based on the actual performance of any
individual.</B></TD>
</TR>
</TABLE>




<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>a57251exv23w1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We consent to the incorporation by reference in the Registration Statement on Form&nbsp;S-8 (Nos.
<U>333-158704</U> and <U>333-144247</U>) of LifeVantage Corporation and subsidiary (the Company)
of our report dated September&nbsp;15, 2010 with respect to the consolidated balance sheets of the
Company as of June&nbsp;30, 2010 and 2009 and the related consolidated statements of operations, changes
in stockholders&#146; deficit and comprehensive income and cash flows for the years ended June&nbsp;30, 2010
and 2009, which report appears in the June&nbsp;30, 2010 annual report on Form 10-K of LifeVantage
Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 59%; margin-top: 6pt">/s/ Ehrhardt Keefe Steiner &#038; Hottman PC
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">September&nbsp;15, 2010<BR>
Denver, Colorado

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a57251exv31w1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 31.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a)<BR>
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I, David W. Brown, certify that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Annual Report on Form 10-K of LifeVantage Corporation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter
(the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s
internal control over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial
information; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrant&#146;s internal control over financial
reporting.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">September
15, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                        /s/ David W. Brown
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">David W. Brown&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President &#038; Chief Executive Officer<br>
(Principal Executive Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a57251exv31w2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;31.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a)<BR>
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I, Carrie E. Carlander, certify that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Annual Report on Form 10-K of LifeVantage Corporation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter
(the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s
internal control over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial
information; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrant&#146;s internal control over financial
reporting.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">September
15, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                        /s/ Carrie E. Carlander
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Carrie E. Carlander&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Financial Officer<br>
(Principal Financial Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a57251exv32w1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv32w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 32.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the filing of this annual report on Form 10-K of LifeVantage Corporation
(the &#147;Company&#148;) for the period ended June&nbsp;30, 2010, with the Securities and Exchange Commission on
the date hereof (the &#147;Report&#148;), I, David W. Brown, President and Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date:
September 15, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>

<TD colspan="3" style="border-bottom: 1px solid #000000" align="left">     /s/ David W. Brown
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">David W. Brown&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President &#038; Chief Executive Officer<br>
(Principal Executive Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>a57251exv32w2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv32w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 32.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the filing of this annual report on Form 10-K of LifeVantage Corporation
(the &#147;Company&#148;) for the period ended June&nbsp;30, 2010, with the Securities and Exchange Commission on
the date hereof (the &#147;Report&#148;), I, Carrie E. Carlander, Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date:
September 15, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">     /s/ Carrie E. Carlander
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Carrie E. Carlander&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Financial Officer<br>
(Principal Financial Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>a57251a5725101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a57251a5725101.gif
M1TE&.#EAPP$3`>8``$N#NDJ"P8%BH\)/3[A23I"0CWQFI%1^L6]O;^_O[T]/
M3\S+S-O:VZ>GIYN\5RPK+(RISH)OGGUDFP8&!V$I*/3T].+BXKFYN<'!P=NB
MHJBO9_K[^RQ&;*O"W<K9ZVY9B?[^^2TN36J.O$<U7.[/S:!+2M?C\/O]_:*X
M9NOR^%1#:Z]B;_7Y^TEPG[IV6.+L]7LU,S=<AY^Y6<S;J?GJYV-/>W=%1O/?
MV\^VR;.%6I2`J,=\>_O]^Z24N8Q!/_S\]I>^6/WZ^Z*L?[5:6RL>.OSS\_#W
M^];'VO#UXH9WBJ"7E346%1<F//K[_;?&C/3M]+>:8H2#A/[[_$]^O>#KR/SV
M^.7<Z+QE7104%9RB@SE4>[_1Y??W]X-@INSD[YU`0'Q@H:%M@,V_UT6&O$H?
M'?W]_?___<G'Q_W____]_?W__?_]__W]_ZRLK,_/SV)A8>;FYM/3TS@X..KJ
MZK.SLKBKR!X>'Z^OKYR<G%I:6D1$1.?FY<G)R;FG:DZ!O?___R'Y!```````
M+`````##`1,!``?_@!9N"X,+AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH8X6#708IZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PK,-%F5_R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX]%E9\5H&VCK[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\``PH<2+"@07KGC!TCQ["APX<0(TJ<2+&BQ6P)RZ"YR+&CQX\@0XH<
MV3#C1I(H4ZI<R;*ERV<F7\J<2;.FS9O28N+<R;.GSY\/=0(=2K2H4:)"CRI=
MRK1IR*0=RQR3FDPJ5696LSK3F@S-PC\:OUZC>A69UK#ALJ(U:[6:VK(3_]G]
M.0D6[-FV+\E.=3H1*D>U54^4.=%,Z@G!@\56?>OUK>)ICK]N,,S5VV&KB!?#
M+6=ULN"*C<MB1CSX\LL3&P23YBO1[T6IJ;_"?@SV,&J\RP9OF*R6-&UI65%_
M9FL[-K@R&[A8L)!@N%WGTM!46%XA,T7#ODOK%NSY-TG>@%E#=&VQC*`X7))5
MB.,&3F$X;MPPX++9;(5!#!"?2.`FCG%L)WC5!@)G3+;8"70@$,=@QYW@Q@-8
M%.#<>NU5@R`66%R06$6#S1'?AQ;85@87#2#``&XL#2:(&R$2)EY0Q6@44AE1
MV"$'`\G$(8<=!1Q8`1YZV&''`PC`X6)N;@CY0/\<B&%@AQX58&97;64PL,""
M>B6V@1P3O"%5'`N<N,$<>DR``'B199FF70M@,4$!93UH!QY4^F87@R?<,<$$
M=*29G7Y@GFC7.G\@YM6=CA4@Y*)RF"B8!0^\&5MO?@8'EI5N@'<@'PO,D::,
MN4EU`0([VEC`'(B^=6>J5AT:6E;KM.H8JU*AD1VL]7%$GD513/``CLC$$6D4
MBU6@J*\03H#'D<J4L<">9B9PS`43R!&E=L%5\(8="G"A&FJQH8'``W@,%J27
M^T7Q0`.P^2:B=OJY:]P"=KQ)UQ_TOLG=9=GMEEH;>_:9&&5E\&";<(=5H,<#
M;UP[\&&3EI;='P7L^<#_Q6[J$6("XUZ0FF?O(I;:P>!^?`("W.Z!FU1P"-G`
MMY2*AAH&D6)Q\01V:.COPYCU'!QREV$;'+_MPGLP;R:+J!J#3\5XKT>]_IKC
ML(O%46\>&_!P@0+E.A/'!!A.\/(?U%H[G07>EC&'!7!4P$"9-\ZQ`1S,)0#'
M'"?0/0<7#$2J`',;+">W;<M9@/=@"1B>-]LLV)8X=1L@DV\!]TX^)N#+P;';
M8<JQ34?`)ZP=8AF/<[%;YVB[[3<#<Z!!=P73V6VX86?3]UG%6(1(8KURR`T'
M'-(FWAS=C>]'76<CTJV[!7GXNL#HR7#!WYX%H%V:Z$:NO%^D>K213@-Z7,"=
M_^AX[S:=W*+O!K3RJ+)`=P(LD+[<;G1O\'AS<S-'&@OW&];YY150ATAV59&H
M`>L/PIH`L=@2!S<A((#^BAQ6GJ6`YEF+;+ZJP!W<=`:I-$\/&(#6GO)@`05@
M(0IERL,)N)0'@(GP#7-@(7(8@``W^:H`D^E5'AJPIPAEK0U<LE@;U)$D>RG#
M<@I08*]PQJX35"`*;CHAZ.`VF#:X24,8*-.>HL!#$>IAA2<LTQO*]`!CL"")
M6!#4,7`WNC+@84\,@-2;RE"Q*-00"ZG!0Q#E0`?3;2`.>8CB&^A@0XNEIRI)
M%.$=QG0LG"$@;8&AU@0T)!Q_P0%E%HM"`/6D@`;42_^!4>*8#1^0@+Z922.X
MBV.D+!!$/3"@`&Z2`_Y.@(=(5:L!DWD6CR)%)^]4A(`3H9&O#IC`!=HE`5J4
M@\=.8+IFH,$-$]##YR:PR+)5@)`36(`'HWF&0G:IA#@;81FX]`8KBA`!,>S2
M"1@01!MB85E+!-N>[,"`#?3*FVTH0Q$I=\1ZP2F1\O25M.(I0@TE40Y2,><%
M&%"OL'72FWH8IZ_V]`8\8,@-J''3&U;#1L-LP$U1D*.$*I8L++C1FW9X63K!
MYL!/@LU:LFD>M+!`AP2\H8?0\I)L$I#$,OJL`K84810VH*>9[@D#-I6GFRQ@
M2@0(AHVF%*%4J]6<-^(4"QC_V,"SPJDLIH$$F!(1IM2"136S'`:(T-+#LB2X
M##0\2P]SN"DIK8E-;9;A@W,[:`*DA\8\%(`.*YP`UA+@MPI(CYQE0`#.VE"!
M"W!)#G!8XAO@T(9ZX6$#9RC`!<Y1KR@\TY^5\V<9T!B%!%CT37"(E!Q8I,4^
M'70=YCQ%--'FA@M48`Y^VVM@L:``S5I`C">09!N6T='!<`&D(J7CGO00!3QP
MX::3)=,$%%"!;F+A@7/8X7.KQ0"'^8\!U#-=`S!46@8TSPX8Q0Q/H\F;9-`2
M9WA(@(Y\Y89IYL%*#F0G32M@6M69R2MLE&/.X'!3,P$2;'#@@F*IR[PN)6"K
M1"H`_Y8&Z+09&7!J"CS0!A@0!3FXR0YM8%97WCH'4S:`KFZRJP7W<U!OK3</
MS0$+8C<0J3P@CIQ;4B<+-I#*)5I@P[RL$LK"IL#/&C$9DQNMKS37)@4RP$TX
M/$$775LMV+H)`Y#"0AZBL`!I`76Z`92H`J3EQ%[)P0*X<X\RBIM1,R47=YDJ
M0P5BB8!QX6R[-T(.[,IPTS.7X9)U1@`?3F"!/5WV!'*M3AE".($VX"'0>(!#
M$K_H'"ZD4-%3GB8&G%BO(ID9`2RJ4J00`&"P+6?4N[EG/>\)!U/JH<Z/M0`?
M#!T_%'D$K!$1*S'+RA;8S`$/]7H`6Y7AUFAZJF(*T).UZO^ZS8BN5P[T6>\;
MZ#.8&?OM,`D@YPE&#30E@(W#>Y*6*9VK6%]]TK/[#.T<#RHW-T#YR?K*4\"4
M+`<K3P`#7&B#'J(8A3E\.0_78N'2")FAFZJ0N*:V"AR0&RDX=90'7)@JSK3%
M77!)I<]&^AJTR@4'0P^F>0^P#:,;`-"_Z;4L%2#GM5QX@6EVL`+U:A@#WA#%
M&S6UU+F3HU-/H&H6W-,""93J`^"P57;5RI<4P35$E(L%H],1RB.:'Q<T!QO%
MVB'J<)`-B=46J3YK,,5RGK036TRZ)+X!/#+<]G1ME6W!JOWLS*P8/9<H;EX6
M$88+&)8^1?N5)+/;6>\&:1E8X$+_P!Y4,..]]V`JT(::T2'E@@U@8&ULE3DD
M,0]<RB?"L4!U'L/QS0F7\YYZ6P`\%*`!+.@SEN1\`I#_>`Y**$#L3]1Q94T&
MY/31VIY:'GLE7"`!%9ND:M`PAW0V##D\S%!1.\B%F%>'"V<HL(FX;4]3ZUPJ
M/^<Y@A-(^@*<O@);+=?1*6R,IW$$#19PTP,DK"Z!/CVE?7O#E2[`[1K:X0Q5
M@:8>R)SX:C7V:GQ08,Z&1G3`.F:'=H+E%9'R``ME?(@&-E'@!L<R5'0G:LJ2
M+WIP!E"D0'LW1WTG6G_79`70=G-R`9^D(<U#4PU@2Q<0!Q'H!F^$!7?P92!6
M3P)7%2Z4_W!=@0:X<P%NP`<UY&`B=0+%Q063A@'Q40!W4`;8I`=Q<`8*H`0/
MB`5*4$]?\2BCQP>FY29YX`9WP"7=<B1280'!%H$+,"YW@#N"YDEFHD%[\G(Q
M9P%1@(2,A@"LY"L8L($YQVW"E#O:QWE)]0`?4@`8X"P>AW06H70/(6>8A"'J
MMVF)13VFY(B^LB")-%QFL76#)U,/<%L%A@5#4F5<$'Q8\`;@]`8\8!6(=3(]
MA$Z(A0%<XHA8D&<5.&YS4&Z@V%D=""<?N&[5XBDB>`*5Q5)ZP"6`10<-93-7
MA@&R.%WSL42\-7FRP5"C9S!=H5PL)4A&,H1L=@8UXX@X5`&!E/^-+Y-XL_@G
M;0<V=&`!!68'ZB<^I,$Y!6!+0H*'O]5#ZG<&\C8!S!>''A8V.;,!IX4A-7-J
MI]2'QL!J&T`SV8@%(39K786(OU1A("$5"4`'>?``0_(&'I-0#R`'9\`%&'DQ
M1))5%/.1<5`5PO(&TC(9;J``#T!=&_"2%\-%#V!CZS0NY!)7#Q`%A"$5,$EJ
M^J23#9``&8D`R!%]&BD'4>`?='0Q4<(`,/DR%J"3"*`N2E`&.D(N9;&5Y3(N
M8Z:5<L"5/S*6<G"&#$@Z\_@`&?@&#W`&OT6233D957DQY1*4LK%=C>958%%+
M)'F3D288<+`PY5)+D-49%Y"1%R-HA\'_86.YD^FRF&AB&%N#DNND+A?S!GR@
M:*/A1&>@DVPY@T,IEVY0'?0GB",REOV&F3%)!Y-Q29EY`<6X'#`9!8.A!!^I
M,H:)-UR0F"3Y!B<B+`^03^;W$8HH$24C%J7A7O["`U61&LU2&5ZQ&\RI'P:"
M#+;B4<X!-%.!')-A*^$RG>IC5FSU%L*QG&;Q'^09%M2)#+>1GI,BAIOCG5/1
MG&*Q&[&R,G@69KD10=>YGM,)'85R`JG8#./)G-[!G<S9GM`P&#L&'>>I#.&B
M&TBS8\JI/KKA45-A<:KBGK:!H,5IG!0Y$N$Q%W-!%R7:&-&Q%?4A%]CY%802
MH[7BHG(1HS'Z_PPJVE8;02A8\32U<J+/H!&QLA&@8J,Z6AA[T'6;TU8=:J+P
M`*2]1AN@LH-02FPG01?M4`T[:GZ;@1=&6ABYLJ5;"J8M&J(=<9RY)IU841G.
ME*78R:,'LA"/02AE:J7$UA5O^C3NL(-P2J5F0:2YDJ=L$9UGX:)5BJ6&NF@?
MV4$BIAEE<2]P"J=L.@U]^J95.JDL:JF$&BI4P:,MFAB`2J1ZNJ=1:J65^E4C
M*A(E2J9P<:K4$!IFP:0+8::&ZJ?74*L-^J?,X*IP<72S^JJ%P07%YRV'8J6K
M2@V86J7;X*8KBJ.C:GZGFI^#6A?(:FLK@:8ODJW:NJU+@:W<^JW@&O^N-.&M
MXEJNYGJNMY:JZ(J<0AHKGV&FD&&MVN`8I%&<`Y.LG"&@#?HJRODS;0$S<[$T
M2R.1ZTH.Y%JPV*`6[*`?W$`9QU$K^I&LPF$P&S(6!-JH07JO93&P0=,9?W(;
M^(JP#G&P(NL6C!$@?(D-)3)4#RLT05,8GVF'\AH->5.:)HL<#ANEV+(T(X,9
MDZ*>)1L1)!NTT[`!B9D'2/L&_G$8W*!8(=>R'(:T49`?N?)>V32ST*`P[U0-
MR0&$2(L'%9`,/(:T"@(><?`&>?`&#>`I@Q%94AMG1-L:ZAJWXN!&4A4AME,I
M]ZH:J>&TLY$8M_(64?`&!:!HJG$&+H4S<9#_B@13*U;E!K)B&L@C(LF0`+KH
MKY7!CA#U?`254J83=*.W5WDG0G:PA%A+M]TPM*B[%3&(!^!C:/N1`,FQ5XDA
M/0D@+5EANQL@5XBC6W*6`->"&OS5DL@T6[(K%?FB`&W0!MM2B!O`7_S%&VA@
M57;E1,`;G[\+O!M[#KRI6\/[LL$B!WK0``,"-G=`A%L$;$OF!H_5!C(%MF4R
MOO/H*]1&L*MK#:I[O[D1@PS``V>P)T529YF5!^7"-P60M!AP+<#W!FK+NT:9
M!WU"A&]P)J1S!PP,:@NP+3B3!TXE%=/DFF-R!PFV`(/+P&L;((\K9QJ8MHPE
M&!6``0C`P"/X%=JR_T-,6%%N$,-*VU[(,`<7\&,GL%5*D%364GU8944TA5E^
MLW"2,HH8LGKZ*P[Y&\5FP;_[`<!]PRT`7`8K*$)4:#H;"#;!9AY;)!@]-2)!
MF$E2A5"'P8S3=0=R@QR6)U4(D`#3NR>0V\700L%*X%+W]Q4)L,4D%52]$R".
MJD][T@!\X$^"X6YB<U-VX"VL:`>U)WX7<$6G2\7X.[>:G`UVFT:CN$51-23]
MMH`8@(R5R`?O6&`/\&=;M`X@MV&Q=`&>1(B/10?ZJ!LRY2OQ-28(H`"GL$1G
M<,?9E&/`'(0=!"%X@`%;`[GJ`<`\.$\-L$0X)!NTX[0/QG>.S+PX(T%.R__$
M(.0&!78!L=+)WC#%5&RWT;1O.%-*HU9/GF<'FW8"W?0F3IM5Z]7*M4<L:(![
M2>`K?#`9?!`B9:(`GB(R<S"_(^0[>*``"A!$PVQ5?&""$4('=]!U$H4`OV<Z
M-`S-N(-OU(@`G%H&&T139;#('KC-D.S-OK(!Y295Y%RLYKP-Z!S%ZIQ6635N
MMN&T5,L"4,;3N^&W^^P5L7Q0/[8S!5T^V,$#<$!R`'Q)WC0!?$#,,.C%XM3%
MO'4J'?U?J<0WG28:R$$S)T0?*,V+*MW-R&!U>:,$"J`'$WQ%Y3S3-,W)<HVL
M,5AZ)VR!XA>)OW(Z/SU,@N&WA99A_=S2!V4DDY'_&DE]&^\"9()%!WZ#!P46
MT7O"!U;UD7*0V;9Y'^T7(5M-:FRT3O62!"!PA2<@+->E:/F"`&90!I<\29`,
M!VA@E-72VF/B;^-E!Q80UW6-#36MOY^,(U\Q;H9Q3\0B3/=W3W"2+_J\13,9
M;"X--E*X`:608Z[$+]''`.F03@A@44D<?%,MT>,E@[819W%0'2WS7\_,U::&
M?IVV#*?M89H$,=F%8.*(,W-@3CBT0;;'.E+A)-4R;+WMVW0]X`W*OV5!W,B1
MWEB@!UKT2'/04$$2;+-=)@W^2:V<?F#CX+;'B4@Y&)_3X,4(-@N`R@UN0WR@
MSGS``A;NX&7R8Q_9UB"E_PR!?$H=189F0JU_\#8;K@=M#4-+])$0N`%\8$M!
M`M@PZ>#J)R@&CA$%WN0&ZFUIE.!!9ABP.%-3BQPF:#%W,"23X<8W9#.I`=G0
M0D):^4D1M>``Y2L-P`5<<%K3Q26%2+T;MN9E]`=!!#;H="0UCI2I5"6C?2^@
M"RUE5`%I?$*IH35!54:3D<;3!8]03N#E%^G(R@!W()HT?`%W<"(#DP":?@<*
M015NT`:@?I'D+!6CW@8,8.J5I^D:8A5[0`?K&!P8L+PBW!EG<.ES<`9M("T6
M0.JXNY"VCAB6OKPGPBQ$=0<+P@!M\'ARINEQ4-J5>P'+6^UM<`'T\0>Y?NUI
M@_\X=V#LE#'J=X!O]DOIR?#;YI[NZCZR3[[N[O[NNM+N\#[O],[NDU[O^)[O
M,'+O^M[O_G[.\O[O`C_PRX#N!'_PD6[P"+_PO:WP#/_PG>SP$#_Q]ROQ%'_Q
M1&OQ&+_Q!:OQ'/_QY>KQ(#_RW"KR)'_RXF'R*+_R3*'R+/_R1>'R,#_S/B'S
M-'_S-V'S.+_S,J'S//_SUQKP0#_T3N'S1'_T(LKO2+_TK&'T3/_T<JOT4)\-
M9E#U9L`.D6$&:5#U9=#:7<_U5F'U8F\&4R_I4UKVV##V8&^>:2`%4F$&05/:
M(``"/)`&=K_U5H_VFRSU>D\-:O_W5=\$AR'XMG(K:%#_]2`P]GU/#4X/\G=_
M]X`/]^`2+Y?!#G.?^&*_^-/0^!C?&[?B]5;!`UES^0;3L5(P]V:`^56O^3DA
M]'WO%8+Q`W3/`XQK%6Z_&T%0!1O``BS0!)N3GVWO]H:1^:P/#9Q/\5DA!5(0
M!$'P!%Y@!0P@!G4P_3U0_3T``=@/`1VP_5O@`2^0`D;0!((O^*I1H,4/$ZZO
M]Q;)`#A0!SV@`Q$0`09@``)0__8__P<``'[@!P``"`!34WY^(B(0$!AQ<R=E
M)SQE?Y.4E9:7F)F:FYR=GI^@H:*CI)UG#19E:*6LK:ZOL+&M9F6UM2`_MF9F
M:2!!%5Y'=3TZ$0(28&`"R\S-_P(&`0&%TH75@]6''1T>+RR.MF4;&SR1:6EE
MN^F[LNSM[N_PE*>IJ_'V]_CYF&8@X.3]9:0$><)`#+$(!@R`,>"L(;.$?@(0
MHE:M8C0_@PYDV_+"""1<N6J9*P-"72U]*%.J;#5/U<J7,&-J0G,+1$E^59Y8
MP:%#X4*%0!T*A28Q8L6CT9(J-02!&PLI4FJELWDSG<RK6%&VK)>UJ]=WC\KP
ML%DFB)4ZQ20\3"BAK5JASB`6I7BT&H"[8\9(E':@;],43<8&E&)3G9FOB!.S
MVJJXL6-080,^.=(C@EMF;C._A=N,Z,2ZH.\"P$C(CVB-'4RP",*ZWV&KCV/+
MGL1XMO_MV+6">!%3["=#M6TY"Y?[&73=:Z&G:(2P!;"M/[!O2_=:>[KUKE*\
MH#6F+*%"X>`?1BMN?)K=`*,KWATT!9$'+KIL7I\?LSK]^[$,[ZIUPA'4)W58
M)@%#RQ@P(('A<4:<4>79)=I=1]U%S5T'0*`:2;B`DP8MDN#G(3OV?2BB*.9L
MN,LY_=7R!`Z6)>CB4.,QV.",Y2G7E#B$!53B22/V6$J(/@:9R7Z%H</#!A7P
M=MF+3!9H0$3DT2BE@QA5V`T(:4"U7X="=LD)D%YZ6<M8-_U1!0,]((-@DTUZ
M)N.44TJ8D0@=I/!-B8>%J><E8.[IHUADJAC@@&P6^LR3<\'_J:A1[`W2%`N#
M29&GGW[V2:F(8OEWI@Z&=EI@C'0MVN!H[!4B")TI;/#<I7M:RBI^M@PT:!?*
M+.EI>`N&*FJ#I8J&D84;G##IJUVZ2NQ\MEB15A<#NI70K0FZJ>NNQTWT8$3H
MT?D#",=Z:6RWC^V"!DUB2?$$;VM"VR:B45+K+@0OG)"AL-R"B]^W]BJ6#C@`
M(O1,<.JV":J[!&/DAX4L1%+&.?G>AV_#7XW+CT!>I,D06YL%'"V[;Q9,K0A;
ML)!E&EQ!/-W#)F=5DVXZ'/@3P!J[**W'HI9FU`$=G"#I"2E;AW+/,I%4UA$M
M'^.==S'+S/&T-$\9#0`X)\PET+/]_TSU2V55(09WQ[1U=-(R#]PTM4GA;.?5
MMEF-=DH!;2V`,EUGEB[80RT]-MEEU[FV;&KOW8Y)Z)@1Q!'^8B8W<,O`C(SB
MB"?^MN'1BGVWHE-(<U&%%9#$(3I^=]5WY_GQ<@Y4:1!.Z#)@+-X6&-Q)4(,*
M*KPE@8!J"FB,`!'DCMD'L"^T3!<.Y3JYQQ6FL.TM4X,.T^?*NZ*.0(,+^!`S
M(Q#Q@0$CJ&"`"B%\$$(-M$9`1`A$C(`0^>4;J,+X*B1.Q.LA9!R\Y,.[6Z$1
M/$#%>?/UH>(2_RDQR>`,="",+8,(=AB!`>2@@BZ,0`X2L-[;1E`#`3C0?"%0
M@?AJ4(,1S/_N`\?X`!$D,`(%`N\8#1%>_0HV!0@8(2`\`N!*F"?#4=A"(''H
MR:%2M[J$E,]Z#]">"#/8%A%&0!D?P(+X5)`$ZQ'Q+:P+00@\*+\4TF^%NX):
M!YY2DAK.T'\E\V(\PF(6'3JI@`8*H@I&D,$(5,]Z'/R`'=0"AB1&X`%3C%\&
MOP.\&A"!"+'S(%Q4B$5JW85.+.BB&+4"QD7>XQ$;>((9#P4P[P!2A'90@0@_
M(,+WR1$9`A"A`<KW@0$!TD"/>Y\;RU?%SERQD(J"$,A4Y4A]T+"6G'A$!7I`
M(+6PA4"6U*`*)F"^]X$A!%BH`1BXEXSN"2"(;^E@*2M(0@6J``O_'CQA"NT&
M2U$5!2,B\`#/<'F/6Y+S#^8P`R14):O?M#)Q$E!!#23P`0K2LX3RC!T)UZC!
M[97R7QV4IUNRI\D1@'"0K^SFHMJ3`BF<0!ST.J<LS$G.=$(B?]&KU3O_12@#
M8<QKSD(<`0NH&<W\<FZ'@E+'%+HK%XXC1?62Z"LHBDL3\2`74E#6=V"V36`R
MQ#?/*!#<@NK1`@5U+2X[$(P2Q=*:5>,`(>,!/Q0I4U?0M)8;^@-9GI`FW_&T
M&2#-S%!]][:+`>5BTTL&W)+QK&0,:*AK42G3FNHT$9A@`[OH1U5GVLB]CB*K
M_0A"@)"&PKHM!(U'2VQB'^([[_BF@#Q<_VJ[Z*HH]%CH&S'U*RFNZL@\!<0*
M""&L@L[ZT9*6]&BIXVBS1NJ=KSI)KI0UY*]6$T/-CH*SB\R3&78)3ULUA'?_
MBIUBA]M:2]:`M$>SPSR/\3[)KC2V4I(05,EBVQ_UM;J><(3@Q`!*WSI$A$6T
MWDB;M5H!C7>4\RPM[M[7K.9N$[;0%14`)"("XT4E++Q8!W8U@5LQIDA9<`4/
M>`T`WO6QD9XC]&,]2P@_ZXE/BM8;HO6ZX,GR)1.E,XMO+$F%LQ,$(2J.&$GR
M]EN)_GHQ$E5($Y/D"+OJU<`.N,N@",&@8#N4,HF\(P)Z)9!!5?HQ`LHEXOOF
M1D@-1Q="?CC`"__N&^*PD#@3)J[A#\S``*ZY2(XUR'$-L-`%`\C8#C0>(?<H
MB,WL[3@$"F#OBX',O1HT\;CS8ZJ1CWP:""02(/P9\9/_$&49_B#%$M!F@C[P
M@`&)<,L&N*,FY^A'MTS1#KDSY3R#2(0\1.#'@`SB!HG,S3G3:+YR.H`X!0-)
M/3^YSP"4PA$VL]'?BK?`Y3/H$*NW8`J6,'M@,*:,?WB]]_G1Q1A.J*?K@AZ\
M2`0"J0)(BO;,I^LR^Q)%*%KB4"J4X*R.GJ5,R(U55RM.NK6DI03.ZCZ0VO?*
M>=CEF1``QJ#%A/6#7,\NL;-);!(.<1=RA0+>:AWK#'TGA(<>-2#J?J?_(&&C
M^R@',,UZZBLO<,1;'O/>;R_(HB)IJ^MKJ@WT,9B%;T,5^>`S2@]4526%-#CB
MX;2).'9'0@NH'"'`MQKN9O0-UE:'[=P@EU)[7FB.DZ,<U6@#AV1ZD+3A-H/F
M\(36QW-.(ZCJ+)THY[/*'>,228S+U)<XB<-#(?0_:+T3JN`23<@QM-MI3.8(
MFIVX#PI*CQN<Z769KPA>*)6H`YT=MOA&.+!N"4>H2N^?R+/0E[V)1]"$$ILK
M0XIA'G/%OJY9:_2@]TKHNO85:NEP-\Y\IV`"__`=NW>715A2Y.3LVH(+<ZAM
MX>$`'T?TYZ']X40%$A!#?M0BIX4[^[\7PKT1_\:S>Q2L0?>L9]!.93CS(9=(
M!^C^^>J&7A;]L4`!"A"%!4`&#W%``QWT4`$6!%X.%R@#%Y00A2BT@3^<P,,;
MT#!.=&*I##]80`&2\+B`\7M[C=ZQ!)1KO3]^P,I,@GG(%R'18%?JU'RV]7RP
M8`MG(`<)4`&JP@4;\`?!4H&J(GY<<`)<H``-(`[B('X7*!8LP`5_@`85((&.
M`'YE4`%R@`$54`$/Q049*`DC&"PQJ'X;@`9((A*U@`1.H`%"0'XMT@7Z9G,O
M,F!K%$]SM$9J9$]@=7.3-8`18AHXPQH(J%D*"`OCTH#PL0%GH`!EP``*4`$*
MD`=OT((,(`=1@`<-\/\`;\``=#"&48``;X``&X`!#Q`%:A@'Y:>&&Z""+,@'
M_<$%=9@'!;`!%Z``"*`'<U`!=5B&94!]4=``Z$`25(`",N``,H`"0C!_`!-9
M1E4H^1=/V3-'!`9(/78ZKE4W\"6%H3$:HX%L46%W4]<86_@`TQ<'7X@&%J`'
M&X@'&Y`'2H``=W`"";`!"G`'&W`'>L`'#C@';]`&&."`;2`'+[@!;>"+@"@'
M"%``=]``"L`%%B`'#/``&,`%>(``ZL<%!?`&9<"!%I!ZM?`#3B`#F>@`^(@"
M&I`%48`09(5*3O(L@Z9C"9$[]D1"'.1!\4,HJ^A<<^6*L&@(XG2%?I6%K[#_
MA7+@!HS`!WH0AKZ8C&7P!NJ'`3SP4,EX`MLWC;/W!@V@DG1@C1A0`(O(!=O8
M`''``'B0!V4P!^1H!V=P`FWP!C)9!NJ'DF^0!PR0*16`B?>(CPX`!"B``EDP
M?T<C.UY#;0W109?T.I073_,T>1[46D;X6CCGBA8!(3A#2S]7BXG!'UQ8"V?`
M?6Z@!RR@`.<GD@A`!QMPC'IP`<NH!PV8`'"0!RUIC1?0@@]P`04@!QN0F"?`
M@C]Y`@V0!Q4PCN5X!AN0CNO8CGN9`%'P!N2P`9=HCT[IE$``!)NXC_TX-XPG
M%'7D;=CV%N3V+]DFEE#X7&9I*@G70BE`D7MED:T0_Q8<V8464(91,(9Y<`=E
M@``-P`!ZL(:>^086$(=S(),(@`!<@`'<=P%ZX)R?J0`;T)<KV(R#6(="R0(7
MD`<(H``6D`"%:(>2V`#D\`,ST)3X:(^DZ90RL(^>^!9$*&B&HCB)U9#F%H6Y
MJ7#TU7FT2`_2,8AP\`W&R``5,`>H!X&-N`%PP`#'*(Y<4`%PP`/B:`&9XZ$;
M@'I<``?Q.`<8"H,8FH$/59D6,(-[P``JNI<BJJ()H*'DP`,^B(^G69I`JI]1
MB0=1D`3!`:!-4H2=(998:45E>:"F@2U^T`&^657`R0JCMW>CUQ\V^`BO]X%Y
MEV>DQQ\7R*5Z%Z9"YZ6OY_]Z;&H+/-`$E^BC0!"D]RFG/RJ5\Y=[GK(DS^(L
M&].*4&H7@R`-$*!=4O$_^W6EP2ET\-9UCGIXY)*FDCJI:7IXE)JF]&F?=+JI
M=RH$_$@[2PJ0=!-G!AJHA5!?Z#`.61)&"<B6QS*I[:"!3E":FKJI<GJ?^]F)
M29`02OJ?1S6J9%FJINH')L`?)["JI^:JQ*)WKE>EG7`"/:J?MAJD/ZJ)]\F)
M6=`;2`JL<?%V!UH:.>.E')*L#`HNDB!^$EH&?!`%!7""-NFLG,`#<2JMTUJ:
MU:J)3;F)09@$0\BM<=%IPWH4+>0-)X`&^46NB$HL88&.#W`&R\F,&*"8M-<.
M(##_`RA`J_5JKW.ZJ?@IE44JD%`$K,<7L$=17T&@"OPP+,ZGK&'2'W&0!^"W
M`0C```40E&Z@EK*0J?I9J_7ZHS^*GYEXFOI*?6\U<'0C@`%[`'>%LE0%>BS;
M);7@F7C0@F7PF7KP!G<`!PG0?K%`C_G*LQE[FG.:GV*KGYY:`$?4FO;GK8$*
M51]FL$V[LN7:+<L8!309?N%`!]>I`.3H/.L@%DB`B;8JMH2KL65;IZ:)FK3*
MB4+(>*+%)D@[K%/0`4UP7ZK7JG.KL,BH`&]@!WFP`!O@G!:``'R(`;.P)6(Q
MKQA+K1N;N/>:L:49E5-II&M2NY?'ME`ZL"6W*HGZM$(B_Q8>.HYMP`4)0+HA
M*9-\,`O0<5]F,`.'FY]/6;;X:;BM"[M`JJ]$6CA$N!88!QZ1:ZH,M;O[T[N9
M^RK@,'Y)B9./<`91H`0DR`IF8+`@5K&$*[;3&[WXFKBW:KT<&Y5*@+9J@70!
M>9L/.:PBL&3Q.[Y.6[[FFZ9>1RZL.@KQ:P8@)@4_J`$:$)5/::\[R[\9"[2D
M:8]`R(^G\Y_;.D@`2[(5(6I!D,`JB[D)NU<D0\%ET`15L`-#,`0ND`,\#`5]
M@,$9?+'W&[U#[,$@/,2;.)5#Z*L$K,+$)FI211,OC(6^ZT4D$Q`/5057,`!<
M/``$0`!#\,57X`)DG`,^_,,9G/^)0.NC'HRK(;RSC%ND_OFG3TJR`>!T+HRP
M$2Q1)A<0XE`$6]S%@OS%A`S&83S&/)P#0+R)3%G$L`N]I#FGV$J5+S*R3@PE
M':`J-)%9<AO#5542:7"!-!#(@ES*IGS*!##&.[`#9HS&&KS&;AR]]3O+DJP!
MY%=:KC4@@'K)$;%%"0RO7J2HEP+*?W<#0W#*R)S,@US(B-S*&!R545G$1PS"
M<JJK@;:]O?4I=6S'+O3+>EQ=H/P-QJS,Y%S.75S(0S#&.WS&S]S(LER]0NJI
M_7BDOJK+VQRP`=#-\$9BPDPIQ`P5)'#,YCS0`_W%7OS%Z5S&K?S#T7S$&YO$
MU&=>XG'_S\.:SRG@S?Q<Q35T(AM@#B1```0=TB)=RH2LPSN\T$!LK;$[NP$\
M()4CK!6MSY=+Q0PL4[1@<B7WT2.]TSQ]SE]<`B;=PWV`QB+,TL^PRY<<`'.'
MT>3KR3:-!B;'&B30TU1=U<L,QLU\QDK0$Y5C'KQ<$?7%U`OLU!+5#Z$L$%.-
MRB`-TEXLT,E\S&Q-TJ9<`@8-QB50`E9]T`A]!2*@4E]M$2+``F+=R7M\3C>Q
M`5)0!6EMRG7-Q01``3#PQ11PS@=-`83,V*9,!C#`Q3Z@V63P!7D=UV'PUZ!1
M.4M-$X5MI1HM0\3LT>1LT"6P!$M`UTOPQ5]0`E]``#ZP!*!]_]<#0-<$<-<$
M\`7$3=>:S<60/004X`.A#=(K<``V0]J%4#DRG=HRU<]^\L]IH-/)S-:Q30$4
M$-NX#0,PL`3DC06;#=D#H-E?8-Y?0-X40`8$H-D_30;@'<9Y/0`K$`$%[,34
M;00);-T2A=U[$LY1$="O_=MD8`.S309T/0!#H-FQ?<S@O=XPT-Z./003?MP$
M4-ZS/=QY/001P&[2+;`6'>#?;%LGHC-E@.#E7`(.#@,44-LE(./F/>$#4.'L
MO02<'=]+$.&;+=X^`-ZY7=4$D`30G1XE7@WY#."HG>*:M>(.-<Z8+<@P?M=+
M@`4=[N`27MLY3@%`_@5DX,5+X`,,#O_DOSW;)3#C0$W9(CT$89!P!Z#D2T[=
M@OWD&5W3$G5[KC?*J%S*:T[7\4T`-@#9]*W>,&#?$C[9\RWC9*#<S-WAX`W>
MD4W5<0XE";?D3.[+^]S4`NY()@?5X5`$*^#%CKW6!9WJIC[2<;W6;(WJ^@W=
M$4'G660:%Z$<ZU8(8S`-T6TP>C'KTVT:A#`&A`!JZ8$>53((\[44$=%A(+#)
M4.Y7Z@35_5$$.V#.!IW?<<W3KB[(*Y`$<M7K3O4TRA&EYGX11B$-ZU9L$*+L
MQ5[LOF(<2H'N8P!58P'M>4[6YS3M*'+#^?WO(FW0^XTMUR#NE:4>R,[NIG+L
MZK[N>*'DU&#_.0\":E**[A81#5`\P5-<D:L-0/$;J6MP[0"/S)=]ZJ$-X1%P
M`'EA,%#3-!*B%,;>[D_3`BT`B^LV7UYM.4FQ[*,A#96SZP8S#078>1RR\;_9
M\?RC"I$J!1E0Y4:>[=G.ZMONV(*<\E-`*E??\O:C!1P0`[!X$4_C*]#]TAR@
M!84PYSZOY.D!:F&?'BW``7ZPZWU1&A=QP$*CP(1=7>-BL//(W>>LX0_.TQ<^
M]<&-VU-/\A>NS,]M,&./9&03`TQP`#7O!RV`$2V@')+?%YI?^5/``1S0%RVP
MFZ$?^E,0^DE&\]`-^GT1`UC0`G>,^A,A#7-'&-H5[7NU]UY'$B1`_\J.;=Z)
MCM>L?MM3W][D#=K=W<7JC<S[[?/!OAX$`_DU?Q=8(/E,T`):P`0<$`*AC_TA
MH`4'X/D'$`+93_-8</W<'_F>'P(Q\/W8SP0QP`%8$`-3T/U:</E2"@&(?8!&
MK]IZ#@A_@H.$A8:'B(F*BXR-CH^#:&A_9F5E9C17`YN;%%]#`SYD)3`4,$,E
M%&04J12LJ3!DIQ0^0Z4P!`-?2Z`#!*440P0EJSX#0ZZRF[G+!"L1?M$!T=1^
M4]78V=H''$Q:!WY8+2U,+5H<`!PA!^4'6-P<''('(1SD!^0!+5@Q=N/E]=AI
MV7=@2H@6!\#Y"1!@2H<-4LJ``&$&DL6+&/\S:MPHZ$P#"V4F<1Q)LJ1)1E5V
M</*UQ->`$DN(D1E&QH<<3P0(+($!LX2-)01DE2+P)=<7.SZ^D)I9JB<Q6,1@
M<,J5:T62`],6:MO*%=L4`"WJA<-7[IP?=>P03H"G)826@2WL@&4RYL"$&-ZT
MQ)@2S^!`.]9BJ&NQD.$!#S]"3JQXLK'CQY`\@A0)N;+ERX)^9%BID]-35RQA
MO8RJDV;06RYU[>0)FI@/+,?(V!@UP-14EU<!6.O*NVM">%,F_#-W,-X!?W'9
M<O"#+WD^N^00MN"[W!O!*0A#Q/`#H+N(%R`44\1,OOQ(R2'-JU]_,0V.9:%S
MI1JPZN426;9DK=+_60+F$%FFY+3)+J`0T%I-6`SQWVP^G'8;`6$HI%5O%&+3
M0CSV^"%'/0>U91P[\<00``??8#A."/J@R,X!'NY%XEDQT*-%.O&TT)UN(AC!
M`P]HF.$C>T`&:0AZE`EI9)!ID'"%@+J,XEIM%/RRA"HPP"`',:S$1,Q_,(A"
M2DZ[,..E*T'YX&4I/NRTT@`14M-=5A56V-T4X%SS%3@?)E2.;@%@Q=P44S"D
M&W/3*'1C0]$D5-<48]`I3580L+#C"6:DP=B1F)9'9*:<FE<&#3LP^5)2)8"B
M%`$V1+FEF3Z4H(LO114UJJLYU<+)%V8N8Z:KH9R:V@HB?`7`&'S"&6=O_PPE
M>R,``<2@!7=]'H1-LG`*:NV<$P:@&[%^C$$-0]9,L44E&U!J2:?H0K9INNPZ
M=D(1&8BZYDJQ?%$*?/.FQLQ4^Q+0RVW-W+:"#H+>6-BQ<2Y[XQA]"JOMH-1(
MF"BSVB[$;'>[?0LMHV]6?,T+$?%P0AI2%-GNR1FMB_+*&IW`Q7M4[1NP+U7B
M`I_,5''&C*@Y]9SOFD-<%8"W@!Z*\-&[>7LC.,Q2$VBRCPXJM34&?_N5-<12
MK-L4(K!PB<@DF\SRV(NH3/;9C)21Q@W__NQVS@#K._//,J\)(580(ZUW5]=L
MS1VQAE%LY[`<(WQ-0Q"<@/;BCYC-^..#E+'!$_\JN6UYW9?';3?FF[1I[-Z@
M;[5U<UDAU)TZWW"#Z+&'^[&%V)#'_H?CLB\NQ095O)>:Y;SG&_/<=O\<A@@7
M7Q/Z\5Y%0XY>`$RAA3=^1%=<"Q4C_5T9M6<_^T?I:<_X[1O<`'?O=O>W"2I?
M?*&+*R7\(BOYG*QP@-1Y(Q_ZFP;%(,+\?-4S%SP<*$C]NI(5.D4*>]Z+'>T2
MN+(RG&`#H.)<[WZAC)?(HA:F,,67R+<OJTCH:O9#WIN61R)FT8,#VN+006)T
M+#@=8`M-@!T#Q[;`&;;+@2?0C`1Y1XH#E:H3K9H-K^!WC*L4K7D##.'>]+$G
M)HC(#VYAV`%$0"(F=$/_8KR91O.^PX-+V?!L-?PBNAXHD1MH@H@N\9=M=N$*
M8WR!#/>Q07]V"+3<5".)2CQ:=\9PCS'$HUOU8!AUPB(")F"1@-QQ"!?&(T8P
M<D^&C>24`QV8$C2N!!D44$VI:N*+5)6"DQ.\"M-VT[P\ABY9\,`+0O#"`1$)
M9BYMP:,V2BD"#VQ@`PB,),O"J,LC^:@24B`!'=V&#%P\I9B^&`4%;&`#J?0N
M#!$`E"GS"#46#:0ASHK!7L;1'7/8B'53@$`*)MG+73ZRG.SR41H<""HT4D44
MGFB%EVKC*E?8YFW'B(#?IAG"0Q60(=($%\4T%J>&;,%KW4-GNWBI4/;T*`UI
M_V@"#S9C25V827V]XI4Q8-6@RUT!&M/X'#^/1ZV"44MARRIH`+YS`DODLJ'H
M8BA,S8,&M44T?)6SI+PXPU/+!0UOLARIWD)J,(5Q!Z5!G99#6!">2\PT73)]
M*F9J:HD3-"$(%.5@17E'`*'-+V-"%6'RJF&\O0%`!":0R$1>*M4C1;6ME7'I
M"8)0!BG<8*L`VQF^>->F:!`MK/U$5K5$RA4`0"`($5DK7#/UUL6ZZP0/#`)=
MX35,?/IN=_FZPOP:PBW"`O9H)7V8F_RIFZ91Z*PF0.Q$>,!6Q[*GL:Z]#-OP
MZLY]#4$$G\WM_;36O#H8X00364QLA03;X4)&"O&B;?]%?ZK;YBY14&B5%$4J
MT5KCDJ>XUFV,%#*A7#3^U+/.#6\V`%J8`W2`!4V02*4LE=WU8+>])3G!1+M+
MQ`@Q2KSX163K6`K<\$#4B_"]S'L#S!$TL""">Z7OFOJ:U/PZU[1]VH*Y?JDV
M`!-87>>\L'D>"`(<M$W!:WK&0KSEX!+?$6(Y^@$(UFF&B;!7PY89,(PO`H(@
M-*$(.07Q):%A-!.;>(]],@$/0""%=:J5D3-^C(R3_`@S2*&E9J0OYCQXU`GY
M^,&#$E:C'I(8B+KT$A9F,DF6+&9&H`&B)\B=E($6H<V"]\IAQ=ANM"6"%$@A
M(F6^;H;S[)CUEN$'[>PNW-K__"8XF_AI(I`PR<+,YY.0N=&'^'(3-J`DY<I,
M?D=ML*$_VY#S4J0)((!T91XM:D(\F060;0)R/XS79QQ.H'+>='C#.<Y+G*O4
MCB$UKO]PZI9:E0898+4E@Q:NK`R+8;+&<G2+[-]=-T;7N$YO2ZO:A!N$"J_^
MBH"?(#:LU27[LWT[Z`F*;`E&.SME>SYW1HSP!R-78M)1KF@NPM"T6&.LK-\>
MJ30-RU1+0/3%ZCY/N@,^DC*HVL,)KIN\(J3I?$\34($RK!&J2W"!3Z;B);$$
M#^#5"PDN/`E$B[7#FQO.%^`2X\\>.,HQLB.1479N_>+$;0DGK)$W%W$O(.?*
M2P)M_X)/Q*HG`'9EB]CM:(C<YF'EF@D@<NN=6SRA3J<Q"*8-P1S_;`AA^%O6
M&H[TT`$*K4->=-2?#LFQ*V*2$9$OJ(98-ZS[*=-<[SK2[)1H7-K4W&9O1,\#
M;E5+W/+7.<79\*+1-V/'7>X(2W03_FWDO&MD[^J&;"6F?8(#YY@9T`04B>^(
M>*0-,*5<\\"TP2P)QZ/[XJ;?R`9^8.T0:WM;G4<>N+ZUK-`W(?4\5SGN'R&%
M20O]?%?A5NQE?V)IH+8)BML]1R"_<\@^D++?;=WP99\L$I?\!ZQ5_O)UK_U%
MX/+)N,-!7P'UYNF?EF+4*CD/?E"I[C^>^^Y'Q)?K6@4/$/\OH/@V/\(Z9HV$
M="`%0;`8%!=_90-_!%@(5>523<`")@`!0*5_9J45=))H*:!J+)9\!]@X!IB!
M@G`"-<4#MW1G/)`"$-!C$(@PU51+/Y`8-O4'&,B!C,!\CF=5"[@%^X,H>V1:
M)_@HTZ(MYI4"/P*#IP=U0FAF"O@"#CA[.]@5QT9G'H!>35>$D;&!4A@Y179G
M36`$-H@54+.$V+!'=0$!)B!?+E6%%B&#>5=7_V4&&]`$)`@.@N*%CS(-H8=J
M/J)S9N@(:&AV\^=29M`$]N=F^3=]Y#<-(M`!1K`&MO9E>:B!J->(\F<)DD!5
M.P("+&"#('2"UY`0XH1\1B:)3@7_B3%(A6;88CXB"2$Q9"MX`B_0`;BU@]T!
M`4]85<[G4@`GBHFPAV/W2V8PB3758N$!62;@BORW$!`G.H='(1"WC%;&'%]E
MC`:T!4:07I6`!J/'B[A8@(^8C1=A<*VX/Q93-:U34E@&>B(@B[]5AMR($;IX
M@&7`6B>@A4F(5/RGA"%$+=F`5.?X`BQP9XRXCA?1C@0(61(A!4%@!,.X/WVS
M=61E2F]6-'X``5OP`DV0&!$Q20,(D+E(BAI)"'WH0"SP`EL``;CU:N0X4LO2
M$%,$`1U@`JA65QK74F77D8@@D/$'D\X'62NX`0@YDJ^(?N7W7`]S5BSI`2GP
MDD>FCC1Y_X8<N91KE9/CE@83T88LD`(>T`$D61"#>#S'*`+GN`4F,(W]U50@
MH&(MN)1,N8UHF0B3A(W3=F<D$P254)4F,)(DZ33'6"$0IQ#GV`$>P(\M561K
M:&NU"%%K.85J>9B-800I8`)7"0&0Z95>^1O,00V2"9DL"98OP`6^IIBCUI2>
M:1'^6"Z5QY@O\`(F8`)PX)BIN9JGF0(ID(YJ<Y%1&)HF89,TJ3;^-A&T"6;!
ME90@T'($"8H9:9M#.)/&>1'#^9%?YB.+T6(@*#(Y257%F9QI2836N1%]2)WS
MQXN_]&^F&(39Z6B@.9Z)P'B6LE[HF9[>V9WB:9YC5I[P:0AK-?]_P76?S'F-
ME3"?N9>8_/D(?>B=O,B<8(:-_[E]_GF@"KHXN+F@#DJ>"?J@$KI0\CFA%NI>
M%7JA&HH9#;JA'JJ-V/FA(HJA$3JB)AIC&7JB*LJ.*;JB+JJ'+?JB,KJ1)3JC
M-GJ=R'FC.@JB.;JC/CHDW%.=/SJD@X`>'NB+2)JD2KJD3-JD3OJD4!JE4CJE
M5%JE5GJE6)JE6KJE7-JE7OJE8#JE&/`1=D>@9GJF:)JF:KJF;-JF;OJF<!JG
M<CJG=%JG=GJG>)JG>LJF9W`'%W`&"Q"H@CJHA%JHAGJHB)JHBKJHC-JHCOJH
MD!JIDCJIE%JIEGJIF)JIFKJIG*JH?(`S`160`*(ZJJ1:JJ9ZJJB:JJJZJJS:
@JJ[ZJK`:J[(ZJ[1:J[9ZJ[B:J[JZJ[S:JZY:`8$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>a57251a5725102.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a57251a5725102.gif
M1TE&.#EAQ`$'`>8``)&1DH)JH$Z!O<)/3WQDI+I23IN]6*.CHT]/3^7EY6IK
M:]G8V5)[KTJ#OWQDG#`Q,<?'QYR]4P8'!^OM[9VS:;BXN*BU:(FGRO3T]-F=
MGDM;-%PG):.^92Q%9F]:BOKZ^S(M3,;5H7.)2_[^^59$;3I?C>[&Q4<W6^GO
MU,_4Y:"Z6<&SS&F&LK5O4(.;4D5LG)*`J*9I=Z[%WOO]_6-/?.3M]9N]38RC
M6J)*2CY".;:&6J25N=7C\>#>X).K7/S\]_+VY*.GC<5Y>?/L\[+%@_;Z^F1X
M0OGBXOCW^)B]6]7(W=KFO_WX^YRY7<W!V)>^4H!]@GHV-.OR^;.?8NSE[_K]
M^_[[_+1;7/3V^/OR\BLW(/#P\!45%ADC-'E%1#I6>TY^OI>R6UQA5/K[_2D>
M-IRE?YRX5#L8%HFD3N?GY_C[\'U@HX.77L5-1X@_/9@[.R$B(9>V4L%75[&C
MP>??[/W]_?___?W____]_?W__?W]___]_]'0T.GIZ8%CHO___R'Y!```````
M+`````#$`0<!``?_@`>"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=CP!]
MH#.CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^K@`)`!,S=7?'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BSW4`:<-U=7_K[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\``PH<2+"@07K!T*D[R+"APX<0(TJ<2+&B17[F%%[<R+&CQX\@0XIL
MF'%"NI$H4ZI<R;*ERWDE3[Z<2;.FS9LX$9XSN3"GSY]`@PIU&+/GT*-(DRH]
M6G2ITZ=0HXYL^O%.NJM8L]YA=ZQ.L:OPC/TY]@=LUG]>/\ATYW640*_I_XJI
M[8FU6#VX7^^HY:@L+KNT:UD:2]?5J-2'5#V"E;>8;>-X5[=:Y;K57[HQALM&
M%GCG*UZZ@^_%'?5A5.:)60G_;7L:9=VOAR4F[E@WM6?0MV>$35W;6&5^=Y!L
M";RN#@9BK?5=G0'A0(6]Q9?#GE>,N7.[&Y-A;;<%"?&5O&-'G,TQ+I\#$+S7
M^<"G0H4B,JW.Z..^0@_=[P8G<`_AZPSW)FG6#F\$(@$``A#PAL&!?`Q&H%::
M6;60A'7H(88$<&"G&7T5]+&=@[5]@(`$",RP%8C1E17=20]JAA59*K*S0'WN
M\6%B.GP@``5\DDE((5ADA><B:.I\*%9J`Z:#1?]]$,P5'H&KJ99:80]&ME"5
M13X6$GGEU3'B`Q-8A80"$G"!@8-W;''``Q*T^0`?\"!S`!=E+A`7FPG&-=I5
M^U6`P5RF%9,`FV)T!D$%=LZP`!P20+$G:Z2T51V28UUU(1SN'%,!G14LYR1O
M,XR(`*!C5/?5&&I-ZM6A-G[6FZE^K0-%F[1R`<5]'\PJ`7+^975;;W5LX5X:
M'T`'E[`5)%"*GF>MV`,"=):IP!:I1EH'$KWFMARSV];V*[>0EM;M=E/M]-U&
M==CQ99C7DFFF@W_,B>$##\`!09S'R"N!&$44@R>XRQW09H.OK0=`#@W.P*@"
MHRR(<&FFU5&JJ<76)>[_MV.0B6D[6VTJ0:>CJ?6I9Z)VZ^2DU:['J!BF!CJ:
M:9^RHRN]C$J0@[)\Y``%$A7#>O&WZ<P%09OOQ9?.T!(<`*C+D[(C:`YETLQ%
MPC.DJJ=<GU5=3!7`^M<9:U;[!>S%>$6,$I?H>BD!F&*Z>V9GQ5SX0`]88+!`
M'_C>,6<.T+:*YP<57+>D<X"3*0$`!Z31`WH+H(=!X!"<1R<"!RP@[`%4-^X<
MK^?Q@8$@K9;6G"`5J'=IIG=XW&ES/:B)J']I")+`B#GL@43@%<SPN'-M!8[>
M#(O3F0-ZMQ^P^WZ55[U[@^W,RL4"'_0`0)L`L"<(!I=/X!P6ZYWGW)]7Q>X<
M_Q(0Z`I%Y5=^4'Z;"AS0PWH)#)*`N#W=,<&(]F*`10\*W#>*[TWRRNZPH#GP
M&<=W!/.>5<Y3@>$TAP]J<LX6K..GN%CO>^EP7?S2<S9S):<BZ5I7V\ITIK98
MJ$S!P!9^4*<W+E!N7]C"T_VXD`,DI`%:",``U&@%A\"Y,`=<4$`:'L`%,4`A
M6BA<`!$=M04HP($+4$3`<ZIP1`0`D0MO*A4`G@A%6V'AA!OCRA]4=P<Q!)&(
M+FR0'2IP13&P"0'!@E8./G!#%\X`"P#HX@.:@\0B3@"(1^1"!<SX`#O-B0L'
M<(NLRJ2L.@S19CUPW@06!0<SPF$+?5``%[D`@#-]X/\`5^3DA6H%`*Q@P'!M
M$B02UJ3'ZFFH#GQ@$Q2<!+X<=1$.0@0>$!6`QFE580)'+%,.3')$.*1#`5A\
M'S+%@$PH*D"3&(+"<#+)*"[``0K$6``6S8B`"710(R!)Q[K*,B82$B8=!Z@F
M`@!@I[S-"0&#X@($QB!#J,TQ#5#+(2_;Q+?FI#('P2#4`:"%(<HMJE$SR./:
M@&@S9>F*AL([)@T14,U.G8YCJ>-4&?_9)GY]P%T4;=.HMD`[.N:S"A5XHA4?
M4`$(,!0..MH"FPHJO3)YCDQSTY#S$A`7C2U`5Y.LV0/$T$0HY@!J<*A>#]0)
M!YWM\`%2Q`H>GXH@/JB33G#_6(`BRR(P"?"!:\O!P"AS,%,H[&^F<)AI]>8$
M4[*FH0[.6X?&>&HX&M9L;=546B"M&,TZ+(!6.MO"-WD2DA"NS9OM,B==V!@M
M>+K3A1^8G@*P(,.24B&?Z&R3G>K0U6G1D5!Z65@Z#HI-I-K(<*4T'#8OQ(6R
MS`@#GZ/3`?2@L4R-4:.L!<`6H/8`+%@5ABXE4;#L^8$^8'9Z"-L"!'BJAY65
M1J9ERMT,^$`G=C+*44;9:3KLX%.@'O1-=>C#POJ`S\,ZKWKE4R[1<-32EK*G
M30<X9ID.L$HZ*8`]]>'#]"2P6;#(2PP8R!F&>M`#-O4PEOM*Z+[N5CJX8DBN
M:[N/_[N@,`:/O8D/U'ND`C!PP[4IBI_W^>!%T'81<1Z6G&XS2SH>-U,$/'94
M$R!B!>II,QOFTPJ<U>PH!";/8CRR4'58F&NONU0)W/<#2FQ4%=Q%C%G!`3-J
M(FO-#O"'BU*&C'+CVI<>1R<;A<IF>R!IC<L+QV=%[0`F^<#*]#"#&).H7S-`
MPJS$D%)Y-F:GIG'R3]L4U*05HP=8I1>='B#F'/0`8LPA6K%V:#/UP3<=)RV-
MJ'1(JW4.[%?[[<$8]*;9`AOY`VYFF8";>@#XQ/4/&GO?I3STV^HA@7J`GA<1
MUU:''L!W+H,]ET6N\B4/&<==PYE!$;Q3K&*(^0%5*\*G\O]%(JM,SXT2@,#]
M:GQ9X>:8OYF5IU5^G`[1*HK(;%(`CJX[`TE2L4R.-!Q9X9NQ!W/LMA\[X0.,
ML>5-R;-8HFHS[6Q8LO`B@$V(G($55N85Z+HX+17`$$[3,)T_:/<#"6"4H;W+
MJ$0B&:M'/>JT+F1H8COZ8U6#0L;%C;3XWB&?*K3GF#(.!8\=.1WPV6\[9>YI
M<4-7#*,-J2#+C>X9X%29&#K3;QV%@>K&NJD9%T/T'JUKCI`8A"::GA<_R:8<
M<%CDSX$"%*"7`-X68:`,FP%F\N5"JQ2X7M&>]@,2@&`X7KM5/(;`,7YL%6^3
MUK@8:A(R#^?S,A&S3,RADUGE1>7_VF(4R[2^PY>0\%LQ5-B>]OL2V]^H*`@4
M(>()5O.^]%`'-Q\\@RIME+A^X[Q#\\%=B:2XGQT9[BV@*G(\Y^3CI(FTYY`&
M56HI>3'<5;TM-@KWQ0(U:TNG*#$TCDY$'36!P]UY0NF!#Y:'@'T=/#4,X`_H
M<,#`'UI]+>KU(=P8>#T?QF#KI#7=Z1X,YRBVH$Z=/P<"C"K1E_B*2!'9U#1D
M1X!\=!5ML?)SAV[750@@!N=1)G)W!]RF>5!5.=>U!PH%5<+S5I+$78"'8%`U
M91L51NO0,9PB;_2V-G\R(BY4,RZV!>H&@.4`4P3E*)H'4\/P1BZ"!*-D9['B
M<"+U;_R4_P#GMBL'%5]>X3P($(1)56M,16A(DP-TYB#%@#10!0':5%!8I56^
M8F%!"$00-$HXB%`U%RR$DE`J2#T*MC8$E5,:(UA#]P<?`(9`&(0/4$I_97XB
M-F+I]Q$2LQX50%!E@B!U@`40($MU,&.T\@!*4TZ$YA5R8D?KT6'1-A\C8C-D
M4CMU,#M8Y4_:=@>#LGDI"%^D=2V^)TQ\H!9,1GUQIE`V,R('8`=6MH$9]3%U
M(#<?^``8\!\[9$0D4AI]T(@Y0":CXC%E@DTQ5U:>YR)A^``>HB$V2"LV`PIJ
MH7J)5`QR=E=P$%^`(U1*,P%[ATAE02%B12<[MR:!>`!?XS2=`?]*M;)A=-2(
M"H<M229NH38&I'A-=O`!<H95Q:1J&&*&U_4'&$`]U^)$/)1(Y>>#*?%TZ`(\
M$!`YZN$5/0`!>#,#RG60OM9YD?,!%#(#:>"$5O.06V`5#WD<3O@7T/<^"7"0
M9X*&(1D^!XD$O@4![Y,.%QDY)60'"]DD>;"0GX@9,]D'"]D'>K``L$<7:7*0
M)N&3K4*4"T$^$+`%$^"$5Z&12PD]2':0[_,7?4"2[,&4K($$H@4/(WF0$WDE
M70E;$'DEM>:5[%(,/IF48E%Y4O@./1DY<?&02?D;\#!=!]E?HP!]+'D5*XDK
M(1D<>CD_<L%XRZ4^?(`$?T"4WO&0\Z/_/LO5%C/)D"LVEN<GA^`T$I)B%^=D
M-D%C&Y4R%A`#%Q84?./R`7_Q!Y-B&IKQ*\O2*ZZ2*H`2-!4IFEB3)5R1%F'#
M+-@AFK&I)Q(R%S_R%U1BB%E!70BU&Y<AFEW1*V"U(GJA)V41,62I&^?2&=DH
MG>>G*KYB&UHS,H/!FEA1&I]R->/Y&JI2#!22:W$(0M])(#]2);^Y'4`3*?[Q
M%T"#)<""G[3I&3>RG:\DFM)Q-1,"H*Y2!U6@+:JQ#MI)H#]H35.9'_I)*04*
M*D=B#`T7)=M9F0^2+5."G?<Y+K1I)`R*GP,YAYAY%N?TGBTR)"VB%>12'"R:
MGQ1Z%7M!(/TY_Z(`TQ,?&J*JF*,QNAV_\2K1>17MT4"GX9XJYAMK824`(R'9
M^*(8NIUWX9X(RALJZI\9RJ13$J$E>IGB\:5@&J9B&@\$.:9F>J9H&A1EFJ9L
MVJ9NVJ6$]:;H\B/O"4(J6AE3`AF>N0]08@_GE"5:2B16:IMRNA%K6J@'\2I0
M&A%*R!I1@IZ3X1@+RJ<,*AHY6AM1&J#P@J@6<:B<2A"V`5O8LIX$(2&P54*"
M2AAT61P-`UM%0JD0XJ<1*JBN:1:?6A&>>JL!42Q_XF-D!0#&R*AU8`5NQ#`R
M$1<JZ1UCD1^@]F_B1JKN4`R/(X6D6@?#A@3>`5;.B*VO]`%8@*T&*O\I6(`%
MN*:KXV&BYFH07J$]_Z8S_8%YV,4BFBJC`/.CO7(',%@7D416`#4<!.)Y5<*?
M,:*@,R`P:[>B,0@!;L0W#78MH/0`.M.2=+2P4C07PD!6=$8_T)JN^9"K'(L/
M<;9W@3@!\/JAN;D>M5DVN&8;HCD6;Y0ES#%3M$(PWV)PNKDLR0D7I[DW/%4U
MK)&@<:$OJ=1)"X)$D,0<C(9"2-`#HS2TY?JQ!>&Q4%L/?6<K"9``3D1>US4"
M<M$R*.L6\NBSX8HUD4*:ZR$I7N&R)!(=TV8O"<`__M,RQO:R;4$_$E(=Z<FJ
M,Y``&``?XBF@JP$%@CB2$C>2(K5G'W-*T07_B`\065"4+$B5`.$XM0,AM93+
M&/85?$L+<8(G!C"5(,4%`/625F;E5T,%`12%,*,U5'?85#T0G5A;+X)HFO@J
M7*A9!T-@3WT0,8^3`W"05F+@(3;K5YJ45M(EB[\[+:"13H8V*&_BN3F0(+<9
M7A,D<+03/_>H.U^R`%"C-(#3)JA+:]<&,AM[N?)@N>8KG#8(!\SS%VE038&8
M(,:)C%#P85`$6`V"8??+3UKU1\C(2>D`@YIA@B)U`!OI2$EK,UM@<$AV5QC2
M*2F%C#RU&M,#!SV0`*G$0^T[(*7AOPJ0`!J#!%:!/PGW,>M0>U_R/OM%OND+
M$.C;PF(Q*X5D%(Z4_U?[54J1A#E]2&MO&(VZ$E\8AB$'H"NE5,'HP5IP\K*W
MVV9FY";5"```P`<Y4B>>UW<L%;YP`$PD4@&G%R#%80<5?,%#JU#Q!:$&DG<$
M#`<BK#8]1#0G3#3!E%;1PL(M[`\OG+XQO#;MY+X+\P'[>#CKH5R"P%M^U28[
MHTT!%\10D`=!#`!_P%N(8S@-(L!8T0>@Q(WQQ7B"X"Z60WD2)PBL%3_6U#Y]
M`!V:$<88_&D]F!E>D4[1B`2*J\8C_,!N_`>UETE0U%3K59EU#!/HVLM^NA5.
M1KX2\KZ-$BQ@V`=-'"W(5GYN*%NPQ(^-O`>,=K]34[MP-"2E$3N3LR`._/\\
M!J<PM5(F<)`&!L+,$_S%J,R//1BE]J8T#AG")M;&K)AH(/>0!3@U.@O,^W#'
M==P'R!>+;58Z"2!X?[`%_)A;"R`WB4D]=_"$B=3(VT<]CVPS3K@`"W"8,T#)
MULJ0P1=_G?534+0``+LR&(W1AU8U-07(`[+.Q]S.&W@5[_P56%!ZX=6]\-<H
MV"HPER2/US(&^[;/_-RQOSS4=V$XZW0@<-`'!=TH!TW1(@@`P?0`#7TX#PW-
MC1S-AW-;003%S^0OS8::S7I-`(!:^P4%HELG-BMU:`T`1E0.8@#%ADS#+NV&
M%6>??S@Y4`S%T.<F!V)3,B@MT'1?=PC%#`7/P6K_U#KAI8I-#[6&AWFX!4T-
M!4_-=Q',3VM3U0!PU7XFT1)]2GT$1QN]MK>+`<&42M+$O8'X1"3]LI)8CI&%
MC(9&UP.6RHX"TZS*?\AHP*<=3=BRPY4&/9<M+8UDRHV]V'%ZW([M5Q6@`&(0
MU_WKW%2&!<_=*8_CW`K0W(Z2!M4=B<_4*4R;A.'=*?-Q`,YM1%X&!7&=%9;\
MW'0V'.ISWA4`!1]LVG$]`U4@/>[-3M-UWNPD%M$Q2`K0!\J<A"`L!M(;G07K
MW@S>'\+BWL83%^7SW/VC%NW]W`?`4XNJW/#@SW4LMZE9%W>K-3Y[H%[!>;6J
M!WKP-17"9OEYMV?+JA6"_QFW<0=L=C+\^35C0.-P@1F-T9JCP'G,$J3&H.+)
M(.1Q8>,#FQ<H'ADJ+M0<7@\>WL)4,IY?H;$VFA6]N:,;^J)7&J$NLR>_\J@A
MRJ,_BB6E(8Y=SLM1S@Y3CL<LF^5Q/J$"&N(@HIK?@M<%@Z.S^J(9BIW'^B+#
MV:>KZ1]`LZIM3J9%G>BK<>8J=B)2TN>`NAB1<2)#DBDM2I;-HF(KXAA6<J48
MFB026C^0K@X^LJF,[LN,G>JLWNJ6F=RN'NNR#A%O/NNV?NOM4.NXONNRKNN\
M_NNI[NO`/NP<+NS$?NQ&;>S(ONQUK.S,_NR4Z^S0/NWI*NW4?NV<:NW8ONUN
MJO_MW/[M9^KMX#[N8"KNY'[N4F'NZ+[N2Z'N[/[N0^'N\#[O/B'O]'[O-6'O
M^+[O+:'O_/[OZ@GP`F$'!&\'?U#P!9\N"+_P!6\5#.\;RR#P`>'OVT[PA/'P
M>)#Q&I\.5H!C5S$"(#\">'`5=B`=B2WQ^D#QUX[P$)\,#%_R/SLE"P_R&F_P
M*&_'BW[S]L#RS?`.,)\.&Y_P)/_S6J+S^*#RSW[Q)#\")#_T&I_Q5B!V5^'Q
M3%\'4.\K3&_T&)'S6@^A6`'R5H\'5L`$L#P$5$`'"Z`$3K#V3B`#,I`"*<`#
M/%`#4H`%15`J'`_U5]_U*<_U?,\.1#^L2#`$=.`$*S#_!SL``P&P^`%``(Y/
M``$@``T@`"P@`)3/`BQP`1?@]G-O]WB?+G]_]'X?^G7`]%A`!8:?^(OO`(\/
M^7[P^J_O^)+/`)(O^0TP^0(`!I>O^3+``^1:OEV/]+%N!S5O!V#_*T.P`"N@
M^HX/^\[__+%/`)9O^;B/^]-O^;I/^9N?`C4`9U9OK<40\ESS].DR`B@O_*X.
M\@M?^DQO!4BP`#L0``XP_ZS?_-!__WY```V0_=8/"`*"@X0"#0T,+!<I-44C
M/R-U,S-V=B,C>)EX=99_GI^@H:*CI*6FIZBIJJNLK:ZE`&D`$W5UK[>XN;J[
MO+V?E<#`>%9T*S`.!`[*?@3-_P1^T-'2TLT"8((-A=J%AXB**46U,W<SG)<C
ME9QVONSM[N_PG[&SM?'V]_CYI'=WP7A(3F`$6,;,F<%I"*DUN&9HFS8PU[I9
M$Y!(1HTQ,]!9TAA,G\>/('/-HV4KI,F3*$'56EG+"C%CRIY%,W@P(<)J#+,Y
MW`:1T"$PWZ2,<5FK"L>42)-Z'%E/J=.G[>[4D6J%23$8:];$I$:SF<V$!!9B
MV\F3(3=!B[#,P%@+&-2W<'$Q+1FWKEU3*ZW..19-&4%H765^G4E@8D.RB`=U
M`\,@+5NW=R-+]C1WLF64P:9*76FGUI`5`092\TO:SS)G@Z>%S9EXYR%"8+HU
MYC&F#O\ZENHJ7=Z-LC+OW_@R\UM;[@.&@*F3*R]H6&?KYXH5730Z25(M/.N`
M:\?G>[MW7\$Z=Y:$9,$.T<O3VUP]%KK[A4`MAA,WE=/W^^VZX]_O*GPZ)E08
M$X!Z!-Y4&&ON):C3!3Q\@%M3_$7XBGX25EA*6^-51<<Q:T3388$%LG=8@HE=
M$ULVB:0@13F10&CABZ90"..,_'!251:@907BCH`=V!Z)K4'4$R(,EE/+'3,F
M.8J,2E;(3R564'$>5SR&*-:(0)8(D40L\%!$;70UJ2238O+W)!X+\$685U4N
MA]./6;;633<LR!!.=F4F26:>N]F!W25UL%4'0&JV6:6(SL7_"1V7%C%AA76=
M(<DG?WM..EEF1OZS`C*&MODFEHHNNE!C-3QZI'V6XE=IJG=EMA(2<VS5Z:%7
M)AIJB89D`Q$+-:Q4#IZL;K=JL'%E%@D&.\0DV*PA^@CJK61%))$`71J)*K':
M#8LM5)+4YI*4R+!I&K-6(@BMG--:PP(XCQ2Q;;:RD/2N92Q%N0,!'Y++XZ>V
MGNM0NM@TL.X8550Q[V_:'HQ4'3_\8.\:R^J[(Z+^)J8K-]D,;(7"NR7,<3["
M2=7P$/?ZD:\#$C?;7,5:FI7-:UU^T")GP'[LE,<VVR/<2LARFK*GM;*LH$2)
M\/"#)%7\6G/.2.',]#NN>C9'`.+^_PPBOT(//0@+719A[;5/-QVOBV&#%%XM
M2(`6KM6TFILU=&8)<$$-5=@F7ME).8UW+T]V5I43`Z'&]M7.]OLV8D-F<\%\
M;>V=DMZ.Z](/E%8H@14S@[<-Y^%!YIJ-G6`N';D^D(]^"X91%IKYQ(5S;G&B
M/PF2`IAAFD[ZV+7;#D];>&21[.J&4NPZ6>GJFG$-+>K^4>G*KS)#P4P`#KRG
M/B+R`@,G;GE8T`P(4D()N5KS_?8ZO3911.&3+S<61T<Z.1[-O\-\_*A,8L4"
M`VHU_;YB-?!%%QWH`@/Z)Z0!,N8:#.C""QKPO;A]H03>Z-ZH/">($TEP+,YA
M@`SJ!AG=T/^/'?/[8"DF,008[(]ZY?L""%CPA0XPX`L/+$$'.@`^!LSP!1W@
M@@O')T/P\7"&`RQ!"UWHOPZ\@"(T/&+Z8):"&6BB(R+L10BC*(H1?&!3T/C+
M"=43ED&H4``M3.`7&%""%PH0!&.\G@(%,,,2@(",;.Q`&,,80#&JD`$@*,$+
M%)B3\AVB,5*H0R:FXD$JZF**5*Q7"JB6191MD8M=-,3_@)C`!;+@!240(!>Z
M)X`]=F^&,T01*#N`"`5V(`=L;"$:T>C)@"EF,3*@G2#A9\A#XJZ6N?`5$I(U
M(,`\DD"1!.,;8U-),(!2DYRL)!MS,$-!L$".S"PE#DDI1SE>CP'_K0R?'Q=2
MK19E`I<BN24X7\$2P/6R(+],3S6P$<I1*;"2_V,!*]5XQ#:"`)-QO",00RE'
M-V+S!9Y\V<L"!I\+L"]IPQCG+1`9/TO4J!94.(8CTUDN0>"S@F7LY!?P^<*,
M8A(,^'S!1CMY1)&.L9,^/.+W:GC2]!6"F.#XP0RL,`:%3DB<-CV%)58R`B;$
MBJ*L:X[A7./'9YGO7(>8F\.L,(.<MH*AS;-$)49`C',"M:+/LMA8>C(\BL22
M*$YE!525!XQ+I&VB5X7DRA05-\Y!9&ZF"NLJQJJ[SER"&#"(6%K=%#0M55`L
M<8//4$.E/3N13:ZPP"EB0V&'1QUM:GM5_YG;HB54;0!4$`S@Y+E.)+!>-76Q
MIZ"K[1I;BPWA*[+`[.MS.FJ(:9;1C33LZ&!)Q)A$!,`)3/@L:!-+C]R!M@XN
MF<&FDH%:=;;N.<8$(!(WBL9^RO$++`,*%&)0`"%D0;>[79)BL\NP'Y0P7\7E
MZV2C-<T&['&,>53A$+O7UFV8;T[6L"`+8B"'-K1A`'(P020R41WL9/</HC5=
M'0KF!+2&-SE8<T\'0,"83`*0!3;\WWJUBCWSG4@`,(C!%0I0@/OBU[I2V41U
M1!?6`(\.;;\[L#I52]EK-!./-.0"^,`XR@Z\#CX2%-ATKV#?`LAA``48P`"N
MT`-(U8C$3C5QY/^FT@-&JE@Y"88.$/=X/31VTH76M/%S7F-;^O8XR$+F,)`S
M\(."G0K).56RX^K`!"QF\<FI$5Z05"A'&X(2>RZD,0V#%!$63/?'809SH(4L
MA".4^5%20;--U;PW.V`@KXV$\U>B;+',9A8BF8WOI2G"WJ-JXX]^UK"01TWJ
M0>/7!#^8SZ_^RVB\U0%_.M*BI%7#8E'%]S6QR35\=]+E`7A8S*4>-9@+D($L
MU(TSK-YN3H/1#RO`R@$?THI,H-TA'9VL+QTR,'A-9C5*P^TLY).63GJ2B/E>
M0=B"!C*PT4WH(U1A**O.;JLY-M4,172BR4"&LB#&;4<.!-KA0D:UH9'_;0]P
M>]O,DG/%WOL:+N\XW<&.>*GSBP1X^U:N\U989ERBA%YF&P0T\(,'3N`53GF`
M!,KJBDT\``(#Z\O;"Y^36*`0@`U[6.(X)S6QC[:)BY=8V39UE4^=[``/<($+
M'O``&:"==&70@`P>B(DRI+V&I$?=-,I0^D`,_C.%1Q=]&!9USL<>;.M:H>>*
M5FC&#R;TO#JRZ%QX``F47G00G&#I=R?!"4@0`!#PG0PT8#D)_-YWO]/]!"?P
MR\N/F[784"O#Y_:UNLE.]BL8&NW)[NUB,X,'*H1F&7!7.@G(T/<3>$#N=&>Y
M`\C0\M:?(`!/=P#A/0`'Q#O`JN3R^F:O$>H._]\7XI3/>0%,D`669%Y>B`5&
MB`&W+*/W_0&D!X'?YZ[TJ$-=[RSO.PD(H/79<X'PV5[\6J/+@@#0M\/I7G?P
M<2Z$]AT6XT!7J/)K,8>J&=T!-.#"T@D?@*HO7?9^=P*$9W<$$'NS!WA+UPPN
M%SRU=BZ0)W$<!GSK%V;VU7Z"]'X_IWG)EPF7X#NDT0QT%P!WIPS2!P)19W<!
MH'75EX+2!W4B2`-UYP"#IWBYQWCN%5]"(B02@3[F-H$^&'&6-PZ%!%IK-R]^
M@@>7,`3_%BX*V`RA\0RA\83]1US*\'FA@759P2D#,2#H\7(-Z!,RQW!;P@`!
M``4;]H-HJ',FH`>4D/]VXU2$[W*$D>!YIH$:S0`Q*(,O!@$Q>O@,=U@0?D@3
MU>85>D4]X_<0GB-0%!$^?G9NOR>!:5AY&<!48+-8<+@MP5`Y`[*'>$@:6T@:
M?L&'-($RH!@8A0@TXZ48AK&*C!%J<I!^D?B#')8!3"`);@A.EX@MF;$"@2B(
M5)-OH,<I>6B*"JAOIBA^J;A5G/43#`!Y]C5H-Q>+$R@$3#`>QX>!XY0.5E1_
M@!@3.N(,3&@0ORB(R8`OXWB,7IB,#;&,U&)^9QB-TAB)5U!\V)AF\9>-=H4%
M)5.,@9."I,B$WOAZ@5%URD`"-$",I[@O-O@OWO"`7Q:/\1B$Y7"-/@=.//7_
M:-DF@ER`<GYP`AMY>Y\'DBG(!?U'-5&8@J2'?QY@A05QDE[8<$MT,9@%!688
M>6%&=I`H?+`X;!$(9&%V!!\PD?)VCQ99#GB@A/G6=ZRWDF10>P&@=WO7D21@
MD*1'`RB'>('GD7QGD`ZP=WLW$(AG>BJGD+C61SO(&`+A93[8!F#&EH'V:\&V
M;CVI<S<)9"80E+>(2[E(+-;1>503$R"0`X#'<@^0>%E)>F1@>D;'<E9I@H"7
M?RMI>$@W@H@W>H$!-/#A,CLX7S$@>3_HED$V;)X)?.HG?&%F`DA`"12Y6'W9
M`YQ"`*6'>'Y'@"DX>@%`!BB7?X!7>'GG?+(W=TL7_WN`-WAW6!.L(U!G21$!
M``-7X(CW!8_KEY.Q"&S$EIIY64M[&2Q]N0#&*'NF1P;1EWB)>0)P\)LC:8`H
M=WN^*9FPAW=+&8Y5<S6PD8/-J&&A*9WK]XP0QY/WV9/W^9""5IVJ.90:*%=]
MJ02O67H`6'I*1P-W1P"X.9*WV9@T$'C5]YNQ]W3Y5Y@D-Y:LDX,Z47[V*69R
MB9^EUF$XX)F2EZ)"9E\N^IQM\&,N"F3VA0.^)VQ"@)>KB5A]66!4&'C<%W*!
MYP=6:95$:G`R6'0P:)7I6:$J*8-!6GTLYP$>.C&*&&J1)V;P6)ICQV$;D*)7
M(`<_A@-G,&IB^HRO&&:`!O]DYU8`&Q`%*CH`0D`.UVE(V<DJD#)<?=%_!)<_
MTJ`5_B:*X0AM'B**1E>A9""*@G.<A\`"S$EJS\EA+FJB$5<`9(H#41`%&[`!
M;K`!$A`%5X`#FXH#5Y"I4?`&;\JIH;JII<H%9V"CI$:-V$6$1(E+=E4'*_!F
MBT>,3(IPU),(9BAD:3IY$-D&EZJI;KH!5W`&EOJJG2JJ&R`';L"LT^H%K^H%
MROJF<9JCLVJ)M5I+=H4'N3HNNXJ0\=DIG!FGZCJ=Q@H'HNH%<C"JS(H#7+`!
M9_"J&^`%;3"M<O`&9V"M]OJEVEIJLOI?`/:MAG2KX[J`U$.,?)@R,#`%+?",
ME4K_J<)GK*\:!3D0KU%PJ60:9&*:K_MZ!G)`IM;:DV_:8;&:F@9[IZD2K@NK
M3B@3?H5HKL4I,0`0`1:@`S89@?<IC?=UJ6\:KU_ZJJ)ZJF_@IEXP`/X:JOCJ
M!F^0M*,:C;(J*;OELI9RJTZ@J\J1@E1Z>Q:*?[8G@U1ZCI>I+P#P!$E@`1(;
MH%R*AK_G!I::HCA@HU%KJ6[0L07P!C:*`V[PBJ#JMQU;LFZ``U0;E%9+JP4:
M5EK+M<FA=%#7E;,I>S1@>!UJL_KB``=@!A'P!#:PLS;W>\7ZB"0:FFNZIL(6
M<6BZK;G5L@A+1;>J!`6B=TOG?'U7N58I@`9GLPFY(P$0_P1-D`1/\`0&P+8Z
M@'X62WEM"9V3]XAU.:.AZ98$RP^NN[A.U1:OQK`)@7^.F721BYN5*WT&20-.
M!CR_&[Q)8`;JJP([VP(2^+9=2IHGRI/$>G-NFVX98)T[*E>5(!6NZ:MKH@PG
M$'@N.'BCEYY0"0)0U[L2$P!ET`018`!J*[Q/P+8M@+H^F;PX]WL<++T^28$/
M*7P9H*,$BGS\:P=208>3]H>5BW@?N84@IPQ0!W)3>4(.#,$2G`1)$`<&T`1-
M`+J_IK(029=FZK-U&V0VBI_#1\)7^[I1U+]V@)0K7(SJ^7])AX)=*<`"&'+[
M$P`4T`0&(,$&D`0&8`8J(,$_S/^S0<:\:#ALHBJW0+:I<+JIJOJE&!R7)H`1
M=4I%6#LIP8"14UR,6@&#:S"5,&@RARR#A]S%%!#&8BR\-J`"9B#&9M"V0_S!
MHGH&4>!C*1MD7YJW&_`&E(<#1Z#'^\NX4^53``R(!T$0O?1V)E.%#-S`%!`!
MDSR\D$R\DCR\*C`%/#O$;IRR9`JU.$"T<DRIEM<X)5R/MCI55K`"JWR9'D>H
M)A-MG3C+Y!(`$'S+:CN\O*P"G:NV%JS!$G=S<J#)`T"FF;H!>!L%__JFL%JI
M0T:/>QQ%?3PI_1`)6QO(B_JGIF'-X+@_,+#-38#+.AP!-D"\2=`$*J`"P[NS
M=[R68L;_L25;I@7P`&XP9)R:KP,KS]0H2/4L0O><)U!\!_B#S7`F<##@R"S=
MTB[MR'%PO*9VOQ(HO5<PM)=ZTW^;MS<MN-))9D*YS!79S)/C>2C]9.&RTB^]
MU"P]R6Q;7Y`ZHSG'EI9JKV>@K)UZU:OJ8]/ZI6.7`2,0U$ULO<N&PIU10D>M
M8LX`!4S=UF%L!D]@!A`]:A2+DY(G:&P)U3\&LA^,<\.'(:?L5)'2&4R08K.V
MP@X`!1S@UDNMOA$0P>/,QA!XUVVYP95W!.,1TA\TTF7B/G?PS-I[V`7A``#`
MV&[=T&-,`3(]OY--U3X;:"4Z=A^=:(&=4QAR!TR`/Z*]P@%0_]JFO=0^O,O%
M:\GLML%23:RBJ9,[5Q^:33^<+288`EPEM-OK`9N^_=LN[<../,'C'(GPZ]<<
M9@*20-M"S9KJ4`N%W1?4/0T.C-UNK<-DO-"^_-W@39VIZ]>69RK,K'9.7$LK
M40&OW,^2E@P04P;N_=O!6[PZX+ZJ>\FQ6GR85][<50NZS<J[3>#M?>"F+<DZ
M2]SJ5M>73&RU&.%C;<*_!5')LC;4#9M:8>`:?MJ/_01QP+YM"Y<.+F178`)K
M0>**:^+F70=7I.(KCC(!X`,OWM8^K,,&T-`Z#-&2'8^%5@1GI\PEOM^VW63G
M.FO$Y<5'CN3HN]!@3.,,?N-CA@3A@/\=_B7A!AO%]Y+6>[4,7-[EP)WD.MS0
M*M#D:GSC.5X%'Z`)5HZ+_0U.=A`]63[@T`8#%B#G2ZW+#8W+#6T&2<`!$GOC
MUH50?C(5M?U;(Z#"ZTU<,)"^#6T#9@S.GHO+/JS=CVT`-F``$>##-F`#J=[J
MK#[KD*S#:BNQSFMJ?1W5'SX`&6"PVD76OS4#NQ3::JT,,,`!K0[!$8#:\/WL
M/3SKLQ[!$*S=8&SM8YP$KV[K\JT#=PW;.:F?'69YP"X*SYTJ*]%Q%PX8*//I
MU,[J$=RY2MZYL/[8$>S(KT[M30#KS![&$:SM:IO#8]S=I2:Z\BQYM%CNH7#N
MEK(9C^;FZ23_$\0%!?TNP<3[!!&@Y([<[)-\Z@C-N<VNZLW^V*@-QL3KR$TP
MR3JLVC9)UY"HI3G>K<#.\/C<$J`!\12U#(H-QO9N`(O=P]?N`S=@!BX0!F;0
M!$9@!!S0!$N?\BK`T,'-`13PQ4Q_[4N?!,X>V<H+9I6N\*!`\WQ"#I<043B?
M3LL``"Z0`RZ@`C80!AJ@`64\R>J;]&&@!6O?!!K@`B*@!1J0`S>@`CZ0`V]_
M`T:@`5H@^!J@]&80!D80!@NMOKJ\LRK[BDIL`DGC]?(0Z+9J&T>3(UK>%Z0M
M`ER0`V&@`D8`!SG``3<@`B)P`ZI_`SZ@!6Q@!C>0`Z:O`42O]CX`_P=HL/=2
MGP-&$`<W``=A$`$WH`4,S>$83_+S79<0*`1#(.683QF:#ZX[50<;\B&R%EY5
M"``BD`-V;P%:(`8:0`&L;_B$KP&Q[P(1D/A(KP$1P`%OO_L^\/T<H`*)__0:
M(`+O#P@&9BHJ9D\1-A$&3193+05M`Y*3DVUR)C\?5G^<G9Z?H*&BHZ2EIJ>H
MJ:JH`&D`$W5UJ[.TM;:WN)]V=G^[3"MK?@[#PP0$?LC)RLO,S<[/S@X$#FL!
M92(Y&F+8V!$<9F%:;$8:/EHN*EH4*AH:WNT^<!I:(G'L&H1L8CX:;!%-``T8
MB!`A21(#3YI,T5&`TJ2&;80<T;0IE\6+&/\STFKU*I;&CR!#XMK5JXX5*C"D
M&9OF`)K+ES"C3:MV+0<_#2+(<7"1(P><<>6TW'"A@8,*<F8L:#""!@X%G>R,
M&+`1#EL8&P$%+@*HPL:3)RH<-1Q0`)*D`B:LJ)4ELJW;MZ4XPF(+MZY=C7;P
M[!JAUHE*8\1B"AXLDYHU;$U\/@W*AHTX<N9N+#4304Q1-AINQ`OC(T>3>RK>
M:3'"(8*+&TT&`OP<^FM""SKDG)TD)(O:&3_NZMZ-4:Y'WL"#F\J[E^^0E`36
ML#Q&N#EA:2VMN1`30808#CDY&-F>.6>8S.K,V!"QU`AJ?F',B!`1P8@(@2J(
M^L"*,[6B180H"R+_U*C%["MI63&#)L(5:.`HOM%UX(*\$5='%3^HI40`?@`F
MC7,8Q@2=']:800%6%*P61Q-A4!!&!!X"!!6*880A4&JIV1!''%@U85`$*H1(
M53E)$$205@8E`9`9B\!V15D99'&'%55\@`>#4!:88)14UI47'K&,4,<'3.P`
M73$9A@G-A1R68<-`6BVBR'V($&2&#SZ8(2=!B1`Y51.*I!:'`4G$$4$<@SR1
M1!A9H<EGD`894(A!%K00PQ$SS+"+'7=4::E=4UZJ*5YX8!GI#'4PL0`,:Q##
MG)BH*G/A&C"8^<]]9NR)YY!-V&##(+@"1%`3(:X&8ZT%]8@CGD\DDN:A_XKF
M!PZ>MS;!`1\_V#%#%7R-L>FU(&6*[;89S<"$7\%,D^JXR10#`P7'IEGK9TT,
M$M"/J]6(U51YII;NO?BF*6@2-JA`A!K<!OR1M@(73,L8,V#@Y4KDDCN,'^?F
MNZX9>*(HB'T^VA#BLL8.]&.^(&L5K"!$H,"+P2C;0G#*+),2BQ5TP)#<J0V+
M^7#$^6(5QGHBN&BKCT1^!Z<&%/R#\<<AX_NQATM$V_+3K+@R%]14@P*J21,:
M4W.J-UN0[ZXWC-:.K[WR"@<:.U/``:]<J9!TR&LV$8(:H%9M-R@KW]UR++[L
M$`#-6V,XS!H`>*VT(F@(18%01N2@!=%$:0#'#?]HY$`!3^V8^-G;^1YD!A%`
M1*J@WE7G33K*N\3RP7$M!6ZS'P"XJ+0@B9-C!&=-W,"%8RZX<'93YKCPG1&L
M<8XO0!:@H*66I]]M>O,"VQ$+;GB,ZGJJ`*APT+UG1E#[4BJ$X=[NBO\.ASD^
M<-!.(78:?VP2'#1=QPC,0T_U\_9ON\L==VC)A!*DNIYS6I>][=T+$8GS@0O.
MT0X1D.\&%#C;#<XG%*44Q6V<8].A*#8W^M%O=/E#&?Y"R*TZW&%+?E$&X`08
MC0J5H5#'8E;8;J`^;(R#"S>PC!'.-\'O].,<:VL?W-9TJ":4[`>2FA0)6S;"
M)5XK%B?\P`H>QD(-(>/_A?:ZU[H@&`$?W"`,+E`@K]"@P!&Y@$AH"*.SA)BT
M>J$(=!&JPZ1.YD2#-;&.ESIA+*J`A#G\+1A5=$E+"%"&11Q0349#47X*H0*`
M$"H_L%HCTMJXE<\I+Q9RE!X(\8BM.W*R2IC\P0^&X#<_`#*0+;3&/PYI'X&X
M"46P;"2,0D,D>"7A$,:SC[]0H`9,3NHWG^26)X-)I?G1CPI>HA`J6^@`,V4Q
MAD?+D\A>I!K5[&M[!FPC_#[7M"3.D23$W-8PP\F@+5FA#@F;0^N6R8SH.%.+
M6ED--0T90\JD)DA?293QPE"R*NA!CKJ@(SDU-<Z!&BA43*B#*)&P@Q6R,SH?
M_WIF/-$D3WIFT4<<X(!`-)K/6]XG:3WB``JJ8,S491*<!KU405-Z($Q^0)V!
M0<9*9AJXF9Q+/R"+E0'BL!,:H8%G(E#*XS16CD$8ZEZAL560^*F\.;)48"M]
MJG`P.8,^!F"=%9JIUK9F4W2Q\5YRXLDY#/!3ZVBA,S?(@61<@`@B5?181IO*
M(D(`!"V=5*K"E!HP\:HI3)H$`TY(23*TNM6:=54022.2>\ZQI_`M97$Y-((8
M")&(>AU05]Z@*Q+YME>^JE2OF_0LE*8W/2:D0+!9U6I-J7$N'(6,2$0*7B+B
MD%8?W*,G;!`!:BCST73A2$X<H*M=.1M:T3(HJL;E#?\ZZX`'E`R20C3EZC%@
M@"<,OO9-YQ!4$\C1%0I0`">C42MO\P4H%5A@";T\J5.3:RGDLO<N>C3)$/Q(
M6(>B2FM0:`)87KM3`P3O"0;@P#DJMAUS?/<&?H)AFB)``=!11+U*?"^5W"MA
MN)PP=58`;`"C:]AC`$"_$DV7G,R`!B.,Q@7;U0!`=G([<T`&$2`+[A;T<,Y.
MF33"%3XN:'-LJ5_&@@ET\.,I`S?(#R>$<V45`1J:X((E+Z+)`'&!D@O16XH:
M$;U78ZZ/<<QC`U&XRW:Q@Q6R$%AG,"Q#XB)`]KZ:4SDE+306DR<BG!4"%%P-
MS)W<,9XOI4DKS)=,,153FLO_$!KW:87-U^45$=!;!#WN>5-??G1;[B`Z*R`A
M!7[#ZGT'^4)#&P_`06K3E8%0!=')HKB2EI*>4PTE3?(-#T@`X-_L2QCF6,.Z
MG@Y9/GT57!04`50SL.L?4,UJX$2ZV'CQZPE'\`,JK$!FR4&5.W&=Z\X-A&(6
MJ+,:2)JE$2"[O:O^=H%(PK\3!KO4&%C!56D]F`[AJ=H@(Q$%LEW73\F1N4\2
M=Y2.K>]<?-.$=QC#&"`T`@PH80=A$I>[JPSO-)FAU_=&)Z@ZU:E^0XG?%G\+
M$WK@1VH,>1GU74D`*$`Q[2'*(+[*BFLZ&H>#N,F(/4!"I3*>YXX0F^8'#145
MG+`#_Q@@X^/-@$XU/C000AB=$`@!,(`%\I5#&41.SB*"MC&)\VMAO.H@46@L
M8+WSGE_55,MX&$1M(*24`^3DV7S1BJ6.`@QD^=18_ZS-XP[*:6&2?DP8@A+F
M`(,`?+TE6`U&Q,Q.JR!Y#$>-Y(#4E\#+'RQ7V3>G.V^N+OF+N%J.'\2#%9B`
M`2KTP`ESR'0QID$`*%C`1THC!-ND'@+&`T$-F]UZI[Q=>7#/O?8+^F:Y([X6
M+@V!#@M0P@I"WW,`$,$"%LBH\A5/A.:'H/6,YR7=[)U)V><;]_L.-_:#X]?4
MO?WQS':\%3Z`!`P,@0I40('ZU\]^%`#A];!'XO?]:DQ\;]P_^[>_?W"^:5+Z
M=_N#_E=J\[-E^U,I],=_)E1]**5_7J9]#/B`$-@)E!>!%)AJ$UB!&`AF%YB!
M'"AA&]B!("A:'QB")/A4(UB"*$A.)YB"+,A)*]B",$A"+QB#--@\,UB#.&@W
M-YB#/,A$#MB#0)A2.QB$1"A./UB$2(A'0YB$3(A_4].$4.A$2QB%5&AL1UB%
M6`@U4YB%7.@66]B%8#@P5QB&9&AU:;``/9``:KB&;-B&;OB&<!B'<CB'=%B'
@=GB'>)B'>KB'?-B'?OB'@!B(@CB(A%B(=<@'&!`(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a57251a5725103.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a57251a5725103.gif
M1TE&.#EAT`+E`^8``(2'G?/S],S,UMO:X2,O5X6+HE%9>F5KAZNLNM/3W,'%
MT+VWLL/$RDA2<ZZSNE]FA!HF4>GI[7E[E:&CM+F[P8Z2I^+BYSI"9[J^R>3D
MZ?KY^M34U*FIM/W]_!`=2C`[8;*TPGZ#FIB:K920I75ZE+2XPFMPBYV@LMO;
MV:ZGHN[N\9*5JD!);)N=KY68K-?6W+2NJ<O,SEI@?[_`S*BBG>/BWT5-<)Z4
MCJ:INGEM9]#0V>WLZG)WD<+"QL;!O5=+26]TCF]VD+FSKMS9UNWL[[^[M]'-
MRLC)T[BUP\O&PX5Z=-71SO;U]\W.U^KHY7I_E^CFY-G5T:.FMV-74ZVPO\[)
MQM_=VN?GZ_#P\B\K.).(@O#N[/+Q[Z2GLNOJ[?GX]O?U]-[=Y,_0T<7'T4$W
M->SJZ):6I;Z^R=_@W&YB7<;&R?O[^\7%T.OIYU538_?W^-?7UJBIN>#@YMC8
MWS\\2DU!/Y>:J*:ELKFYQZ^ONWY^E'=^E*.=F.;GX@<71?___R'Y!```````
M+`````#0`N4#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*C?UM&7W\U2ZA_7TM6?P%#LT-@4$9;@BA+`80[1E8=DURS:!I./HMK45$:
M@UQ+4*33U-76U]C9VMO<W=[?V$M\?%Q%*3`T4%`TZ`M6,#`I?`M\0C110BD+
M*6U_'44T[`E9TXI0!V%KA`ER)F@(GW@IJO#YLX;A0D$!X*40T@L-.QK)P(D<
M2;*DR9,H4ZI<Z8E+%#Y+:%C1(`1&$1@:UD7Y\N5F#2MKXO'9\6=!LB@TX'38
M46.+#Q@^VOCP(63!DJI#%B2!^N:/PR]E4M#@@P]&%2-3A<#28"0`%#XU_SJD
M\*'!82Z6>//JW<NWK]^_X-XN$"*L!A\:500)21:`#PI!.V@4X6.DQL:B"PC5
MK*$1ACC/]?CXL(+8*Q^P8N%:>2G62#Q"25)L:5S#'Q]8@'/KWLV[M^_?W03C
M_(."3T1!,)+\J2EL79(.0U)(+_*G".%!<%.-4Y["R)^/1'VD,#T.QDLCT@\+
M^;.!AJ`./K*#R:[A-O#[^//KW\__[ULKE(&10A'BR7+;6](801D78%@10!OW
M:/><%;%1)UX*W'G'#ED:S&7:#EQ`-\Y,ZK'G7@#V0,$%"G#`$X!$8/0GXXPT
MUFCCC90X04,`2\BS`!=<T)/"$C2M]P4-2$I&#_](@T0!@W%5O,..%4(DYMD?
MYP3$3BZD#4+:`E#1,.`?48Q'6I(!;2&$<4/@Z.:;<,8I)V`:["`,%TX01)$3
MN:RQ0R]+[2`H%VNT489"@MARERU@=#!;*3'N$!,43L3XQQM$"8+I%Y4.^@<3
M1&$JJ*"Y<,K%G*BFJNJJK.KG1!*]M"KKK+36:NM?7)1Q2!+](-(!&M(,HLX@
M:UAA:0`H6'KKLLPVZ^RS@VQU"!]M'L)%/)*U`A$,G(XE34Q/P@'MN.26:VZ-
MTOI0FP]1_$&M$8G5$-(?8"3ADGM5T%`&A%5H\!(4&M"01+TT*'ONP0@GK/!*
MTM*P`9;)4%O<&D505XC_>'\D)XBT7/`!!1I\]#-?;0N7;/+)*$_3\,,>4EN?
M9<&^%U]M&O_!L<<@.Q%+=BGW[///0"MBQ#_K@?0&D]16=PXA8.1SZA\*"DK9
M'QU#L0:3/M#`2M!<=^TUPEN(E4*;$J$3<9L[\)'8(!N,,PZA`$E&4-7$B4WR
MUWCGK;>M7-20:0=-M9$+%&!P(9'.@[BECM44J:/G&E"PTO?3>U=N^>6TEE%$
MM9AW[OGGH(<N^NBDT\I$$ZBGKOKJK+?N^NNPQR[[[+37;OOMN.>N^^Z\]^[[
M[\`'+_SPQ!=O_/'()Z_\\K1'\$<3?D0O_?345V_]]=AGK_WVW'?O_??@AR_^
M__CDEV_^^>BGK_[Z[+?O_OOPQR___/1W7\'S]>>O__[\]^___P`,H``'2,`"
M&I!_]X/>`1?(P`8Z\($0C*`$)TC!"MH/?Q;,H`8WR,$.>O"#(`PA^1(HPA*:
M\(0H3*$*5\C"ZI&PA3",H0QG2,,:VO![+RS?"0:`@!OZ\(=`#*(0AXB^'%H/
M`@1((@&N1P!G=.`#1(RB%*=(Q2JFT(C4\\`1!L#%`4"Q>AYP'A8@T(`@F'&)
M5DRC&M?(QC;6#XO3*T`AJ'`]&53@`1ZXPB`4Z,8^^O&/@`RD'^`8/0(@:A`&
MR-[]")%(03KRD9",I`P)Z0<0'&(,V(.`G@9Q!0](\O^3H`RE*"=(23D:@HX/
M2*4J'W`!/V"@$$\8I2QG2<M:OA&#U8,`%@QA`P,<0@%^^$!7!$$$"-CRF,A,
MIC*Y1TD_`*$0*X"`%Q!A@D&F3@;+S*8VMTG+9OKA!$@()Q(@8,I#8,&3W$RG
M.M?I2&]2CP!$4,0)V$G/>MJ3BNZ<'A46H8$OWO.?``UH"_,9O0\T`@0"3:A"
M%]I!@@;SD(A`@A\(\(&*6A2-#,VH1C?:/X?Z89^+($`#8D4()F"4HRA-J4J+
MB,OM$<!YB5B!'\Z`"!>L]*8XS>GV/.J'<AJBF#*`Z""(8`/K7:`"2'V`3I?*
M5(7R%`(J0,0>_!`&1>#!>B#_%80_F\K5KJ:3IW[PI2'8T%-&5'-Z024$';W*
MUK8F$ZQA-8!<Y_H!`@Q3$9V<W@D*,0"W^O6OHX1K`P9+V`8D\:Z)L``Z"QG/
M080`L)"-;#M;RKT&'.(,95W$`:I7S@P84[*@#>T:>9I'1&Q6CXF8P1%M,-B3
MBO:UL!4B3Y^0B`CX00:)8$(#8LO;WE;1HQ"P@"(*X`<\($*FV9-`ZW#@V^8Z
MMX0>;<$B`D```^RR$`'8:O4(0%*#L."YX`UO!AUJ2$9,P`\LD(%ZU]O*[+D@
ML>;S``0^*][ZVI=]#KU`(S`[W_[ZU[_4LZPB@D`^"5P7N?=-L(+%YU%+*F(-
M%17N_R)((#T(S&`13-!N]R#0%0N,@;CU\X)K%TQBKGKT`]=%1!R^V8@!H#,(
M0C4$@K_'@C\0U0_TG9^(2\SCKO)TD>:$P`<LL@@11*^JC&!"COW0VNI]H`%0
MM.P++E#7Z$'```\PP(@S28`E6[FBT]LQ]9#HY8E^H,S!_,!B>\SF9>:3MG^0
M@ET105P!/$(#QG3P(EY0/4$0F'K2I:.`!=$"/QS`(AIXK!]*\.?I)4"]82#"
M`")PA:+ZH04-F$`&FA"&"'S1"T3P@A<`X(<'R$'21`C#;J/'`CEL.@("((`"
M&MD`(LQ!!UBP:9MWC4QW7F":@FC``0ZA@[!&`@/H;:PBE/]*/3]7+]!,_M09
MD``$&3B#"B9PL%(?4.SI?6`.'J"R]"Z`A5:V(`%G#:L*EBCFZ$%9>@8(0Y3#
M8&GT)F``B33`%;[H`2H4FM<`GZ4[>4"(`GA@E:J\@#0E452?'F(&:XZ>LP']
M!T'_80!HG,,?_EU6+WC``_*>'AZ833T>$+<%")T>"`C<;NL!H-`)('E!-6``
M"&1@JWEL;\!W_DEW$D`'FM*P]$@PB2-XX*6)Z,!W^_R'1DL/VI;%.(XO18"/
MAUNK?C!!#QG[V2L_0`8VL$$>+MU(Z16@`GYH^42Q;``6F(`*'NA`Q/T@``,T
M(`'5HP*%><YW2.;3`%2@PF:96(G_:CX@$6MENM.C!_6++]&@B-@M!`+PV3V@
MW0]!(`((3B"%&61`HIBFWMG3?M(@9&#S.%#`%:A`@#]8;P(&,$$86D#[VB?@
M\GW//2#A:CT<5.+F?DC`(50P=XDW_=D5C[;4#?H&,SK_C-$#0"REZ<D#)&#-
M'P#]JLV.]G8;X`@Y!KP'-#!B"V#Y"!9-_Y9US_XT\IYZ-D"L),[[@><[O^R*
M1[[%I>Z!7<I\JQ`@!Q``!,PU2+@7/3:@?:+7?1@%`H,G/0=`1P@P3]/#`TQ@
M`!\0`<77?AS(1N\W/1=F"=05/H*`!P5P@B?X`8TG=2QV!3)`421@`=@D/2!@
M`B7P10"P_W71XP$SH(!QA'9RX$\5,&,0@`=T1`!'<`(L0``VL`((<`2)5`*D
M-CTF@&8=>(6R15D,=@ES(#Z((`,KB%$A2"Q3)3T?H'EF&`$A4%<-,`,NX(/<
MYP<N``(L<`$*%P$%4%<&P``@L%8>L`(Z,`!C0&!CD$@0$`8N<`$$P`((,`9"
M)G18&(DW]('3HW&4T`$/^#T*L(F<N(DV0`(*0%P7H``XD&,/D`!><'H:M@+;
MAV,K,`=S0`5U!02EIET&,(,AH`,"('DK\`(#(&<?D&[5XP7^Q`/W=@0S>(N2
MN(Q`1(G28P*5H(,U)`,Z%STDP$?,F(U2Y(P[>`23H`'52$,R</\$5,`##Q`$
M5#`&ZZ>-[#B)6C@^-C`)NN9#!&`"+G`"+@`$5MB._#A#W"@])1`)E->/!.E<
M_VAEW<4(,E>0#/E:!QD](?`(V#@]!%`!"-`")/<`)X``(8!&-E`!]!4"V/21
M2'4`GF0`2(54M'@`#ZA>T?,`(K`",VB-(/8!*8E4#0`!3X!&'U``%UEV`%!O
M3U"-!X!4!=!()+!TU+,"96>3/'F`@_1%%?EQ%?"4_L9L!U!V0^D'6RD]++!W
M874"5%`!K>0!55E0:&='-VE,#^`",MF0_/B0?N`!ELA/K6B&`S`#!2`%&=!*
M!6`!*U``>;E$$O`'BG8`'3!/$F`!G.?_!6A7`7)P`I(Y5500`,PFF6%U!2+`
MEVC4?Q`63)*)!9NG90/02C^GEQ,0`;&4=@GP60,@<T@@`&*9`;38!(OG!Q?P
M!JH5/;YT5='6;*MF4!_W!U!T`190`@6``W-@3&,I/:_I!\\I/4&@0$"0`2U0
M`&<@!</Y1995:B<0D)()`3(0F1-`!)`(EU<HEUD78W-T/3B`28443'^P?2]@
M9!)P!1'0942@`HHI4;CY!Q!0`8D7/52`!9[V3?.$!T8VE]+S`&&`!P=8FH4D
MH2#@FUFG9&F'!;L9G=&#!!)@C<5FF]7#!GMP!>UE`&\P:K\Y/?-94'^PG8MF
MH>C4G-'SG!R*_WG0XP%OD&Z>Y`'$Z6ZN!Z32<Y$[B)[LJ)YR&#L"$([2(P?X
MYP>Y.#U1*@%(T`(",`-Q@)E4&CU!99:S1WM+1`4K(`)A@*#&I@`'0%]A(`,L
M8`'^)*$3):%80'(>(`#$Y04F@`7$=:,>&CT%(`!^(*+>U@$0L`(EP)M><`$=
M,%A!*CT;)P$2<#\PB@50]&3O1@4,`*D20`1*=:/3&6V>Q`*#!0$^6@&0*EW2
MTYW1<P!K(`!I:J3:B*3E8P%W60!D)3U/@'=4"@%7H`(0H*58T`0)@(F#-`<H
M&*8@V02;1X$7$`()\`;?90#K!@%-,(70V5X$(*%,,)-:U'T&H*@-P/^GFQ8&
M6+!;@FIV,W!E>!967H!Y6!`$C2IQ($!["/"B/@I%&69H2!`&=$0%"5![<PJ=
M,O>ION1)+8`$3(!'?W"1*->HJAH]%_`$+Z`!]0:KD:B>'F`"*(B""XD]>'"H
M5H9>?Z!S"B`%?K"EO62F$J`#7_=%`DH]S4D`6'`%\U1UT8,`"$4%5\!%&="%
M-8JM$DJ*TB,#*@!%7I!(/$`$`2L]2!`'7X=&YSI1;]!%$2!3!M"N'S5-P.FB
M,,H&YQ4]+TNC`CNVT@D]3323KWFO0KJV$_59&#!C%IN>[U@^,I"0GW*>TV,`
M`<"4/"``184!.I"5.""A6RH]6NJ?TE,!.N#_?-A$HS*P!O,D!2``!"8P`%78
METET`6OZLQ/:2@V@F080!`/PM4<;/<8%FQ\Z/4U`!<Y'`$'P`DKT`.=TM58F
M?%LKGS#Z`$QPE$&0`/,DMC8J!<X'`9_Z30,0!`90`$1@`&J[HLZ+`W@0!"9@
M`9D8MQVHGMYX"";+/1>``7,P!CQ@=CHP!PB`1C(`8M&S!U-UOM0#!)UH4P5`
MBWXZ51Y0``HP!J06!`?(`\B%`U\$`?[+:G@P!P*0;G2X@R#0B@4PD]%S`IUX
M`2L@C#/``BR0<N@%3-.C`-BJ`!^G`!XY`X*H:/$K/3BP6ZG'B00@`Q3H!R0@
M`'.`![OE`1X,L1B,_YLU7+_WB[[6*[<3:3X`D`AK4+T[/,0F-K?B`P'*=@C7
M1\1,7,0]3#[2M0BKV<14C%,'V7J,<$Y5O,4J=9`>D,2(`*A</,8;]9"#A@C]
M1,9JS%!RJ0#RM,9PG%!RR0),@`AN&L=X_$_JN5>'D+IY_,?LI)X$4)>#H`,;
M",B(_%9&3#Y6U\B'G,B07$NR&LF4K$Z37,F8G$V7G,F<?$R;W,F@+$N?',JD
MW'-_(`<(E\JJO,JLW,JN_,JP',NR/,NT7,NV?,NXG,NZO,N\W,N^_,O`',S"
M/,S$7,S&?,S(O,O&53K,W,S._,S0',W2/,W47,W6?,W8G,W:O,W<W,W>_/_-
MX!S.XCS.Y%S.YGS.Z)S.ZKS.(W$$$F8("?`$$>D"V5L(#%`!=<P(&M")FTAD
MCZ`"(#`!,Y#/O\>)8Q!5[)S0"LT-!.!P@U!7N/4!*W`(``!/%>"CBH"U8;8(
M=`1L@B`'%R!?N-D!P#0`"GG&?W"`'B!\_)$!;\`$J/4)&?`'+JT(;_`""YW3
M;]+03'`&`W#/<O`'#.`!!X`$?^#35X`$&A":?V`!2$"]'H`$)JT!+5`!,ST(
M[5H!HB9J'<`$>#`!2/8'>!`'6(`%L10'0"<(.[E+<@`"NWMI=H8%4I`'=<P$
M2'`%;(`'-I!][WS1@I"?`A8`;HE:/IT`!8#32>W_#$2`!-,T!V!-"7%``%1F
M`V,@"@W0!`IP>(GP`79HAV/H"+YTV8K@13I=VC;2T!A75TA$;SC6>@U-1RR@
M9C56:!-@3`30BYQM`Q#P2H+0KE$\"$L(116P!AAH6")@3`,X"`#@`1.`6F&`
MW`<@!QYP9A"@`WQ65"9Y=%(P"'[]!_E)<"#PB`#\!Q1596S0T7\`3$A0VUHV
M`9-P`O#Z!W,@8!DP!E==55.=`#$=!F-P75?P!@+0!`J1`3H`4Y>=V0'@T7*P
M26(U""K`!`D@`'7]X%7%!$?`TG\0VDW@#[K($!T@`"\P!Y!GVB3.'ZB]B!8`
M<0`@W4]@TJ_=4ZH9?(46_P9/X`$#0`1!\`$J\`;4B-7!-%?NK0-A8`$FX`%\
M)@(=,`9$8%-'$-,)\%W!.`8:P%QGD`$D?04)D,)\1@`(8'XL,``IAG:#I6;Z
M?0&U%@$/``$FQ0()8,@D@-[J+:H0#L:.`-^(]`?(6&V5_0$N8`"8:`('8$DB
M\`!`8`#"!P1/P`,&,-$Z8`(F(`,T=>`/$`$FT!6Z=5<-3F@DP`,R`(U'4``'
M4``N:`(/P`/"H.%O`.J.'@!,P))```0C7N*R?A\G;DKU]Z*+].+3I-Z%YI@^
M6FX7<(+,Z^,7H$IQH`$20*JM-`=%90-XL`;H70@.2*IR4-(T+0/R15%\MD@/
M@/_2%WV":W@!=,0&@H!)66[K,@#G?H`$1D8`+2!_=1[?3=``'8!T<Z!?9MG4
M#Z`0)BH,^Y:P41R/@Y``\2CI?_```4D%?"P(*:Q>T%@!>R`(,O`""D"M?\`"
MV2L!<9#A\]D$"#!L?V`"."`%/_P'$Q#KLY[RO%'K6@6O^4[>!:#N59IV?DVQ
M#=")/O[;ADD`8]`!=#0`'0"%<ACMFI+/;T!.U@YE6,`$)O`!?`92W5X(W2W?
M?D!J]2K6T-G06I7N?J!'R&;4<B`!'I#ICW`"CV@`&?#<JN2C'@!L)D``(<`$
M4O#;-L"R.,WQ-]@`L=WQF2W6AY>!C"3U;MQT2*``<(;_T7^PBQQ_V210[`_`
M`GMP`)9(VM<0`.R9T7K&%TS@SV<0UOVQ\"JO#2Q/G"Z?ZS&?=NF][KUN4W%@
MIQ[@UD_@WKU]:80`!`00!AV02,@H7!\0`H?J`C0E"`?`YR]`7&R`2=AIAW_P
MW$[_4<)/`'E@9X)PT;3G`M\U!UI&!7C`V3"_]4<05GGP74A``L;5].\=WQ@A
M35O]HH00`+`W!D3'\&A^][[$87^P;WQ_>$$\`V0/"`9_@X,5"H-!2`H5@Q!>
M@R`D?X(-304A7ID!!26#8Q^$H:*CI*6D2!\7CX0S,C(&CJ5-#::UMK>XN`D$
M2']A3X,/5+G$Q<;%#P:NC`7#_W\>Q]'2T]35UM?8V=<V+7+<@P8%?Q=2@]P8
M'RI_31\,".EA+`12`2$$$#:'@RH?"*%R#0BP>/*!S8%[!N80"2AN4!,@!#Q\
M8!0@X!,%'P@H,Q#F`P:'%PC@(23E@\D/,CY:.``!P@,Y?[Y-DK#F"00")#[,
M`/`!@LYH)X*(`L`#@PMQT'P!P1%"0H=P&$RX^//@!;AQ",:$`%5)P8-!)2`D
M$'7AA-D3<@PA4L3H#P@#):0T(#+I3Z4P!B;,./"B(P($#T!9L*#-5("*JT)U
M,''B#Y8,5X[\L8`#PZS"F$L1>6"C%X(&"K`\D((G#I;,J&\UR$"(B8P]ASR$
MP3$CM?_MV[ASZ[9-A$F'WOL"_`$^G,D;+QW^:/"BX7CR`'*2_Y&C0SBA#E[>
MB,*BX\KRY`.J#](01H,H"TU8#WHC1WL$'5BPJ,"N?1_AUIF\T+T^)\&:0<2I
M<%H'+UBPG'E>Z!"!-`G4%LH:4I!0P15_3/5'!R44T,)I7E1`0AS_X;$?"-,!
M4``&Y5`100:=^/*!=(2X4,&,%0P@@'HSA)&!`(2`\$0!<T#RAXJ^%$`""/\)
M\*,`Y:RPPFX-)$9("!7\IP`/,E1@00,`A"`#+;MATX$,("3R!Q`?!#%`,D0U
M\%^8J5TP`PA!1O"!#4)Y\$0%#90#YY^`!BKHH(06:FAF#[#_0.*AN$4Y!Q54
ML,8/"_XH``%A!C@H%Z/$%"#"'V:^\!55GXXS%J?3F&#"$Q=,`&ICS[`V`"BH
MUFKKK;CFJNNNO.(291-FP31(`#((H$!#!*QR6:^#X,`"$D@8```1H@;C3"7,
MYH(%!*\.DI07!&0K[KCDEFONN<8PP0244N)A'0]X+#*(#"-5"":S`M#(P@$9
MS#&J,(-@BZYR'TT7;A`M>#L(N`,W[/##$$>\6PL)ZQ9E*"X8((*7&LC[QP`V
M5%#`E^::^4;(&0!L5Q,-8]'`$R+(D#`5!C#R;;@2YZSSSCSWO+"4MUD`XR!,
M2#%#<DSLIUP<`K!G[A7K_N'%&7]D_W#:=/4US(84]_TQAPY>#]+!`#Z7_;`&
M0Z2M]MILM^VVVW_$(<'<=-=M]]UXYZWWWGSW[???@`<N^."$%V[XX8@GKOCB
MC#?N^..01VYX'+CHD'7%N,U0@71-="ZL!@)8-4U;A`Q0@'EO=-[$6!&H'G4Q
M7/`A^^RTUV[[[;?_(8,?O/?N^^_`!R_\\,07;_SQR">O_/+,-^_\\]!'+_WT
MU%=O_?789Z_]\Z/6`JZ?,>'601`5<$;$&Q]`RB,1BJ[0_3&TSNO"`S)H$`"D
M0`!3P1.0JF-,[+@+H`!SM[OM&?"`"$R@`A?(P`8Z\($0C&`#WU>*%1S!!M:Q
MP1]T\(00!/])27N0#"&PL#\$=&`3$BC`:0J`@!/HX`0`($&0!I&!`WBA!>YY
M'Q#`]H<#G(H0<V@*#L;6`J*`[0T%>`((XO<'`G2@!6_ZPU[^`P!]1`.``\RB
M`'4GP2YZ\8M@#*,8QTC&,D*0@J/`@@TZ$()%:1`(33A"`@9@@#@^@(=_*(`4
MYB"#,3"A!`.HP*<@\(0$4($%.@`!$`BQA@(\P`2/L,`%C,2&/[QH$`K`@2CD
M<(07-"`!"KA`$S!P@#^$H`4)6`$3GP`$('3M`A585P@.$((0O(X86-2B+FO'
M13/Z\I?`#*8PATE,!QK@>F@4A11,$$<9F.,/$^@3$T1`N3](@73_6:H`#U18
M@`,40"C<&E)#A!(*"QC@`V&XD"^^<LD_9%(4">"!"1I`!0604RBTT@`3'6,`
M&Z13.1,01`>2TX)JPFZ7MUL`%'RPQ0(6\Z$0C:A$)TI1+V+@`=9+Y@@/`"DJ
M/(!E&KP0&WA`A1`,H@"N&D0I"5&`VF`!GX.@PCA'^((;5D`*V?D#$TR0QWHU
MH&N#,$%R0E#/>UKR-+.ZCF1:<$TO+*B)DQG$$6!U4(363@A?^$,`HK```E;T
MJV`-JUC'2E8_G"`"%ZB>1@>!`-(UX2L-T,`*FE(")DA@#T\`P-7^,`9OFB`,
M>UE!`20P#DBTA;`+`\`\(9F`!RBV'$PX_\`3@O"I$X#/!2%8@0%`,`;$$O8(
M#PA!`2[0&@GPH`$\P(*H0@`$5Q4`""%XP%.K:E7:P:`*-=#`&FK`4-KULJS`
M#:YPATM<`P+`:QZ@WEJKIC0"?>P/;Q``#SL@``&8)Q17&,-^!C"&-Q!&="J@
M4%1#P8;3`6@,_X3N$68H`F<H1[I74$$`[G,?3JIVDP6PC@K&(+H.S&$,UOE?
M;1-J!4(8P;<.+:Z"%\S@!B\83'A0;L.N>ZM<UC8%5DC.&JR0@C+4`,$.CJ@'
M"&`#5]C@`\D-\7!]8A(($'?$)?X2BA><%%-.;[EFPXV%K5J$/VS!!S20710.
M/+O?JAB8$*B`Y?]&T0$=N(``1PYKD@6P5[&]()ICA4`!FL;D!+C@`\7M&D:C
MA^,<VV;'"$V!$`9HY"B3D04XR)HI-$`%&Y!5(T`PD6(-`&6Q;C:*I>A`$X*0
MXHFV*L"F>$,)&C!<'@WB"HR&WG+ED-+<N#<45T*"%)1&"%@!E1!4<'0M=%"O
MU*!9BS1(@:I7K6K;M=G-823!;'&!!0`4>J(0``(5A"6*.>#@`+<6\0JJ?(L2
MI%6B09CU+9#H8N!>.@'-=MYRF\!3W3A(%`;0;@F([99!(%84S;@%$DB'FE-G
ML0:D^(*K$PSK+T*@1<<00+2O%^SL$7)HIMAIO>FM/0)\.A<!..;V]BW_/0AH
M,AICZ#-9GQ2*(TBZ%DTX@`@,<(+_).``#QC)%28@`1E8Y004`JQ<#;`")@1@
M!3*8P!J8$%L$4-A5+HB##"3`A`$0X`$@<,$59N`"(,@`)D^JP`=*>042'$`R
MS9A!BUI`X02H2D9_.,(!)!`D)#[`'SJ8P,@6)>`!)\%M45CW\5KB.[(KSP,M
MF;?R0DM<=%*#"&#&G@CBKCW9&B,,D=:>K;'7`#D?HP+;"X':I?<!EDW#"W07
M*P]&007N0?P#K'&!"RQ@@S=H@']T?`,6PF4"L@$+M-/Y0R'_((()X*$Q4A+*
MU?^`@,5?[`$#.,%7B*!!9X+J0A\(P!L>L`DJ_Q"!M!JHMB]DX)L'5``O:XA`
M*0U`M@H(``E1Z@`)KHU+VR6A!MC/?@U0@&JQ&T\0`G<$X)5'52RX@'DM:,)P
M/R!":LPA\=2KP`P('CT/K`#0Q'C#$[97`39<SP"S)0"+]P<`,`.U9@`AL"`'
M`!,>%`HAH'='0'_,`P&B9DHC`0(%L`8!!1?0Y`]CL$B$D`$*%U:",`HD(&T0
MMU)_8`(EL"A2%TB#``J=MPXGP`1$L0(:8'PB(P)80`)`8$*$H'J>!U>/`'LG
MT!:D97M"(0<3H4UA$&X5<`05X%X@8%)_D`<54`(',".E1``S$@(3,&Z#\`(,
M1UNS,P3I=CM"4`2SL_\`'\9+[#8\&#``+B8%8=!G'W!.O.,3O",1A78""=``
M#4`"Q$(`?<:'/4$`8.8!-@`+?I!^$-``='<G"D=BT<8"`2%,!E4-5#!XT5-*
MYT=O%B(-';`'VB,4!5`]$#!#-.0!&:`"!)``$F``"*`,S\`R%V!%%Y)WU@.*
MU0,^@P``SE0S&$``5#`!'R`'*30D^W0&$@A1I#4*;\"+R3-M++`N.W%QR7$"
M+@"#EM1#DC$!)Z!["Z$#))!.\H$%'6`!,D`VB$`50V@711A[2*@[@[!(3'`!
MVD$AX98!!M``>Z4#*[4G"0""%&(#%$($&H`$#Z`=+7!IN7!J-+`%0T`#,+#_
M`TMP.SVV`#2P!'^@;G"(/!"`!07``C'!.XQ`%X!7`#;G!Z!`=R>@`+TS!C&)
M!+P3!%[@!P,09P5``$>@`4R@`2S0`F$`$V/B!U03#'Y@`F^03@W@`240`/'%
M`L"D@M?P@-:#,V-6/0U1".+@2:!S8N7`!CR%!1=092:0/24H<-)3:H2P!]MT
M`$S@!S"1`-#@`;BHBW^P"WRGE-)S+T#D`5C@`7.P!]66)<M(!?LD>EE6"F'@
MB<6S7#J@#"'0``LR,JKB"Q9"6B!@`T_P`!,P!EQB`%@P`%S2``*``5PB`11&
M6`>03@(Y"73QFA-@(2:Y4@8@"50@`R1@`!U0`8N2_R6B,'%`(!6F9`*2534-
M4)D1`'T/@"7XA@NGY@-_,#L^T`&W0P-0\)%_L`,IX'W'8P),D`%QP#LFH`%I
M)0@RP))0]I*]$Y.\\P%8<!$VZ0<XJ9,:P!)XT`0N!@`0P'3W,`/J-V,%T`$0
M((4NZ0%!L"U^L`)R`$R<9@TJ\(S,LRX=<&S3(U2A,`8>\)L`Z`%XL`MY`'U2
MXP=2P@1L63VT<J'28Y*C\`(><`$EL`804!LSP"T>H``=0`!Z27K8@S,G&3W^
M(PHR8`*"4`$A=0%(\)FDMYA>@*'.XP%2.J546J56>J58FJ58RFV#H`/,4V;H
M$@`OP`+*5@QB.`W3^0=5P/\'-(!NN$,#:/`'W.=5R5,"&9!BI-$[G,6>+FE)
M[[D<=-%X"E"?][F3O!,`:=D[+>"E?L"2?@`$,W`$(_$!+O`&>,!H1Q`&,S(,
MD/E%P%`8)W`]IV(GTQ,+BD$`JBD%2S0(+=``))J30/,"V!-.'P-_S...H]`3
MZX(''L!G_L!G(=&C`="I44H(<@"ES&.5H3`#?C`2[),1/!4&?J"(B_D'+0`]
M@*DKC;=V/4,$4O!#T6`!X'H,IY8"7*!5YC$$M6,$.]"N6_`':[`#4`">QU,!
MZL<[$R"3O,,`>%``<@!EI`63_I(HO*,`S.H'3Y"3IL,[*G""BGJO+/DB)C!T
MEN3_`3)0@R9P!@,0!!Q+:&;D`4!S#41`H<I3,']P!B/H/!`Y""=@`!?P'AX@
M!\12``SP`0/`K"&;BM>C'NY$LL+CHJ*@@2PPB@,``NX8`"':!%QZK=>#1_(6
MI;C:<#T9-1IP!$T@'0/0!%<@.J(0`3X;/-FJ*PZ+/&!J9IEA;C"``F4`!480
M9+2S!%P0MW++!3M`K\9CK[W3D`<A5`T@`VL``!=`(C"IK[U3J?TT!PJKLU20
M`/)0`!^0?KS#DH(`9<!P`3(`96/@`B:`!2P``<K@2]&(&519/53U!Z$*/1"`
M:(00`'IR(4%P`38`D.B3AR8Z"E?PM<CC#X3`M,W3E:$@_QH',*3&\*#7@SG6
MY#Q`*PI::++'<`#/$[:Y,HW5:+:`LF.I1@/8F[UN6UNO1CQXVSLAH!U8@)6'
M\`:,,+B_0P`4D@$3D+B\@ZJ#$`^0VZ@#0)A8(`<D`A?)X054*07FH0(\X$N2
MD!GEJ3QY\`((G,`*'*$2`#V^2P@1$`<08'@Z)5X78L&D$(?&<\`*W,%`X[S-
M$[+8D++'(P4=[,&B$,#,\ZF8`0+/6PUA@,'K40):FUZ$4%.FD%.FT!%D2RAQ
MP`9$<`AA8`,KH``4G,$AB$=$T'ZEP+6[L6-&\`=)(`H@>3LPL`1K1J?0$Q%E
M][7$BG;$`P&W-F*^`\:_1'U_@/\'>?$'5R`M:W`%!]"WE91')5@!!O!I%K`\
M1WP+3_$\7)H!*S`&T\"HRK/'MM`!U'@\U6H!G6L`;T`$!C!B'T$`_GD$*.$!
MPA<*6YD\/6H+*8H\P$@(0(!VP^`"R<4";^`")[:;+(!VX^H++UP+M!>UHA`"
MI1N,K7("`QP*9'($H1L*'L!UI3`')%NVJ5$!2*`!=%$`K$$$7$H(\8.>T@$$
M%4@*U7H;.U8$-;``;!-VMX.&4FP%1`9B[29!%$8TAA@!QP0"?-FYP3P)?J"4
M3GPAN&O(MA``MJK(I2`'K"@'32`<3:D!KY@!&?`"T=D!N.L']BS+R/I]I&`#
MS&P#KJ+_`VRP`N'B!RP0+R#*K*Q("!/`/)U<"YR[/((L"C.@"C<ZGFS`!A"`
M`17@`0B@`@;P`!D0,J.P!K%L"E+@$B#P!B)@?'L%`GB@`P50`0>@`.]G`%0P
M`RT0`4%P`AQ5(6,@`PI:FX/@0>QW"P<;F<5@`28@`4$@&=XD`;S7&D`@`0!0
M2@7`,BI02E3P!#S@*LBL`MW``CQP!E(P#/L#+W\@`*LB=*%@`A]AEAV``Y-%
M(I[R!.TH;T\@`'+P!!)@`E?0`3$4`CR0,$E$`DPL#>:F10OP!U%0!DD0!1I@
MM^7,0+0:"E+@!XQF`!H0P!7P!HT7+L<DSZ-`K,"ST!!'PL9C_WNB<`(7\`$`
MT`%C<`$7P`+A\0$/\`0MP`+R$,J#T-#%H]NF,'_*HZR-8``F8`,2\`(R<`#.
M^P=^4$D*@#-X.0IC`-+'$('*\\J`&P1HD@%/8`!```%4@*3@P`C+>-O.`[VA
M``($\`0,$`+<T`#"ET)4X`%>8@,"8+DE8,<#X`<\P!(:T``G4-\5@``$()4>
MH,ZO3`HZ2SS&W$,L(P"EU`"UX0+P1@53\:^@<@A>0`OS)4GFBP1>(`X%\`@5
M<`)KDGP:U`!!@@=,-`>2``*N`AW'"BK#,`%/DD]$\(03<'%K\`8DP)(AD'S)
MR]D!5`3O.@A53#M)L`9\4`-)T&/;*_\[W7O:"02DV.8''H`I\=P(\5S;5.$'
M\]Q$A1P-B:H\N]P:!(`%;P`!;*#,0XRWX2MT'5``T*O!Q$/=I;`&C"X\Y$06
M"?//(Q-U\:R3[F3>AGRORA/2M=`!((P\M/P';*"^1$`U$#`&&F",=IS??[#?
MHL#;Q^/?A(!X5@$!AZ`"?J`>"`X*K3X`,O,'$.X'&A`!)FKAY1T,!5``B\?,
MN/#17$T,\<-3%Z,`F%,`3^5,00#CM##A)B!^-H[C.GX"G?D`R1`^N"<*/A17
M/:0JW$).+R`.M**:01`R+=@L!7`"-H#NMEY]5GPA:P`&:X!F/>8#-6`$3L`$
MIJWF"93:H8#_`7Y@>\Y;&W/@!]RR.SQR3+Q&"+C].XY."KRK/.0V"$@@$1D1
M!Q5``#*@94W0H<0N""0Z"GN./"$_"BNP/"`H"G<X8F%P!(I(E>)--LM^BZ/@
MZ9Q\#"-_/*5N2E+Z)"3@$P20<[8G`U-!):3P\<+S[U+S`58Q]9/A!_[SZX-`
M`,*>,,5>HC$>DSA#!2'!,A&`?Z2`],,SXB_A-2?^"-A."`C@*EX`#2&@24=`
M"SS5`1_0(>.>1^5.1_'[!RR03A@A"CB@W=-A4CMZ>W\P[U"U@LDA`A6P>6-P
M!BS`DI_:]%UG.]0)`V6P`$50M[>#;H3`AB&9/#%:;V)<=EI?/6C7_Q(^2TB)
MW$`U)@HR:7OI[0<VX&+#(`(83Y6_3`CU;`QVV3S&NQX^N0:;TR<QL=9)\>HS
M+PI!H,?&X(S+X]NCH#1K\,RU(/'+`^JEP-[*4\W:D-"]P_4G$[A2P/($0%5D
MWT1G#PA_%08#?G]>?EX-)SI^!A9,$`0=?P0G?YB9FG]A$'Z?H*&@#YNEFRH'
M-@<#?S)$?T=WF6LA-A(&?P$&-@`R?P4&$C9$+6=$%8*O+7%_5`T-5']R,HLV
MFP$V&9A/!GH7?R&8`\@5+#---C)Z+7\J.!@B(G]2SWBF]_A<?/O\^T5_-+CX
M6`"P7S\?498L,+BOE:B'HDC\>L@``R@/5_]:0'S8X`R!C2`A^L+48<:'D)\(
M#"B`LJ7+E@E,)3"`#),"&1<,(,#$I$4#&P^:E"+R$I10?*7D>"H::H4I/`U8
MA&#BS,0#*0-P-0MW1&(I$TS]'$6J2<['L-;(JL47(JP?!6LS73G+-%JI"`'B
MXKOB%E0#M6$F7/F3X,0130GF9,"`J42`(V'^#!@3(-H;*F\4R/F#ATH$##;8
M_2D1&5\&&R])Z5V-:23KU[!+O0$BHL*!O+'OZ6/(1\@?&#4"</G"FU\*&L4=
M%ATSP(L'41*8/'?4X20$%A>>>SC)@L4G"2H,?(1P(3NH#P8@0#CIAT!443*P
M'&@@0\X$/Q[*+_7_`V&7!Y4L^?$!77T5^$E-:^&V"26FL!&6"05$*.&$AV6"
M10,&/G'/&@HRL<9K,CPXX8@%5(A)`-ZY18`I1P3Q`B9-X(")!B7@$$$F&4R`
MQQNEH!;6`21..(8F3&#H%H*9S/2$!7\TL0)<G!4@Q8=_1.!"`3%M,H:!?^7F
M929AR/``$W$=4)1J7^(S0YILQA4&#E0,UF8FN_$&`Q\P.+&%#\7!L,,?22QP
MIT'*N60#%@1H$&(HD_#PR01-M*<!)@D0@,L$F"#@028*0##I'QE\5``G6,Q0
M"`M$7,$$'M/Y(8,7[+G0A*>81'"!'Z@RT4$3'ZSDQPD6$&A@7UK-F8F9_\.*
M(L4L)`R+IK&8I)@L*/:0!%:!`FSB`@$$0#!#!1!LVD$#'[#@`9,Z>-```0=L
MLD:KTW["#$G-]N4:)A;D]\$W%Q`PJA00'/"!+Q&PH(H?;&Q2`9?0-KQ)@*DY
M+/'$%&-29S\T6,$%%$(4MP\,N7"11`T7-[2H2S.<\&LAHE2`R`7RI<2?',#\
M`9:&`1-AGG5R5/!`!ZAY8*H?1#S!'Q;7N@HK?V\*R!\5"G@0`$L>B+?2!,'&
M6Z`'GQJK`;S3FMC6L!_<D\$#A.02Q-HNP`@$#UC@`W:R/&("<5_M:D(`"$$$
MT($&LXX&05X'^"+#'G^\04"UF,R@=2BO8++PUO]D9H('!$]00>4#!7R])B()
M%)`6"?=JL)];75;<)A5A/:OZZ["S5O(^3ORQQ=\I>.S#&C34D,0_R/53*$H$
MK+'"`QH:($K9-A3`\@=2,`#"%2?@\MQ?!+QZ$@$3S#`]$B'(`8KS9<=10057
MQ`&*#!VHX$5)`[8P0PD)#/`->^T-P&00CQ=X";0EZ)\?-M.,N;E%!:4(E0GH
MXP4+^"%"RS*)!(!``#EMHA&/6Q$F3F#`HD"@;IB8`+=6P*/`'0!QL/"`6;+5
M"J^T1H`0R`0.3N>6<&0B``_P``M`@`G.A<$/<H(`"`X`!$SDX1N9`,&P(/",
M)CKQB5",HA2G.,7*E2+_`1T$B>M*T8(G/($'0T+*"DK0ICB()DTSL$OL2C$[
M&OS!"C3PP1_X5!P?="`%OEO"&A@RO)"(@`@#""06[B.*.;1`!ROX!`8P@!T!
M5.\/UZN$]OR```%@AP%(>,`;,.0!#`Q@12Y86Q"4]PD9!.`):'M.`:Z`G1/8
M[P^W2LD`(B"%N0@P+`0`(9O>$$NM<8T3-"S0LC9Q!`]0X01QFX,'$D!``SRA
M`VOXP/\V`83^L0`3.A!67S"EB29@)QR!XX%J,`"!*WR@6@8`0))N6;8_S$&;
MN-1E!T8)@;AQCB@O^IH">#`2%Z3N#2>[I4!1$D-39*"79R)+$+S@!1VHQ@(W
M_R*)'"95@&BL`8$GZD`$(A>`#W5`5WG1QAK",*D35"!5.-(&)JZ`T4.T-`-Q
MRT0#_X"%`!`0$QR:$9G>,-$3G4@#&NAH3%<SNQ0`B@]N-(+'4O"%#GSA"W\8
M`A\#"A)/G>P`6)!6*7.1H@1H!`(6>&0D+?4&@24`!_RQ`!(\L),S1""0?A@`
M#K@%@/U,$A1Q2`!_0%"(#("@7"OH%4O"@("!%F6:;$)K_[X1`'CV91*;4)0?
M+H"!#LR!/QY0)P%V\@<2;#$`6;17+AP;EGIFH@)A"$(+OA&XRR:`"1<8E0D,
MH($$0("`:T!6_W#Q!OP-:U288$`!@L"2P7#N#T"1P_\*/GBY&83A`PB2@F&G
M"Q(DEN(!?=GB)H*0B2*&0`:\`!5]#E71V9PA$P_@IPV6%13)N,P$!SA`!&2`
MD[#29X?SD$$Z.X`'`QB`&2XP0`/:-@'_\A`35!@54!K@0BRT<P(*>($!9,`"
M5G#W#T%0P$TN0$;9,<2H1D@!R#:0@MSQ)@5_6H-4I^H2$[P!7@-PP4.PH%@_
M/"``6`A#8:SG!^SY(28@8$$``I"!!"#A$Q>0`01DU9XLC<&N2P/%!88L!P44
M@@!S""&`)JN!I%$7)%EFTSL%&((UD%)KYRT%&Y2\$S+-8%,?$(T,U+D)E?7O
MF5I-UH4[$(+G0.!%@0.'!W3_R"-S/D<>&Q1H$,;U.%:T0P8>@(!3_G``9&"C
M/:69H0=X\*G&?OG3H"B6)L;F%NUJ(@B!!,%(+'"%=J$J%[]`0.8T\0`R=L``
M3&CO.+QP@9C(0`>)6\,)--0!)&8@`P=(``]8.`!2=``('6!!EC*1X#]\@!)3
MS@0)CE#L/[S:P1C&1(85D"C8%-44Q.E'"HK@,>%1-5F##D6D6S*=>7\"`N:3
MP0H"(`%0J.<EV@P7J,/"`@MZ*<_Q:@$`!$@`!?U!!S)(V05.(```=&"&?P#`
M!>:`11-A0@ZA[8L+^MT_;K9F%I%K!Y,T$08%O2"8\:K`PA_W@8@*8DVP0?C`
M!UK$_TTHL4"FSD003G`"QVA@O3BP1COMMB]@HS?,J-7U>S%Q@:Z9E.H:,(`4
MDMX$+(B`!508`TW.YP4LK,`&C*OV2!K@!0O)``,2\'8FRG;A<9L@-FW<@-[W
MOH$E&,0W`4"!#TS,FS[N'"4>.(`4%(``+Q]^YPT8*FS><.;^'2#D?2DSCIYP
M@0\```LS*1</._"$?2'ZAM@58.6U!H%AYB94`UU]O![AI;(^_LM((@SFM:A0
M3;"R`W*P!A`P@P<B%&`%<FB`@I"'A0$T8`U/$($&"N"R"P-`!&M00!BN#LO?
M>\$&3<!#!#)@`B*P(`-$(","2H4FM6."[;0V@'%!\`8\D/]B%>;7\(5?,[MV
MJSL*?V(["E%X[W9[!GB`(6$`DK<:6)!Z",@4$"`CW71@?]`!82!Y5]!V#_.`
M$*A&KR$'",6!+M$`!L>`CB>"\2*!*Q6"K4,69V0W%3!RN?`$`/`$`8``0S(#
MG/4'#U`!(4`"<!$!/%``(@`"6"`:3%```"`!GW%@//`'+E`!*R`!81`'7C0D
M9_`$(8`I)Q`"(>!T?S`&.U$3(2!Y1S`25^"%3_`*&&`"-9@`7H5W_C>'*;`$
M94`)>T0H!8B"?'AX!/`BK#$'+-B'&^$!'@<;A46(+5$!5+(:4:.(+D$`++0:
MIP&)\1)&?Y!KR1)T;?(`CK9&>B'_`F]7,?TWAQAC!'?X!^GF;I;8BJ#V`!JH
M%DQ@`KMGB8C%&D;CBB#Q`8P1%T0@>[KX$`9P4V3!!#Q0B\$($2IE,]/"B6QR
M!5T#BFM!!`OH,*4XAS1@!'U`"5LP@"R6C.#8/Q!@`B60<J>``3P`<^'X"4"P
MC'$Q!WL8C@8@&/B`!7A`B^M850<``BUU#7A``J25CX7(((G4C-)XD`A))Z;(
M&[[Q!VNP!(3WC0(YD05R`95V`E1`!1-0`29@'A3Y$!=`!0Q"%F]P`K[UD0)2
M:0B@`$TP!G@@`D'@D2@)DD`R`1DI!1QI+C/I$M>40O'BC`D9E`USC?Z7`E:`
M&VTP>`2X_Y-,V9330@`XX(Z:8($NH(Y.>958&2\:<@56V8)"218#8$/X<`2.
M9EU?J0E$:8HP$`6?4@82F95P&9</T1\`$`<*<`)ZT`!=*9=\V9<;T0),<)+.
M4C$MQQ/M4VA8\`9D8H$QI0(:T%.YT`$,Y061`U';,`%Q@U%K,`"?@@46J$MK
ME):FN`!60"5OZ9>HF9JJN9JHV8;]`Y2Y$7PM`"2"``0/8`$R<'S-TUDM\`"8
M\@$2X`(?$#=!P`3G,Q]_,`(B0`)%U``'$`UE,P,-X!,\Q`(F(`(V8$6AN9`,
M00-)<)05"`55,"BLR)KF>9[HF9[A>(*;.#%?B`DF(``R]P<ST/]S(C`J.C`!
M/F%MKR`%0W)A5V`"K)`!4H``95-1F%`V0)`79955>;$"KK>=W-D/#;D#"A$\
MIZF>&KJA'-JAZPB;L0$$G_($>%`!+S(#=P>%SO,`".!/UH9@<,%=&O``V:(+
M6W>@=J&@F6`"%I`6)_""L2.:?1(%Y.DQAN>A2)JD2KJDKS@QC<<$<P"+%<`*
MMW9\#5``&-`V4/&BS1"C'6`"5$"95V`#P+<B%7`"DU(V(8``_"41/MH"*A!F
M03JA=&HR3'JG>)JG>II=%',$!=`"KR``&.4%,%4`)]`!"+`"G3$/XJ`-,X`%
MYU,![*``%4`%;;8".X$I:P`"Y?4'G`7_AQ%PB*HCI'5:GGMZJJB:JG<*HL;R
M!GL0`D]0`-5XEM`"!D5PJ[B:J[JZJ[S*JX+@7\`:K,(ZK,1:K,9ZK,B:K,JZ
MK,S:K,[ZK-`:K=(ZK=1:K=9ZK=B:K=JZK=S:K=.:>[$S?K0ZKN1:KN9ZKNB:
MKNJZKNS:KN[ZKO`:K_(ZK_1:K_9ZK_B:K_JZK_S:K_[ZKP`;L`([L`1;L`9[
ML`B;L.TJ!T37L`[[L!`;L1([L11;L19[L1C[L-.FL!S;L1[[L2`[KGBPI^"*
M#Y=!!7RU&GB@G6RB``K2!+%X#QV5&P*0D0H0C:9@`7*J"40@!1O[&O;@!3%A
M`1(P+Z6P!J#I_ZXXEPE`FB;VX(&LP0YCL!D)8`)-L+0Y*Z>"FB12*1LXNQHU
M2P4S\+6;8`&3N!IK\@8?0@0[Z$XE6*X<1Y*3<ADA"QL*0+)ZP6M-T!5M$Q<+
M!2V&BEX.9PKM%1LF@`--``(VD+2:H`!0FZ`)<`"8^!K<161_L"3XT`2WZ*X[
MRZ5SPEWWPAK?T!RP]"&=NPF.FPE^F@D7$+.FT`)0`AL/@+AX\`&,RRE-NQ99
M=@)"D16^-ZOC>@5=NPFP^P>`4[>O<01["EQKH0CXT@!^!9]_(`(30`H"X$4N
M\*4R1P(:@`424``\8`$=4`$%\`17$``A$"&Q2+0U.%1,D#<3(`\ZX/]%[)``
MY!L$8T`$'W``.P$``$`"6:8`>U``$[`3`B`!(>"!5ML:"3`#(2`!T8"^-1@!
MCML!<="+"4I^8Y$+>P``5_('$Q`9&8`,4O"#]L!=?I4`%_`$<<`#>1$&%#A;
M3J$#>_`$%3"2:R!S`,`*(O"_:[*%3P@A)'!ZL`"KR[*1`,`#I1%"#QP-J_0'
M5S`J(`"K0R(",T`*\H`%/```$U`V<A`"`(`DIP2KFT%]`-`W%B(!-3@IH*L)
M&<`#(2`"X5"&A#$&&G`E0,`*WX"#;``!>I``\O`&_EL`>5$")```+:!&Q?8*
M<Q`..J#&G9,`*S!<&%`D5Y%Q_YLM.D`"?QK_#@+@A2;'@T=A`@T,JY@R-4D\
M``K`#G%`!?P&`)/&"4[AO>T0#G]D``<@`@/``O\K(V,0$S08!!V6"\`5!R\`
MJ6?,"C4AAEA`@ZYG`?[+`S?"`Q,`!&N``S18`945JQ(0$Q!BPW\@`"!0-$]`
M`AK2PR2PL@UPR44$S4E\(T#@@X2,O)L0*7K*O&KAO$QP`CPP#@E*:0^@`[=V
MS")P:PCP!B8P!FL0$PA0`;:R!EW7`CC0`2N`(`$0!AT@`6W;SW_0`$Q"!%Z`
M0TR@`%@U!@W0`3)P!GG!F?8W+G.0A`5`!"9P@0UP4PN\RZD2`!'P`".,`VN`
M!Q;@N%1``B-Y(1<P_\XWU0(GL*G?(`&]2PH60&1TYUX('=(D0$8\`(8SL`(J
MP`0L,`=84`!]^P<8```:0`4:,@=O\`+6T`#=_`=_]GT@%`$JH`*D\+T!@`,I
M^G!8%08'(`=X<`DZ$@$F<`46<`&Y1<HVDW%4H`%Q4#8R,`9,\`1@&`28@0&X
M8``M0`N,,U+3ES!MG`D&X+(B\!?PE[IRT`%'4$3?4%&!Z04(_0<K,`%O,`$`
MH`MR$`$&X($`L!,'\")$D`&*<@0*$'EC<`#C:X2$\=/0UFM,X*(FH`.XC5Y"
M`8*IH@)9E0$BL`)K,`,)L,HS0`)8T`0'4%N9,(M_D`<$8`$EL"PF0-%GT/]\
M!)#;,F`!4.-MQW8!(&0#FS%EYZ,!`H!K(Y%@7@`!)V!S3S#1>-`N!!`"`S`#
M!Z`"NGT)+X"H$@$!`H`%!J`"2'###,6_[K36R%T!RETV"<Y?#,X&9<4X]$P8
MRYNW3-0`X>#/+WH`:Q(&2/*WCFL!:&,"W%4+)_`&-L`#/$!$2>)?#1#+]%G8
M7M%?./$"J?NB[?6^$]8`*F!#43P&%T#D#<`X#W`!],$*+3!A%]`$9JD`0=`K
MM#8'+A"KC),6B^W4DD$*P/``,<1=_GQA3``$O-1-EZ`#3PC%J5,`)D#D/Q,"
M!O``9=,`CM9.!1"+<3!A92/GOHL)*Q!F"#`J,'/_31/0`$3.`G*`5=)K767S
M`41.F_^,"9G-"IH+)O2EV>%V+^WDO*<=IB20Z-?4VM&`1'>WY3Q@`K\F&E$^
M(UB%1#-`YE`C&MQ5O%1.7RJ0%E?P%[[^`%X.Y@;`T)+>!'O]!PH`!!#`"@!E
M`!A\<PV``%)@`F1R=[PK&5IAM?=]8?"'"26J;'\`!'+R:P/^Z$LGO=&"*)8N
M&B*`3&@C)EPZI1V^0?+`9[C^!\7[HGO-`EB`1&?:XIG`,GFZ[63AO&`2#J9C
M,T*1=93P"CJ>8(<1`8M&"2&``R'`)!H`0N_]!^8SE=8)B.WT!%">HZ(\#XQA
M`=+>!.];`'Z-"9*WP)@0_P9=$A0'\`JZH@`/<`;/TDX`T).8(`&;T:/@`!='
M\`!?C`DK@N?(L'\D,`$4V"27H`(70`D0G@D3<%X=\`8Z4$31U-$:Z.@:F%68
MT"Z47BP@\#\`P``9=P#J-`<:0E.++;TR@$`)4#8PDSB:P`)M!UM_D#:M_G[:
M@`?L$-H)RB,FW=&14:DK(`]KD.N_L.O2FVP.^081D#?#MUU6S.^9L\KBQO!P
M`0(\9`'M<@&2'0)_<0`\HIV%R^\RT`1/X&@!H``V$`9C0@D=\"QLW2X'T.Y_
ML.Z5[NXQ^GXQZX:#`00X=P&H@$#WJ?$[&AD:(/KA;``18"LG,`%#$KD%/P`'
MC_^BV`3WI-#P93/3QDO^$T_QTK"GH0L(?X*#A%X-A'\&!@\$?R9-@E0V,B8=
M05Y_"E0"+$`A05<&,BP61`TR!@J#(`TF#Q6(5!>#!0\'-B^:@A]_)RPK7C8F
M)H=>(A4"L"`L,@<!@X^#'0<FMTU7S`9ANA-/@PB3)`42@Q$7,CPR?T3G!P]_
MM@>-07\#L/2"`A`:A%@7)']`3'J`9=`;&3(:('@C#`BO!IC^\/I3(.(?$@<.
ML/@C`=(``X/6\##0`("@-Q_X_:G0P(`W$]#^6#CWA%>34P94#,HPJ8&`1`/^
M-#DQ:$:K!RW^T%,W2`<S'H<PG.-!98X!($`VSBI`Y<__+$=_`HAJ,&9E2ZZ(
MSA#H(,A%,QM4%"15^N?%A8H7@+CZP^38#)"L4#T3]`#2H!#N+EP3Q:*)W#\3
M2"2P\0`F(5Q*XPB"*>""A(^;F\2E^P<BH1.'_LA!R$*5C@^H*J8>U$34A:!?
M_\RIT*(`CIG5WDVL,`!)A3`>%`%A:`+((;L%)`JUC5M0!:*(LFO?SKV[]^_@
MPVOWXJ>\^?/HTZM?S[Z]^_?PXY]G"KY#041R-.@,L&80%@N"!,"6!F^$)4=8
M?W001H$)AL$$(D1<H<&#A&@0`2$68,%$!P0*HM,?&13(A`4:%%0!%1@4%N"!
MA/!'B(),N*A@@1UV0`0A$29X_Y\@"JYAV8@=/*.!'&_LE^"#@XWA0@C9$1'1
M?VPADB&/"Q:$190?;DA(&`$\PT1_]B&2P8V#4"A(C@@&*,@:8720I0512B,'
MA5?^L0:#@G@108?/["@($QE$D%J$'3+1II5\%7C?8#(Q&H$*'1*R1@:$C,G$
M&Y$.=D5!&H2AP3,5(("!"6RLB(B+<G8)YH)_U%@0F_T10J&6:69PY:)W\C-8
MG8)@(`$>TC@XB`HA;NBG(!H,$.M]5Q2`!P@&4,I$?L]DR>&77F2KTXR:%O1A
MLLO^B:=XY)9K[KGB!2#?NNRVZ^Z[YVV$[KSTUJO="RX4,(.]]9:`+@(N,,KO
MP`07[/\=$U(8K/"6(CB[\,/9K9"PP6LH4`%Q$&>L\<;;P>OQQR"[FQO'))=L
M\LDHIZSRRBRW[/+++H?<K@?J>?"!!S2GE[/,[8X,\\]`!RWTT$07;?312/^Q
M,\\$@-!>$Q>D-\8,#WR$'B]^['%`>A!X00#/ZD&0]-ADEVWVV6BGK3:_$(!=
MG@0!!$&`!P>$$+5Y,D!@PP4F!.'!!0&$0(`,!%S0P`%[0."!WV/@,0H+?D!@
M@@=_M.WV>6*OK?GFG'?N^>>@S_NUVQ4P4<$'."!006WF*7!!"T>(,$<!,B"L
MF`$%#"!"`A4T`D$"1Y`@@P!^R'"$'P$L?7GFH3?O_//01R___<FC@_T!>2S(
M4=X>5+3^>@A^'*"`'UY\X$=MOOEQP0N-^'%"`7YX$``!)P3AQ_&7HS?]_OSW
M[___TS.?VZ[GAP8,H#Q!<%IY7-<"^SU@?.4['^Y.X(</L.\/[H.?'U;``^+Y
M`7+Y.P\`1TC"$IKPA`I;`Q)0(8,'N/`!08AA$$)0@!KRIGI,6X,+",``$!Q'
M!MYKH!\>2#[SH8^"%FR?"YK`@\@Q@8(>:`(.\U?#`GPBAB]$Q0$`A,(N>O&+
M8(P>$:C@D!#"YP&)\X`)[#8?O9D/-GXP0=L(=P$;1.X!BXO<'F3@`0)8H`'Q
M"X+ES,@>%H1@#'$*HR(7R<A&(BT#_Q-XP"`)2<FK(4$*RJOD>3X`A!(<RY&@
M#*4H1UDR#4S``)G4I"I7"0$9`(N4L(RE+&?)+PV,(0237*4N\P<!$B#R.Q?X
M@#"%^8+OH`41IX/`!TR`B1"\TCLZ"(+`_N`081HR5K3,IC:W^3(F8&`/=]NE
M.#_V@2#@X9/<\4`#JEB`*WRGG(B8@Q](@(`"?(!2!(A.=^[4/8L(P@`?N-C6
MD&"0:?(ED=Q,J$(7.B\O4,$$4QRG1-O3R@EPD5P>@`4A=OA!'?S!"P;XX*CB
M!X$SK,(/01D$$#T``2+@`7($2%@"(("`#T@R<D`@A").X@>38"$$-'L`I0``
M`0"P=%\5^/]*"QIQA09XP`9E8:A4IRI5)-QTHE@]SU-=@%",`D$!8$W`'UPP
M`0P(,P(`^,`<)*86&[3@HMJ#P`%FP!800,``+7@#"`"@@`?X809-B%\#\F`"
M/U3`I(,`:`M:8("NP0,"<5#+1B0P1"K,C2*-^,,**->2%R"#JJ`-[38[T`0^
M9E6B%XB#0<VUM$/(`0`D`((?QE``#SR!4A+!!R%><`":$0"?^L1"`S>[1#\P
MZ0_]1`0J(:"XDFK``RL0Q`%G0-EGX(!\!<AL!2B7-P"@4[3@#2\HF:``H)Y6
MDQ^0PD7MY8&*9`L+`Y!K!;:F`"P\X0(0@`4\M1,`/$#@'?D4Q`7_+E`!HZYN
MMI$@GW)!TBH>0,`"?L`!LCP0!\HFV`O9M0[EB$""#T!@`N(-L8A!&8`2@/.\
M;GMJ!730U7IEE!`5@`!;KJL`(A'A`+Q89@?P-(<GW&A^ZB#`$SJ0`3\D+'D'
M-DSW2*13!F.AMW\87(%B?`4+(Y=\VY5#!_`HE#=<0083&;&8Q_Q%%3PTHBAF
MUP6>,(/5\NO%3?&`#++K!P78``(A@,T?5DK02-#,PQXHIAT]X#4"1RW)@DA`
M_`Z@4_1$!P?,_5ITK-S/,92GCQ[H``$(D#C+D/G3H#8A"/*6YG41X`"&R=@8
M<#N(,$BA!!FHKP844%9D80`#XWK##"9`_X4+K:,$B'0H#B*PZ@`H@%$O``&+
M$@U6!8R!3!^E@A18M(T\*8`?<IB``BQ0%@WL>E^A#K>X`2B``N2RU.<AP(K'
MS>YVN]MLLP8`"-%]@1"T^=WXSK>^A88%/'3XO*=&`+3W3?""&QQE1X#H.).C
MF8,[_.$0U]@<@'#N$-H`#V:*N,8WSO%YK>$(M0VA0KZKL@`DX>0H3[G*5\[R
ME2^!(NR,N<QG3O.:V_SF.,^YSG?.\Y[[_.=`#[K0A_[S%F2\X^%]`P9",&^/
M)4=V0]L!'Z9.]:I;_>I8OSH,,(CNKGO]ZV"/S_60/N;^\D"`[6)!`7Y)-*EG
M_>UPUSK7PT[WNO_;'<5C)_NGCR`/L0>!U49S>]P'__:MW_WPB$]\)?.N=U#C
M"\U^((`(EITTP1/^\E4WO.(WS_G.NXOQC0=U!\IM1S_88.UHLSSF,:]YS[O^
M];`O#^A#'^H`8``/;J[\ZG?/A];'_O?`O_OL:4_\DZF>]W'W??"7S_Q2#[_X
MT-_8\9%?^+DW__K8E^CSH\_]A4W_[35`01%H<'GE9__\Z#?C]E4VAF8[>UXJ
MP$-9CXZN(S1;`"I16`*:37GP2,$%W8<RWY=U5B`(4%`%,#!XYI=^#-B`Y.1/
M+K,TE/,=XH`(3+!<!90!&=``8O4=+L!HB%`]<C9P!!-2Y1%@XO$`LQ'_@"0S
M@%F7`DNP`X)0`PE8?0YX@SCX+NN7,K;U`CXX!PDR!PGP(>N@`SJ!#08P`'AB
M;J72!`?0`6<085KV!U?0!+B%!0OR`E[P`!\P``.'@E+@!W.A`4>`?X)P!1G`
M!&,0!H*0`5RD`FP((CIP=`:`"PFP-?[R!]NP7E@P!AY%&"O(@M*W>S10!5``
M)AV0`C:8@XS8B.VQ@R@#9SQB.=#U!YC4-B?@5^61:D#5<()@'M=3`>8!$BV@
M3F)H'N0P""BH`A'V!S.0,Q#@48PP.M'5`%^Q7101.7[0%8G%8%=03AT`2.7Q
MA)!A'@1P(2HHB"7C@E<7!?RP!48@!$7P!S6(_W4+Z(C8F(.0>#(VHP@&@`"N
M:`%R<`!BHP@:D`!7@(1*6`Z0\P$'@`%_$(4XH&46H(4MX`=S<(\7@`<JP(5>
M2`B;U@`-``$7@`57(%?_T5A,($DS,!,;88L:]@<L\``=P`8#5X<#,`=&105&
M-0-KT#T3H`,]Q01V,0O)J(P<PXQ6UP90D`2*V'M60'Y9=XW96),,N(TF\S<O
M1`5,```M`3DKH4Y&5QKO@`A7(`40Y0%C<$"J$!`)$5)R862"$`1AIHKK5``D
M``$N@`%^$(<SX`<O\``V(`@.41JW2#DD(&<+H5-]I#A/Z(Z#P#>ER"`3X`<+
M&8@H^3`J674RR7K69_^3@'F3$-@RDM@+'L`&;P`_@M!7'I!3#5"4LG(2[<64
M]3!/&L`&=5:*AD&5V8&"CG`!W0.$?\"5`W"2G-D`$U%;@H``(:51__0!+6!1
MNT`?Y72/@T%!;W"2>9DQ>TD#,/";P/F;?3F3?QF8QHE].%DRA1ECF");%"%6
M.%8:-C`'.T*5>.`%7WD"8;!!+_"5^X(`F1E%@I"5+Y!2@D``C]`$,T``!C`_
M!#``.D``O&":O+`U5,``./,'(D`IPM!DB%"7+G`%`.`'>*`]-F`!KZ@.NKF;
M>DEX6Z<=/I!\Q7F<[2*0%`IVR4DRA2D'S`4!0$E9-+,O+E`>':@;)AA'&V+_
M1Q>PA9$#.7(AGGK8-B:ABN>1A#(A0"QP(_3Y45^#GIGF5SCS$[V8'2'G`1+V
M!S-5'C)0(`O*H`JSERE@!%(ZI5):C<3Y'O(Y3#<#B@;``CL#`;:X214G'UFJ
MI1Z#.W/#`T^0/P2@`4^@3,.4,\*D57-J'NLDC%WW-TUW`0803ESJI>QA..8!
MI@V`0T]E`)#',QG*,41P=$R@`Q'P!A'A!4W@:R`RF%6X;`KR#!TP!W.@`5Y`
M($2`35C0?TZ2+0+3`>4Y"`&P*!\2`$/(!&22`4UP+%B`3E>@`WZB`3JP;*WJ
MI!"SEV\WG-8XH>@Q`=F2K.:#9]*"`%_C`25P!40`_T09B';EP0*9&!]GD*S9
M@C_ODA2%.@#D<3D3P`1"EJRQ!D3;2JU^8`!>`)[F`0L:Y!X0<`(#JDHD@`$J
M,*X0(`(Z00030(D`0"D!``+66AX\P(]<UP`LIJK4>@$8T!\6L*;J-YC`>K';
M(:Q39P14EP(H$*%P1Y.H2`54X%%8\#6P`+!B13Q`D`$?4`!%1@!,8#_H\0[W
MJ%7K`0GN=UTXVQY+`Z[O.:Z7%C(R-J#1,0<*8!@?P"1X8!XF=:*&E8N9M#2-
M\`+K,K7KD4E'\`9K,*Y$$083P(91:%SK(`5B=4#H@6N?V`AK,`'(^@9MLR\@
MX`('`K4#9+$8F[>#H+%\L/\#4E<%_%`$$BIVI6H^\N,UY;$O-@``<P`!0(`%
M!*I`F/,,D@HY%8`)*D!!Z`$)Z7&Y^RD47Y,MC]LV4N`M(RJ&I1&TY6$"[J0"
M%#L'7O`$\Q.OAN`'3^`%0"0#&%8>%:`!;1,=U)I33^!':]`VLT`$Z`$+.!`4
M%E!8D7<$";*>'G`C'1"[6O@U<>`%D!,"AD``",`/"0!"VO`';P"OV5L`1-`!
MXX,YJMNF%D`SL2@1?A`!3-`V'@`"\(`>S/6),"&*?I!3$I!I'@027!E"BZJW
M*,FW1?`I?U`&@CNX[_$!-[)=0Q00Y@$0)P`!85"I3Q`"39!)$/`384`%`?4'
M.K#_`C\1!YL+<S44-4EQ!1/@3N`C"%C@!1``+`K@`F*U`J@;KN1A`&_0!"1P
M!"*A8%A`!(,$$D9%*4TK`O*;$J<+O`CT!WNP01=!MO<:KZTB!1,0`$Q@`QX0
M!EX``!7PD1#@+UA`!3*0%(S`%@,J!\6+!QJP)/#51TPP!R$@83Q,4&&``^ZD
MB<8HKK9;C.41'?>5">;!:%RY:01@OY^HR#@372#@`4/2-@!AM0:,MPB,L<)*
M`Y[L`QW0`4)`K,4*'U_1`27@!]&AN14\/A>P!URH`J*05C7[!_?X`5=@PY$7
M`9IV'JDVE:@+/NIPCX)@L+S0N)$7`!I``$`KR!C0`39`_P`LL`9<B0D&BSFJ
MNA$;0@!'@+PC:3G1004%L`*\##F'L)UCL,S)^P=-:\52,)83L&D)$``L4+7E
M,0LKH`Y#P@OQJ0$"L&G@*`,`*`&;%@!OX`$$%5+><+J!3!ZPX+]^0`\MH`[=
M4QX@T000,``:?8\3N,NN.`,/PI7`D@`@H!/RE,E`XP10L-(LW=(N_=(P[=).
M@*3N5],V?=,XG=,ZO=,\W=,^_=-`'=1"/=1$7=1&?=1#7:+<`:7;`;*+"!\0
M`+TV0,#FX0WS"@%7\`1/@`7[8JTVVZZ(7!Y$@:?GLV<(`6:HZU>\0$&[`-;S
M"@D-T,SD89Z"($^8T'3EX5%)D?]3+:`!3N,!%E#1JMPB61P4(/&5ZZQ!(*$`
MJ4@(C%`7YM&'Y0H+27$`]#$(JY,='T!0YO/5Z2;(``&O46L"O.!!<100&;W1
M\?.)%80'<\`&J@`_$(`#+Z`#P.*MEW/`&D/*U(=U-%`:%QK<RX>7V0&E7'#<
MR'W<#_S4A62"L`!$6*`!`O03X10'BJ8D?C"QY_'5%Z`"$4`S'G`A.,2YZ,'&
M%=0+?B`(-#,++P#>S\#,J2O("M`!%\#(;8,)$043:S``E-P??@4`OFL>D_8!
M4_0._,"N6@RO)H$#A[!4C-Q'D%T>);`&U,RV'0`!C:``C-S((`8$&^X'G%W!
M-]O0D?/_*6U#`$#X-7!BN/!(UI?&VI0(+%'#7.61%`R=VYJ<,KS=VU;WVRXN
MW$#>><2-"'S+>R*K/NFK`!@7X-%1L`>"V!&M`FU3`B7@`4\V'Q^%`Q<`@-DF
M5J*]B4+1!&(>A>:]UNFM-.4!O0D@!4$ABG(-UF%0`"<P!X"$WUPC"!2T+][L
M!3Q;R'M6,_R`MNN,RB#P!AW@I1D0``T3!@,J-AV``X4%@O9S("))H!T@SIH0
M>42V`A40`4`4XIY-XG[@Q%X``NZD0-[`!"#`AI6.'AWM`0D0`2``A('E!P&#
M!VS0`0=9L4"SXSQ.=3X.+Q]``BMP`L;>,$X5Y,J^2D-."$6^_P!+L`1\\)(A
M:ZPU.@/1+0#4Z@$\\`)$)@*6<P%L0*W3:6:3!`&()`<>5@!M$@84?!Y4H-'R
M?CP`8#5="#\:#8LGD`'['7+US@(EA3\'D``=$`$38#Y'$%_J,081Q`->$(:,
M1M8\8#7J<0)CK!Y/,``3T`1K\`+.^P$@H,Q'8()2(*E`&@;(,>J[&WDM<`6J
M2K,&,`8Q(A5B.`#FDX197!X!K_/'H8?O/D]S0&3Q7#,:'3G$H>MQ,#H'H`.?
M@@>EA](_X^N#EP(^X.O!OB[UA@<D6"%-X`*HM.Q@GS_-OK>KYP/]P05%L`52
MWWO6KE47`/#Z:P/6BN&8`ZAQ7ST$$/_-8;/AC1PY<W.")SY%'U#/@_KW-*[S
M<E_XZR&?ET;@V;V^YH%IZZ%,%8?A+*7WD?_V2\,":%>GE+])=X8Y`P:+H].6
M7#-)!%"H7)/X[+%IQLCZ@\H"%Y!*UI/C*+/V<"<$?[`#1F"EP`[<\=$`.$"$
MWP&%Y!CVR!\R8R\(?+L#9;``7``#7U`%$)S\FT0%>&W]$Z7;&8/[PQJ#@M`&
M5<^7P.\>(#\O86"WVK_^[K'\N[]Z7Y`$,,`%*<`%TE[M[)__:<;]$`,(-'R#
MA(6&AX0I-7]_:T6$-'\-?I25EI0K;XR;G)V>G`($EZ.DI::GJ*FJJZRMKJ^P
ML;*SHPV?G3O_B+I\-5Q&8%8=0KN#,'^TR,G*R\S-SL_0K!]>M]76U]B,@L3$
M-#XH8'];2UM;D)*G!#/9[%<RT?#Q\O/T\;;7N=R%"P&,'4/ZC-4;2+"@P8,$
MI[%;R/#3-GV(A/SI4"-)"CYHVIR;5.I#DX;8L!Q`2+*DR9.I[EG+!W$0C21+
MA@4\AK*FS9LXFRD$R9/=PY:%8`RY&'1CQQ<]L;W+R;2I4U@JJ[$$2H/HS*=8
MLVHUN3.I5X=`P[I$-\K#@*_6.MC8RK;MS:BWI@9T\H<+C"57W>K=RQ=65[2`
M?P*M\J6PX2]R(W&\)`"PM0`?$A8P``_"9&<-*ICH:[)!@<6UL,GE_U;C#0HN
M1=8LX":0L^O7K_\Z]BJXI0\HN'-#L6)(\2@`LZV=@6#JB9?C7N:X(#[KP9\6
M4.-D(-OQSXEF-M;\&<#T0P+D7@#D+/"G@BFXGT83`V,$!I<4XUC3A$V__E;9
MP7G6%MN-.J4/FN3W20<AF$)>`@J,T4^!E7A`BH.6>`"A'Q\$L=8I$UH20@<:
M^$?)A!]8YT>&&#9((B45_.'"A1^R<F(I+XZ(R@58$*'`C4"T\N*$)\88(R7D
MF5<*>IZHMPL7<+@GQ!=5R&??DU!V1XV`20D&@P]89NG#(X@0M@D7O7E(!96W
M1,#<*.11Y@<!?XSAH`S3"7`!)1"$H,D,<_]Z4$$`'4Q`G`TO!&'`"W%0\L`+
MXEV`P1]$;&8)!!!\!!H$+OS!Q`H0A(A`BA9$1D`+7F"!0&00O"`%"1KX`4$%
M':B8H0U8_)$!'JJN$"L(D7GPP@LR7'')!V<PRL.:"8!`R:`3K`F"I210`L`+
M!K!QP@M-.$C`"[168@L5I92*!`\:O#$L)0=$\,<,D7W`!AXR!$"``=3,H*8,
M"<@ZDA^'FK`.",2Q``(35U3@8)#GB1:6$7]\T4$'8#H9Y<,0DX0?F3X9@K`G
M#1M2!"-<=`Q%F*`12?$?.)22)IUM>G#`'VP\@<4:'WB`QQ^$:K""'TUT($6*
M`WA@P!\%1+J&@\O_$G!!`%?LP<8?3XPBJ27D%;#"'!Z$V,$+<OP1P9H=G($4
M%AY`\$>L?T`0;`4K_'&$)1=8\(<.+7APQ1\"Y#%1`QXP$JLE`&(1PLPW+RJ*
M%'_(`($*1/P-M!\MC`UT8Y21\,>]QVH]1Q,,5L)F!QE,T*%X$OR!00CA$C`-
MGW_\+,`>`S1-7@0GQ"J"'T%,=,3G?AR`!1+F8N`'P4,:'%82-;01!0QY1:S\
M\O),//(U5A911`!0%.$#%R@@XL,?J^GB6R4X/.])`"^2A\$)$X3Q1PAR=_`!
M`2L#\$`'`OQ'X1]4$$#`S`;\7(`?(9B<!U10OS%)0'\!6-LEGE:)M+F`_P7$
M"1$&PJ8)XA#`!A<8TP7$UH$G$&!^&-#?S$11B<8]P`\\^,,*WO0'!.3M.9&I
M!'!,8+HW!(!V?Q"/!;@3.@#H+P)S^!3-;.`!6]SL!6LX$X6.,`<%Q.I_FON#
M!M*E`1T0@`E,>)_D@J`0%WS`%@EX``$D](8LJBH#6&!![?[W,V-5K0%MNR'P
M2"$R3ACI$$8HPGZ(T1KF^?&/RW">^&ZQGP6L0295",`AJK*%)-#@D8+YWHBF
MQ!,-D*TAE(-:)UH`J8D,8`!9RP-P7&`)&3#JDT3X@PG\YX<+T`T(?VA68S+P
M20UDP&G^84'6`C"!JHG(#]0@@`Q>\`8YI+(!8O\+@[/^H()/JN`/++"$"?VP
MJ*7X@6XO)&$E[":'6I:-`!V0@RD#)ZM/ON$-+&C<O3S@!1W8H$VC@)0?&E!%
M2[").Y200P1,J8%/3F<%IW.0!\:D-@.$:`:5*$'A:G?"$"'!`R&P`!,&P(1C
MS#$T^&@)%QH1A>Y!I(^`#*E(72'(07IB/U7X@P\&@8(.&"()G\C86!93NVK$
M`5(XA=01&$$%XC3`7)O@I`BL,0=2D$>,]1J6!][0`19<X*D?6%FV'.1**CSU
MJ1!@I1^6E@`B.$BA(;CJG!;H'P<=8`PJ#-%U@/F'$+U!%&E#YA\40"[1B35#
MTP0.@T)4@A>.(D4\N*O_'PBG`R:L!3@%N&OC%D.XI8%F1-$<40`28$\I$@<"
M;YA#B)C@U*>:S@OX'-$'3A"``4"@`TQ@SAPT8`.&W@\)/Z,LSBQ:GH)E%"(I
M6$(_I#@$F?!Q/B,-KG`[0DF30@\1-.C0%OKQL4)<KV/0Y4)SC4*)156#E*-0
M@-K\8(.F@9,1&5"9=JRA1""E;DW:F5,`\6"`"KP`4A_!`P`B8!X+O*$"#6"#
M>;3ZLS\DRP\&Z$`89/"`*["H$@S$1!,,$,`*J)42U`C1&B[``J3(E:[$6@,)
M##"&S%%BFIA=`Q4J4-$'^/42KMSG`>1PH7?^P5AKTH`[>D69Q6JN54081:4&
M_]""N:V5$FSZ0P)"8"Y2I@T!!A#!$:H&6DK`Z@D-V*$?QM2Z>B$`APW]`VQI
M)DQ-_*ZVP;LM4%+@@QTPP@@.&ZZ:UUQ2XVYBCPLP\Q^L8)5"T$`(VX`!\NQ,
M':#>PCQ/^*2@*TJ9Z9A'!W]X*P%2>8W'?EE-)OC#&1R4(D9((8*-8>8[/K#3
MB>1(JQ[HAYIR!]0YC-42"?:#"2JJ-E^N-9@KD]5.+UP)C^CMA-+\`ZXO<)9$
MG_#$ES``V2QP:G/A>I[3^8,%HFGC2JRC9"C6+B-<6-DP6+<$Q/%`XQ@A`B;C
M\P*9#@"NA\H(/V'YM1XX`2.:D+4O"XF.PFN)$(P`A?^%[8!+NP#IFO<MTC:[
M^0^U>4@*]L@'B1`%#C+EP_?$9HW_J=L3<])$R<:P!A-X`-'8:-8E/#!&S75\
M33;0YG\@V*`/V(`Y'`=1S![EU!=!X.,->BJ$","<EP,9@B^W5GD_0/)+Y#SF
M+)B0_F#4<GNN/.87@-#/U_2$)KSAU+]J@,B!3#,/7""&F@MY)>19ZYX#6>H-
M^CC-_Y-TFW.\O):HXR;N:`@?U*!#`8B"'F?2O[K;_>YXS[O>]\[WOOO][X`/
MO.`'3_C"&_[PB$]\X(%PR7\3LNT[$()N=G,(.-"E!I@/`!A`1@E76F,D$Q"`
M`A+0*D8T#0$JH,P5N$6>;/S_F-\W"6"?7L&F%V!%[8Q@>R$V.F>"'\(8C@^^
M\(=/_.(;/S^"@>D"#H.80_!^$VO`"Y\Y8DIK/-;6EM)F`;QPP86P`?;=F3HK
MN.X4W/]!]X2`P2\8T88JU%D7QGB`_.=/__K;__[XS[_^]\___OO__P`8@`(X
M@`18@`9X@/[W!+MU?`#''^D'!>\W?90@.=9P,S[#(IWV!B4@!7/P!U?'!`E@
M`CQ0+]:`!>!W@O-@?NAG9PN@6U*T4K^%@C(8,?[F9GLD!%&`>34`!_!7!4;P
M@TG`>7X0.M>0``$B!Z)`@9S0+#.`!U5#<\%B#3,XA<V@@F%!9D,0#FL`@_D&
M7%3X_X6<48/&M4<;M08*8PZ'D`+/5Q="2(0+(1[]M0ET92<?``$9<`3=5PTF
M"(9\&`M6"!%%``6;4`;NESQ]>(AL(88F54A_4`4HL``^P!N'D%)0D"7X-E.4
M4'W5,`>LQ@C#XAR;D`&9(F!^4'V&8PTZ$`]-9@OOI@QC!PM#YW,&``"+P0(`
MX`(FQC=/(`(F@'87$`3`:`(<\0!!<"80$`0Y,EQ_J`\;Q06.!!3ZAHC2Z!2*
M.$C[L3U"P`7#L`:(``,=$('4Q0+6D`!A<P9KT`%(0`F5P@@:(`,>D$HJT$I2
M)'76<&7PL(I@I@P.!0O`YF2;("3`L0EAP!PR4'K,A'7F!?\*?J!NF1-ILZ.,
M\<8-10".:3:-%BDE#*@-B)`"*F4%`;`#7["17+`%&U"2:":!JF(-"@`A$M)Y
M"R@><;`)S7(`E!%`U>!AEA`$%7`A$"`#R%0`CO(!,G`!!#`N$```#E8)^+A?
M[G@`05.*^-4@(5`!8^4!,L`"!%`!(^$!H:,#,B`*!%``(2!^%;(')!1K0[EU
M(%`IYN%*&M``P/('LT,`'7(`0M17FA0"#6``]>*3C%()Z@-U([6,#FB(%WF8
M-5&-XK-'$PD#6P`&37(($L$)"2=)C><)%O`$&P0!%Q`"EV0!#,8)6,`#'_`!
M`&"0GS!JM:8^?"(%\_0'5S`E5T;_'C.`!4T`0`&B`3C@($OI!TC1:40P,Q,Q
M$C^%6O>U)G\0!L^D0D'&"%<9`$SP!E-D"0=0>@1R3?]X":SH!RGB*!#`!!D0
M52I2"1GPEIHT+SGD`1T83>\D!VM&F(49@X@)(S\RG\^@F,]SC4O@?BFP9VFH
M)5LBA'Z`5M>`!0F@`XR&#1E07+<@?C,#!"PP,S9@"QKP!`KX!E\F8&'%!!9P
M``^`:!(`3-RQG4B!`R:@/B&(`']PFP(0`%?I=.\S-B2P(0/P`>01*!^@HD#@
M&9<0E@=``M))`$08!)&E+;6U-*=F82EB33/C*.9%&>FF2GX`2^9!'AH'D6(6
MG_+Y1S_W_XK-\)VM.`MGEQ,MR0SD-Q#X.3*U$05?P@W>4`/'LTC4T7K_YBL]
M^@?B]@`I0HM"1@EHY0'DH4P+*:7SI`&WV9M(D823(X\#4'ORIZ(5P"8E0`EA
MX`6EJ664$$`JD)01<@````3J@S>,`&_F\1&GAF@&4"FCMBQ.^F6<X"ZJPB$$
MD`!,4)]^!)]:VHU>B`I48%J5<``Z$`$ZX"B`>H<DY!&">0$%@)"G0`5-\*S/
M"FVQ("DA$EK,0`5R@'61`JU'T$NL8`M>``TR`*U-8%6M\!'-,`#A6A!I2C&"
MP9%0``,IQ86(L`C^$(0H.2*=:%Q-<Z=O@`0`BP0[NJ*4H%V`.O^>?A`^2\$"
M("BBKVD>B7INU1HB$1"PW\(FW.('ZGJIZ4@N'=@!JFE?(O`$YB*JN_JP?I`V
MQ%I,!!!IV.4'%F">E4`>%O`";!`"9Z*B2V./:H:KR"4$0!NT0$N1Z7>RI:"B
M?T!">X"G"J`"':1J1&```L`M$"`'4)23NK8*`]`!@C8`&3NMDE"MSH!9XA%%
M7*NN?;H*'U`!9>L,M8,%H(2GS'H*Z,H,ZFH0[4HF5J)2?,"1/`A_?Q`%_;D#
M:$A=E$!0QI5:I#`':D$A[V`+M^D'!@L\!9D`5S<FLX.H22NQV^$'<F"I\S0)
M&$L)&QLB.E"'-F`X*P-C*3E!'A"J+_3_/MI96RS0`41PE<M"2@3`5$!P`94"
M`AER,J,0(HTP5FO;MB'EL[]W"_2JJZOP!!V@':+P`1D0`)-@2@&P*JD(`#GF
M`@E07A>P#O(E"BRP`@BP`H*IL42@/_I#'$#@8"Z``TM1`51Y`F_2`@A0`"1$
MK9W;2BY`!<N*(B1P`=Z:J9$ZI4G)`E2ICM,91>MK-+&2*160(QY``D)R`%)P
M`KV8E4TC`PY6`3B0C`!V`@@@`00Y`1-``L1A`">``QZ$M7&@/T/EFGIZ`@%\
M+/B;E'4[E5#G&2VP`O/RP2%<"0^0P2QPM^S*H,6WMXYD#"CP2%W2@'RP!"Z5
MK_CR;]E2"V_@_P5C<`5$``&06[!_<+#O-B8J8"Y-0!R:*PJN);9!P#E->YNC
MJ[&6"@':D0$R<`;TP[C6Y`?52P5XH`F3\$P9<+64L)U^X`(<T@\)$$/@T@&Q
M<@5%^J2E<!8*])KK*E+*:PB*4`-E\`=.4`-?``:^!;BJ\#-'@`2;FT*32@DJ
M:@`/P`0KU@+M(GZ@^`>66GUD<V#JR[X=IUUS,Q'OP`AGX0%#M0:QH@%SPK_<
M\4YOH`,:(`?$\0=R4%$3,B;OD$K-,@$>J"H:$*9LXE55PP1@\S-TY0'HNC)A
M,!TL(+;JEJ`G%&E$T(%48'7*%JH7T`%`E+654#MK90OUDVQ2%!FPM/\&_>">
MZ#HFTDH)Z[`)[_#.FW!"3\`(J;3%>*O$Q+>W&(,("\"WO*!(5JR>QO4&<ZLY
M4C`#$S"])\`@>V"_+-S'0``">$`"$+("_S-:[P``)_`G)Q!-!&##E,`""*``
M+B`*$*#!0+("HG``,X``8P0`)0`"K4HA.(`!/!`")Q`9-H`'(*":%'("UB0#
M5(`!`F,)-H``,R`":,?")9T[5'!LHW4S@QF1^@`%V<,'"Z`!I>R\J&`#^@P!
M8R(**2+7.)0C)O`"/64!%H=VH7,`8:,!'3`GMD`^EM!KFS`GVB4>"F4>C#!@
M(9(`H@!+D\K,?H`''2`*2PL=G:V:XDB5C-#_5Y9$"=`[=<VY"9-@SB."KBH:
M3>G2N>KV/T-U90%05'Z@4`\`2YL1&7M*(9=0.S%,`,MB'ATW5`!P6M-I`,3Q
M$8WSLII#'*945+_M!\'M!UCP="B$RQ>=D5*<?M$%7=-E"&:V!9H0!0(:U,8%
M'?9IGYN,"%]`WWP``U\@?5TX(S%K`.&;.I;Q')400)DT!A-@`)J`;5A[0JA<
M"4@QR0/P!BVPX2T@"MHE"@3#"&L!2_WJQ[=$VAGP!C=2+VN#IVB'!6,PT4>`
M!:'CFE?TM5'$!`50`!5@`6O``KB-SL<08-L1HN[<5E=,!11[(V[C8*V2`>;Q
M`;%"!/:+M9P0!A(R_P$)\`*-40$_$Z8?P0A>#4`Z,`<[%:[J%AG.T5-_D,6?
MF]X9Z7OZD`*"^`=&$$D>X@?<+#Y6E-_Z3=?<X`0:L)^??(E\;0JQU@D/4)#X
M!`%G<6H`T*@6`%!8T*JN]4[$[<=(7@E(;`G:11PA7C97+"0#Q!VD/0`:L.,[
MOAEO0PIX$`!A(`<_XS;1]`0:('YLDLE?7N$04"].M@+J8P)'KN;X<T^J_AFM
M5`#UTI8%T!CX30FUDP#T>P#$$3XGT%[E\4ZL2PD?`0(:`-IIU^8R$&EHCN1K
M+C8*Q$Z9C*88/7QRCEO[(4D-TH$C\P:.YN?3N-^'4`1?X`\`49&D0`#`"/^,
MB!8"=8A6U\[-MA?4AK54S9(!>V`)L.0"4A<&!.(9K5;9`3#P07!"G^YNV&DM
M2,,##:!NT$':A!,$[]*O!#L**;0X<P,V?I``OC,*;++Q04`"P1("[X0%#U``
M7G8`$O`!SK&LOFWN^..Y7F``\'-"++"L/S,&3_]4V]7/OU0).^6.P%$!$(`%
M'4`"GK$9'S%0<FD)D58@/U/NQ,XM8:`!M$@XZUX/>4LE[[Z1.GCW?VNXEL`"
M[>X8(8KO\ZGOB^0#5>"?6ZH*@?T?`FT!)`0!`8,B3#`#G1+NN%R:E!0&S&K9
MQ"RYHA[J$&(""Q@*LP67G?L!EBW)UQ2Y&U=1HA#_D[12G>F+G)T01&;1V>;B
M!\O"".@T[$D^3Y0T!ED)?:EJD,>&0Z_G!WM0>EEC'C:P@$N&KAX0`4U5:P&2
M2FK?^P:P6R^@`G%/#W,O('6_O!MMQ:5TF;/Q[(!_F(*OI=%X"E^4(0WP``=V
M069M.*-P`0]P:@UPE:0`""P-@X,L?A<-'GX$#1]^@WZ1?A`&,A>2B!`>#8:1
M-@^)D0V7DJ4V#9$?!HX65*6EFX0L!)(>!@80B*DRN'Z;AA^A$(V1M@^=BY6T
MR3*.I8S.I1\R-L/.E):1NG[!I)$0O,/`PL23O!XLR*_K[.WNKQ]>?_/T]?;W
M^/GZ^#1\_O\``P8T\D=#_Q6!_VC\0=7N@H9]$/6%>$>QHL6+&#-JW,BQH\>/
M(#,VB+@#H<`47WS4X,*291&3_V#\"4FSILV.%YHPO,FSI\^?%N-%'$IT:#^8
M2/D(@?*G!@R$"G>R^Z"C:,0`)H!JW<JUJ]>M(R&63,HG!9<B5G:H5?L2J<RO
M<.,64R2WKEVN0JWJW7N4K,DB\^!`74@1`H(.>^\-,'"WL>/'D"^&W3?6K^6`
M;R-KWLRY,\^\B4-#['O9'XTE!0\.ENKN00;13$YXGDV[-LW)^BI?3L$[!6F$
MF6T+'TZ\,6C1R._]MISB(9@B0J(+"1@5(Q`L>CN<6%:\N_?:N//I)EOD2ST?
M2?^#?U_/OKW&X\GC_UGN5^8]+M0)BVPQE,T!".X%*&!<X>$S7E)0O#'$#D.`
M\91;,U5$R0/>:/.``71),DTOK\0RR#+!<'=(`P!>]$$%3[@#0`71<&4#AC5=
MP,LR#53`6"E`5*`..ZP-6!-\\B%''UDT)&'DD4F@!U!U&WE@@PD53$`%'E3@
M(,(3!HCHXY9<WE3@/0<BQ<40/BQ!`Q1MP:1>0P+,XP4)WZR`W1]X../!$Q',
M<\2.!-0CQPH0\/`'`K6H@$6)%AGPQP#NR-/C3Q`0\<<!%'U`107OW*G"/'/`
M6<`?F):BP!]!N//!!T1<H&67'0$99&A#E@83DZS6:FO_9%_:$R9,.\!111LP
M[+!$>A&ZXX$"'5#10@!_`.C"'QFL,,8?+T1"PA\JB`!"!UYDN`BT5(`@CP@0
M(+8,`(.VHTDQ)>;2H@>(7G"!M^M.@FAADM2[3@7SZ$#12$V\HJ\,T*X0!Q$M
M^/$IIHA^<,&]\$KR@`X9)'#CK1RY^BI?LI9&*\8@A]Q5KO7L:E(41J0P3P</
MJEFL.P3($(D4"T'`Q!4EXO$'8W)HX`Q_!3SSARN3,)&`'R#\`:<?+W1P,3=T
MSM!!!P50@=@8C_P1,!5_%/#&'P(X,L`?P?PA11,%\8`!8GCX$<0?LOGA!:,G
M#'K%'Q$$84%!0+#CQ1PZDZ)H_]`>S",W/0\HC-T:,P#XJ13?1/(I'G+\@04J
M_#W0IQ<X(*8`@`\TD4$33XL<E#P;)Q=KQP)];/KKL(=$,CTF([5`%0N0M>8[
M$,RQ!@$/#"V)H!/T&7`DBOHK29]$?_"&OQ_\,0/4&'@;_1\X</W'$<LN!+`?
M7/_Y6M!CE_W'!#K_H<`)#UWP=MQS^U%W!BXD4)"4?R1PKQ\$%Z#H&<CKFB\,
MAX`_>.$$+-A#_JI&+5L$H`-CJ`!#/A4`$<S@#R#P0^;ZM+T"3,L5IU+!!U85
MNZF@+G4H3*$*5\C"%KKPA3",85%J%Q`A&,$(T[',[M15@O/Y`5UQ\T/P9G`!
M]4EB)/^,6MZB*K""L:T@$@-@`@%6\`<>P.,/<_"`!R1U"2J"0FO@FY0?0@`W
M/Y1O)`R8Q#QH$8>=O2\2\:M;T(J(-0]XP0LM\H/]YI6!W_EA<`.<R?<@((`W
MT,(#%S2$">8PCP`$[5,X4*,`-/@'S?W!CP3X6HD>54(3RO"3H`RE*$=)RE*&
MDH8QJ4<.=?<RF%4N;B/!@"3(6``/="")0C2B$NGQAA.4Z%,M4$$'M!0])$3B
M!7^@Q=N^N+4_7()@LCGC'Q+FAWDHXE,&>*/<Z$:J;Q%M`'@L11'ML8<_"K!P
M@@3C!R(0AN%54D,MP`X$%A8),&[0@)((`]DZF1&-F?*?``W_J$`'2M`@H=(?
M3/'!`CI0`QVVDATV>&#?)!&!-1C"`_9S!-HFJC.9*;$$!-"2!["PAC\\\8K&
M9%HRW5;)[W'MF664)C6MJ3`W8G`2:^!FJ9@'Q7!*0@38NJ,7.L`$6_PA#M]*
M9\`\((!A1F):+(```$I$LP_0LYH!N^=*R]4L?F+$GP4-JUC'2M:ROO"@?.!"
M`/RQ@PXXE"(1_4,`FD!75#SA#V\8@SS:QK\W=.`(E3N:T(BV#AS,HT*I^$-*
MD:G,EH+QI?R+*=E&,M,_7'-G!IC:$?*D4V_V-!H$Z(`*,J2S`URO"7N;21$U
M``(#F.`/3``!,H\@/]@>X0AKB$!-_T-ESTIR,`(EN-M)O7HZLQKWN,A-KG(I
M8QF6T(`&.YC/ZORQ0U/0];HZB<0!-ON"6DK"`&>XP@!$H"4(-"%4ZS#``-C`
M#@(TX:1Y:`*`9$"ZG$2R`DUP1`.:,!$J-($`.9F('^BJ"!,TP08>"$$8!@"$
M,[@B!$V0F7E#184S<(>^*<+$>14FASD`@*Z^F(!X;>"'[5YA#A4`$`1(H(`,
M6*`$BFS"TIH0R2>0KD]$*,``Y$`NXIKHA,L-LI"'3.13-K<#:BDI6XA5$2TZ
M68NU^,#^?#'"=D"Y'028\ERV[`NZ0/G*70ZSF*\,YI"&V<E<!K.884$7,X.Y
MRL60<H=&Z/]E,BL"RIM;!`E]W`ZP%OG/@`ZTH,5B&2BTY-!I,DEU^>R>/#/Z
MJT`>M*0G3>D_HY5U?%CTHS<=,C]7^M.@#C5`+\TZ37/ZU+7RM*A7S>I6KY#4
M'3,UJF?M(U6[^M:XSK558"TK6=/ZU^VQM:Z'36QB\[HTO@:VLKLC[&([^]FB
M/O9EDKWL:MNFV=#.MK8#+>VW6OO;[,'VML=-[N1VNSX/!;>ZKQWI<KO[W4$^
M-RO73>_AB!O>^,XW*9FP@7[[^]\`#[C``XX"N)W@X`A/N,(7SO"&._SA$(^X
MQ"=.\8I;_.(8S[C&-\YQB5/A:_H.N<A'3O*2F_SD*$^YRE?.\I;_N_SE,(^Y
MS&=.\YK;_.8XS[G.=\[SGOO\YT`/NM"'3O2B&_WH2$^ZTI?.]*8[_>E0C[K4
MIT[U`2C@ZEC/NM:WSO6N>_WK8`^[V,=.=K+/H.QH3[O:U\[VMKO][5T?&]7G
MKMPXP/WN>,^[WD\``KW[_>^`3SL."A#XL).1[H@W;OILWH1VWWP`2!@ENA)/
M^;$NON:-[SGD)>]R+S1`GY4O]N5IGGF>;UZ4DZ='"(+`>@!<4#0?X$\)&!D1
M+$S@0CPX`@I=0#"(\!XY%;@`8NXA!0)("H524-100F`#(L2!@X!>P05`S_+1
MS[ST.S]]*%._1D8T@``>P(!H/,`O`GP*_R(:>,`F9!!2N;^*"H??!_Q%XP4(
M,"`?"7-\?/`@`:($(1ZR(6@%0`#NMW+6)W/8IW/:!TK<ETSGUP$?$#P=@``F
M\`2ZAP%U,P\MH`!7<`(%X`*@1WY',`P5(`<58#_YLP(@]P<AX`'\,0\9&`8%
M<``BP"P94`$#\`1[D``#0`)/P$@)4`%C0`(`@`488`(KP"S<<TF#)P6;(@`5
M4`&ZMX1+]``B@!T1<((`P`/3<@\L8@]8(`(F,`$NX`?1DCX#4`%8T`(S<`('
M8#58)`(%<`)YPCUL0(1>,`-0@AT"\"Q85``/<`(!H`$84`%5@QC_=T#59$'S
M\%[#-P\)$`(F(/\%7W.#5HB%.`@`))``G?($]G.#.@``07`&&E@")<`?`R")
M!217'D@%#Z0`'TA[>%"!NH=7)_``$Q`"!.AR!QAS"9AS"_A)#6A^],`"!,,"
M'@``B5,!_G)_TU,"5&`#!?`!=F19%4`%'C`-&?`!-C`/-C!.\Q"!C]@OFS"`
M$'`%"C`)>P`![-B"T9,P%T`I$/`!E#(2`_@')O`!(F``4O`"=S*`&G"/G\,"
M*48`<A`P@4*->5(/84``I$@/$`@!(2`#`.(%00`!\T`"?0)^!T!B-%,!,C"`
MH55+'V!%`%8JBE(!A3,#3I)B%;`&'Q`$)N`!P9.(`4@A\R`#N-$V,J#_BP4@
M!Q!`D!!@D`BYCO`2`D-I1.8G,T`UE'X`!)-D`@4``<%S"B+P`0H@!1!P)9D5
M-!5P`!Y00`]3`#+@`;O8<KT(<[^(<\$H0\/H/D&`(260CFSP!QVP!Q[`!#9`
M,*#`!&L@`%1`*%Q#?@XX#\;$B7X@?O20C/=P`3;`!']P!1ZP`NDH?@F3!W\@
M`M64,/8#`&;X!T"`D?<X"GC`!!V`!\DH!U\SF@V`'40@50&3-%C3A:H7'K0E
M?DXC-T?#@1]`1@1P`)=$`-?"!`H``F7871Y0EU9D/S(#*H5S"H@A!Y`9`7B`
M!_]!*@!831DD!X<"5"O#C8CQ&JO@FK#I!S1#_RB6Z0=AD([:PPD!H`G,N4Y>
MH)),$`QC\#6`(@57D%O)Z`57(`,LP"C:DR4%J')I^4FKP(T3`)JG<@$FX`4O
M<"JG`@1D8P+,,@&6(@<?0%<2^@%/H*&G8@,+&DIK.5#3**$8(`7@^`<VT`(8
MT*%%U*'=2%#:1P4?4#=8<3U=0P"T9P%9P@(N$*$=J@()J@HJ8`.GP@(A\(C#
MJ`J.<!@3X`<@)TMRX`(0\)XKT`$D0`F88XV%61`04`'D\A#T`#SCV"S\$HXF
MD(YCXPK(9$S3=#@!Z)P["C;ST@`ZH`'_87Y4LY'QQP('$#!HPRBC0@\!\`$T
M4P]1>C<F)3<0:`(XX/\!KT&,9!,$`<!^!F`(33"`8Y-_?R`!U:22R11_^2,O
MJU`X-EE-`4``$K`"!$!]6.`':;I&"C0/@"JH1M2F3,.F\Z"+80`!,YIE\D*-
M<F"C'B`#%B`'9?D!$P`]\D(`'X`UM`<`9UE]`.4P(+E%JV"(DQDP)!"%2>,+
M)U!_\D.HZ7@`48@'C)(C&,(LH%2B`A4$!!"%."BJ9:IC%=`W3_`L_!.%+SA0
MVB<;$!`!$Z`(\_":"=:K$-`"0(`G("FK%5"?!%D!4L`$N5`!6=$F\S",GS(`
M'O`VLE2+`.`!;Y`!?I`B85`M.A.K_$&8!)!Z0,`"-@"<]4`"'M!&=FDUW/C_
M-5C@`2[`JVZJ6)LII]5$I_<(F4UP`=&C`0$P$0)PCX+`+!;[80.V*'Y0J+W:
M`)!9#Y/TD(PA#TC5`,I'J3'9-OKD+YNZBYX*JG3*`LJ'!6_P!!SD`JB:G3`8
ME()2#XR`&-B!I%);GF@#M+N*-/.0J>\9/']@"8BQ!E_S$&>P8AJP!BJ0%=/S
M@E\S!V&T,]5J@-=*,+2E`[>P1A(0,"=P=9`Y"01@`@!R`N:J,%>'!81*)WY0
M.>^J?P$EKU>G>_:Z1N?'JS.Q!Z];4`$["2:0944K!1Y02_)@LRV`3#!8M&0C
M`U?W&E3Y!Q;@!X:UL?9`J5&Z+?-R`(Q!14J32[HE_P,"D#@MRR\/HUX&I`@%
MV@&&8(R:@`?^<@%`D&5$(+AO.K3R,*>B.H`0^``EX)@K<*-/-`#WR`;9R`-9
M9@&X&KLK`P':4P\1V9$5:9<`,J)D&P0!(P$"@`IIVZF'P[:B"D`7P`,KII*F
M"'[8J8CSH%M^\'KT4`)^\"2I*P<+W,"XJK_I"`$'@`K/4KU@9``ZT@"_HS9A
M*@$70`5P<@680@*Z^"S?BV";:Z#7&C-2I@$84F48<#S'-!,%<`FDV[J2H`",
M`JW9*$KP>KOY0J?W.@^^*RK"&WG/2UL7$#3S(+8XS!]$$`K*-Z?[%`G\PHY2
MY@&;HKWU0)GT(`(T\P8MT/\`#[!XM/5Z$=8`5%``;2*%?Q`&#3LG#3"C]A``
M5`"@`"!W"1"S`"`/%E``DC('!2`/"`PV!8"TYW<$_*(`5*0#3\`"$H`%*M`"
M!M``/83+_4("+%``>7(%!7`W.99:?^`"#H$/$<!\*W`$LYR3%W!\BCQ-.H,'
M#2`#EXR.*R`I3PN9&/`IMCP/`F`"+"`G`;`""70I=-("3+"IQ?@!)64/"@`*
M*P"9G7+,R;S,ULO*?^@%Z9@')F#)B'&-]*`#0<`"`'`W,Q"S!1``%K`">XDV
MR7(+$\"W!4"0&##.O'C%/<E(JQ`TZ(*K]"`_UCD3K'NUZ4C'5@L$B4!]G[3&
M`/7_?_6PNU\:QQD85L-;26<0@,H3"2P0`%<0`&\0--@!R#%9#[DP$=Z)R'IQ
M.0Y#ID0A`;B0O8"VJ@=J#W&`(5--2BZ0"$F3.KX[=U\=0]-0#Z';@B#V(@;P
M*?)#5"[=NA=P"SAXM7*`"&<*0SC]3T%@"[<007\4NI0:QZI@`#0+L#(=@,QR
MDRQ`5]A(@>"@M(CAU`1P"]=1O9KCKG_0@$2!!2Y0@GI1`E6S@G_V!DV`U1&Q
MJ2>PM:4$BU*0SQNSRL>GU@!5`".J@?S!!"0``A;`>JS''T%`F\>=-P,P`,0=
M!%*@W'^``3QPR#=MNP!%!<VM`S/0W"R(AD&PD,U-J@&E_WUC\#;S4-XL>-:A
M305.?``D4!5_@-[S4`#$7=$AL*!S$`0:&]JAU]\#M=8L%]@RUY8Q)-K^?>"A
M!.`K)^`Q1^`P9.`('N$PI.`JQ^`PY^`O!.$2ON$K1.$I9^$OA^$NI.$<7N(;
MX^$H!^(N)^(M1.(F_N+)@>(GI^(MQ^(LY.(POA=L,`(\WN,^_N-`'N1"/N0%
M``!#?N1(GN0\7N1*WN1.WN,2\.12?N0F,.56?N1Z<.5:[N-&ON533H1>'N8A
M$.9>WN5D+N5Z4.5G/N7Q)V])401>7&^;80)]4.=V?N=XGN=ZON=\W@,4P.>`
M'NB"7N=J<`>#?NB(;N=[D.B,#O_H'-#HD`[H`!#IE'[G#E#ID$X!&X#IG&X&
MG([IE_[IC5[HH@[IJ>?F2`'G<MX9=%[JC.[GKI[HI![KB+[HM"[HCW[KB#[I
MNB[HH=[K>:[IP#[HGC[L@?[KQH[GLY[L>7[JF&89JK[J<\[L>@[KU'[GRW[M
M=6[KVI[KVG[GO/[M?8#LR2[LXF[GQ7[NXW[NV:[MSO[LY!'GTOX8K2[NUO[M
M[7[MW'[MWG[NX?[MY&[LYJ[NZ7[N`<_L^4[M[P[OJ2[O\]X8]?[M]Z[M"<_L
M^T[M_2[N_Z[M!P_L`W_N!2_N'6_L%9_L"\_P?^'P#V\7$:_M$W_M)6_L%\_L
M&?_M&W__[2.OZQ\O[B$/\.QNZ/Y..RC?\)M!E0^01YX0!&5I+-Y2%S$YV'+1
M\M?^\M0>\\,^\\E>\^ZN[CE_ZSO_[3U?ZBB`!K[.YS7@;XT.!VI0`X">\'#0
M;VR?Z!L@!G8^!&(0]WI^\D,?$-'^$P6H`GBP9XG53>O`'TW0]-\U#Z62$078
M`1D@`HA_$>8=^5O1ZCT@H28`!WT@JW8^`>&^`=SH!QW/`WD0Z%1_YPA0``70
M!7@OZ'!@!S>O[$"OYW;`C@00`HF^I02@]7>.]75N!K:/^X=>^X0<`WO.^W:.
M`+9_`&2?Z"K)`)+.YW#`CL#:`XB.PNP8]G;>]4[V`<9_Z'!P_PEABN=?K^?S
M8I;(G^=EJ447P.?:;^>>Z0E6@.B,X0$\<.Q\K@;Y\N>'#@@\?GX08GV'B(AJ
M=XF('X,>9HV3B&*/!H>"?A]PE'T`?Z$[?*2EIJ>HJ:A%38.NK["QLK(#H;9_
M;Q>S?@1(2`:R+7]-'K,XH43%N[&UMZ$9RLNR0:'1TM?8KB:'%'XF(000<"8E
M,68;#01W'#$(0"%^#B=G?7<Q]7<>#Q0U+7DU8N[`H7"H!T%/?8!!X%4#8:-'
M'QSV682P@I\*!_P@Z%.!PHA##I[T:-0#0H4&'CHAW(.P@!\`0/QT$5-!385#
M')[<2Q3CA$L95CQQD'CG(@`_3SB6L/_3J<<3!Y3R%!N)$`#"#7YD5/@0$8$9
M"@2M%+C92,:%"A6H>H+JT,\#.Q\(]#GAPHZ:B4'V!$WT@`"'$'D:4=@@\=`'
M&RUD^-E0(@0%J"B>`#&4B,*)$Q`P>9+D$(`'>1X`H#B0)P2*/@6T-BHA\^AI
MA&PIJ;E8@D5$(`!XW#-CX,#K0W#\A+!T`"'%21\,4,@8HXN,`A/Z])!A(':?
M&@`(8&)=P,%A3Z!$J1I//A6K;.AAU9I@P,`3)G^.^/'0X``0&00@/>@+208`
M$P0(0XPL+&#Q1P=_/``+"T\\88`U@]2"07LR'/-'1GZP\$`0#SPRWWX$?!!$
M""P,0LT?Q1#_L)\NZ;6H#3=^$#2;(`80T``$$'CP@8Z#V,#+(R[=1`@AZ<1U
M%B_%27>0)P9$U(4?/=AA(R;994:8(C)$Y-!QE%C4!PI^2-`'(7(=`($-H35"
MV%%7>L*2)RYM4(,'W?$BUP-G>D`6(C&$V.8D0SE4E&$RC$F`!VH4X($-$!2:
MB!H0-`!E9U?Y44`?>T"0D`<0C%#2!7&I=$B3)A2`AD/647)1'_#T(4..)4P0
M:5QW'=(G"S(`42LB@Q76QP?%Y>''&9[IV0-7*&W4R`GQ(,1951Y<1P`06)VY
MP:M].6HK!/<1T!!LQC7;UZ\>$!!#"!Z8<`$!HF*UQ[%R><)E(L#V_V$'E$<%
M"((',N"IK".8H-N09^#9,DIY")-WGHOHU2*!*RZ$`D$+:]@2!C`$A*(@!%0@
M^,<+&`P#X2`K_#$``W]0\0H0`82R!AX0UL+L(!"$LH(?0<`7BA<Q9?R'"&&$
M$H"D)W**QQ\1E,APB]OTT<U!9VX2V@0=;L!I!03XN`<*KZ[JQP$>[('?!@Y`
M\,@!#!2T)"4U4O"$'S%8]($=,7C`@ZQ`-'*`EL8QXHE%8L<X)@L4P$%G'V"+
M>@@"Z4KT)B4N`:$@"`YD2$'=721T@>(8L.#!`:=2$BA"1>UAPN&\Y&%UWD?M
MU`<<R7$P:565-D!"U@E=M$&-<*CA00B)`/]P08G`@]N6AC:ZZD$>5AAP00U6
M7\I-N69JQNN?"'&U-P%6'%4!')G*^8&VAUAAX[>4/`M>5I)R@)4!8LQFQR<>
MA-Y'#&:'N-=:X5Z`$@F_^L!=(%"<'F@D$3+@5+GZ1HFXW,@&:#@*5'C@K3Y<
MP'J&P<03-(4:/Q1,/`D+X2I:L31L.,P5X8$`":XP!@&TC`GETI@?A/&'.93`
M"Z$84"PR\`<`L.`/&LC/)HCPA\N$`0/,**(K:O8'EQA`!4<8`Q'_0`"?_4$.
M0;LBSD)!@&,$P$,E1$_3GM8'!OB!!,*AH!]L$)'?;>`P?AB*2RY2`V^$A@47
MZ`,:+K`0RBC)(<#_F,\V+#(4,RPF(?%"Q-XD,J]&6(0%#9C?F&XB!C]$IP5^
M\"-'O%&8QTW")1>P@20J=X(^(`%N?0`"`?R(AKMLD!ZB(TJ&;!""AGRM#Y64
MQ).0@(B;O8)2GL`*`5AP@'L8@(,7R..<DG0(,32$C:B2R"8:$(2&R(`%AVA`
M`ZX#@>)-A`!6"4(BN8$]3SCP`9T@6!_$V1`68+`/ADR;LR1RE'Z5H`]8*:7\
M-FD_1=VO6<:3C1]Z$ZAZ]8$`A3H#0`^A!C'TJ6FR\=M#@%6`@44+4Q!`0PW&
M]Q!,8+(':&C2!_]P,!&:E`\+"^,R:F&&X0$`03.8CRML$(IT:.P"!HH#_\T,
MI,-7@`(:?J@%`@9A@%`\;$CJ^4,"T"*".81"::[PV0%\-H%!G$!B)YK!'[`@
M1)5F8XP9NM$'T+`)%J!Q1PD$P!M]A%#Z0"!KWC";I`S@N;>UR2"`_,`&0E<!
M#Q`D!GX``@*XI3>^R4NBD_!2(E;5!Q9DIG&(>!L$6,""75'"DXV($R(JYS?'
M/LB3>UC4F7[3B-%Y8E"+;1K8:H1-1*``+!9I`3`I@17IC8J#E<.C!_Q8@RKZ
MR"H!]01C#W'-0YS``Z`J1"),$"E]"*:<#60F_0[!@"KJ(C!\^IQ$U$<)=1XB
MGX<(@A\N`%D8Q44<T9370G^5)-8<:IN).)0'=O_+0.1(5YUB",=;L9><Z^AB
MOO?LKL%.>M*4>I46SOB#%\XV@SDDX`RAJ)'&9!`*,")`9+$(F@Z"$`0V;+48
M$-#J'ZXP`3"ZHAFW>,,<#5""%[S@:'\0IPS=PL43A2(!!Q:CK0[`X^\AK@)B
M`T`,[&,"!$2F``>HP`-(8(4N/`#)$["###AP@@>8P`$8\`TB\(H0$\#W$"VX
M`%6VHB+%]>$)7SXL0BB`V3T<!`4%,,$*[->'+NSASGO0Y"0P6QF]\&D/M1+#
M?^Q`9Q28P00Z08AI9=-F9:%A!0<H`'1CL`?H(@*XE+""FQ-Q`DSG`0@D@"4B
M,&`Z[DXB59,`@*CK+%O_;H0``'JV@AWV8`?2.LW2C3##OYQFVQ@`(`08:`2Q
MS#P)4PM[!8E`0P5V4@,.`&#7ASC#6"Q+"52[]@1_XD"P&6H&#J"OF2VP`ZXG
M@EA$:/M1T3D$"EK0@G)R(,`UZ()=JC)@`HO0P#E^12V8X(4(O``'NC``@D"P
M`A!$V&</H/`?P!@'#+_B`@D.A0D&\8$)7"$4<EB(OD>L`*?^P06#P.D?9K`"
M'+PAQ@@?Q`-J+#0-_&'B^98&1'U%\YISV1,H4!P:Y(0(.+@N$3EG9+EK3O25
M%/WH0D&ZTL&S]*:#Q.E'[Q74FV[LJ=?<VE87>M:/'AZ2VOO>)(SYQH_Z"A'4
M_Y!F!]<8"UHF`IKAL*>#\+`*!D#W`1`Q`X,0H@QP&,@3*]$#0;M",9[P!R:X
MXN(R3I#*6?X'`QPCB&+?Q<RW[JN;4[XPC;R\0_BL>4!UON:8_GQP17\]TA>F
MZJ;?;.HCNGH!@_#K",.WV$\(BY(%H(IF;WS*+32#`E@@A]:0ZBN*^H<&V"``
M`J!.!/X`U0@I,2LN9PT/#N18PJ-\QBNG8M$(@"`\1'X6DV_]'\6OB*&WGO.F
M7S3Y/[%^U8M?ZNT_!.I7CW739[[U72\I[!46]N_3_A4?X'*AD$42IG@$D`"V
M@`5'`W>@P`0:!PF_5P(&<'&V(`!)-#.6<G"_AW&AD/]X"D)CVE<-WA`*&/)]
MKQ!^K6=YXG=_JX=^I*=^Y!=ZY%=_G0=_\3=_J4>#HL>"J9=_^Q=[_1=Y&\(B
ML/`!(8`1!,!AA\)A'O(Y%?`$AQ$$"?0*!Q`$DK(@',8ISU$`#S`R&^(C-,-A
M"D(`/%`!XL2$'L"$%)>%(A($Q>`!0!`$?6>"@X""JZ>"K<>#IN>"H@>#XB>#
MXJ>#EV>#[8>#IB>(G:>'I.>#/\A_=/B(D!B)=&B'J8>'JZ>(HL>'G^>'^!=_
M?8"(6T>(ZV>(I`>*EX>)G\>(C:@*LB>)KOB*L"ASGFB)J8>*G:>)G<>)JP>(
MK6>*5B>*Y$>*HN>+6V>+FJ?_BJLX0K&XC,S8C)P4?[1H?^;7@NVGBSWHB<0(
M=<`H?L+X>=EH=<9X><B8C*;0BKQ`!>B8CNJXCNS8CN[XCO`8C_(XC_18C_9X
MCW-(A1NPC_S8C_[XCP`9D`()`@@@D`9YD`BYCT@@;@G9D`ZYC]3RD!(ID.TV
MD18ID!)PD1K9CQ.PD1:)``S@D2(I:2*YD1U9DA.YD"AID>-(CJ1@C@2`%C(Y
MDS19DS9YDSB9DSJYDSS9DS[YDT!9`6`8"Q<@`49YE$B9E$JYE$S9E`?P`$T9
ME5(YE49Y`#)`E5B9E4?)`EK9E5%YE5X9EDUI`V)9ED@)EF;9E0\`!&G9E@;0
MEFF)_Y9PJ956.9=A:7U>YY*G8([.V)=^>6`2$'&".9B$69@OT`2%F9B**9@#
M@`2+^9B060"0.9F$"6.4>9F".0*8N9FWH`"<>9E-@$.?^9EW,)J?Z9FF29F-
MF9J7V9(NR9=_&9NRB1Z!R9J3>9BV"9FKF9N/*9F\F9B6^9N*J9G"F9BH69P)
M%IK(J9BEN9R%>9S.Z0R[&9T)YIKD")NSF9W:"0NU29W.@)O>>0O3&9ZAX)OD
M&9SD&0K$F9Y_`)W1J9SL:0O-&9_M&9_C29[6F8S8N9W\.9O=F9[@F9[W&9[F
M&9[HF9[KF9[NZ9SP29_S&9\+2IT#ZIWYN8K[V9\8VI?_2?^>`4J>$TJ=!>J=
M!TJ>"4J>$8J<#1J?#\J>)^J<'QJ=%=J(%YJA-!J+&QJ>'1J>+^J<(4J=(QJ>
M)1J>+2J<*<J>*ZJ@]NF8\1FC/SBC-?JDD7BCWIFCWKFCR]FCT?FCWAFDWCFD
MOUFDZ7FD)IJD],FD^^>D4)JFWR>EU$FE$JJD[(FESJFEU,FEU.FEO`FFY"FF
M0DJF2UIO>ED*:*JFA)IC;!IQ`=`RH?`&BFH+&J`SB^FF$<<$C;H&C1H*&G"I
MB6FECFH@">@,':`"DRFG"18!%%AX<N`,3!`&'@.<D.D%&Q@*'1`&FIH!GCJ<
MBXD%660+<G"K!V(!OOJ<CYD!.E#_J73G#'/`JH.IIX1)K,:*8J&0K*U*F'P:
M<5@P!@AH,6/@JV$P!LNWF'AZ(#HP!I#Z!F/@<:'`!$>@`],ZF)SZ!RI0`C-P
M<M%:`NAZ12"0K8IIIK`WJ(7ZKR5TJ+>`!5UX(BZP$!(@@%)0#"8@@(DIJ;?0
M`:>3?52P$";@J2"P$#(`J87)J6_P!,B50_EA`*(Y!H_``CRTF*1J"V\`#-F'
M`0OQ`:)9`L5P`;M:F8]Y%`.%(%?@(Q[0<+@`#!Y`0XEII\[@`L5P?']`!"4R
M,8L:2$0KK(HI!12W?"T["`=0,5>;%>UJ"\PJF%2["58;2%D;M(,@`UV;8-7J
M#%X@1.'1_W;S<02A@$EQ"ZZ*&1.;@$-7($1`@'%*\P#T2IB<&@:'\C45HS+%
M`+0@(%,ELZ^`&J@H%83+\)97.`ALF1\5X`6*,0L3X`5O(XE&&0T$8)0,,U]N
M-P>PX`%GX`78``%(^2";(`$?2%02`(;\07'Y^`H":PMK<$S4H#(AH%,1(Q\%
M@!DF$*F(F9A@LW(PPP,P0W@6X`<\L"\*MZEP2ICX`7$6X`$&H``V`D3:,08A
MDK81M[*VL#<K%P&!=00$`'$Z``$/\`+:H9AT>@L:\`$M0+4"<"$$H`.GHU5@
MTWM^D+R%:;2WT```$%,7]BI-(%X(.%4"<!0B)K6%V0%EF'$A\/]R!#`#K'$,
M;7<$C)/!$?>U"6;!%8#!&LS!?N#!?@#"OY.8:WL+5T"RZ#)RH9$+-*6^!8`%
MQT2^SA"N0#`&<N`'4I`@$*`"5;6_4Q4!9C0!UIN87@"X!0`!.H`%PK$&:(0%
M&3`^?R`!'A"XA,FO7^>D5/`'`:!Q!Q!A,Z1XLU#&<Q2)H5!5\Y&M+O(!)I-W
M"I:ZB(D-=BS#Z\)%KI`!0123)T`";[,"`#`!^R(+NWL+(M)X#>!R$A8"$(`@
M3V!%ADG`A0F_?\`#?6P"=@RR;.<'#BNXUTN8#0!Q537*&G!<<JL``ZRRB]D`
M*S=4.*0R5]!7+M<"'D"_CXD@2*0#?P#_`>%!`!FL)P>"S$6KF!TPJWX``E>P
MQ@O6M]W$12),P8II`1!0,A]``J%P00O7`"3X0R,LFI"IS=SLS7\`SA\@SA="
MSM0*F1T@817`1''0RT.5JF/@!_I*F.$:"MZ'`0'P$G^P!NE"17OPS<?;L:=,
MF,ZC`ON,@#@V!JSA81K@`46<F&)L;V0<"JSQ`<T`#!_`'QH"OR0R",CC![1,
M0"%`7@8``%-X`?P!OVS5(;2D(!?P!$'P@*X@JR6BSG\0528``%V8=QW2`"&P
MN7U[!1V2,6U+`D"P$!ZPQQKB(54-@'\P(0;@Q#@P+)T<<G_@?1"``&^@`R5B
M`'+`!)[!R(_Y_\@-H'`\T,M[$PKUC+R+R<D'0,[@<"%,-%3!RI@-+9BI_'&]
M_`=^7<].A;IC(,N*2<M_0+4GAT1R,,6A,%2^_)@@,#X(LLT5YLU^D'L08+[J
MN9A'T,Y,,,0&]P;$-,P5T-F*^<]_(`#:X7($8'VA1$7$IRZ"2<(1)]L&0-NV
M35/S^W(05Y@Q/+!F(K=U_0?W;-A^H,_\_-K,O+!/8*D$;=#'6]L*_<2)J0)]
MH57R(<PZT,+>!V$!X`$7IM&/&Z@=K0(=@!A(TW@9"`Q7U3$*EA]7I1B>F=YR
M(`4>(U["H"!V?$K,:R`=D+FAH%"P@`M_,`8L(`>*.@@-L*MGD!\K)__0!9T1
M*"9C`?`"H;"X4QW4WARV8W"_6#TSO6R!-$6S?M!P,?$!,S`&2``/+8`!`G`$
M/.T*C6P+CPS*<K`&[?PS'A`!;V`6=JV8G#S%OZ=-?U!5"=`!9K*8[UI\$+>X
M^[M!?V!&QV`1L5J8HEU3*R<?>&#!$/`&.A4R<^VJBSD!TZ*H%]0!Q'!5ICT`
M&H&KB8D`(VT@;Z`=:W`&3OOF<N`!5V6<BUD"!/2M=&4!T-#:.QT!80`LNVW.
MBFGH!X#H+*#HR-SHCY[&QKV8$5`C(.`%';`O)Z`!SJ-%+H`%.ZVI@AFN?24!
M5P`?;$0$K'$T9D&L'I![IIR8%P,!<3``3)#_#$$@!W&M`EML`!FP0:*JWJ\'
MN1T-!!U@`1V0`)()#-7N!U?5!`<@S&^3WW[@F6-P`*EZ!3Q0Q+`<X)OP!P0^
M8H)%UR+<58,P#$<CJB(\'TS0`0!@`R60,C06`4%P870NF410`'_\!ROP[B$^
M"$00O94,RR<NX6$]"%?P!FBB`1J@<1A-7O/1`'TU"SM>8=00!F^E"W)[!2/O
M`66LF!#K#)P\`!\P67Y0QGL^3$0LY8$=<8.="_21@<7'O<+1F[.<?6RUQDR@
M&(^@ZSBKF#C&*1!0FE2[(PT@J@I0+CK"L8-IP!A',TZ[N(=2W#1[*!^P[-@\
MF&'P"BN7`#E2+D24_W'S10"2?@N\?0ME[PIGG_8$L/9V__81=]PS-@BBK@D>
M8'`O!PD60NB&^0JMG0#*X,[B&W*LGF"<^L;?7D1OZ,0IHPR-R^QY";F1BQYE
M?`&@P+37?NU7I0MIC$G>[IGY(9F^-`QK+.#J3F-HE#%6[-4FY@<B<W%44-A9
MT42N0$0J\@>SG\=V3.>\L%6#`&$[LL=K?!9?C=5OX`7+OKFM[0(4)OGI\?$I
ML]@C)@5`DX`3T`(>?N2)&0<BI@)2X`+H&@`XX`+";/.%+O@:0`4K(+?I6@(K
M,,&*^>7M"0@"?W\=,U)S@W\:9Q.(B8^0?WB1E'\J5)A488-A$WAOB18X)?\:
ME9$CIHE8F50#G!,8`8ER4B6@J8D*N(-,"KX*CBH8,Z6#;W@S6*9-7KN)O;_!
MP\5_Q\G.=\Y_84W=36N<8\J)86,1VG^ZN&_>3>?58XZ\1SH=S@-(NT0#_`-,
M@RITJ'@4H,DX9P`2[>##L*'#AQ`C0BS2Q(_%BQ@S4OESP4,"$GX*_#$0<J2?
M$W\^^'GPI\7)/S+\Z()0LH+%/Q5;_'G@Y\(?)"O_!/%#X(\7B_E48L3IQT""
M#QX&^9'Q!\#%*W\(L!Q:].B'/P,L=D6:TD.3/Q8;_)&2P(+2BU^O*)AQHL%%
M"%C*I<S(MZ]%">@":WMQ5K#A2O@.*XXD<O'B28[_(_]!)5FQNLK:F&%>G&WS
MX<N>[^4+C2[AH(424ZN>6-$OWXT7_-B@*9)D[9<J6;I$&7-FS9L514[XD!#H
M5J)&R;X%;C%V5+0?.ER9?>#/"P_'QW[-``'"6#])S:+UX\$"EC4G^'Y-WW?C
MGSFNX_\EC8XP?='WG37.7PDR?UR4_5<):`+BU$R!IG2&("4$+IC8@I"8]@=J
MJU68&D7R800;1K?=AE)N+;W4VQ^T_6&3'TSY-(@RQ@F%W%'@[;54:Q8]9U$!
M]O`26W;)09!C$-^%=]9%00Q"4D;K^?6`/3%EZ!=@$#YB7Y2#/$CE'_M!Z-^5
MDW&93I2:>?F'@EPVB*"5_U1*2*&%;#J$H9-^F-`"`1@9T()*=N8V9T\M\/1`
M"[&1T(('3;709`M/6"3#&,.U``2?-O@!00LG`K$G1HABY$$++C4'@@`5T`2I
MI)1:9(,`&'PP::5S>O!$I\AA06A&!/3IEP<G8`#GDUY.226:46:YX)97!DBE
MF?R%Z2695R(K(+`0JMGFM`V]N>NUV&:K[;;8GI'!'R9P*RZ45_H:);0+"HL@
ML50:&Z6S]RG+);/'<HDN@M)2.ZVU&7E@P+\`!RSPP`07;/#!"">L\,(')]!!
M$S(P+/&_RV5$+I7F0GAO@>H6R&Z4[D((+WWR7DGON_:.=F6^^K+)+T8?>"'S
MS/\TUVSSS3CGK//.//?L\\]``VV57P;D8?312">M]-),-VU&!4U'+?741KN@
M!]589WVT#%IW'74(7H<=]0%BEXTT`&:'7<$$:;?-0]MIHPVWUU;/'78("K7<
MYLOB]NWWWX`'KJT)?11N^.&()Z[XXHSW0`'CD$<N>>%JW#'YY9@;OD?FG$/.
M0>>@0PY`Z*0?[D#IH%.P`>JLF\$ZZJ>_WGGELH/.LMZK\2WX[KSW[ONNA-?.
MN>/"9TY[\9AOCKSDGR^/^>C.2QY[](FK3OWDKE\?^?3:(WY\]XG?CON%-/YN
M_OGH\QX\^(@3S_[AW[]?N/+R-R__X=#?WP?WW5NOO^'_V?O?_OX7/_F);WP1
MT5WZ%LC`!L9G??=SW_T*^#[ZO<]^_\O?_?BG/?\),(#_XR#X*,B^`R+P(0IT
MH`I7F#X(RD^"\B,A^"S(/@SJ3X/R$R'U//@_$.I/A]J38?=,>,)JE8^%2$RB
M[USX/AB^3XC:HR'X;'@_'+X/B,[CH?Y\N$$"6BZ#>2NB1%*HQ#*:,5M,9)\3
MV0?%ZTFQ>U0TH`"QN#PMWH^+.?2B`(DH1C*>\8^`]$L:P;?&$7Y1?V_47AS?
M9T7VT1%Y=I0?'J^H1S">1HQC/&(@-\E)C`PR<UUXI.(*V;TV4B^1UUMD"><H
MOTB^;Y*.K&0?4(`"P]6@EH9#_P,:#C>$&B`.EX:#P^%J8`7$\;&(?NRD,I7X
MR</!80\8*%P(2F`X%!`@!GTPE!HP1TH4=,$$&CP#$,A6N!K8008`6-TL`?``
M.T1.B!@P@0D>9[@N[.&>/5AG.WW9!W&:@)J02V0,[KF'$QQ.#'LX@/VZ<(`]
M8+,/<`"`#%I03,4ML@1`^$#A,"`#&W2!GX7K@@UD0$\T`(`%/!!F'WKP`!:T
M`*3X2QP';&``@#K```V8`.*ZT``#Q`X.3[C`$U1*`1GD5'$B-,`'ECJ$?C:`
M`"&H:.$XL-06%`X->R!``\Y0N#,\-:I]B"0#@@`!:JZ``"SH0D@O\`&K&NY.
M%U#K_O]L0(`"^)(!7P5F'WP(AP9X@`5BZ`,".F*"8C*@(P]X:!]*`!43"%,,
M=C$`-C<@`P]<@*NF.QP+N@,!.*#`!![X``CZ4`,2>(``.BV<%4![`004+E00
MR%X7"."!$.R2<I:#0V4/4+@3T,D`**C!'L@#`#3`(5($B)T82`(!US*`3BS(
MIQD(90*0'O.$R;P(`2Y`)[A<@"8FH`(+7",!*C0)?1>(S44LJUYN08`*$^A7
M!:AP+0B8(`1OV6YW+?*![UZKF893`U&:ZH'\/>`!A:,3@`]'RA[0U@"&BX&_
M8J)6T(:``!\00PTP_"C>,DZ&#)B*#3QP.!E\`)\;_@`0(`#_80IXH`$4#NCB
MNN"!>QJT<!*^0+A&9]H#=$0,UB3`'K"SN$6:0"6+G0H/_!`"P]GD"7[]W&P`
M0``"U*`$$+!!")BL.!Q2P`][:``$5KJ2<+FS<':(4TSR^=0*:-4*(9:!F1,G
M0@+(H`(50`,%(-"`Z7IXKS7>LNO$;`:_HL`*?/9S6-6Y4Y(XP`PAX0D'O@R$
MX=XXOB$X@!]*X.([,UD-_C(#!&1P.!\6(*UH[0%V:"P#"1M@MC8HW`9&W04(
M/,`*&!XL`?J0W@D8P`.,'J#A"`"$$YP`#0^`0!<,`($-@-91?L!L9;M0V1Y`
MN@!;[H(=:NN2)P38<C5X`@%XZV(3_^2!Q0#P0!<@#0#N.J"RM6S`!QP0+AK7
ME*UY"(E+@F"XZR(PNQ;92!AF90,C^4$G//'+1@JPP$&`Q")QD`JV"-`$^KZH
M7T-R$@0F((M!'"%25*$1!-[0@?TZ:<%]$/!?:U#@PL'!`]1T0%.L?#E2DI;%
MAC,``:Q0`WGW`0(\Z`,#/%`!#O@AGR'P@%Z]=\CJ]<'HC#;`!0!P.J/GLP!*
ME\$%"O<!4C,ND=L&P$L-E_1B/D"C$`!"'S9`=)=@<\@P-9PJ;=('(-!<ZX:S
M00-(^X$'B.$D20:!W7V)]_`E;IM8[\-3=ZGS84,8#5J-@1\^UP4_V!,"C-\U
MXD2892!\;O\/$"BF"33?!P.PH'`L,``<_+""/DC>#"$(?1]&'P-7"M@!!(BU
M%5+_5%]^X/1]8(%&-]R`LPNSLNDN)@G&#,#$'?H#-AA]8+>\Y:9BO99/@(`O
M@603KE8>*.[\^XT+Q[TL/Z`+:B``OVL`@2=X(.AH&/7:N2P&`AQY[WVP<^%-
M_VW#?8"W!_`!J\-P%Q!K?4!7@!=B:E5;I&59?K`Z+B%FA7,`S-<'_C8^`.<'
M[K%E$(`!!G<!#T`GWD$4+#`K+'!VDD(G:$4H628JWC$K!$`3I^4!$,`"=&)9
M%7,3?Q``OY4(,(.`-4);-=A=!1<&M#46;%4C0_*"%N$=HG(1`E?_`"0P"=SA
M!W*P!NK%$D>`+2@G8.&2=-`#9;YD`S:`9;#4/O2T.#C'=1#6!TG7!WZ06A"P
M!S;A2_FV38L#11MP`<!7.";P@AQ0AWUPAZE7./SW=44&`5`1=!.H46Y(8GY0
M`84SA^E6."Z!AX@S=W[0!S(`?"1`>O]7.`W0`%_V.!MP$IU8.)_89:-$`!#V
M`6WXAH7#@*7W`4;G2S40B28F322V>8IC>E`1`P%8.(F'>FUH>@*6!Z3E!^/D
MB%A'`;;G!S(7/,!XC,RWADHUBH5C%7_X6IO8?(A3`Z!5`IWH2T9W`+WH=K/G
MC!X`$H'U92[A6KDHB8;#/0\@=9OB`07`_W7A0H_0EW*31UHL(`/JAWH7H(U]
M,(RXY7^\I76^5'FN:(@T04U_YSJ1.(ETXDL(X`<?H'FR:(%AA$DHI$FNX1XE
MAS?V8!LF@1(A8`]S0"B\(1-_`"5'8`+%0!((QY$_$10N(`>*8`".<")+,0A2
M``$"D"-->`:)P'!!(0+?\@:QX0J#`"1_0`20817BP7I_L`(640)_8!<7X1-A
M\!8;D1X5L!80]Y5<.#FW-S2C@P(>\#B2!Q<UEX:*LX:*1W.--X=KIX^5MTTV
ML73PTW3>`P$7H%BDE6!`\)=]$)A25S@7T(:+DTC\-'IDYP&^=`"[!G1]8`7Z
MF&;"])&9R#AT1_]6OO28HFB`??=W[@0"?D`!9,5X6V=XF_=BM<1LN^1S";9W
M\6<`IVA5Z<$!29>;CIA9B;,Z?]<%Z;8ZNU@XS=EU5L!E7S8!%0!LG"B`T>@`
M2P517<=LM121I6=EB&8`FHE-LV$3PF29X&@X5D!7U!1[U,1L:99//,!\TX5-
M2K615F438L"`)2"-QEDX@?5W%0"+KN<!9A"1IT@"?8`&_K)8$!`"=&4%\1<$
MFEE,D=E_7'<`&^!^KB5F!%D#D/=K"!9?);`!=@:0FJ93IK5E&X`&_=5O(2F2
M1K0K&X$*#(`%7K`")N$A?X`%4D`$X"(B,AD!$_`/;T`%B(`'![<3.MG_(AU`
M!2_@<4I)(AGQ!SI@`5CZ!P@@<=]R!@#P+0S'$E$ZI0G@!R#P![U`D%0Z"!"0
ME1[P!F?J`4QPIIB")1BA%D3@!RP0`'OJ!UAP!6C$E@`Z7J-3H+SH``Y@%9@(
M.3;W<Z_8`F?0%)HF`GWP`+6U5&+@F03``Q[@=7E(F(:3;QX@3PS0B7LH`R!1
M`)Q:GWN7;P;`$VXUF8L3!,2!5GWP`6;0`ST!!#5VJ:4Z7F+P<@2@!W@YFHM#
M=U\6F2&!96?`E?AX.GXE`]X15HH8$_M(FX:39BQF`&(@8"Q@%UV``!!0.7[0
M`..U37Y%@090`P)VD)9'9X?'IRJA!F*@*G8!_P`NY@`<$%JQH8SA8H,TAZ]^
M,#K9:71LY0%B\'?]]9H]]9\).ZS>,5XG``?=81<,NIY<1Q2_MV&*Z`=V`*,.
M&`0VL0%0$1N2&!,=`6$\`17%27YRQY&T%0,$:%E]4'D=&7HU!FFJ\@'N2A1T
M$@,8T!TJ83_?`XN1"!5TT@5?QED48!.T15,%2Q2AA08DH6!P28,>@(D7B#L9
M"!LS,`@FT"$K^0>1`@0A$I.Z@+)_D!Y1D1-.^A4M8A5?P006<185@Q,$8`\)
M``%247`6!P$:T`&VAJ=?X15@(19J2BAXFY5HFA4\@*<8H0M+!A<2%W$V\`0A
MLI:2$P,?\#@HP`)V\/]RU&0%4W=5+*!VDO.H-A!T$"")7<!69X8"]6D`#$`Y
M.K<'MQ6JBS,<2R5:R58#)]"1MI5R.@<$N-0%514YB70&S/8`JP,!!FN#V5H#
M%V8#]!0#.D<"*B53C),';4@!!N!1-:!JCS,!`UE2[<8#N,12+A5WV]AH`!-8
M-]4`:K5G^30!/?530354A2.^]HM4BG,"!W``](10,C`!-5!_IQ-/\[2M#Q`"
M@=4'"*S`B[8XSX1->?``/(!99V`"!EQW>U<"!P`$F,4`)/``S=.AYP=3/E0!
M`!##DB@&%?`$RCA+-8P`-7`&'C`$<%``-EQ.=E!0]?0$>>:+<O<$`/!0>;#_
M!P6@4B40`@406`W@;7E@Q!/,`"&PQ#@&`"&`60O96PC``F8`!RV@KP):`!4P
MP24``"=0`PA`8A0``'903#6@G`[@2RA0`070J%VK-U_+$1#@!2>@CSU:MB"R
M&S`ADR5R(DR1DW(;%%R1'#&2M\&!!;\F%50Q7!;ADWWG(MJ1N!=7R8Y;'0!P
M!E@P7AA!`G^``QA1'?`Q%7\P`TW`@X,*.OJ+.H^Z43:`F*]C2H4#!(Q8.ZAT
M4!<P6K*C2HSC`!<@F*'32)"S;+(C2HA3`C;0O9SC2I@C`V<H.=T<.2/P9Z%#
MS<=I`';).?&C!MZ:.3SPS8OSQRT3R(&B$F1+$A\2_Q2*/"*-S!PN\`>)8@`[
MR2,PDA176A&E2AY2P0)_<`0T\0$:("L"K9-AH+@#71891P!O8!XE,"O:]098
M\"@<>19#(2E$H`%KP*2WW#FTI,OGK#AJD$_%`\Q/)U6R4\S!U-*EH\R+(P;!
MACK0_&$3S#KD;#@;T%2AH\V7X\N=X\Z,T].@,]3#Y,R8$S\U`+^1(]63`\_Z
M(L\<<LCVO!>Z0:2^(1*.7!%4H0%'``HM,LD5;<F:(G%'`!92\`_A$M%%\0<3
M$(*4+"3C$8EBVQ<A``X6<`;V,`,8H;E#FM(1A-.E)*KL8]/.H]/:\]/:`]6L
M@]3=P]318]FR(]/+H]74DO^!*_`"RQ$$+Q`IIATI`$#:3?$"5K':)"$%+T`3
MIITH?O`"^79P'3``#_`"+F$`+\`3$/`";&`1+<#:&(';FO("+W`1>R"D`G`D
MP"W<Q&T1>,,$8E;=!T?:'I`'S<U?;NH7+"`%@R``YZ6X3,#1_R5`NQP]GHT\
MD+T\DGT]E'T]G%TZF*T]FNT\]\TZ[UT\H+TO)&E&ZNT[!>X:!^X:!;!P&9+@
M?8-RSM/>SO/?PA/?R#/?U%/?U-/?1^W4DB1`,*L_%%X[`;XW`[Y,RW0&$:``
M)L=`$+X\$KX\(U[3^H/AT:/AF]U*'OY*("YL$^38X%/B+G/B*%[D*_3BR!/C
MR#/_XZ]CX<5CX\Z#X_RMXSV^W\O#X:7#Y*PCY!:B0!`@`6`>YF(^YF1>YF9^
MYFB>YFJ^YFS>YF[NYI$B2.S-V$$$Y-WCY,(#Y9_-2N^3W]=CY<B#Y:2CY3X]
MHS3*!PI$`$BPZ(S>Z([^Z)`>Z9(^Z91>Z99^Z9B>Z9FN:7XA`R7PZ:`>ZJ(^
MZJ1>ZJ8N`BM@ZJJ^ZJS^Z6?<ZK`>ZZ#^`+)>ZZH.`+:>ZZI^`+K>ZZ%>`+Z>
MZRL0!\%>["10[,$.[,ANZZ^^[+:.-Y=TZ#5JY-2N1!<3)1GC("I#)1TC(!\#
M(2&S("-#&B5#)2<C,BGC)5Q>(1E8[>Z^.]<.(=E^)ML>_RQ7\NT+$NX(,NZA
M4>Y1<N[BGNY<LNZY0^3O?O"\$^\+,N\%LC$"TNW_@>\(HN\%PN^>X>\0`O#[
M+O`K8^@TVNX('_+;HO`(PO#/4N\0`O'\(?$%0O$"8O&;@?$+HO$5S_%IXO$B
M"?(BO_.[0O(%8O+_X?#_H?+YP?("XO+_`?.8(?,(0O,O;_-10O"JH?,\7_7Q
MX?,"`O3\(?3\0?3W8?3_@?3\H?25P?0%XO1)#_71@O.81/56__86TRN%\2LH
MGR[W+B9=4B9@<B#+@O=DOQE<GQ]23SYP7_@C+QEQD*:&H?7Y$?CWX?7T`?;\
M(?;Y\?>18?8"@O9CK_8+,OB9!/\XV_6$?*%?AA](6)\(&6``80L3BF\4!'`.
M(M``.E`?<V\8,R#YE.#XE9``$[`8D)\*<]`(@H'[II`'('`+AD'YE*`!<3`#
M.?(9A\'\SF\8F*\-9\#H\H`-CF$!C%ZEAF'YJM#H6($.ND\)5\#HQ#\(GI]`
M!H\1%=`$\2461]`$D9*3"B>YZ-,$KOPW)@`(38)-,R$>?HB)BHN,C8Z/D'X2
M?Y25EI4#?A\9?QX5E4`F?QT??GN7J)8O3:FMEJ1^!JZSE`-(M+,/?AZXK@6]
MKBL>!!XGP)1XQZE$%Q`0%QK*E2/2E&$$Q++5E`K5U]G535[;J38?!'Z_QW?D
ME%0?I1__Y-WM+_"'R<>V[7\8\'X0J@&HM(./P8,($RI<J+!(DTB*J/Q9PP*1
M.@-^9%2X\.A`A0800X;\\U!DI%\9!H3I\(>$R9<P'4W"E<F#@0Z>*`6`T$V`
MGP8?U@!;12X."VW;]I&;88(7.77DJ*P(TP!IKWSDL)C0,<'/D6W4JETY,,!0
M.WK*QI9UJDP</TM$7EQH0$09NW9OO/`@@&$>OS5>\G@`$$"94G)Y0T"8()`@
MP\>0%SHT*?%/!IM,*&$TT*+4@\XGCIA`])DCB<X3CAP@4"&!"W2E_1!H`<3/
MA18-GAQI`<$$&R0<%Y%D!"%$$R08$1$0(6!C"QF+?B6_\(>)__(*.A#82$3@
M1),G,G#''(]H)JU,>_P(^_3G(Z4&#8Y`,-:+*#D#5J4=WE:!;36H[0SP@2C'
M8,6/(>-4$Q8YJYW53H/2N/56)0UXT()0Z[RE0$8#^,4/%L-@P)(^M_#SPD\"
M-$9)09&U"-ED(DDTPQ\%)-!!,AA)YX<QF;VWXQ_0=8,%)1T41@D.?K3PAR[R
M(.''`W\8^4==E+QQB"+#*>*!'!T@($=+LF4V1P)OM!?='\DY-4QF7G8`W05E
M7H&%4!*0-YYYLV2B0`N(?**"!SK\4=,A\M3'RGWY&58B.?VU`^`V9T!@0#0%
M3O@`!)4IB)@-!(SA8#5O<.IIA`E.^/]'`E*D8]=;`6#0``$>\J-`G24H^A83
M&!@0D#0#K>CBKY*5%))$#5A`B0LZZFA,>I^L\&.0?XR&P!]X>$"=3THR^8>3
M4%)ATT0$0,!)*5@*B\@!?P``D!<)]/9'"X<H6<&9"!100#)=?8*1/!;X\8D+
M`/55IYTPX>F*GFOH\DD%-E#R!`%44#%OH+C8MPU^`2[*GW_2/"J-"S:5<"@P
M!HI5804*7`'6-G.<<X("/5:#UC$M=P<SJ::^`804,W@0PJKME,##$0_`NLW,
MU0SPP`Q(9MK+?C*;<`00NRK3ZQ\L`JLU'S`.^\<%-S5!0+)H_NC9N\_ZT0TZ
MOSCKQW#9:K+_[9-_!"';E(C<0FXB6292ZQP**!``$RP,!-U/9BKRZ`SHI"A`
MX)1X,"TZ?I#PQ\`$FV1P*QD8D,`?6,@``A$0?*7!`RY0PH0,(AC:#L;D0"U-
MHT_Q<Z7<E;9#A2)*:EJ-VXB\$.LQP/LA?%NE\L/$`QYX\(&Q&;83!S$0I'XT
M/SI<T/P#*MC:#A[$>/"$BEAOO777$$G$$14@D8V1,6?S:0RT$*@Z[]L/*7F`
M;7-#:3>L7LC;'_:&B+XAHG4EL)>]"`"E$CCC#(E+Q"\J\`!6C,8/(/C#"118
M``\P9CNJPESF0K(Y8,2A`6^QF*F\M\*.M5`9)7LA,!8DPUX@K8:H_Y"0J30`
M/:#Q(PQE&AXYO#`D_6B,''*(F=4<8SY@H2\2ZE-<V90U0+K)#TAJ^T/])EC`
MATQB#B9($;?J=K<`^D%OPO%""];8@@M\H`,)@,<,..(!3E`B`A&T2-E8`*Z,
M_.$,'[C`#.HGB@#((`2%J=,9O%"_$4*BA#A,A0HCV0K941(5'KMD)6*H2530
ML).7N*$F=0C*5-REE*D0)2@M6<JK9:V)+7HB)*(HP2F6#7Y63%LWMIBXX4"@
M>W_L'QD!*$`"ONT2T#$!I;"X"QZXX``RH-&9DL.#/_C$7Y4(P'8\2`DL",P/
MK*"<(V6"2E1,$I6L!&4F.\G)<GZRG*JD)/\IRUF)4]*S$O'49#H[Z4I8_DJ6
MC_A`A11!@`;4KZ#U$^@A(``431C4-@,M*+D:$!P"R,`&'F@H0]&1T8HX]':(
M@(]('RH;&<A`G%(@@0$.H#*0$)2D&1VH;62@*T780`8?",+E(`K2<2X"DJ`\
M9RGWJ<EU:K*=J'PG*O.)PWG>TY[W_`-3*4G42_;3G[$TET^WRE7BS*$2&NB/
M3W4JPJ[^-*J4$.HJCUA.HUX2J:54:BFG*D.GTA.J]Z0K#JM*R:MB]45:-:M@
MMTH``\C4IQ_`Z6`9`=1.JK63?(VD6RD)5U#*%91Z;:%=RXE7>F96AI'%H5__
MRA"`[L(9J$VM:E?_R]K6NO:UL(TM;,,EV]K:]K:I[:DB#O""WOKVM\`-KG"'
M2UPDY(&XR$VN<GN+AQ8L][G0]6T0HDM=Y#JWNM@EKAZRR]W?2J&[V,T#&\!+
MWA&0%[S?/6]UFZM>[(Z6M`T)+"(^X(7ZVO>^^,VO?O?+W_[Z][\`#K"`!SQ@
M=3E"!A1(L((7S.`&._C!$&Z!'2!,X0I;.,$G`,"%-\QA!3^@PR"FL(9#3&((
MFZ#$*%YP!5),8CL@@,4PE@",6;SB&8<XPS8F\7OABQ#3.@\>0`ZRD(=,Y"(;
M^<A(3K*2E\SD)C=9G(PP01^F3.4J6_G*6,ZREGM``2U[^<M@GK(:[A#F_S*;
MF<I[.+.:O<R!-;O9RP!XLYRK[(`YNYD"&["SGLV@9SO7N<]K'C.@W;QC'AO$
MM(M-M*(7;2<I#UK-7'[TF04M:3.GN=)@;C.FS1SG38/YSYZ^,IY#'68^D_K+
MH#ZUE2FMZBL7VM"(9K2L9TUK13BZU5:.-*ZKS.I=3_G2OM:TKZO<Z6'W(=6J
M'K6QJ6SJ91][V;WV]:MY'.M:6_O:@KWUL'4][&CO&MB[%O:RBSUL9)]:V<YN
M]K+-W6IOXWK:\*TVMN=-;X)IV]?<]K6[6PUN7(O;V.3V-;M#C>YEJ]O8`S_U
MOE4-;]+*N]X0CSA$[KWK?.]ZX:?N=ZO_/>R`[_\ZX9LNN+$/7FYHDWG<3#1T
M0AXN\9:['!$4Q[7%<8UQ4FM<U1R7MK-!CFF1#YOD`C>YLQO^5Y:__.CUCGFK
M9][NDQO[YJ?.^:X]CFN>5]KGO@;ZQX6.<E^I?.7R1;K8):[T,X=`ZE]F^IEY
M,($^U&`#-3!SS<%LKRG#_<Q0MS(:T&!E%/3]S&C'LM^K7(/!3[D&<3\SU<.\
M]RH;WLP@?_L&)I_X&J@A\6[/L]V_7/`8:'[*:+B\E2GP@#Y,?O*&C\$0J@P'
M*K?>[:N?<K-10($85#D&/>![E8$0`BNHX?=JL,*4X7"&U_?!"F*8,@I>OWPJ
M@YH!#DC^E*U0@BZSO@'_=]C`@JG<`P>D_O5B&+P:0N_T+Z/!^]PO@?#=W@,U
M3%D,M@<ST;%J]+';7]9EK[(8&M#V/AB@_WT0`P209P!@`R5@9FIG92Q0`%,F
M`PPX93W@`7G6&78@=^6794/``D`P94]P:R@``7G0!Q3P`4^`=_)W`1=0`'&'
M`@\@4"#0!RC``RS`9PY0>E\6>+=G`!]@``PP95U@#D#@=SU0%;9W`%;7!XM7
M93+``DQH`&X'`!?``A7`=W9@`U)F!0;@?I_F93T09%U&`:_2`%T&!Q35=BO`
M`YRG>590-"0X92#`*0V@A5-F`$'0!VX$#R6(!JOQ`:8V`?^'!B<@`][7!3+0
M_P6R-V4EP`+#H&D/`P$R8'QPX`$4X$"H=8`4T`P?T&96```/D`<QP`,F$'T`
M``36]V<%D%"M%P,&T#PFH'M]8`8?4`/]T3P0X':GZ`<LT`-]``(R``1G4`)`
M(`%JP`&Y`0(7J&7[8WU[``$>8`-Y9@9N)`8UT``X.&7SYT]&!S;!$5(U91(V
M@`0\P&@$<`#)L0LZ*%@VX%+7EG]4I@:RD7R#064R<`!3A@[L6&4)6&6(H(L?
M0(]3!@1.V`?;<0$6"&8;@`@GT`=+2&5V0`#_N`NN"&9Y-V444#GAB`!]8%!/
MH#THT`4LH`80@`878'UL5F8LP(<"U0=B8!-/X`$DT/\'!X``#M@"+%!F24AE
M!;`'M5&39N`'0:`+*]`'$!`#+"`&#Q`"909R&U`!%8`1MN=&)Q!(<-`%#9`'
M60@!QI=ER@8`GO`$%>!V!,`"+4``L6AW'N!^''`''P`!=78`$%`!T.$`-:`+
M#P`'VQ$"&P`22/F*4X:"%$`"MI<'?A`"=N"(5`:%Q]<#>0`!-H`":``!+)`'
M!K5WVH,``LB68H`-NOAL,>`'/+`!>WDI9]"3%=B7Q68'_M('7>`!$I"93M@#
MSZ`&D?(!8K":8GB,6'8_708"?@``&"`I&6D'3V`&)K"!87:-L&1T$N$%5Z(-
MY1@2T70"B^8!*C`'1+`[E0/_(H(U`&:TCF'FCL[3!_'8!W#@!V?0!X(I`Q"`
M>6E'DEX&$!"``OUX>!"0?#W@!_LCAU\V=P=9/V>PD,?'EGV@!@0P&@E99A/9
M!PS@!V;0'Q10GGS6F1/0`X5U%'MY@V6F@Q1P%'U@`@[9!RT(!P5P`00``!"P
M?O)79@7@!\G7`#79!RS0`':H@QSP`9`'9DNP@WUPGU^X(VK@/$#P`>ZIE9I'
M`',A`[I8D0?(F]9G`&C8@!Y@B$)9AT+YDB-:`&@0`BPP`7!@!@MXB#6`BSOH
M=T%0BWU``F8:B9NY`=B09Q79HQ10`P`@.F)``J&X`0!@`IM99]+)`N-8CX[V
M`38X_P$?H'E=$`M\%P0?^@2U^(D5$`,Q4``ML`$,(`,3<`:X:66'.@)^T&6&
M8(T>T`>G"`$U&I%PEG)?=VAAUPB5(9T0<"CE>`^(X`'.@`C.T#SA<EJT6E,V
M02ZTVDBU^JL_$1PL@%&+(`N]$0":H`+JJ`BURH2+8!/;2*O-`T*)P)V-T%&+
MX(C4TTB9<X\#VIM/,I[0-&6)Q0`04()AEH]4Y@<CT(SSV:$R,(>-65AEQI^]
M&4A,.&458*-]H!@U8`Z6]F4;0"X?$`/N^&>I&0-=8`<&$`(&\'E95HW6F`AQ
M!J#+>'D(<`9B:0#J^F4W264".*\P2K(+B09=D`<$X(=2BO]J8,8#'I!\'.`'
M<1>F7QD#%&`")B`##1!_1#IENQ`":WEL?M"#"UIGG>FS)$`,">DSYNJ/D'AX
ML<>7][F`SZ"0'_JI2$B0RK>T9^D`?J"+]WF$SS8O>Q`"O=D'!$"E%T"R'_"`
M`[J,-NJAUFBF7E9SL'D`,SL!-<"H4[:B=A<#;ZFC\H>JJ:J<U=$!%[`"H%,V
M-@!,1&`W$,"=C,D$,X`X\S(),Z`R&@``T,,GLK`A3H$X<L`*'2`%H_("WHJ+
M?["`EY$`]\,(7G`%,_('<H$(/%!$1\`1*`0"8:!5V+H(!T`E]F`1T1``R<`G
M(P2N"8N::;L!'B"VNW`('PIF[`K_M'?@`(=`CU8`@GTP!+<3L]^9J55VD`5`
MH+C8EZ5)0!@99@G:'Y-7'&C@`1O(FW_&``2``!<0`C):DF$F/FC``[5HHLEG
M`RR@>\4I`P#P`587LE-F`O4Y92U8`V@@J(?7`"<P'Q?@LUK&<V+0&\KG`7KP
MKQYP@'UP`@W0`C9P`"^I9<IF47TP+QO0F5])`N)K`@'9!UQ:L*4W%S40`YY0
M9GQ6`T&\BC'L`0Q@EP19`YDX?"U@!??)`6+@!T]0`RLJ?5LXLV(0B?2H@V)P
M!A[`@!0``9JG!BM@!3#[BL5@!?NZG^3+KZBE"3'0%1RP`2@X?0U@!PVP`A>P
MF:?J=:FJ_ZJ402-_<`0J$`:M@Q$$@`,%<`)8H)WH$@<)<`7;@4*9^P=A4`%]
M\0=2T#N2(E6[0`F(TP$BT`+1<`8%P`GAF`@>,`,9D`%!4``ZL+J*,`XSP`-]
M<02:$`!SX(`:P)LH]`98()V*$+S<\09A<`!/T`&7RT<!\`1!T"'*^ZW?Z0=R
MB1%Q!@`O2C4G<`)H.Z19=KU]X`=D9C?T6``L$'<=U`4.P`%!#&;XRH#]49,U
M&G<($,8.X`!_ZKXWB)\'8"%]$`0>@%,?P'<HP`(GT`/[V[]:1K%]``\\$$CD
M298RX`&FE@<7L`$*S,`I^F4??&L(\!,&%8)]\`2EI\$<G&4\5_\T?OS/NG(`
M<<>F%-`%8'.A6*9L'=2"_FI0JXB&0*R%</`,&-5V\`(4!(#%7V9J!E!8+FEZ
MV+"6;0:-5-8%SW`.R??/+``!-AAF=2:?@00!NH@`V``!A0JCQ68(VE-Z<+"*
MVM.R6E9SOC>,Y%QXF`@!U@<`,DJ.`UBX@!S(B'L!&70Z.H*+#V``R4`N>4`)
M=H.YDO`':"L/1(`(XQ*ZH?P'B',B7J%%V!2[W`&9&O`!))`'NK`(1+10@6(A
M[0$?`V`=*!0!4(8(Q@QSJ=T`XS(^:!L+:+.\8;9_NE@#_Q>)/3B-7^EV#[NN
MX(QE"/:/9C"_)&T"<+L'S/O&RB<#[5O_`"5X`9T&`'N0>!4`KGV0H'W``?C1
MLDW9BE/&`>H*`!&+H6%F!0?0`"80>S%0V"W[`#VHBC:M90X,EQQ,`0:0W'V`
M!C*09U;IUAW\90=PH(=7``Z8>&:@:7;Z>*+V>68@`WOP>7-J:B1@`_IG`@_0
ML@X@`R8@X5YF:C5@!P<`@'W+`YOY`<,]90P0!)])91-@`@K.U8=7`0#P>7A:
M`7$'QA)+`2%0?BT0`DC]UM)-92A0`9]G!SNN?';`W<?M:H;[=7]=1RNJ(Q!T
M!@C0/>0")5\34F8R"?]CN[`]0)0]NBA4$MUP"%S$"!]@2"*@`U#RG'[@!6'@
M-UHT+9?`4'\@_P*-$-N#B0H-8#EN$TW3;&]O9@=;_6;B?&4EX(]R-G=8)@8R
M0.)J!MZ8YM">YL">1K:#AG589@45H)^`IG57!@<`8*I]1K84P.GC.W15KG)_
M'0N\I(-_<`6(@`-5]`&''``*@`Z6W-AECMD=LH-_8`&%)<IKC@AM;C^,0``S
MD"I'`#!R\`2DW0$8(0-$@`6>F=M9S=B,,``J$&3+/@&',%!PH@$BL`+CD.B-
MYFR/7FF4OFF:7FFPCFF>OFF@#FBBCFNHWFK]_FCUKN^S#FNKR@BTI$>Z0@1A
M-0%#4@H(H`%2:";#3N9W8^P#1`!E,@?0@SALW@G0O@@KH+H[0N=,8/_G7J`!
MP-X]SN(!3?`&"$`%*H"VPS[N'7!?7,D*)1`'3#`P)J`R%F`,@*[;RS;ODE;P
ME7;ODI;OE;;OF#;P>O;OK1;PJB;U@*;TDH:<361T!:``!'0`"E`1%S!>R!+L
M%Z``]T,%OYGVM2$#"@`=/)$J?H`#P1X+3:`#8K\A:4_,+J``VZL`M4%0,^!2
M'D`%<U`\B.`%`P`$>7_;LO%=KE$_;M\(=A\X@5,;%I(`J'(EZ%`_`['*U'ST
M4ZYP2>YI3/]H3K_U.^=K5*]J5G]J6-]G6O]H7&\^]7=_=L+XLN8!$1``.O`E
M;_#:Y.'=F(;T!'_Z]FYLJV_[K;]KKW]JL4__:K.O9[4_:+=_/@FO^^/$!GC0
M^S)P`CIP!!5`_,4O[Z5/:M</:*D_:,V/_<^/:]%/:M,?:M5O9^O?9]FO-;D/
M"'Z"@X2%AH>(B8J+C(V.CY"1?B9]E9:7F)F:FYP]%)R@H:*5:G>CIZB6>ZFL
MH!RML*``L;27#K6P%!NXO&:\N+>_K:7"L`!_R#M\R\S-SL_0ST5-B!!!U]C9
MVMO<W=[?X.'BX^3EY2R)!QOK[.WN[_#Q\B`(\O;W^.M(=OG]_NQ`_@FTUV*@
M07L2#BIL-V&A000,'$HL(-%APXH#]V$T>"Q9M(\@H4U#1*")R9,H4ZI<R;*E
MRY<P8\J<29,FB40-_T3HW,FSI\^?0(.&>!*TJ-&C.@&80,JTZ4X#3J,6!2*U
M:E$95K/RY*&UZI,*7<,>"-N5*UFI2L]6#8'LC[*0<$&.E$2WKMV[>//BE="V
MK]^_@`,+;ONBR>##B`\/0)*XL>.V!1Y+'HQGLN7!(RYK[JM@L^4F7CR+OB/:
M<^?2DQ>CMMS1;=S7(JGIG4V[MNW;A?BNEEQX]V/5OAU'#HZX,G''F8\C/JW\
M+^CFB4E#/\Q\NE_@UO^V?@N[.Y^YN,.+'T^>D.[L?GNC[XM]/;+A[HV[[YM\
M_I_JUI_;;RM]__W][;FWG7?>@5?>@0@F*,EY\ZDW7X#KP;>>?/O5-Q]^T__I
MYU]_^V&8'83H#4@@;`8J:.*)*/K!H'L.N@=B=A*B1Z%]%KKG87,:[L>A?3=.
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M87%9MFUUD$%HR`2@`C(:$"&9L\\N$^VT!)M8K5\9//'`!/#.<``5?ZP1@@6/
M7>O7%4$8$(*\9SQ0P1\=A&"88_3^@04`,@1QQ1\)/+#'&VN(T.U?V_;E10$&
M!)$!RS*$`#,`.C@V\U\S/"`#Q'\4\``&?UA``A./?>N7``?(<`(R%<C`]`"M
M-=;N'V/(T```4+=@@`M_7/&`O(.-*UC88Y=]=MIK.U;N7UB8<($!E;U@@`SR
M\C`T9X]-8,,%(73P1P@-2'%?$(HW5G+>'WQP=0(-L)!`!RO4[!?``0]<\($>
MV/"!M`?7>P$!,OB!-@1X_WSP!P!`\#9R8@U\\``$//SQ`0@01`!`$)*5S`,!
M!T#0P!\/Q'$!!CC8,)GGR(0`@0D0R/#'!0)\`#T+CPW>5@8>--"`!UX,\`$"
M-FCPO&12MZ4!!#88X$<8"=@`P@<=7("T8U]C00-N$@?R,<$#<I#!!!#CML`(
MD(`&1*`"'W,WOU`!`A6XP`7^8``0D*`">6A`Y`#H&"80P`1`\$,"O-"`,$#@
M#2PHP6]\=9@2?,`%K7M#`9Z`@`*`8(/_LE3`HB&ZT8FG)(H[`2*>,`!T'"EU
M;?$"U#Y`@C]`8'\"(,"Z'&.QOF@@`!UH@/988+TLLHUD-#R,OTA`@#^8X'AX
MN/]``J;GF'YQL(T&J``!6G"!,R9&?&WQ%Q;\,(,,0.`)!BA`[>#W&"]TX`5^
M&$,&/A`"%@!@#Y/Y&KPTX`$1,`$"`,"@`1+30,!LLI.?#&4%1DG!R4"-!+*K
M@.D0``$_>NTQ4*.&`#KP`1G8P&/%2^-@%.<"/V@`!`0@@/..,!G0/:N(1L0-
M!/X0&B4*P@,>&,3'&B`F*/:%!!`X`\L*0`4"Z*`"*^/B[1JS!P\(X`\9:`$&
M"("'$+P3C9+!@1\<1X06X($%(BB`#!]#O;:`P`]Q^`,11*``&X@@!#,0FF7>
M\`'P_6$&)SC!!4`0@GTA9S(-(,`;[M,"*GR`"@788F+_OO8')K`@>/"4PAEL
M@(<#A.$PI02,2V&:`9G2U*9VL\P*/+`"D)U!`!=`P@-<,,*52B8!'[B`XN2`
MASC(H`(/>`$^"^<Z9,P!<P4XP`-&ZAAGT@J:T;Q-]OZ@1`^`0`,=2``+G@`U
M+'@AFT7RYA]4\`!Z]N4!(B````Q@R\%TL2U8D,%)TR6#%GQ``D"4G#`#\P8V
MHJTM(2#!`4SP@9T)QS$!`(`'F-H6$X0UE)XMSF2:\($6MB5_R`0"\3[*Q0O8
M8`YM"<,'V/`!$QS@,5_3@6UOB@PF?&`"!#B![-J&+\D(UP;$;>EQD[O<Z$@F
M`$&```[6T)8](+("+``!<!]3_\X'-'<.!#@#"PJP/,F6$`C)[4L%#A`"$P1!
M!(\Q*Z;0FE;;:$^)H\1!"([0RP'<APIX39$WL<!-CQGG!#((@`<&<('4(N:P
MR.!F(AW'5A$2@`J134S)4GB!`GP,;!_``E0N8.#/-N8F)1Y."5B@XAD0H,6J
M?4P"".`'$A3`,!V0P0JZ-X$'1,TQ&>"Q:=\9@`>L8`X7$`$K;_F8TST@",8!
M`A,),$^<-K?*?KAREK?<Y<94L"\`\(/N?OL'##3@#7F,X7@;(P=L&N`!XL2"
M_EZPWO:*>+*`"8$?"&```^Q,!P2(0`%D((.$EE6(0ZQ5?T_T7S_\ULW:_`,W
MG^@8.?]4KG)/,-D%Y/"')Q``O^ITC/G,5\4WU*T%+#BQ>QMS@%6/\@TR,/`_
M32"9@I)@U<N#\TW_V;O&`/(^P!8O%1+'/!:,X<B22_8?/(@,$]C@GE1V3*$+
MC8`_#$`&Q&S`LYEKF6T;H-O?#O>XK?L8%SS@W6PF@6$B(`/2DI#.[WZW./$P
MG!5D=:N)D4(V(O"'"@0-"P7H6F+TNR?^3GHVE48H,E1P`3]LLYO^P7!P2A:<
M@N[FV,&)WW%8ZIF<*N?,RB%Y:3CN&X9_R>$/STNE/4"`#V`R#A;7-,;WHW'?
ML'PW'E\-R'TC<N*H7#,F/P[*1\XL`4$ZTM"R5<S)4VD`A,'_!6BK@!\B(P`0
M)!A%>O5-SW?S\]4$'35#WTW1@W/TRR2=.$LW>M/7XW(AP7SJ=C'```J@9@RH
M@`DS@(`?+A"&#NC@ZR<*^V[&OIJRH^;LI4G[:M;NF[9_YLM8\@\R+*\9QY>F
M[B.Z.]Y'CPC%KX;QJ/&\:"`O&LFCAO*[X;QDWAZ<N+-][B%Z.M0%)G72^SX2
MID<-ZE<.:"?9Q_6E@?UJ9/\8VOO&]I7'?79`3R#1__[WP2_-\$6C>L^PWC/(
M%XWR4<-\QSA_-]"/O?2!I/O=6U]:'OBT_.=/__K;__[XS[_^YQ^HC*^32<6W
M)L>G>7\P?J51?HUQ?JN1?LNW?M-!_WT%TGNC-V4$&!P\E@A:@P$:N($<V($>
M^($@"((G(`(A6((F>((:.`$%@((LV((;>``N&(,EN((R6(,A:`(VF(,<6`$Z
M6(,B0`4]&(1/$(0]R(-$*(,J>(0UR!8>L7O,\'[PATU2.(546(56>(58F(5:
MN(78M`B44`RLX`E@F`K$,(:HL`IF*`JOD(:H,`ML*`K!\(:9H`MR.`J^4(>A
M$(=XB`EEN(>9`('=`877AW=?Z(>8((:&>`E]F(B5@(:,N(:,>`EN&(E]H(=[
M2(>4:`EWF(F5F(F+R(B`2"(2.(BD>`B%&(F(&(F?F(B.F(B0F(F3&(F6B(>8
MR(F;F(FSZ/^'JVB(H?@:@EB*DW:*C)B*C+B+?MB*AOB*E!B+C)B+<EB+F7B+
ME.B,>&B,>]B+0S**P+B-PIB(Q)B(UHB'R.B'RAB)S)B(U,B&T$B)TBB+GF@*
ML-A^4/>+VQA-W6B(WVB(X5B'X[B'Y0B*G)B.:;B.D=B.S?B.G(B-<$&/]3@Z
M]^B'^:B+\$B)_8B'_YB(YVB(`FF&!,F(!HF."!F/3>B$WZ&-#3F(#[D):I!1
M)Z`&?0`'9N"2?<`!8I`*$;D)/5`!.@D"?2`&%1`,7<``9#B1HA`#.ED!7?"2
M2%D))<"3J5"1FL``1_D)*+"4?5`")8`*%PD*$W"4E9`'%1`#?8#_!A6`!JF0
MD9QP`D=IEA10`"Y9`R)0`ZFPD9B```!PERYY!D_P"6@``"@0"ATI"G:)EWV@
MEWSIEZCPD9P@!GO0F';0!RBP!P50"2=`E[:0"B[0F'L`!WW0!2;0`WT0`P4@
MEZ>PCYC@6YOUDCQ@`KL`EJR@D&!BDB<)"8C'"*U5F^*1DIH@:-@TF;WT`97X
M`59@DY]P"B'@`1#`.WW``@8``5:0!RRP"ZA@FI;0`GZ0G`;0!R;0G!2``1]0
MDT^)"GR7G+,`!#)``'F@!A`@G:.PE9SP`<D)`2\)`0;0`'UP`"3PFJE``/$)
M!S7PFWW``P?`"I9I"0\0?Q_``2@``=:#_P(H(PJ!&0H'6CD*RJ`0X*`RD`J*
MN0DEX`<LP`(\<)\FP`)V$`,$`)ZH4*!]L#H?*@96\`$`0`!](`-0J0G4:0D>
M<`$-D)V#=0``H`87()-M*(^1QI#UB`/P@G"/<#6G@R"ZF0E[P`*7X`%B<`$Q
M``$H>@HWJ0F<902D^0%W``$,0`!"6II$&0H5\`%G0)H&8`87@``7,`&M4*.8
M```?$`-L>@*Q9@,(D`KNN0F@!)X,\`&PU@470)IMF`H04`#@"0<)"@$E<`%_
M.9>L4)\<8)8;X`%YX`%V\`&(R@D1"@J6BJF:RJF>JJ&L@`!^8`9.^0`'8`,5
M(*:MH**L8P9#`/^9,$H`(7``GRH*-]H'0V!IH]D'&=0`X/68KTFD0V2DP-@"
M?Z`#."`OFS8(M9E-3)H@3XH)!R`(Z],'*]``47H"(#"I6EJ<HY!"R.D+'&``
M3\`"9D"30XD*6H=-JT`!.2,#/(``93H*='H)?(=-%=`'/6``YFD"^JJ5K4``
MV70!NT`",F"G('"I9[F?V?0!G#E8>L0!"-"K><@*!YJ<M]`%,F`&+-`%9L"9
MH!"JG/"Q$!"R(UNR)YN8K%`"$/`!'I"A*.!C/0-"!)H*+,"?$."2$P`$=G`!
M+5`![.FK9PH*&Q!5$$``5E"5874`.LFQLJ"LH2.;L[D(%X`#/,86@O;_!%0@
M`R!P!'PG"`<P`V/`0[Z#K:D0`RW0!:QC"2$@`P;``B9@M3AIKJ*``AS@`"QP
M`9:`,@:@H_%Z"C6``"4@`QY@"5W``D!P`1]`KOR*"G"``!3P4I8P`0.T.DGK
M"JW```[0!1X0L"^92`1P`6BY":NK"3W@`';@!TDYEHD45?F9HJP@!A1``=9@
M"0:P!Q_P-X#YN:>@N[P;!+X+O,)["ANZ";J0/)9@!Y!;N%F)NZ@0`S%P!GX0
M`I6``A]@J,L["K\:FFA@G:!9B1<0I38PNZ<`FW*AM5O;",>00HRA`1F@.-ST
M6X;'-DUZ(-DJB1QP!KU4"11P`4/0N!^PKZ"P_Z69\!4.8%M?20`UX`$Q(+C3
MN;2<T`(\4`+-60EB``$QP`(<T`!\*PK]:@D%P`,%+*-]L`$$T`,D?`&6^:>9
M@`(R@`"D*P*5X%L/3`'VF:BG8`5\:@9^$`P`T`!J\`$V1*FIX&03X`'<2ZPV
M0`%0V[@I2[RCX,107`FR1,568,5VR`H5T`"P!IRA^0%#<`$AA*RG4*#>"P""
M-KL/0`(.T``<8,'BB\&;P`$P:@`>L`MP(*9```0D$,7MB[7/!+_QJPC:\P8\
MQABM$QG%%%'<]`$WU;_E\;^5@`;V,VA\":DK2@`/0)RH``391*9C^0&@>:#9
M><'R*G@MF\I)&4H2'/^>[0O+G_"?<FH&-&>6[<D*&U!Q?I"A?0!K*(`&"MN\
M=8H**"#,K=P%'V"6-MNZF:"B-6#*?M``PZF>?^G'I@NJ6!P*UYQ-VMP'W-P'
MWBRS-FFS%U"]-G`"?<"[!D"Y<(@*-8`]UU,)+6`#E="<<FJFS'R>'U"<!^`+
M:O"AOGS((^F$S+J-!?`&6-"DC&%E?V"=<S!(@K!`F$P>FFP)<("GE5`#*!N:
M85C"XGRKFC"<AXNX(XT)*FW+B!O.+_W+K6`%,WT)-RT*U%S#.5T)/0T**OH+
M*HN'RER'05T,XSN&[ILIBTP7VM4!8]"_$QUF%>T'`K`&/.8!$;71X]'19LC_
MP'*8U&!XPF9(PW6XTV]XU+@PU'58U'*HUK\@UL6PU$2DR$U-"$P3`"J(,WXP
MU49FG6BC``<P`>C"U;G)B6#]AG(M#&0]AF8MAVC-AG!-"VPMAVZ=UB&YC(A\
M5G9]UW[@`7]AG7Y=U27A5>]DV.'AU6.8V&RXV+_0V&#XV&\8V6DXV;%0V6]X
MV9*=V>:XV?O5V9Z=3,+-G]=Y@30G>-QZ`<AY@4Z*V"8MD9P(V\4@VVQ(VV9H
MV[D0SH:HV[7-VZ#HVPT'W)Y=,*H-AJR=AJ[-"](M#-2=AM8]AMC="KC-AMQ]
MW=Z-D>#]<N(]WM-2WL5PWF:8WKBPWK_0WF;XWF`8_]^L,-]I6-_P?=^\F-]V
MM]_\C2O^+0P`/H8"7@L$S@L&KM0!R8@,;H8.GN`0[H=T'1M%(H6X0:@M\.(P
M'N,R/N,T7N,V?N,XGN,/L`@/H`8^_N-`'N1"/N1$7N0<T))%GN1*ON1JP`$C
MP.10'N4_?@!27N5)_N16GN5%#@1:WN5`;@=>GN4G@`1A7N8A4.9A#N9H;N5.
MON99GN*2EB*=T02XB1<NGN-XGN=ZON<TON.*<``#$.B"/NB$7NB&?NB(C@=4
M@.B,WNB.'NAGT`*//NF4+N@\4.F8SN@GD.F<SNAZT.F@/N@X$.J<3@5'0.JH
M/@*H3NJCONJ9'NFNSNEP[O\,#0T)<U[G%4X7V2<:V^<9W;<9W[<9X><9!B@:
M"$A*F%<G!'CL`-<L$AYZ%*X7MY[KL['KGM'KF_'KFA'LFC'LFU'LIN$>"H@:
M#$A^#@@=LQYU1S3<R83<@C#MU)X7UKX9V-YY`4@J`ZAYX+X9S.YE!%CN!WCN
MS9'N3QCMC``86C<(\![O=S'OFE'O\W+OVI+O_K'OFM'OY*9Y`&_L`J\<!,][
MXI%O(B_,[_X'=,[P>^%_'7\<W'X9WJX9%L\NXI[LD;+L*T\<'U^21;+P**_K
M*F\?VGX9+6\9+W\9,6\9&"\8XUX:&Q_N0"_QQY'SM5X($+`"*F8#A<#S/0]\
M/]__&%>@`Q[U!V'@+]1$<,V.&$2@`^D$3YZ%!11#4(]!!$U`]F)O]FXO49+1
M`5^U+AKP`E#S!W(`+[1%,IOC+B]`5AD@^-G6&(8W!FRC`6-`]G,0]H'A?(W_
M^)'O591_&+8W!R"@`Y'3!.-V!5HU9XW!!!A0`OCB!26P+X:W^8/!<7,@!51`
M5D<0!U!#!.*57\]>?0;?"#J`!7DS!X*F\":/ZUO??SSW?X-1_%J=-`JK`NX#
M2"7SQ!G]!Q<$`4>@`8W5:X[A`G@E0^6D_>X34<8F&4P@S"R@.)4S2MWS]XU1
M=!V`]8,&-090.7_P`A>@4LL!"'^"@X2%@C)^'AX)?P\-_Q`1<Q!8AH5-7I69
MA(B*C(Z0DI2:A7>CE5)^$'Y`?VP?%RX='R"FA@JU@V\$'A`0F"P/!!T3#;B#
M`TC&?U1^!!`?:S,$#Q)K!Q7*@@"#.WS>W^#AXN/B14U^Z.GJZ^SM[!]_!`H&
M*PCJMTT>[OO\_?[[)J@(%&B@GX0_0?XI7'@PFT-3+YH8\^+'10`@%_XTP$!B
MC`P7#I$I(P`D@`L/&DBLJ.`"P(&'!48"T0``@H8#1TRT-)$-C\,)?L)$^%`!
MBX<,%XA`".-PA+(9?MAX(;#M0@8/*@@P<'A+F0X_.CJPX/''0X`+)3[HJ'7I
MX=>P8\N>3;M66:EL$![\.>'A#_\`EB8DA'C8%1>S`;I(_/F@P<.`"W.RB336
MP,`:.7X$X&APA)Z,A]L$=2-'NG2Y<PM3H[-)XD@(`17N_<FGNK;M=16\>"$B
MR(1!A+>#^VGXL+BAB!/]=)0!X0\.%C96R%#107(R8P1DC"'A1XZ""RQ$&`A3
M/5M,[#($'.C^W08``UC*X_*9#2@5#`1>/F`11,8$)DT]Y<<)&$!@P!\D`',-
M@-D4ALL`?@"`1W9[V7#``07((5\F;844X82?G6`AAAK:Y=`%'\2!2!A>&"!#
M"Q>\<`57RHP180L>%%-!`P6P@,,+&YHR&2X'$%`!#WZ`H(()!IS0P`P291/:
M'Z.99B7_:>8(]T\!';SQ1A@$R$:;EF3V0\`''ZSPAP*J&!`$!$"PD`@)%<AP
M4$)EID:<<7S^@9PQ(?32BR!A"$"`"PWPI,R0M9RP2Y@9_"''`$2Y*(HQY^'B
MPJ-^1#I``C;L*,.EIM"G3`0&\.(!3V^\()X$-N"0C5/&!""#JI\Q\0((+`#0
M`$C*.(C+$Q`XHY>D(!A0@`T2!&D))@\1:ZP@<B2[;+/&W*7,$2R<Z0<E&CP6
M!PL-"-"@,AH`0<`%'AP;0`%`''#!$XM>AXL%#US0@!\S"/+&!178P`(MRDQ9
MY94(@Y-EGON\6$"88NK#\,3K[-$!:GXDPP9"'C`ER`O`4>S/_YY]%O<G+F%@
M$8`!Q?P1``MG7*"`#/T:PZ@I$<BQ!@_-_='!BSJ%$(=YRLBALP'P^&S#"280
M4X(QIBHC0`=A>"#K'S-`!@$3+,R:S1CA^C&!(`,0X(4'.O1LC+!L$6$!!.=A
M0<`8'G2PU"@=.M2$VW`+(C?==GM<B[;&6###%3(DW8@(!^`00J:XL#T*%7)@
MD*0@1Q#P!@L#J%W+S:-@@4,"(7C`VQ\F%+"""1BT;(S!"<?^S<(BK[;'/OA(
M7#O#'JSQQQ4NH'-=`1^0!<*9*H2\NSLDE^S0R;5\D`@!`_1&[P$L?,#@@_;6
M\D`B?HPAR`H&=+#"!P180+0QW^O#"/^"/)C_`03JS^?0'.!_]@<6'\R@`02)
M\IHQC*(/%OCN"BSH%WAL<*YL7``=#0#7!WQB`!O8P'>:R)L#(2A!"EH0@X-S
M2`O0(0]!A(`GAOJ`^(*EC`!`["5_Z%P$-#*->CU%%1"HF11LT(''$&!C!>.&
M[&1'N]K9)`(32-4Z<K>\B9&@`)'Y7C*0Y`<$_$%.?L`&GIK(CN8Y3QG0,\4;
M,("'&6&N.F.LG@V-T8$Q@,!C;0S`'S0PAKHH`W*F"(`;ZQ?'.6+@??9S2`9`
MH(`W""(#(/M#!O!`JEK0RA@1*('_!!&!*%T!`\EC838"<`0!:$`03*B+'N6(
M-V@YA).>!*7_*,=`2EP0KG`ZN)0<2!D&,VK2&&](@."P$"F7`6F-QF!"&+:'
M!4.Z;(92$N(0$U;$VC6@`@E@P@P*D@XF<I%,JO##@8*7C`?Z86@V0(>:MGC-
M='CQB[@((SJYMTZ8M%,947NG,1XISUI(KIZ#T"`^3?'*?6KBGOXD6_<":@C8
M+1-AS:Q=CL1W@HB54S@5L(`,+M`"!&5L,>A@A0(^P`(`D?.AYR2HGZ(DTD*`
MKJ1_P&-)XXG20="SI6N"J3YA^H=^PA2@`3UI20UZ4"LE=&(>H,(GYV`"W?G!
MF@^US=4$H92+2B\1<A@$(SY:SI`25)TEU:E(52I2EL+TI2W%:3UG_PI3FX:5
MI@)%JS:4V5/3_)1AFB->.Y":U-I<(`@ND9@-'I#-1#P@!#;XP`.>6E>K!A2K
M(M4J0;E*4*^V%*PH%:L\R=I2LT96K8H-*$_;BB6,*;2O[*!K74=;5;6.%+,#
M;2EC`^I8E$*VI))])V51:EG8HM:TF^7L.-[*,+AA`#I+G(U124O<Y1G6GX@E
M:&;]N5I_MK:DKQ5I;-LYVY+65KJW56MN=1L.WN;I#%C``A#"``2'%O>\NSON
M/I.;T]2BM+G[?*Y(HTO0Z:ZSNB*];GVSB];M<G=VGA49/.1!#WM44[@B@\`%
M%LS@!COXP1".L(0G3.$*+WBXZU`O/MGKS__E[A.^^)0O0>D;4/NB$[\$U6^)
M^4M3__Z7#][%9DI<`QOS3LP&`\BQCG?,XQ[[^,=`#K*0AYQCT++#`'E(LI*7
MS.0F._G)4#9#!:!,Y2I;.<DNT,.5M\QE)<N@RV"F<@C"3&8J'Z#,:%XR`-),
MY@I,@,UPY@&<V;SF.8<YRW8F\V!$\^+=!EAD7/(2F&S,.P(8^M"(3K2B%\WH
M1COZT9`V=#],T(=*6_K2F,ZTIC?-Z1Y0@-.@#K6H*ZV&.XSZU*BV]!Y2S6I0
M<Z#5L`8U`&)-ZTL[H-:PIL`&<,UK,_`:U[?^=:M++6Q8N_B_,2Z3PR!VX#&A
M]]D,HW2Q6>WI::?_FMC61O6JLRWJ5W,;U;/^MJB#+>Y,Z[K<H_8UND--[G5C
M&MONSO2QN9MLWAE5M-#.]VVD'6],5[O?EX8WP"N][8%[>^"7#C?"^]!N=Y][
MX996-\09#G&!#WS>NJUWF:@7FV9C6-\@7PB_$?YOA%L<X`4'^,$AKG"$-WS=
M#Y^XQ"'^\GB?O-\8YZS&R<1Q0H?\Y_\8^<!+/O";QSOE_5[YPEL^\)J7.^80
MG_G"G;YNH[L[YVW=N99Z[G&@>SWH$R<ZP*V^;J3'6^D(9SK`J?YMJ"]<ZBZO
MN*E9SM8^`WAY,@B"WH,0@@AT'!WX_KK@TR%T@(N]WV1'M]G=C?:+3YSM_]QV
M.\+AWFHTU(#6D,?T$#;`^<O7(`:6AL/E3YUX3'.>\Y5&`1PJ78/5IQKK/=6Z
M:MCV]Z,B>/"X5T?A^WUXF\]]U`@0E`'ZT(5GH``-,C@!JQ>_:3L(:M9Y4+`8
M:F"`+J"Z\:&V@:`JS0*X]8$"+$##ZU/=_5ZLGCDD^'X#1G_JS&.ZJ(J80!^8
M,_P>$``%H9;\J.'O`?G3OP_VAW^G1GF@1@'IT`#$9VB@]P'*EVKN9VE8Y`=J
MT`<+)@-]4``(B&JE=VD2XP%]@`#.P`$U\`!/P&JP=U"REQJ*L((KZ'.#9P-R
ME0J[`$$*L![GM7OQUGONMH&5-@)440'69P`<P/\"7;`'%KA\X&8D%?!I-@`"
M-F`'!3!\U]=JV5$!%0"`%\`!%[`!!-`#)IAJ55@!:+`!+$`!$&`%'X``K/:`
MEC91)W`"8A`#$%`#$$`!%Y!Y^B=J;@B'<DB'=LB&?4"`G.8`?N``#N"%#3`!
M)A`"08"#H`:('V`"%$`!8\@"<M@#+."%&OA[HY9%D]@')V0&(?`>K7:"RY2"
M#!-X7F<5C8`.`#``U/09!8!>CKAN.EAUG!AJ-7$`3R`&?<`##4``=F`#$XB$
MIQ8HB[AZ>X`T`,`"OCB%K)8C)F!]<$``+O(`:B=JV<AI`-0T?8`&%R`#+&`"
M0=!J@-@'!I`=!6`%X#C_4290BY:6AZ&6CC*PCNUX`>_(:H*X:5V@30]0`GU@
M!PMF!A\@@`X(AA]@`T%P>0W``AC1@)N(:C'@!_KB:PZ`)A60B:58=W8'8W^6
M5*KX<P00)=\#`5;T!-(CB];(;'4%C^5VB^C&@WV0!_KB`1_0!S4P`6I`%$"P
M`L8X:EU0DU+8`FK0*R9PA:>&?:`F`X'E!Y\6`W>0D:M3C*>VC9LFCM(S@3'0
M`GGP`2U@`E0Y:N>(@?M2`#B9!P[``G90AOFW:ZU&EGY@EC6`EFK)E@/(:C%@
M`$5RDWVP`3%```@0B08IEJE6`2;P/1#)`T#`'&I(>KD8:GH73L]8`Q\``"CB
M_WI5R9%VAXIY$I(A-P9K<`:M>"Q_0!&?,36"0$TM&7:?MG`R60/X%QN6IBP-
M$`(?$):BQGR:!@?X=P`>6&D&$`(R```$T)K=UFIN"0$A4&D7>3P`<(15F6J@
M)P9^H&YRJ`80D)$'F6K/2`#29@40T`(0T`,0T):PUIW?&9[C69YWF6HH,('$
MTH:6B0`-8`?;>6H3@`8HX`=ZP)R`:0`7&9&G-I<,YP>:^`![``1[``#I!VZ:
MV6><62:>J6]/PXBM^`$;(P6^\1E7<`"TP`RCY9+B!I/E)I,&``$VX`$L4&D"
M27U%\HRGIIN9]@@-X`$'4&EFT`!H\``FT(5)R6H&B/\B'@!ZE#D!]G>8XT=Z
M%"D]OH@"-M`"<``G-G"?HU8#AB8]UD>!=B`&$+`'?,EI\LAI5NHM67H!6]JE
M7RIJ^ZAI2/(![5)II"@#2`.(;(@"*P@!NX:=8E"--@"=HB:39I`*%'EY7?`!
M:$`\'P"(ICA$$?H/V1DFJQ*!MN=L7X<-%>`!0="*?E!1W^,'GQ$;S:$`I"6B
MWT:BXB:38@``)@``5O"-(;!K/4`":YII,OIN+K&..!D"OJ@&0>"3/\IJ70`$
M01!L#M"`1P)ZX)9J'""LP48!2&D'/(";[$9M`/`$>5!I8F"6#/<$R`JF;DFM
MUHJMVNH`W(IJLXII:#`!`##_`0)H!Z"'`A5PCH`8`W;@KI7&`,W:`H,9:C+Y
M?6:0GY6&`+Z(!AR@E)NVJ$3TD7E"(0?0``TP!R+@@B$G#'^@`PI0/7-P.YR*
M#K*8"&LRJJPI=Q-7J]]FL%?W>`,7INYVKN5VCL76K]:&L+'3J/V@4E0$>+?W
M=1[0!#S;!.HC!R&PJ7]@@QW;%Z(:HB'KFH_9;R3+;2:[;E:Y;BZ+:RJ[;BPK
M;E/[:S`[;3++3`J[<9_1L`U`6#A+J;B7J9U*%ECP`IZ:4AY[M*L)<:;Z;5M;
M;$V;;4^+;E&+;EE+:U6+;E?[;7V+:W4K;%V+4%][31,:<DN#11!P`C,0&Q=P
M`@7A_P$G<#M(*[?&671+>W0+E[?EMK<MF[+?&G43QYPB2W=\UI%WUT0$\`0%
M$+O[TG6Y5[NDRFUSRVV%^VMW:VV@*VZBB[6D>[J!2+R#6VN[RVN'>R4TVP\>
M8$M_4'N+6[OY=KO9EKO9EKRXUKO3]KO?%KR".[RG&[C<=KRTIKVUMKP^E;AD
M`@\2X`[32[W/9KW6AKW6AKZTQKW%YKW<!K[E*[XR9[RINW0/^F+-VP]2$+1S
ME;/R^W7T.VWV.VWX&VOZ*VS\FVW^FVWF"Z2E^W8"K+03I[YNQ;Y:,@E_0`2Z
M`0`2JR4LH``N_,(P',,R/,,T7,,V?,,XK`"SR`]"6+`^_/_#0!S$0CS$1#P"
M!4#$2)S$2ERP(R`!2_S$4.S#,A#%5(S$>E#%6(S$#Y#%7/S#(=#%6%P`+0#&
M9`P$9`S&7WS&5=S$:HS%>T8EK-NZNY.=5FB%JCFI'Z<E'Q"[?-S'?OS'@!S(
M@CS(A%S(L=NI^_``/;O(C-S(COS(D-RS>8`#D5S)EES)5+`"E[S)G-RS)M#)
MH!S)+A#*I!S))%#*J+S()Y#*I(P#9\#*L`P`L,S*JSS+H9S)MDS*(EP:!WP;
M\=O`Q:5A]<1A^^1A^`1B]21B`45B_F1B7X1B`:5BS<QB,+7+G<5%'N`"1V`#
MWD2[P.QUPBQ/Q(Q/QEQ/R"Q/RNS_3\R\3\[L/-#L3]+,SM3<4M9,#KV\#V5$
M!`?0!#98MGG\S=`6SN\TSO54SO)TSN^4SONTSOC4SB7SSOL4SPT]SR@%>PM`
M`XQ*PL)!`%<T#R*``RL,T,\FT.U$T/)DT.^$T.VDT/C$T/7DT'T"T?@DT2]-
MT3M5P.+`!1I@!#`PLQH='!S=``KP`!@P0MXLTB!'TNMDTN^$TNVDTNO$TO7D
MTO($TWPBT_5$TU5MTR(%>U5`2ES@`QB]OEP$$FO0`7(3TD@=S*;%U.WDU.L$
MU>@DU?)$U>]DU<:!U?*DU7?-U01EBC"0!)_T!49`UEST`")@F\%EMFL]TFU-
M4C`%U^B$_]`S\`"6306*]%?5(05Y`$\/$0*6?2PK\`!'L#\'T$JX0-5/$-IR
M)`4R()H:$#\-I`PM8`"V+3Y4T`!#8RNGDT&FE`VU?=O+H-LN(P.]'4*2X;"U
M^3M]:D*8/=M$@B8?$%4D0`!C,S/.H@D&C2*O\`=AP`(74#TG(-"P1P-%$`5<
M\`=<X`0=D`(C?%Z_?%[2C288!C>(S-9JY=;K)-E?A-`ND!</@-D'X`(7``(S
MH#V>[1#K8MF20A0-H`$-8$4"A!W`\``!@`44Q=$RH";0'=UZIP,1``%LD@'7
MP!:_K0P'\`$?'N(C7N(F\C5Q60!6)`.,(P(ET`"H'3D.9`!6J/\""'0$$!``
M#4`P-N->FK`*+!&])K`2&&`#QXT+L(<&/@,%29`"/O`'/<W+/QT<>US'=QS?
MQ/4!$:`;NK$O#-BI\(`$CIW?D-U2_.T\"%T!!``"1U`=#Y"1XE$S4/,0$,`#
M)3`C<N#@$R`#(#1/>"$!?W["&0X".$XCV2".$\`(2B$%!-`"!F3BQ0'ID@X!
ME&[IA8[<RF`Y+H`#O'%"B4@`D>'HQO`!RN(33'`!>V`#/```V:W=1EX)1.`'
M1UD].'`!3=(`SYU,JVLE.X`"6<X'-)`$AKT['@`@*.P%*GS4J^C=+RPGQ6#4
M:0X^^(U6^HU.;UXR_@T^V"!1`/!7&*#_1H&4#3-(`+Q1`0_0`@20`!A@3(8^
M$OI@PH,>!Q`P!ACP2;=D#$6E"C[!S[\E`%*02;Y='`'O!P-_``5_\"^^+<_@
M`0?2`06@(B?0`C-0ZYE@8A,E/6N1`!6`!RQ`!1702^PT$>`!`6:Q#'%P`"$P
M`2WPZ:90SW[FND,+OPSL=<5`3A]`"6_@!8GS!TCP-%APQTFEU.C4[5_T[7VB
MT@#R`'TA"`5`CGPE.*7R$!K0`2J0G81R`4B0%V2A#%2M`6L`(5?#/PP``2:@
M/VOC$+[3`02@&(+@E1`@`AE12L41]W,_"':/]Q'/1H94`&KC$C*0D42NXT7S
M!V\0(8220S;@_P(,5.39,$-'X`?O<P(R$`('$`0B(.QP7!HI<'JDOP%"P+Q;
M?AM2@`"VC31JG6^?$09S,`9!6T)A0`79XS-XT"\1\,_&]=A^'5`(30(\3@`M
M,P87<`4/,`$?T.::(-5R<`$AL`<>L#$_LP("\`$30)JI?2H?$`+EQ0AOP'=7
M8-U=\^^UT`$-<``DX`%2(`A`\`1E@Q^FH-?JS_[N#__R3P#T#PA_@H.$A'>%
MB(@5'T`$#8(8#6\&%2PEB9A_"IF(6!`-#1X)?T0L9P,L3P:<A0-(K(1Y$#(?
M!`%_.@01!3(R<;"$`(,[?,7&QWQ"F#[(S<5%37[2T]35UM?6'B"$%?_4FTT>
MV.+CY.7B%Q8Z1V]_!GZ/+=(??V$>$.P0YOK[$L#^_X->-`%(D)6K@@@Q%?A'
MQ<`'&0/^K#'!YD^D`^R`X2%(Y`D+%A4$S=@3X,V#!F<`COB'Y<D%%@4Z_#EB
M@IV)!MO^;?K7X82!!@!N99`1H$,!`QLY-?%2L.?/H'^&%CV:%-@A@`-(&"`Q
MZD^(32]D%+BE$R`"$R:H"#H2\H\+(#K^'?2'9<4!KH(F8(@:XDE&?\($$7-F
MC(:0PX@/IR",#-J^Q]/FS7C0ZX*W/^`@:]XL;E6<=W_B^9F'1!I3`IQ3^^F7
ML'7`@:Y;SXV=<"'M@E5O(URIN^#.WK"6`D?_>'4XP-_&#;Y*#BSPG\&,HTM_
M%DUUN3DRL'T+9[T[.0\-I-GX\QF>O#^E_9SV#IDU<U8"WRN7S\HV?42Y[R?B
MK1\1<OW"]8=)<0(6\I^`LQ4HB'/020<#%%Q$R$41T_'A&'O70!#&&TUT2,)E
MF6$HXC2C"%`"$7]D=P$I.#1`FFE_H#9B.>XI^$=\-OZ1H(+V%9B?C?S9>"!]
M`>8H"($Y#JG?C@4R6"$?7/S!Q0Y44CC=A3-*`P$57')Y`(C<9<E>`WBHL,8`
M(4CC`09K9.#B`*(=,4`^8HI3HX(XVLBD@#T*^*."02JHY'M%&HFDD$;NV9^3
M%:ZQ0PHT1/HDEG6*_[-=I1A>8(.,:MKP@30$T`D!IYA6<V>!>2JHJ'Y]]O=G
M@8$6."ASA>9XJ*")+I<CH]-%T08-3QI#J9@7F$!`F-)<6NJRS(YSJH"I%KCJ
M?:WJ]ZJ`L0HX:W*UVGBKK+D:^0>OA,'`Q1=?2(3N%\Q<65V=;9F0@#O3*-OL
MO?@^VU^T".IJ8[7W7=M?MOUM:URW"GZK;;A&DNM,"C5`(?'$4"Q0X;`C$O#'
M`V,8,($48.(K<K/ZZL=O?]/2!S!]`NM'L'X&#X=P@0H7S/"NPP2KL[#O9JGQ
M!PK(@`#(]6*&+'L0&*#TTDPW[?334$<M]=14&V"9L^*>O*2_/.;8\GTOW_\7
M,W`S"U@SS#?;Z#!C25A)@Q&+N8LI&TQ<D8$&-H0\8@->].WWWX`'+OC@A!=N
M^.%>?#;.!7HT[OCCD$<N^>24FW``Y9AGKGGC)LBP^>>@.\Y"Z*1C[GGIJ%-N
M0^JL/_Y`ZZ@?P`/LM!M`.^ROWUYZY[JC_D3.T]$0``J1PO!'$A?WG*4'5$00
M5C7VCBR]F";T8?WUV&>O_?;<=]\#!=V'+_[XUJMQ!_GHIW_]'NJW'SX'[L<?
M/@#RUX^]`_;'3\$&^?=O1O_YPQ\`W6>^`<9O;<WP02+:)1V,-2MZTXL@AJIG
MP/9]KX+J*R`&T\>^#8X/?AY,'_U".#X!DE![^SO_(?G^IT+QF;"%V=,@#+6'
M0&0(80@:X,(0=E@%8,FM4B)X@!\(0(5/%2U$$DRB=R@XP^Q=L(G8DR$4K=?!
M*8)PBM@;(1;[\$(8IG"+UV,A&+D(1BE.L8;-:-O.+*2\$4'@#R;P`P3&(`*]
M*?&.J6$B%I^(13-"L8I0O"(8M8C%+K;PBV,4(Q@-.4,_-A&-S:`!#"8)`Q\V
ML(TBFH<1$8``.^+QDX_1XQ3Y.$5'SA"0313D%@DY14:>$)%@5.067=E"4\(0
MDL<P0B$8&!T'BD@`$7`!F^B5+*.!\IC[$"4420E%6[80E3-4)199"45:AA"6
M6Y1E(<MXOD$";SH:6,,&_XQ`3A@D#U,$*,$5$B`!Z!D3F?`<AS*;R,PF.E.%
MT(2A-,<W@0KXTWIYJ$`,^H"&"J!!?=0,WPG\:=`^4*``:NA##410`_59<WL(
M`(!&(WJ&)X`/#0!`@?BPB;Z,;K0/'?UH2-.G3?&)80\PM4,?4+"'`ECO!!?5
M7DZQ5X`#^)1_=GA`"?J@AB=4%'WWS)[E#E`]./#`!/P+:/MP:8P`U&"-OAS1
M!^CDR7CZP0-'HP8+0A'!><ZPGHWLYA;SV<)]BN\#]H!`'^!```/(H`\\.,!1
MT9?0[H4*`A"`0PTN(`,6]`$`#VC?3K'W``]\X`,<0,$']D``%%3``'OE'DG)
MU__8QT9VLI6];&;%U]+PE<`/'^$!7A_`@B[$X`,1M:CZ+O`!4(@!!1<`P`?Z
M(`.V<B^IV//`!1I@@#Y4P`8/J(`:+#'5;THG"5\H`F+B=LE2U1841BPF$N-)
M@#AHX`]GN)H,&BN-B&1W9&:%(5IA"-P0^O:$;@T?!`H@TC[T@`4(N$`)"'!0
MA*H/`A6H;PQ,`8$8$$`,BFV?TM10T1@4&`)WX._X-CN^!3?XP1'N+_I*V[T\
M^.$,`^V#`7BAVSRX;['6^\`!'`"'/FS@`B<@0`5D,%KQM9>@?BA`"2H*``/P
MH,=]G9]SHQ,E0O"2,5EECPNXT=5C>@!%1,C`N&`D(_/_EG6,ZZVE6K'X7A+&
MMWO38$%%&P`!`$!`#%:8JOJX<X&*/J#,$*!`FF6KOO#(L0?&)8`9+!'B\%%8
M?':&`)XKH&<^JX_#W.O"-)K*@@/LP00,:#&=T2<C#R#8#CB),_C2=^,8<.<#
M-;#"`1ZPAP?T`,\('3)C?)"$5K?:G#\4D\8*$`89S"!O1PPK*%?@EG#8(!Q^
M^4,)VAF1`^!A#-D167I;F&45WGB#70[AE[G'``=TP0,5L!X:#`"`4&5;A.KK
M@0/,X(<N7$\&NH5`M._7O@U0@`(0",*Y>?"!"R36S_QSG[OA+6_KR8#>]F:I
M^\ZP@0/(U7H3^``/7+1I]*%X_Z9PB($?]*!M`G#@`W;E]);'MP$TQ.,,Y2-`
M"%YB8A&J6CJ6/&>=YJ$+`*^@R:`,PQ\*L`(1F"`<<9`)$2;@AXA<P0)_Z,#5
M[K5L%3;[A,_&X+HW.&WMH<`$"+BV3/$J`Q!\(`_%!3?ZK/``!-C!#PBP7B4,
M[(`+3!I]/%C!!"`0`NNUP`8@(``</##2?+<O[6MO>Q_>'O>Y"UQ]+7C`VW?;
MAQA<0`T70$`#IN[P]*$@%7LHMT1)30$;M,#L2-WX^X`B`P_PCZX4"(()>*!W
MOIZ<,#ZH01FB0-WJU@D"&F!!`O`0A@+`_)/LZ``6!/%R`JC@#YOJ^1^>0(`C
MP%'96/]N>"DUW\2E8[#IV3.\>-*<!Q:H80,$N(!-M4X^,5P`K#9(<PD.CX9Z
M.Y^,Z:M!YU$;43$00`U62&W=W:?^<%B_#^Z'O_PWW+X3P/4#+>!O-M4"+&``
M?48^*(8"!T``!'``!P4"#8`&ZL<"C#<^-U8"#4``'_!M`$`"?5`"-L`""&9R
M@O$D"R`1M[`%*8=DF"0BEF$`.H`'R`)!Q[0&?_`A'\`$?_`IZR%\G](/08!\
M8'1T))1T%71^!@1]VK,!DJ8]3<A7[69WV?.$"#A%?S9#B`9##U=!1FA`5%4,
M`<`%BU$$?W!DA)%DF$*#H!01,C(*+*`>,5)>.[@:?Q"$^%+_="=$A"'4A0.$
MA`.DA"049"VTA?USA3"4A8/(36/TA7S0`4M@#']@!"J7)050B998`':F7;KV
M2;\#`@<0$Q80#E?@%>Y@94`HA%NDAQ[$AP#DAP`$B"$DB"I$B/ECB"V$B+.H
MB-Y4@A42(>:4!&4XB3.2"-V0:U[U57@@$W]P!78F!8+02:98AZBX1\K73,QW
M2EL$BQXDBR=$B_9CBRJ$B]VHBZMT>LVP`,HH)2MXABVX+&IX3!?P!$)$#0<`
M!/E0;^&0?5S5+'A(0JJX0:S8/Z[8/]JX0=Q(0MY8/^!X0N*(D.0X3>9XCCL`
M!FBPCNR(*5NE'>]TC!SI!_T80O^(_T$!F3\#F3\%B4$'&4()*3\+24(-J9(/
M>481N4;-@(:JH2$+<@WOV)&@])$>%))<>(TP5)+V<Y(5E)(>M)+Z(X79-$;6
MHY3U,Y+V0U4^0$Y664["."(M$`$/L&3GI8D\R9$^N4%`:4!263]$63]&Z85C
M!)7MTY(A])))&9-01%4UL$!9*2(S``)RU`[6L).I\0F@,)B$69B&>9B(F9B*
MN9B,Z2+D,)885)8#=);RDY;RLY8#A)0;Y);J`Y<>))>;29>/-)-\L`2"4`,^
MD)H^T'HL6"<*``+VD")@=7NJL0KB\AZBT1D.L)N\V9N^^9O`&9S":085()S&
M>9S(N9MV$/\"R=F<SLF;#_"<TFF<S#F=UBF<*W:=VLF;!;"=UED!$^"=XLD#
MXNF=W5F>T[F<Z&F=(4":?``#6_`';<":KI<E!U*,8!F67E4R]Z$U]Y$R\K$R
M\O$U]!$V]#$VO5$V_7$V8I,V"L*(?.`$?_`&]-F:8B(#09"A&OJ&QJB?\<2?
M].&?]`&@[R&@[T&@\F&@\H&@NJ&@^L&@!^J@3>*>*1`%'1``9MA+[5@J@.FA
M$@2B\B&B\D&BS&&BS(&B[Z&B[\&BM^&B]P&C*RJC`D)51?!=;5!)DI*7#[21
M/@I*0/H>0OH>1)H<1IH<2,H<2LH<3$H;3DH?4+JD4KHHI'F7B)#_HS6YHVG(
MI5V*1U_*'&'*'&-J'&5J'&>:'&F:'&L:&VTJ'V^JIG&J'U1E!!0S,183:R+3
MHWLZ,GV:''^:'($Z'(,Z'(5J'(=J'(GJ&HOZ'HV*J(]Z'Q!*DS;IFGJ:J4FT
MJ<;1J<;QJ<`1JL`QJL-1JG(P`,(J$P'P`LHH!^D(#$QJ`1W2!+\7`&-`%CJ@
M@TK!%`7!K!WRK-$J"-/Z#ZL:``H0KETQ`W&A(S)W',?1);<P!U*P>P&0C'+!
M-:P``ERR#1V``2!@@Q8P`P3QJEB%IY6"J;1Z+[8Z'+@Z'+K:&[S:&[X*'*6Z
M*0R((JSU.T&3K+#`I"0`5MJP!B<A`VL@_P`7L'O5BA`9"U;YVK$?&[+>2A`"
M,`VK0`4L<`$O\`874*@LR@(:&P8=8`.]\`<SAA7RR@D:^T9X4&\E$`""UZ_N
M29/4,3T"&T$/H*$9Z@X><"S2L`JV%T$%"QP'"QP)JQL+JQL-VQNE2@`\@`1(
MH`$68``9``%,4'P$P:0/8``O\`)8$`9O!`$"0``1P0JI2@AS6[=WF[=[V[?^
ML*H*X`>$T``8$`(5``1ARZ(;.`ART``6``$)@`Y`"Q!^\!L%L`=44(D/4!#^
MNC.Q*B9/.SV&*PBE,;IVB+4_FC6PH2=!VQ]A>QMCJQNE"@'UUIY_P`(?\``V
M@`"^01`&,"HR$/\!'?``#?@`$P`,?SL(QTL`R;N\S?N\`+&J?,F[SI@`$,`"
M$V`#%JNL`"$C+*"#]A@'!%"N\?H/<Z`F)O`'<D!;)]``OZ>TO,BTEHHOJ2L]
MCU5O<<&\SD@%05!7,T<)-Z>ILMNJ*N,UM_D'I=H"!0`$?F!\6/`"=@$$.(&N
M`#$#%;`"V!9T<N`"3,4")^"WUDH0'@S"(=$!(US")WRX!($%+D`%&2@(3"``
M'W`"-F``<L#!_G`$((`#?M`"@K`&!M`"#0`2[?L/)="X?G"N7K"!,3L'`(%+
M*>!J6IP$L%:?ESJK\/0(&>`!MBD(Q/4'VWI\(K.UO=&UO?&UMW&[M)'_N[=1
MJ@@0`.^K%C/Q`7-``!/``D#L#W@@!U@@<H(P!Q^`!`0P!V\TLKA!R(;\!XBL
MR(R\L@#!KA'0"(+0`08`LS-@`#@0R*S0`0`P!HEKQ'\P`0WPR3.P(OXPIA90
M`3K@`E$L$09P`D\``"O`J[BD#'BYO_?2O]/C`1OA#@2P9!,@`TE#"@;`:W*@
MP$;BQKH!Q[0AQ[%!Q[1QJ/4`5A#`%!G``C,0`!#0.:(\RD;D`<;WM@I`!`0@
M`66,"=$;=.><S@2PSNW\SJRPJFDB#;[+`R1`BA_`ON3K#U=@1!]P"TT``0&@
M`8_U.Z]<NXD@!70RNF[QLK70%8`QDX8A!%7P_P=5L`!.L`45>J=."\;'%`1_
MD`#3X+I7.W-?)0C0G"/2?!O4'!O6[!K8'!NEB@54``(B:P$O(`AA``+?518`
MH0$"D,8J$-1_H`)C4-29$,]_@-1*S=1.#=6PL*I-720#D!%S<+]&_0]V,P@!
M0!9,$`&;^P\:(`=@[04VV-1@G='Y*QT!((G%L`9VVA@`*ZO;%4\1D8DL[0>P
MZP$PO<8+G",U[1HWW1HY[1JE.ARGVAI2#1Q:#=D,+!^,N`8U`"Q"T`%5H*4S
M4@#&XD[;1<8X0"I)M!!X0`VCNP);-=B%G2^'3;OBLM@)T=BM\=C`$=D),=F]
M4=F[?=GOP8AH\`=0@/\"8/`'0@#:(V("'9``(9!=RN(!0K4&5/!)'N`%`4!,
M?C`>;\",L/T',6TC,TT;B=T:MHT0N)T0NMT;O(T0OJT;P.W>PLT<C$@#-4"L
M5@+,8@)T@G`"EK$=\88B@H!K=V3"/&`-%:``+:"!/O%5)W`"XXTGLZLJ$$TM
M#GR;[:T;[UT0\7T;\\WA]9T<_FJ1%EHJ?1(&HQ@!,Y"LSSRPTL/&NE'>L7'>
MM9'AXK+AM]'A!/'AM!'B.S[BQH%+-.`#0K``19#D23[2>LTL'S"*P#"/,&[8
MT5SATG+A#6PCZ[T;XL+C`.'CL0'DM.'E!6'C"(%+,/`%&U!D@Y#7QW"ZWA'_
MPZQ`!)LXY9@BX[=!XZYAY@61WKCQP#H^Y@H"YJXAYK%!Y@3!Y_C['-*1`BC@
M`TNP0Y*^W/PM)N,!"SQGYU0NTU;>+[6-XT82Z(<^Z"EL*`^,Z&F-,W.MOR>^
M+)U>"!JPCX'9F+1>Z[9^ZX3YE=;P`,W:Z[[^Z\`>[,+>K'F``\-^[,A^[%2P
M`LG>[,[>K";P[-(^["XP[=8^["1P[=K>ZR>P[=:.`V?@[>(.`.+N[=U>[M.^
M[.AN[1`J!$NP`?!.Z5Y<*C(PK^R!SP_<&[F)#0<`[_[^[P`?\`(_\`2_`2"`
M``6?\`J?\$A@!PO_\!#O[T`0\11?\"U0\1A?\!*0__$<_^\3T/$8CP`,`/(D
M7P`D#_(??_(5W_`JC_&,"(Q&QMS+([*8(.6:3G3))YK8B$68"4":B4&<F3Z>
MN4&@"?0Z?TM+RP4!$`4[X`-?(.\ZBB^\A@D1(.LWORR064&2"4"4&3^6&3\]
MWS\_7T%!CSY#CT%%3_9'WT*,^`5&D`17!07(4^FO]]:(T$Y7?X<YOT5=[SY?
M[SYAGS]C;T!E3SYG7T%I3_AKKT*,N`5HX`,:$`5K\-ET7R>7@`@=8/5YCRE9
M;T!;WS]]WSY_WSZ!/Y5M:85,B46)/T"%KW&+N+1%L)IM("5='/7XP@+CVTF;
MC_-#6(WV))3/E(U.>5BG#_]%AV]`JP]`K9]YK[_JP5,$3-[D(B,`B*#KNU\I
MG3]`GY\_H:\^HZ\^I5\_@\_ZJ#_\R4]0-98^#S<$_EY1-=!G@N7ZZ?/OUH,"
MDE8#5#@^7^@#YP((57R#A(6&@T5-?HN,C8Z/D)&0$G^5E3J2F9J;G)V>GZ"-
M)GVDI::GJ*FJJST4JZ^PL:1J=[*VMZ5[N+NO'+R_KP#`PZ8.NSP0R5U]`!XA
M?6($2[`4&[_(RLS.T-*W9KL4C`U]/1`?*'T-!;O&MRR,:ND$3WTG%[BTN!Z+
M'GUGR:YX/-@%P-*.0X=\_.G0X<\2A!#Y)`I%\1$!2Y6"5-Q(D86,"Y$(*"C`
ML>3_HE'$B+5*.2P?2V"Z7N[R)1.8L)KL=GTL4$!-#`@U(*AAL8R:-5X[>_X,
M.K2HK6^X'/AQX*!''QL<@CRI8(!7.UL?3%"@@":&#3$>4'PH@:_6+3\5QO;9
MPZ/+'CLL>!6L=##BH"$=4O`IL\7OH8DF*:ZP)">QXY`9+"6`X(?%``"+/OQ!
M\K@B2IRW5H*VY7*TK)BF>Z6^=7/UJZ^V#!"08:</FMD$2,B05>V7;-JV<>O>
M!?56%S\&'C#H4^$#@1,0T.6\1>"#C9@?+LA@49RT6UDQ_%QHX(L#!`)V+F#0
M:]`PGQI<_GYQ7PAQYTZ:*U6XSQ_!GQ4-2/$'$!X<\`<"_Q^8LQD$!H#$'R>?
MN::*:!*F4EJ%J*"&82DT;9A*:QZ6`ILL!330@!_?B&'&"394((,KK_3&2XDG
MIKABBR]ZLXL:!AQ`P#U]()#'!788\(1TMHP("P`F/.#',AN4$,(#)C2`P"T7
MPF*%"4'8X($U#%!PP1XR&``'+GO]T9=?-8`AA!`U:/"F8.[9]Z`F<_RAPCMW
M.C;#'^\8\,<>'V#QQQM>R*`9&QC\@863?4H288CDP$AI'UF&J*&''5Y*"HB4
M*@F+&*00``0I5GQ@!@3-&?4+J7V8BJJJK'Z@(RXHQ-`'"1"4`@00#81PP011
MX9('&G#XH0<I&!"0!PL%Y.7=+?\UN)*''U;U$8(,`AVP#FOM&58#1I;X0)^=
MD4(BJ!3I)F:#!F,\,<`;SBGP1QA4L)`?'G]JL$^[CDP:(H649NKAIAMVZBFH
M(8JZ2@T?L.`D5`8`H`8$"!#@ZBX02XPB*15?G/&MM_"`G`?C],%!7L%>X)0L
M#J<"AP?)>!`/'`2<$<,'P&+Y72R8$>`!`37T04%T(31@P`EHANM7$4E$+742
M,)RK","16&`#UAP]8&@E$8#4P!\M9/:'`(L$\`<!7#,BL(<$AVCPA@ACJ/"E
M#'L8\X0`/)$'*6)\Z\`3NL9XU"X]]/TW-((33K(M:$P`P`32V:&K%17LG8KF
MI\1@A^7_I##0#@4M(!G+W*I08,8$:)""`*EH<'#WDD[39WM]5[?="*2Z@^)!
M`$RPP."]?HQ=MA^:<>:'%VOW_O:&<7N(>H5U5SA[B'EOR#EH,GI*2G>>;F_:
M]!*FN>;MZ*/;^_J@0/"'%Y2YWP'*?TQ@MO+,LZW[\QA&OR'YKJF>A*[GH>QA
M2'PUZ9[WP'<I!((&@*LQ'_HF*)'<L>^"G]#!'^8P@2N033R5.(*B-K.(_#G/
M>Y7R'@13(T#7$'!#!JR0`U^B0$\Q,%0J_!FE)$C!VZD/@T"4A`=.$($.6(`D
MBZ#"&C+0@`\,X'A'&`!E]H="_V%HA:9IX6I>B*$82FB&+*GA_Z5NV+`<HI"'
M/;1:$-?(1I/PKT)6K!`61Z/%U'"Q0EYT#1A3(D9*D5%O9O0>&M-HF!^V\9"(
MC,0;)11'"<T1-'4TS1W+A\(]$J./(?JC]@*YL-H1,B*&3*0H$[E(US32-8_$
M221',TG7Y'$UEAP&)CVDR0-R$F^>_"1"0CG*7JZQE*LYY6I269-5@J:5$:PD
MI6:YH5K*\)8[S*4N#<%+7UJ3?<!,C3!30TR9&!,GR$S-*U,32V`P$T/._"(T
ML2?-:1*BFM>,Q`<J0,]ZVO.>^,RG/O?)SW[ZTT6:,``"!DK0@AKTH`A-J$)'
M4`"%.O2A$!VH&?00T8I:E*`RN*A&'?]*T8UZ5*$/^*A("PJ`D7JT`"<PJ4J!
MH%*3EK2E&YTH3#T:@G:ZLX+Q#,4%J,#3GOKTIT`-JE"'2M2B&I4*)M`$$+S`
MU*8Z]:E0C:I4I\J&,TSUJEC-*E./$`>M>O6K37T"6,=Z5020]:Q7!0!:U^I4
M$+#UK&>8PUOG*H*YOM6M=B4K5_-ZUD'>%'<Y#2P&*4&NPAKVL(A%[`N:D-C&
M.K:Q`T#"8R=+64L4H+*832P>,LO9Q(Z@LZ#%B+U"F]DF,(^TI+T#:DD[VM5B
M-K*NY:Q?_XH("PKVME@C;&PKN]C=5A:VOJ7L98/KV,T2E[*?/:YC6ZM<<IFV
MN8]5+70;R]S_Z6($N-8M[&QI"T_<>M<QNLTN1GHKWNM*MKP8&2YZC8M>C"2W
MO7^H[G2?"U]+2+>^\:TO=MN[W;]V][L`WDAXT4O>]NX7O>HM+WOK^][VRA>Z
M],7O?>O[8.L>N+S]O>E_`\SA3PRXO`5&[X7%FV#Q+AB^#49OA94;X?I.&+XK
MANZ(LYMA=VZXPSC6Q(?%&^+RSMBZ)<[NB=N;XO+&F+@MIJP71%"`/_TA`05@
MK`9<\+7H8K8#"/"6'/X0@"<LY@]4&`-FCTPN`3R@`52HQ`0:<(0-2D`#E/VQ
M87'0`!DDX`]$X,$!F(>!(#>VQM.\<8XW,L5(\*``A5[?CK/;8_'*_QFZ?I[N
MD-%;9/&2V;=)GNP%"."D$L!/`1"(`!#29.7*(L`/`+#.'V0@@@.(X`@74%ME
M+UT)#4#@`":;PQ58<`3WL2`.OSWO8_$`@1`8P`,=J(`)7%`!6!,!LX#6I:`'
M_0D/B.#93$#`%%<`G44,X`\?&"Q^&YW=1S<WTM"=='DKG5U:QS;3CTT`%OQU
M;0A(@0`M8,$:*OMBQZY!`'_@@69"4*4)$"!/8Z[L'#1P!#\(@`ECL@$/`-"0
M.`O[L1;X@PC\P`0<7&!I:,YLM#\Y;6IW@@1/=D&C5E#"YOGAV^'^5^\6;5UR
M6_CB"(:ONL7+;NNZV[7P?JP&).`!#9;@`/]2:$`)I*`"RO;[L3,@``\<%0(7
M'*`"+9A!Q2?[\S_(P0`?4!L&*A`'&TBA`I&9K+G)-08"&"@`+1`!$(+0@A;L
MF[(C)V3)3;Z),(![$8:"0`L:,@"6?YL$5^C`$Q0];L;"=^W'17=S=Y[=GD^W
MZZ@->F,?!0'F-J`"$'B`H";[],92P0\D>(,E3M"`)GW`R5SG;78\6`DB0(`-
M81G]8R&OYEMC9`87H%&:\6Y3&]N6[XF)C(.:?H$X-(0(]OLV$S+^AQ/ICN;3
MM?ET>1]<R2N7\M:U/'0Q3UK-)Q8D!6@!P/]0@0?H@``!\(#3,;N?"TB@IE[_
MP!LN,`,#X&#6E!7_!C23'&?P!VO0`'$@`%;"`A:'=W[`:0_@01'@`180`B10
M=965=VFT=\@G"17P!U=0`@AW(B;T<G]@`'[@'T`P<XVG7SA77MYW7.`W7>+7
M7.076N:'6,E``*SR9&'7`;P"`O-767IP`4;(@*O6*"_P`1(@:[$W66$@`U(H
M`P5X!OCG(AJD=B^(6"XPA3+@016P61E@`B:@>L3'%[1U&,?7@251``(P!U2@
M>N%6@C#G!Y2@$=?7@H^WA=D5@\0U@]!5@\IU@Z"5@]-5>I;F@OBE@3W$@6P(
M"4*C(%>P#W3X=W?(@O6E?3+&AT"F<_A5"8)X7(38688(78C8;HI87XQ(_T&.
M^(B-0``=T`)/X$%)Y0<>!``H6(>7F(>9Z'@&QHG3Y8?!!8C-%8K$-8J<58K-
M=8H^EXKPM8H3U(JNN`@LD'8=(`&,@'^GIHM_@(=M@WW0I8G-Q7V^)8R^18S*
M98S!A8RE=5H2]HGYM8>+6'R!MH;32!$7(#R.8(3[<![\(#28"%_BJ%SDN%OF
MN%OH>%SJZ%OLB%G*J%S,>'G.R%_T*&WV>(]\!X[--9#'59"Q=9"QE9#$M9"[
MU9"5]9#'%9'C-Y'H!8WI<Y$826T:J5P<25P>Z5H@Z5HB&5PD&5LF25DH25PJ
M:8,LB6$527(P&9,Y-I/'59/!=9.KE9.KM9.^U?^3KO63DQ64P364@UB4XN62
M/I242MEA3$E<3NE;4(E:4HE:5+E;5KE:6/E86NE;7"F*7DEC1ZEW8CF6`5:6
MP766NY66I+66I-66L?66J!67CC67NU67QWB7U@66ME,$86``EGF9F)F9FKF9
MG-F9GOF9H!F:HCF:I%F:I@D`"I":JKF:K-F:KOF:L$D%"`";M%F;MIF:5'`"
MM[F;O*F:!=";P$F;$Q"<Q$F;OUF<R*F:4I"<Q(D`>,"<T.D"T,F<RSF=P9F;
MUDF<$Y"7&PB/WOF=X!F>XCF>Y%F>YGF>Z$F>YY.&$I&>[OF>\!F?\CF?]%F?
M]OF=ZYF&17"?_-F?_OG_GP`:H`(ZH+&5G]Q%H`B:H`JZH`S:H`YZ7`;J7P\Z
MH11:H19ZH1CZGA&J81G:H1[ZH2`:HB+J6!MJ8R-ZHBB:HBJZHO=9HH'&HC`:
MHS(ZHS2J7"XJ;36:HSJZHSRJHS=*<CT:I$(ZI$1:H3^J=T6:I$JZI$PJGT?:
MG4T:I5(ZI52:74_:B%6:I5JZI5PZ65?*BET:IF(ZIE/ZI=%(ILJE`D[%!)@E
M64?@=_6)!3HP!ULW61U`>_,Y`#K@A)4E!TTWGT30!'!*61VPIO"IIW_*67@*
MGRJ@`UN&64305&P:7&::/FAZ7"QP:#S19I4U-A(P?/-I;"W0'&(V607P<?.I
M_P,?D'XL0&J.I:H%8`#X!Y\/\``G$`).1%E,P!,%0``"DIX"$'PM8`!!P%D2
M,#;P^08R\``M(`$?D*B/10"\RJF^5:D^=*G$U0#?9@E>(``EX`(`]P8SX`5I
M9@$G<`*/ZJEI%@!4X`+?I@(*<`6P-YYQ4(:5(`=JTP%X`*Z54`("X`(E@!$J
MT`&Z]YY>0`#4UP%I-P`N@`!JHP!A,`$3X([LEW$!X#[P^00%4'%SL&]O@``B
MD"<!<`0S()V%%8LF4*?E:0$-\`*UAG!ST`(XH'HZ,``30$2%)05/4+#I&0+J
M]:@!``(NH$'PJ@`K,`9UFA\VRI[U@:W!I:VBM:H58/\#+^`%%W``$I`!!E`!
M)1(9ZOH&3R`!(F`#"=`$VO&!Y7D!VXH15C>L?^(!3R`"5D(N/)N>5/`$A94`
M#=`"/("W=>8")%"W>'81[]D!$%!EE=`!?>L"!A`&`_`!5<<"=X815/``9HB>
M$U"LY#(',K`"3_``'1`$!N`"G\NG>AL`@EN>$6``<$8N3P`$(B"Y33`/<BN$
ME1``'T`%./"HE,JT[^2TOG4!'S"\SZH`-E`)I.L%?M!F!C!:_5=]?_"I)?``
ME8`'>Z`(:5>>\O<'.F`#-A`"%I`?33`V'L"F.G`!="N?*S!:WGL!%F`"ZR<#
M3-``C;(VDVH);T`":.N>1$#_N$A@`RQP`FR`K%1P``.`OG\``B9`+CQP`0]P
MO^99`&A[`#9P`5@@`\;5``D0!")0"09`K1E@P2<(GTTP>A,`P&8@!]1[+R;0
M!/DA!0M<"4P@`SRA'L1EK9,)O+L%M9:@`"M\`D'@!?E!`*=UL-#[J2OP`9<I
M`4V`A.:9JY;P`&/`()?Y!QC[N.D;GW>+$=JJ-)9I`T?0`(YW`12K`0;0P?$)
M`?>+!`5@<);9`$`P`#)0"3YL6`@0P^<)Q!@A`U9K`U\\`T%P7LUK"39``G7W
M`;^:GA&`K'0L`1.@Q)<YOI50N895`G/<N[[;GCKL6CQ,QS\<Q`AL`MOY!W$`
M!$=,_P5G(`,-@05>(,GG"0(/(&L6$($?P*9,L&57K+0>+)]$\`$(UP%JRP/G
MY;5C[(XL&[#R"0`AT+H3$&4L\'PJ(,>>;`ES,%IX8"#HJ;7KIP$-X`4'`&P;
M%+J"W%JY>:X?`,[N60!/4'%4(`$6(`.&@BBN3,F5,`"E>@)XO%LX?"Z;[%H.
M'`0`/0-U_`=`;+65X`7!8FS,HZX:4``FX"(*X,KFJ7@R4`&X*(0G4-%(9\7U
MK,LC+)\8(*OMQP,!\`(&4``66'W%;`G""]!!P*?H^08'<'5[8`!(2W#M-P;2
M'%\K_`<OT``:V\GGR08B?0`FH`%1&`(`(`-O$,@>_&"I6_^>1&`"-"T#C%4`
M#]!^$4W`/:T#P1*KZU>MF:S)_8Q>.C"YAN4%>'"Y[LD$<841;X`$SX:@":!U
M&,$&+IN@6(`$U%=[>`#!A_4";""?<W`&$*P#ODB@3(`'??T^:[V8U(K)OKN?
M95W9EGW9`[K/=8+9G-W9G@V?FEU(GSW:I%W:GQC:3V/:JKW:K"W93$O9K1W;
MLCW;)#K61;#72)#;NKW;O-W;OOW;P!W<PCW<Q%W<QGW<R)W<RKW<S-W<SOW<
MT!W=TCW=U%W=UGW=V)W=VKW=PXT1J`U*>\F7XCW>Y%W>YGW>GN#=MAW>Z-W>
M[OW>\!W?WZ7>F2R-\GW?^)W?^KW_WQQ!WY/-WOP=X`(^X`3.W_[]V@!>X`J^
MX`S>X*YXX.QIWP[>-@3@QY9Y`3(WX6M4X9=Y`8G&=Q#P<9;)`OK3@2'NQ0U0
MXAWX`2C^`1D.,!"NGPFNX>OS>1@@!UNG`DT`PRI.XVVC#A@0!EL7`#J``T`0
M;H/V`7M`!2_@A&\P`"#P!`Z28VYW`CH`K1:@`%SQX@'F`0:POAF0XP)P`@_P
MX7T2X]PUXSX.,!X@`XU]6!VP`CV^YGUB`'F=6!WPR!V6NX\U!M878!!0`(!M
M6&%P`%Q^6QX0@8ZE`0`PY_R!YOZEYG3>)T+M6!W@`H,&`2;0`B"0FB#0:F;^
M7;Y<61U`_P6A'D\0@`<JVU@N#&`%T+J3%0$R`&`RD+V/%0#[$2F0KF&2/NG\
M40!L35D"@.3W<>@/0@`A<`2P3BY,$"^.7NS&;A*IQUGGVR<>$.T<T0"#6EDJ
M<`#I@NT5\0'U>V4N<.H<`>XE,43!/EE1=^;<V8@S'GJU6JM;LP@$8`(`\``R
M1P![<`"%9@!\8A$F4`!=TC;7S@@\]>R@8`+Y8O#[RUD#H/"$9C*1X@$DL.V)
M-0<$$BF:_B!^65@6$/#%OH+W4>N@%0"U>"<4_Q@?D(6=93_WL?+\X0'^`5H"
M(/']_>ZL...,7`G*$VN68`%LXP%><`17<'I^\`#]"PGY_`<E@/\UV\L(E4#L
M'-$"?\`[`..JG"7T_($%*'@G!(#6E-7N?7+`]Z'UF84%.+\1+R#R)L$"@YY9
M7_\@.)#KB0$!O`M:.'`?"9#R]U'SH24`Z$X1NVY\H0`!)B(#&D"P?E"^?W"J
M0L@&Q6/%)A``?J#&WOX(H/L&`F<"%D`"C1`QA98,R#/EF<$"^\XV+M[XSL$(
MA,N#EZ_B%5[B0T,S)/Z*J[\(5H_UZ<(#J\Y9,S#XGY``5V#N',$"ZSY9N-LG
M`N`%PL\)JKQ:%F#\&S$&6$#]GG"XJ[4&5-\9%<#XB9'8H47RCH$!3-#]B8&W
MJS4##U+X]1CN.M`!UD>][-+XS\8"Z`O_N1G@!SH`""=^@X2#87\RA!Z$'W-_
M?TP`@P-8>(\S$'X0CG]K0(./+1T0*QV/1"Q^"H]_%7XO?P1^'["/8XM!?TA,
M?V\/@Q:L)XLM?[^%R,G*R\H$6*S0T=+3CZ[,U\R6+]C<RC*F?U@?P15/'4`$
M+&=_!U1_4A*L;ZG=]84@?PGVV!XJT>WO@'2H\.$#CE;%,!B0YF*?/2E_!BQR
MJ.Q(M`XVGI$0$>!`.HL&,/QI\21:F(D4L>5Z\R$E,A[2,&KDZ)$%2)$DH:UI
MZ3)9L2LH>Q:R(>W%A3=_;"8P0,"`%SD?'H7\)W09M!U\LFK=RK6KUZY%FKA<
M%^;`H`J(".$S_XLC@@4>`,)D2@;A3YA!!@KH;0E"`Q`#`C2D&O"'RA,BQOQ8
MW&,`5JI'&C"QJ!#DQ!\Y?DP\*M#@52P/+SJL`'C&3RX53TK\$3`HQ!,283J8
M+7:L:K<9U'+K#L?3]J!B?Q#X)F0@`C0>,"_@:,$BP00(`1I8KB`#FI<+PY&M
M>#3!-\1H%1K\:2""R@<!&#XDD%"@<-1H`0QD)X3V3YR@*:M+>Q!BU)@0C9T0
MU0?N%/"`-$_,1]PC`\C2TP=([=<?!/\%.&"!!T)3VG``/,(&?D+A=A$!>+S@
M`1,LA#!'$`T,X,<C!$:#Q5S97?75C3AZ%99+(NC`A&Q^B/"'?(-,\/_')WXT
M<$$#*K#P!`XD(%.7#H-8]H@,'@1@@0$&&"F"'P,PL0@"?P11EPI<NO!'@M4L
MXH$,0&3H@0>/$`(+`>)1J4D$H^32$`L!N.C'!2:8X(XKM"FXS`?@[.8H-%3,
MMP<K2-H&00+1-`&!#A=$8(,['7B0@'2MZ,?*&31F5](C)E1%@`;22'0%!&'L
MH1DB%;#GWC0E*)K+(SP(!=HTYC7Q@08-Q/$(`1G$:*`T<S@XWP6LQ)&J0_5)
M4^RQR2[;+(;2=.;;`:Q88UL#C4)#`@^C_7'I'Q;X(1:,[D03Y7PVYJ@OCCOV
M1.T5?I"P)B&8$ND'`0D`8`(6(G202"%,,)'_"0$76"9#71IXH;$7W0W@195E
M1I7QQI(LZX<'P0@@@"ESUCG(G=5)0<@Z'^0BP2Q>N/A`!Q$H<$4K?B2J:#+U
M/FKT'QJ`Z"\TXE9%IC0$?-#A$]_,X0<1#12PQ@.FEJNHJ5@8G%((U'!=G0LL
MK,'$!3,`N`9!TW0@[7`+/?+&PRG5+8W$%QAY@&9A$/#'!15H\$"&T22H8%VL
MK-!3!M3P[3?@@A-N..*LR.P;NJR899M(TWCQ`0&'$'!0'!_<%081$!3-BICX
MLH+5OK2#)99#YV%'K8LBIW*@%RC-$.D1@N#1:R$'-7@RF8F$H<(B$/#D,<A!
MG/B&+!XX^,@B"[GB_\$S+?]A9RQ1!2`+45AX8#/.+@KPQR)D(YK8T(5XD.[1
MCMX['*R/>&%#58R:!@C\@"DL-``"K?L#'CP``1ET[1%,F)MOJ,4*(O3&(1Z(
MD#3$P@9(F``"'D"+%T#(@O=(HSOS,6$XL).2[TRC.\^P@`T0J)H9:((%F&/%
M&(8&N4=T0'$.N14U8`BO&4*@AC?,X1]4P$)7R8$5T:F*_7)S``K.X`,0(,`3
M/\$"`KB.%;7Q3;YJ1T8^]&L?%>B`!N3P!H<-`@`=8$(PWM"T"C1!%B$@`@D"
M@+=!>,`2:PC#,R+0$L!1P0)S6,3T_&"9(&0FD""PP``RL;U9K,$++E#-^__\
M`+D7A,`S>.P`%A(0`"8D8GT?R)D?C(0'$1A'?F&DG][P]ZAMV,.+5,BE+G>I
MP3]$2RCK."'7H"&'9SPB`D1@0@"F(1R'M&Z7T+0$-":9$O'P*@@?6`,K,H"8
M1V#A"F_PQS2LYDQH0E.3K)##M>I!F&F<0`9"[$`8>/&(*ZA`F=-XPSJ[X0)S
M[M(X\FB:/?!!C7?&<YZLL"<^I>'(;GC`G[H$@3@?D0$).N2!K.@``)0CC]CX
M,`P:4$$O6?&E&LFNC&4\XSZ"``+T5,HT>!``%0P&`1R(RP,M.(*Y"@&!$&"@
M"1@@""$.@(<F4.%A+D"AH8AT@!+(E$BYG(@)9C#_@R=$U0\&&,,8$K$"*LP%
M"#$]*EYF>K`)-(0`)Q```@!`!;,8BA[T&\2J+A&$=:S(,G,(P0/VH(-'A*``
MRRQ`$``*C:390X6/PD-/(*!-:8"@`#VD93B4=@W!X2]2%(')--A0`$Q)]A%K
MH"PS+'NT!3JSL=JJ@#$_&TMVXL\+%L5&.XFEVL_^H:3<H!/^%"!:;CPM)BNP
MTF=Y:])'S`ZEM%-I7)?+W.;.1UG;9*`7Y'.$(\@B$YLBGQ?^T)+90B.VBY+L
M3O>AQ$[(@7\=L$`/L?`&(KP!"QJP`#VC(=!ND/9HGW2(FJ9QA=5ZP:-,@&\`
ML,"$"$PT&N`=K60+X)!9_T;#`A%:@P5^]H=2JD`#[CWO-!I"$>\^Z@C[9(9N
M(.S##/30PAA^@X:C@8%ZZ!9_'$Z)9Z6A8G"\09"G6,,5.N"%-P1#&G)(,$7&
MB%Q]*=>Y2$ZRDK$QXT<T!#O5D8^R6DR4J&VWN]/X7ST0:[0^VL-(\+D`"#%U
M`!!^0P8'\$`3&L"".7$"&LV\Y6>][-MI&`"$$`$``PG`A`I<X*$&^,`BW!<N
MA]SW:)ZK1WND$0`L0H`P,_0`N1[0F08)&@('?@0.4N+A1PFB'HQCM*,)<S$/
M+(328(H:`S-]N]Q^MJ$4(2PT/@0!&W3@#0ST@)$\8(,/\,X/1(G&&K0LQI,6
M>?]?1UZRLI>-Y&YFM"70X6ZH1Z==[H)I&O6]!I<?]3R*K+9S)8D#"WHA!^"]
M0`8$>,$:LM:!"VPG&H*2LV2/X)`O*I`%;S`1$]YPA8KBH0(>&,,;#)"+O$R#
MSM@XM-'T88]L0>,`)<$!M52LCP`\H!%RF\#U"`HI3DMV#4(NA,(?`?$_2+P7
M%L!,!BX^AXQO'-XN_FS@4C)?>4"@"8AHSXU;0"U)7\%%8:#2MQ^1[9X0^=@W
M2C:SE\[T^3PQ&MVY50,\@)L$>(!:6-2!!F3Q8_H>5K(:(+8]0LTT%IC@``:0
M@PV"\`0URZ!#XT'"D!QN-T-+]@UB[X:]`?"!0AG@"@__,```6A<>J:!%5](0
MFWW!KGALT/T1%[#!V660`18$(5A>V.NR5A&C:&#6(9UVE"3J,?+!2?X`,@B`
MV3\Y`,W'@O-?M*6K:>G&E`S],G[XVP,J<(8+`"@J'NB@B_[PL>UZ?3A'1[J.
M6FV/[*7*^3U1'ZS]&(3J19\`V"=`B.<#0I[6+RC;3XE%HH$$TW"'@0\@@`<.
MTJH+R"=MTV@B-[:]F_SB;AH`>@$>CH`'9YBH"3(`'`T@=P;P>)LD;_@3+`[A
M0JQP1V,@`$9"(B-$!150-P7X!X@7#7!%>I)E?_4@,-)0``:0`'@P!@C``EA@
M0YFW:`0`>R?D<?B#!^&'#"\6_PTB2((/^`$9H`^MQX(N"`WTYE`+]CC2H`$?
ML`(#(`5$``1`P`0%`'PX-WS%%V;%]0?'I7Q?H737(!Y>`%?XH`#,<`$MT%J*
MX#)E&`L]\4!Y,(-"\0&4@1U18P'=UW<F@#T(<P$A9P]"$@T,\`&+5AAB=@'0
MI0$>T11=%PULR`BT]'GW-PT\D`Y-$`#H(`,7\`(2\#0'P`!'PH"LT%O)4'JY
ML6D488`K4!!&4@`$8`,V@`%2``2/``0040'`@6!VAS\#Y!`4)`UUR`)]Q10R
M\`&H`1PV@'-388,P:#0CY!`U!PV[V%?I]XMR\`3"2(R@PPJW.'M'8T,]06C1
M(`<-0/\`,J`!&7`!'R`#"U&)EQ$5*@",T?`"B5@/R8>%6Z&%S&!-;#`(F@6&
MRU`=GZ8,NI4,#3!U:>A++=`"3W2-BH('&3`'7R(#3:`"<O!G5)```_`<OD8$
M"8!P*4$NMK4;1+`/$%!](CF2U;=,K-!B+@&*'0D-GDB#)$F2<,<*VD@1Y;62
MK(`%%"%]+UE]9`.$+G%[-LD*\F</#["3(OEF2_2.A<"-06F,#F64U2<!AVAU
M0A&33=EQ57B%\L@5]+@,UO0')``!1&`*8.@!*_`"7O`"D@`!/X,%`]`2,A`8
M*D`%?_8(*X`%$7`O`R`1OC8#4A``5W`O-G`$:R`'*R``&T+_"/PX"'41A!]P
M`CN6``U5``/0(QUP!"T!``,@'[[6`IJ`!TS@!>D1-',P!@QF`!*%!W\F`@+0
M!!40/2!`!'B@D11!?T')B%+4*`)P01ATE=.`D]D1;(^@`TJ)#+9IDXDY'+GH
M2WFX#"+BFQ0U-*L5'RFQA]#Y!QW0>"GQ`11F%\VI;=?)"AYH&_&XE6;$?/4@
M'D<0`1%`)IJHCQ,P`Q*U!A?C"%>@`!03`4R``V=P!5/W"$V`&UOW(N\3%6MP
M!"N3/@3T!R#@`A;0`?$V"-4Q`X=S`C\T"+@Q!A/@7F9A&2H``L;!8(D2%>4W
M*04I`+)P`)31*BQ@`&'PC9GQ-XD`_XY-8`!Y)Q3&=YU%YQ+C!D$WZA!/%PUS
ML`*+E@`A$`*PT`$N``#&,0#V]@@,-QRFD@$[6@]]10T8H!<%@',B4`#/<`3/
M.0WZ0S>L,%T]\8?3T`):"@D``!P3F1MQEAVAM@8,EA(7<#_1H*9ZP:9NVF30
MD`#%68_@4'M5D:/20`1:2B9S0`("6@$C!0T;2)[&9IY<B9[=(!X5`((Z4!WZ
M>#`?0"XRLYA^X`ZMH@DG\PB9$`R=L3U1@9/!%PO4HHT&H`$1Z@</)`>IL!"*
M-0M,8#66P6#4$BDCJ@M^@!:E*'+2<G4BERJ"-A]6>94?DQT].22V88`%0(Y_
M<$=GYP%SH/\`#["D`6`#W0D>\S%7M%D/-?D')K!V0<`&"6`"(D`";W`!AT`-
M1-"2#O$K["`4RRD-Y5A]?P``<6`"9X"KC^I#9%@5N=B/XJ<;_YH+`DNP!DL-
MHV<;'(F!PP%FTV!UU5<,W$D`1-"EN2%[R#>IE*H57:D,F*H8<K,08'@!2!DI
MHHIS-.@R.+>J!1H1@^`.36%R@W`!;HD,U6$>'\`"Z@8!:%&G\B(^C70PA1$T
MB4&B!]--FM)T?F22OJFTOF$EX^42#L8*YL$.'&D`)(`!)I`'1ZJQ_CH?^P5$
MT8>UT2`#(L!&JQ$".!`$#Q"FTM"UU;H9M@%=TT``9Y`!ID`"(/#_!""@@[FQ
MJPJB'SJ`K\P@1($[N(5[N(D;61?!FV?Z".4W'-$V#2AJ`>)$`(V&!,)I9PI2
MGEN9L@`)-`00+"Z[2NKJ!^,FLW_P:?AP#&YBL^-!H!X0%8+"LUEB<00@$K4J
MJHST!S9`+L<#'7?1M((CK'\0+$31N<#F#IICM6@:E.24'2(QDU)TL&';`/4!
M``:P!BOP!)3Q@-,0+_-A"0@I%#7Y`',"`0J@I"$0!R2`!W[*"LJC(,H"OCU!
M`'BZ+'/R`<HD`2Y``D@0!YC+-$,C,#,B1?W+"NKWNPF\P`W\P(_@ME5A&529
M'0:8K:9:$@EP`#-@`$E8P%&:E2=;J12Q_[(+`H;%T`(&8`F1(AYRX`+I,&`B
M@`!R8`#_N+0X^[LZ.ZIH*`'\<P2!(K1_<)\*<`0:$`"9L#(8L`(6L`:M`KU/
M>R!7@`.'4'X3H`!/8"0Q9K4=U)1\I"`O0)S9\6Z>%Q4R,"GJ>BNMYP+F.'[0
M4+'#H0,A[!MZ"UH!H`$\H!\)8`,3\!?5"`WGNHUS$*C,,%?PL08J8`/[U58/
M((*'Z&3TLP*J-T'\PVB4;,F/@,F:W(Z0>QM0H2`$$'I_@!@OD&XD)P*3(;F/
M8#Z*HKKRR+K(P`)>P,<-X`4#Q`+N@P52P#$G@W.X;`*'H`$E\&<:,PAGT(5^
MH#&_ZP5!.`'):/]J`(!Z;Q"$Q+$Q7F`!%/JS((`4%I!?*^`%K0(!R!QP'4`$
M+N`%<>`'>Q`:D?&=SL4"FVQ;6CL<5_"CBP6WI1P5+?`!,X"?H-(`"E``4H`#
M!P$-<J@@"3"4`!2DD,$#&+"IKL@.`F`"#6V=PD`_`A"I53$&TL#.`J``'X`/
M7B`#*N`,,J#'C_#(](,#-\,AH6,"*]W2Q`?3,DW36&#10G$$C>P2-A#*)UD`
M<X`#BHL'!Z`##6"$PI;3J6NR+\S+SJ0,U])]0K$"4O`WA,''H.9B(#(G5@N0
M!VN+BM)`BK*]?U`"1#$0"%0?4E`,G'(!X]H!5NVY"2L4#2!K`:M]LWK_6]LQ
M!TM2KS))/Y*F(!YPI?+P`%D$@@<@$B=`*+T4`9!L#XDV'(`;V9--<I:-V5!T
MU`[1V0IR`*@UG#/DTT,=``YS`;_%R4.CRUBHU6F=##Q@?'F9VVG]`4!I-/_L
MV\L@34')L,2M#./0D=F;W,R00+:%HL[M>!T9=M-]#080W(\RGK%C7"\\CY9Z
MW=>`0.*]="12P+J1`:5:WL:)TC:I`)MMWE2`WKFA`F/*WO4#`$K]*!WP'/CM
M#?WL*)CYW\G``H'L*!E@VD:'U2>+VP3^X,WE`2$PKKK1`2!@TO]]`:YL-+$,
MX7Y$`AB]&S,@T`1N`#2]&V%@`JGLW!^``/N=_QN(&M]IC;29EAL!@`!$W=U6
M^-TH&]X>_N-+9I8!#D5X@.$/CC#1O>+)[0%,K1M,D,)`[@UC0-_9>M]1/B@@
M0-`/]II77C\BP,'0@`4(H+FUS>"4ZN!=GN:V00`F@`%SD`$1,``"4`$VH.3B
MW3"T--Q1SN8@D``6\%\"(`)UKN;)8&I2H`-A\!0)``*23>@TR`(%(``><P4O
M@`'HX.C&*0$*\.9QKE-&3C^VK7QHCNFD7NK\:MR[81ZFONJLWNJ8'NI(-^JN
M/NNT/@B0/@:W1P08L%&UWNN^_NMI#>O')NO`7NR$?G4R$`0%``!`\(MV;NS0
M'NW2+F)F;I[$/NW8GO_MVK[MW$[HPEYDU][MXC[NY%[NYMY<WXY<1?`"!='N
M[O[N\![O\C[O]%[O]G[O^)[O^K[O_-[O_O[O`!_P`C_P!%_P!G_P")_P"K_P
M#-_P#H_OZ8Y217!)XESQ%G_Q&)_Q&K_Q'-_Q'O_Q(!_R(C_R)%_R)G_R*)_R
M*K_R+-_R+O_R,!_S,C_S-"_R$9]2X9GS.K_S/-_S/O_S0!_T0C_T1%_T1G_T
M2`_T6MG@2=_T3O_T4!_U4C_U5%_U5G_U4[_T9X[U7-_U7O_U8!_V8C_V9._T
M6F_M99_V:K_V;-_V;O_V<.^;9[^Z<5_W=G_W>)_W>K_W.C_WN\SW@!_X@C__
M^(1?^%WO][=M^(J_^(S?^([_^(Z"^*(.^91?^99_^9A?]I(?ZYG?^9[_^:`?
M^CN_^<,N^J9_^JB?^J=/^N"N^J[_^K`?^X+/^NHN^[9_^[B?^V!/^Q*O^[[_
M^\`?_$'/^SB/]!%SDX>X!EI^G5=PXC:9`3CGFUZ0`&_@!>Y-2]8_#400!HTU
M!TCI*$R@`,M8WR6X]DT`YK85``J@`4PP!LM/]A;@IV&`<V'@891N6^W__C=)
MY:P`"`D#?X2%AH>(B7],6(J.CXMC`0$*&I"7F)F:ATQ-;YN8;WACH)D[?*BI
MJJNLK:Q%I7\2?K1^'K%_7B0>!80B'GXL1']A+`0@_XL-"KA7!4R))P2XAG,5
MA!4?F1(7A09!B2T$`U2WI>2'`0>T'C@=#P^;`WZ#F`<$\-/Y^H<?UON$3?QX
M>>&AB3X,)S`AJ67+X#]#!1H<VO9'AD0%4@@5R!:+H$-"$&I]6T'`0(<_>&0\
M2^3M(:$.!B2Z]!C0BSZ,+C,-6#$L(#V7]O#E_'/*E=&CKV))^-"DJ0Y"5Y`T
MRB5'PP`L<YA(F6-(A8@+O:CXP1#&`($.3PI8@/"'1"]#3%X0F=`(SYE"7I!<
M(83'#QN;?\Y(4?$GFA<I>P]=D9*`4-P.<008TO#K!19L6$YD*#1'"N!"%`FU
ME.-%0!Y"6,)T./='0YP9A/\L$\H@YX^*.$<(L7[YX8*`*S@.:'CW0DJ`0C,0
M&,IPXL4?>8.N<#7D94+C/QD^[`E3B#;JZ4TF'/]SQ0*A,%@ZO'@SG1#I`5(V
MSSYAGJKZ/V_.K,1^@EYJ%1-P1T@"9WSR1S^'1'#"=$2$84%\L3$Q@"5R,`:0
M0![%Y9IY=IU$"`AX?*?!!,Z]<<`'LA'!AB6((`%!4TWH\`P62,A7G@8Z:&"9
MA8=8@,1^`008$2$1Q#$'11EDH$$0%ZSG16V$('$:(19<(4`<!N9'CT>&>"!%
M4Q8$X($&!\21W6>%A#&!"BW]$<$$DOTAQUY,0'E5@YG)=X@,?LADR&+TE'?%
M"83_Z:C!'(TPMV5!-6$Q`!,3[(4'$H5`Q@8A;[P`('=8,+E>5P@($!<A&DB1
M&WZ:!MC="8F1YF@N2$1`2`L0X'%%IAZ>@0!AV-$FWDMG3&5(D)?FHIV`0Q6%
MU+)&P5+*4@-$V\@)']C@00M_;$0`">2P\`$$=QG20"\7R!";'TVX($,++"`@
M5"$*]/EM`Q=X0,(?`A!@[1Y_F!`,8C94^T$")T!PP;>)$;("!`W<HT&\!K#@
M1T*SV=!G"148_`$!I(3P@0RU&A+:'RT=S`($-OS1P@=>G*-#21^K8`(+?V`!
M`0X8?&#`!P^L5@XA;/C1WDD/$'`!!#2_80,+#6^6L0$0_[0`'1['&+*P63T7
MX,$'!Q2"@`?'\="`!C)\T(`'$_P1A`&$?-""%WW^_,<%%[!P,C(3$`"R"-EN
M_$`3)1$P0P<`0&#6-[2R4"\I)-!-0`D'^D-(WC(0T$O&QA!06]Q$`$!`PP]H
M4)-'\08,@0PL>&""L0VP8$,`Y-#K!Q4#$."!,B5\?@&+AK@8[0"R'O$Y!$^H
M_0$+!LA#MQ\A%B+"\6C_<032!TLT@]'><B/#`W(0P/``0PYPO#$&F76R`5AD
MH*_>?W")J1\N3*!#!QH00(4-8USP42$NW&[,-WDS"_K6)@L(O`%N`LC8P31W
M"`!<P`1^FIS>".`"M1F-``0(@_\\H-:$PAVN?8P2R`D\D+F(^:%XM3/`!1K0
M@8`HS@-C4(#W&O`3P"'/8G_0P>D^]@<7+NX/)`%91AI0.1)@0%\0(!<)75"3
M""C.&%3X0]$N0(`/7"$[9L&!(:A@N,\%H`5;Z]I0B,*L,K;"6:"0@`<P2(",
M>"$!<SB`#=Y0`#]40`YBT4$&'GB(<?W!#RL@Q!K\``(55,`$;+B`8-KSAW@U
M(0Q^D$``2""-%LY!!`*IR1\J0(`K:``#;QAAM#R@'*AXJ0,"\,`9XH4##1!Q
MB^7(6!C45X$,^&$,A.,((496,A8$R0]?9-DY@,!"]2'@"'Z(0`D@$``6/&$-
M<YC';O[_,`&Y$>(!%\`"`_R0`01T\@T-D(#-XO"',6C0#]ZL8)K064X81JXK
M'K#5!^(``@^\H`,K\$`&"'B@M_6I>80XF!>P<`!N$(!O"(``%NI8@#"$8PX)
MP$)`,("2>=`*#U@@@#6ND(`7-``>""K$!WIQ!GUF+`.`LT8P,)`!#U`!E:H<
M74'B=80P>$`&&J#D'Y[P.B]X``-BP0,3^!@:$M@@`LYID1_8&()%-`%\;`F"
M!W@P!WD@(``?6!U>X+@':1R`!4P@`M/^0$0B$*$W%8''D+(E$0.@#PO8))D-
MF$".(UAR`A@J2"&PVAL(9$0!!SB!6TI0@OT0@1<=N%X0-``!_VO,`0(3X&('
MZH4`'!!``[*DI2&6F8"U8@JR?X@#!);T@0S8%`?R:,`,@D;1O@R`)B+TP`#"
M`($#O&$7?R`F-#\`@H!@5*-L/<0##*""#OB+9#W+EP!\F]$*U`YR!:#9V5P@
MAP#H8`Y/D`82Q-%#@7#2"P'(KA0O$`$=,`\#'A!`&&0%E0\\H0-R&.D[QTA&
M,]H7%6C<Q%)>P-]&%(!A5?3"1G13CG?TL1<0N)>;_`";/ZR!!3.P`0D@P*M&
M^H$0+BV,-'"`,@+,0Y,/,%<AH@$2;!$B7FMH6P7B10A^$O@:'!E7O"!`XPL7
MPF/=N-<%)-!=+ZRL9;<X&XUY\0<"X/_`!/#P`(U#`H)I@L`/PKHF/NSY`"5#
M8&LN,H0\:'&=%P>4QR$MQ`$,8%DILNT/'?"#`OCI-KA1U!`[)C#<ENP''0Q8
M3A(S@`4*5HBH_9BL!0B`66Q@N/D2P@]T5@`V".''V5DXQ9&3:1-8_(>H:?A`
M5@8D:PP<&@%\()(>ZAT$^/N"O7PM8!<.`EB?,P\IBI@0A6O8A?T87`)0C"+;
M"VYP24F(&5RX36I.I;?FX;Y#J+H0]T.`#1K0U`L!QAORF(XWKN`7/ZR-!8%<
M-*`+85X34*%L;V8UG</`3UO+0S)\+C%LO4#B=[)XR5?F@2;]Z%E&-[L$%T;T
MD`LP[P*(9<G_01;Q+VQ@NS]L=Q`UN0`/""$`@1CX#R[%@@'\<($NQ\M`0&!;
MF)-UW_OF5Q,C`TENJ"5@F6SZ7=O^[W'R.9X*+#QE-EC&B6V<81(?E-4#"(BL
M`/"!DQ"A`^VV-"'DD1LL>``$E';Q'UBC[7')@SMO"/4??%TB"/`MSC7Y\3D>
MOA)J$<`Y(27,-%5@KY-@(2,/MZ<(+KN(FGG@*6]PE!]$8("4%2(@C:'V73:.
M'8K?ZQ>-B)<<>)"TJ,%M?W.[P$EX#O$HMGVM`>B`6$G@Z\U$,P%_'E<)/)!B
M`FZ<`&EK>]-[H696%_WHDJ:TI4G\\&&<7!;<J!DQVGC`4&_W$$>?_WJJSPP=
M5W>)HABX\'!%(Q$6\*`#D]6>6NT^I`\`02/2`+8"&K`ZZ!3[#29^`LUJ=H$`
MJ'8&?K(E,L)`@""\@9UKH*`4[W$$8#QE](5(0`/F[STQXH?!:/Y$N?O3ZLK_
MX?+KUFX(PF*YUG;]EBUV=V,0@`!-$!)S4SP&*!"`U@3VY!C;%@"E=PX'UV-/
MT'.%P19I1P5O$`!,(`.O5CLFQ@+WPG<NH2P=QRP?IPUKA$'9H#@F$&!K]7KB
MT@M8\"T7X`>0@Q(7D&(21F'P0G-11&([`P2?!CQ^X#974$4-``$*$'0F1@A/
M<#OZ\C`VIG0-UR[P=X-E(SEH=C2$=@&$@?]U`J%UMY!*;E5:B^`!=H<'AM,P
M:S!-C;1&J6,``9!V+\`$O0$RC9&%4%,`T)%1S8:%'C!H)\&"J;,,&D!%!N`!
M%2065&1XZ'((5%0WO)8Q,L!':_5?4(,`QK6([)-Y#>4'VU-H&[<PJ&,2\%=Z
M4@1@-B`Z>35I-K9ZTA`!*#.)6/!ZEH@'.V,65]`"$A@E2T6#"5`V)O!I:L-[
MK19BAM`;-WAA\:(XGS-U'D`W:)5K)Q`,G241<["-J2,9TI<Q0"`QKZ57A#`&
M2U4OH<<"410'RY:(V2(O$/`-%6"*V?0'3P8"Z0<!)P%_B%!O?]`_GV@N^]=[
MI6@6YA*`TN!N%S;_CO3W!@?XC2S099ND,_V#+XL8,"TD@>/2`2&P0\5#:S;X
M`;=P!5L#`#5Q!1!0+5XB15-&!5]C%F\Q*_+2?8;&<2]81C&("0E`!41)!<B0
M`2U@':`T!S*7`<B`+W$"+],1`#C@`D_!<`+R((S4,A^R&7(`.0$@!2T0!E1P
M'`13&W,A`HWQE810`LA""!C@`E1@"5R90Z1@"#,P`1$P`&^F`%S1`2"P`B`@
M=8M`!140!^,Q`XVA`B(8!J#DE.XA`BT`)?X8E3H@`JR"'4]I"!8P`2Z`!Y8@
M`'$"`HU`!%+@`G>I`7@@F"-8ECD4A"^!`2LPEW#Y$ZVA``:`4X00``C@_P+%
MT@&K.0=D\0944&%?5@*H"2\K@)C_)W,=,`83H``GL0:K60(GX9B?X)?M(YA'
M0`H88)L=<`0K(`6-P)<GQA54\!EX()>6P)AQ5TAUZ99R$H1[)@*#`)E0B69$
M202B,`%<098&0AY%:90J$"0M,)1VN9NN*0"G`A4G(`46X'@OL`(ED``R)P`N
M4*&P<022(0HXP`1,>1XG(#7M>)7IJ0$X(`(Z4)984$C+<0(BT`0GP036V9:%
M90@=4`(KD`!C<)5CL)SCD1F-,`;-8YZ-Q$B<(7-XZ0((\`DZ<)<E4%VNZ6#5
M:7:%Y)YL^0??F0N.%P:8.0CN>:3X004?FB85,/\&,\!'[1,_M1&FVKD&LNF:
MVFD;+7`".O"48R`%<A"FU2$"<2*:7?D'"3`!H'D(1^`".#`,6FJ;.>&"/WD4
M04E?DCJIE%JIEOH0%M`;=SD-!@``E_JIH!JJHCJJI%JI`K`S/%,?I;JJCN"H
MC^H*D<JJLCJKM%JKMGJKN)JKNKJKO-JKKOJJ2=&KPCJLQ%JLQGJLR)JLRNJK
MP(H4L7JK(L`W#]&'<P($5SD-6"`'A)D(>+"9.C`!VTI?C+H/4F`-,_!\A4`$
M5)`1RUH*1"`?<6"/F"`!I(`>A``$X<()LLDK>%``+9`P1.`"!3`#D(8I)W"P
M5"`K)=!@Y#$!>C(&//;_#P^`I(X@(9_Z!F'`(BCG".RF)S,@@HGP*(EPKA.Q
MJ9G0!`=[`E0093EA%13R`./Q$%20DX>`$">`6J!P!!7@7)/ZJ\V:"L]JJP_W
M#X=7.Y22#U)@`XKZ"+]@'DZTL9(:D2Y!0.W&:%O3KJ6P`B(6<O4`&Q=`3I5V
MA890.*T&1@WC2^1!<%,HK80`-U5D,"JP%/RC4,AA?_H@BY<@/)^J`Q]`#S9V
M"0'Q`"D6``&6"`30H(90M81P``R;"5KS`?/"L@]!?MRA22YAD-T0DQBDI)=P
M1#90-P7KDS][1K%`!4<@!28P`2EVAP=0`'N!>0(010I0`!-@'FLP`2;`$]A1
M_P%S8`(%T`@O(+!2\`E#BV8ET+JUD0$5@`$FT`(G<:`B<"L@X+O<4;0$\",5
M@`=!L`("!@1QT@1[0`)/84A-$`0`T`B54P!VA0/^MJT=H#AH\0%O@'TFX`*-
M@'E\`5#^"`(%0`)S0`4/T`Y,4`&R,@`5U`%2T+Y28$>P63,KX&VZT:\FT!BP
M&T7-<`#M\(R79J:ZM+L"$`0A`"7@*[ZV44LN<`57L+/7@0%`\`1Q(@5X``!!
M\):8IP,F``#UP08D0`)Q4@%>4`'[(05C4`%!@$>I^Q)2\``^["85T`0F4`%O
MP`0-T`\)L`UQ<`";^0<64`$:@$_F,091Y`(#(`"G(_\%3``!(]"_C'0%T$%M
M&0&3]Q("!/`)*H<7F:@"!'"^'A"$-J!5`X(M'XL##]#`BW`"2KP9AG29-5,`
M0.".RR`'!8#%)^$"<S`!'P$`=B09X',`",`[<&D"(3`(KE$`%=`8`9O"*H,'
M(4`">@)$'O`$420TOML(:R`%![`"4180['0`6P->";P"M;'`0(`,D%PF:Q`-
M@"4"GR#&*M`";+`'3R`?"/#$;""V:T5MI$"_%;`7#I7,GU!+NTL(<5``G8P(
MW_@$)1`0,_#$-F&Z>!`B9\`#)"!S%A*PLL(&0```.HN``$R*AM`F!R`1%:`#
M)^`%'7!DX#R-"M;*HCNZJQ#_M(IP-C(0`A[0-?]5`C;P.@6C.M%4`0900017
M`$>#!?'B?/;R!U(@`S<(#\5+*]^6#:7#)QGQMB]P@QY=9]:+!'##-;;P`-_R
M'(U51SH@#P1@`J=#5A``!+(Y4CR)"!;@!P#@4AT`N=@PQ^U6O),(!+;#`GP"
M`H>W=+>0CB(=`!4026"+9B4A!=="5A6MDBJPT28@!XO(20K)-HJ[D890TB(]
M6@,0U'5&U`20`$4-!$"`P'X0`NJ0&]]R@Z,U8DNU`I`KJ'9$T;)"<01082II
M#R0T<>0TQ2MP-!$0$$5=T4Q@#!)P!&H4$W[0943@!QSJ!P4`$_?B4@QP.T!\
M9<TH_[5#)TU^P"*<]`<V\`W_1P!7^-7ONSK#-P`_E;C2(%6JO:EO4#DN<#!6
M@6@]AT$;H6:9^@!?DS9K!`&.]P<\$$D,P`:G\U\12PA?8\MGT0$VP`/6@@4$
M@4%%!@%&W<%1?0#8\H1`<-(EB=$)V%WVT!=,Z`631T4=4-8R0!>&\U]S\(T7
MH`Y\XU*U0P`\<-0N`$CYI-LBW12%\W-4;0QOL!`1/G=_M`PLQG,BG3"%L`)^
M4":B;0(535;U0KLGY"^0XS8@U`0-1P)2X(!UU``3E\5MXD!_Y#UAD+[6PEZV
M`=L&\``,W:@.3;JE(.0G\621"``OH`-[_(T&D0!^0`*U`?_FW,%8T>D'>S%F
MK2$"%6`/-%D(&F`#0,!?$,``\7(<'U5D)L$$N0?</)#3<+,,%_!\[N@%8\9?
M8"$/3S%@?^8Y@>0(WT@"'1`OPR`F('#5[V(`72-:)T$`W)N)YW`BC_Y'AQ`O
M`O`"!2`-#5`\3XVRF2C2O>8'1$"UNHW71[@9AX4!A_X"B>X'A?T&AG,I&A`]
M;<$-\@7F/S%"A''&>/!1_/4!GGI"_."I?1%Y#5#$F=@!GAX0YO$$$K%62]$!
M:Y!AA7`!*U#59+P9&69K(-$+?7$(T#%"(W8+\F4L.0DW3RXQW%%/*C!FH4MB
M02`3$$`Q_N@![-7K*Q"2YF%+"D#_$OPEC8L8H!:VN&=V!FS1#0_P[%K$``6`
M26/P`G9$".KG:Y]!@4F%YG\P9JT=!R^0!U!V=P)A,?[*,BA1`'7$':4GQY;P
M#`5S$M?>>+5#3HL&7$#$X=M(10-#Z7\0``/O(C[_#:7'8EW%Q2';:MR^4Q(Q
MA7L!6MDB#3KN$;#^!_B6+;%']*+!,Y/(-W[``QH@!]GNZ84@#S:``+RLJ@T]
MY?@5"PVP<.4$3`3``N_P`#.0;DM7-`7@CE-Q4$EG`&]``/I=-&^^FW03^#-`
M:;E&`,K14C*GTH">B7Y4$Y43^%+0>XOV9V^P`@WSECA:>IMG"1UP,^F&U=]P
M>Y&#0'_P_S4U4P&I3^J;Y0>!WS5^='CIM@<R`>860.N'H&TS]PSC'@>A_PZC
M[P=)-0>4)`-/W6`D\4Z]1PB$WT8'$_AJS[(#:&/>`.90<@%-+(%#`NZQ1^Z$
M$`(-HT.H@V%1Q.YA._%:-@^^5A]Q!0@&!G]_,QXSA']>?C)!!3J$3`0%$#B)
MA"<$?T&#?P0GB5(0'80-3P-^+W]C?@%_3'X*E`^T!7\>EI<*?H0R!X17'I<-
M'[0/5)DN+AX*+QZDGJ!-?EZ)31ZJ?[R;!A9^!L97UM0"+&LM'UX5!"(`?@/:
M"G\F-I>9A`9!MU0#!$A_Z/Y\`-*A0Q!-B0HT2-0`2`D/&OYT^/]0``G"?-HP
M%.+U9H4!"`(N$4(%;UHUA7\:D"#DH00A40)%_$G@H<D*`F_^B."%4F"%2P8^
M!`FA,>-,/W((7?A)B(@?C1I:BIQ*M>K4'7RR:MW*M:O7KD6LBFT`04&8!Q_^
MR)`10`Z(-??^R)&2X8`!(AX`6`#A1\`N0IPR^#FBX8DF6I=,-%"1@<J?OVH?
M>/HG\("<(Q`F+&K2#\GFE+9,NO@0ALD)+"3_5$@[@<"9#"!FS(%`)8&+"%-C
M_;'@844&''[F(/``0D<QH/HL$OI0@8D'$B\.",/!9K9C/VS"))+C!\0;//`:
MV-H<EXH'/%=($#`X*&ZBU;K\5+`P`>G_Z-*G4S.I,``$A!<&V#"`<4_X]$=J
MF,AWQ0D09%#`!W)@(45.VUS"W&/;Y!,`!"%<@8<'9YCT!TH/-G&%!!>PY%@B
M87@PB@$>[*&B)Z=H`$$+&(I$4@`$/*##<`C\<8('M1EPP1J)?";2,A!48X\F
MG!#R22)S$`#`%25`<$1J$7A0@1P5Q(('!#-T@``\1(K$BHGKS%`7"Y<\P4($
M$3@FPP,=O!"+,XE,*2(A.D`0QQS:`&;`&A?PP,0+08Y3C04`I6.`#'_@\8XV
M+81QQGD95!!!7!@1V5FD?PP'!!`$($1(`1<HH$`)'^S!FV_FO:#<'QA!\,`<
M)/!"Q0QA,&?;_R5A^$%%&"*B)%XI#;SP`@N_L"##'#S4-)L,)'S`TT(&)H+1
M);IM2((%FYYQ"0$=\I7``,V)Y6Y56'TE[[Q@O4M5`P80X`<!"?PQQP5^^!$$
M$Q.D]<<1`!,0Y!GZ>KF*,'](0*D!^UZ0U@&_;,="P)*-`3'&`N%!B`+:>D`0
M7CH,\`$>*./ZDPX>$/''`0%?$$:+VKF0HA?ZBE"`OA<$,`$$D(CDP1B$(`"!
M'Q"`0@3%$%R0<2\25&KP!2[\L4+`-D#P1PA`N]*`'SQ<TL+2$(ALP$\H%YS(
M$Q[X\<$1$5/J]B4ZQT>Q!R$00K,?-N/\QQ4PYO5'!!M[8``I6/\A./\F$.R]
M@D04`Z["+5,U[C'5?Y30\.0PRUS!(%5Z@$`(</X!`0@B76"W!T6M_K4?+&`Q
MY>;$>J#='"7W34BU@(>42,LB1>"'+2*Y+?%R$UR"1\-9/SY!W#(<K77<!"`B
M^R5>:'O"&R3$_4$3ET1@0\`&:,`&!!"P</1LB7S0?.B),"&#'Y)!O#SO?GA0
M8"+T(\0$+D"$#T5-=RGQPR_@)C<YW$T&55N=RD0V0$*,80]2@,][/,#!R&6@
M5&B;'!X,!L$_Q"%@#1#&.N3FA:%=H@/G`P+]1N<R0F!A8WYH0$Z&A#^B#>X)
M*P"!"CO1N$24\!+6^X,.&N:[1"@`>G\0HLS_[$7%/\2+7EB45UBJR)`"=``+
M(L%"1.P%1K$$8(Q6"4!.J(@%:'"1$&]PQ1NK6,9$U+&*;U@C%^_HKB_.,4=J
MO$0<J1A(=]WCC)=@@AS_^(<I,O*19$0C(?P(22X2P8TBZ<`B)^E(>ZV!C_73
MXQ\V64D[2K*/3+"*!D#YK@&:X'Z4>5<;Q:(!45Y"`)WX(Q-2F8@\)B(!!,"8
M!Y`'258VI93NNF(6E[F5+;Y1"O)`IC2G2<UJ6O.:5+$`,;%)")MP\YO@#*<X
MQTE.0L:A`!5`1#C/H)UK:@`/%2@`"#!93FDJDYG,=&8]]\G/?OKSGP`-J$`'
M2M""&O2@7+PG/K.H_T^$.O2A$(VH1"=*T8I:]**,5.A"Z=50C'KTHR`-J4A'
M2M*2"E2C&]6B25?*TI:Z]*4PC:E#49I2KW14ICC-J4YWRM.>KI2F->7*37U*
MU*(:]:A(3:H]@\I0I3KUJ5"-JE1W"E2F9F6H4\VJ5K?*U:[RLZI6Q:I7QTK6
MLIJUFF](``A<L(<'-.`"!("`!S11,@@0X`(-D`$0J:`#6TH4K$P5ZUD'2]C"
M%I8)1Q`!/986L,8VEJZ.C2S3H.6",3"A()C%K$$!&U3!&O:SH`VM4E4`@@,P
M5K*2A2QJ5VL"*F0@L_0,*&=KZEG1VO:VN&5I!Y"`P]6N5K6^7>T%J.#7D_]:
ME:.Y3:YRERO2`3S@M,%%+7"CBUH/R$!X!)UM2HOP@@]X][O@#:]XQTO>\IKW
MO.A-KWK7R][VNO>]\(VO?.=+W_K:][[XS:]^\4N^F#)!"I6CKF^G*V#4-F`"
MQMRG=C=:A&D4^,$0CK"$)TSA"EOXPAC.L(8WS.$.>_C#(`ZQA:/ITC?@X'P8
M)G"%;3`!7OYSP0MML(AG3.,:V_C&.,ZQCG?,XQY/F,0L50#`-*QB"Q,`#[$M
M)XSQ*6,?._G)4(ZRE*=,Y2KK&,@EU<&0-USD"W_`7/U<<CX=;.4RF_G,:$ZS
MFM=\82R+U`(\^'"7+^R!`X1!L^04\S*;S.8^^_G_SX`.M*`[[&:04F'+'9YS
MBJF`)"4?=UY\'K2D)TWI2EO:RH7&Z!N`(&)%9]@$3AJGGAE*YDN;^M2H3K6J
M?SQ2.>BKTP*A,0$@@=DUV+K1U1PU%B.]ZE[[^M?`%G2F*RJ%N,W8TQKN3:UO
M?4U=<[34P8ZVM*=-;1X/6Z)K8*"L8VUC4-_:ULU^M!:A7>UR5]>QQI9P`\:V
MX0^@^,80T!9U"2#O"KM;LA=`-(45!UT.?Z#?_)ZR^S!\;8@&P`0W1C:'94"$
M6Y]RJ>*V*;G-37'Y:&-?9U!!G%G8[]52@0G>:.PP7[W:`O16LA6X!H[U(6`<
M73CEDJ4"%3#LM0!W>!.1_]4$NQO[H!Y/B^04+KA#L;#S&BO<WPT'MS6=#>F)
M5[S:(2!%P$X`-Q7$-0Q`#VX$]I#S!/HV8KY->;IK/%<!V_7EY)8YS7$%8@*,
M?5]>;^P?'M!C303@?A46^D&[F^.C<Q@"8=#`%Z92D$HR?=Q/?[H,5`"*@$T`
M;CP[P<8C^P$0!``+"-`6%3H0`50T5CN-81H55!``#&C+%D106?8R((<X+$WL
MCH4``K`0@!EHZ[H=T&;<`'"&$KRA"0;HZQ'T58`2,#H!)CC#&A*@+0.@XD8#
MF,-./J"`.0B`9@?P_`$2H`%M!JSX>-"`#L9V"`M8@`JO?\$)`G"%,!EKYL>S
M`/\1,)!UZ`R`"OHZP0"NH(#SU5QN#$`$&>`.?F!_^.=83X`'Z]=^`6,".N`%
M"<!U@T%W!$`%`9`!DU-TYG(%1\`T$Q`!;R!D-N8*3+`";_=@>E=0?-=WW)9C
M<P,&L(5GCW1X7\%KB3=M'X`%)B`9*'0$&#`!,@!_DH4'P"<#"6`I-H`%+6!S
M0#`B%%,""2`#!B`;'@`G<?!<'&(`!^!]L-=8$Y`!4G@"_\9X#:`H"-<"&@`$
M0=`!*G``>Z`"6W,"3$`"#Z`"1!`"!Q``8<*##T`$+-`0?@``*F,7?E`U<O,&
M%6`*;T`S<@@$#^`6`?,$OH`%O5(!:[`"XM$!8Z-V!A#_``_``@+`%XX5`0?`
M`@40-P>P%C,@`$S#=@E`!2Q@`AW``A]`BJ8X=I:(B5XT-@U@`FLS$=00!/)!
M!'8A,D4W"")P/Q,P!\7H:C4F/!V``QTG8"DX4!E0;SCF=QUV`3&@`=ZX!IEE
M>!$G<3=8;@1@`3O!@R('>#:`!&%P<EXC;Y2R-%X@C(ZE<W#';FEQ/F#7/P8`
M`#QP!C,@'RH7,)I@<R3@'`&#`P/9`@D0,&?`"MTQ<R<@D2!0`@$S!DB`/]J@
M0PC`;FL8`O)FB``@&`&S`JA0D0'C`@YF`"'``R_`%Q50+`'#!@.I=DU0`NNV
M$D`W!SI0/35#`D\@`AW0BD$Q_S/KIDT$X)-`Z5@SV5@VN2\F``"_0'?U2#0N
M4#-Q%S!S%S!O@'#]HP%T1V--)!=91XT5A078F(TMJ&,0`@9?\`7@"([B.(Y"
MY73EZ&N3,P#[=R#U-@<-X`)@$P#IEA;&MA#:4H]=-S9I,63_UX\%0`12R`:[
MT(5R\P>(YAN-Y0)'X`$MX&!(L`OOYP<G()IJ%PL;J8XL4"8J=P!ST`%A8H@N
M\)"1*!BE&3`PMP)8\`#!MY$5H`.-)06LJ'9SD`&NXBI`1P`XP`0J\`$-T`%/
MT``R891PXA>NTBO*R9S8^)O!R8H9H),/\`96&000,`<%8)!;R0MT)PQXUPI@
M.6,I(O](18>6$\4$^L:6:^F".P"7<EEXD$2#Y)B7TT8`@K`VN&)L%1`F.$`Q
M3`!=87!"?H`#-*F8]\AV?A`!#W$\-L(+[H<!4A`P(%"9!1DP<]"!WP`X70D!
M#/B9`1.:`:-VMSF:J,F1^Z(MFD"+`0,`>F*(BW,^!!`!<2B:,/<"[J<#OCF+
M@*,!<:9V!9`!^D)OE-<_&6`"(1!R*V&4'L`$3Q`P]^,!)3.E3HFD%Z"D:3$V
MHS">?G`FNY>>\Q`P.H`!2[,2^?EA'H!K<+2E*$A1?\-CVOAA+,`%_$F7_VF7
M=VEAS(%W?.,"`68`O4)Y!?"HD#HV..!@(9(P'W"")0>I)'#_GP)F`TUP`M6F
MCOBC<@9PA.[76-TP`&'P`NQ&H8Z5`"JPD2P0!A8P`!&`=R*P!G(P$!+"#R(Z
M=A<P!W(P`')P/@7@!3J`!9[C!RSJ!RXZFC%ZF@J0FMI@9Q@@`&S0&VX1!K%Y
M<2L0``G@!4)$FD(Z#4`0`#C@6KYI`3J@`P'P(:/9$G(P!D3PGOLR!VR`!Q;P
M`1>`H0B`-$;)"!'0!`D`3"R`K_JZG>R:K/!Z!`DP`8Z!IL$:`3&9GC.`!=/P
M`3IP!;"ZIQ-F`P4:LB(;LA^424-38-7X3^?I8WWZ828`J/U9EX1Z57@Y;^33
M`BLY`"40`4\Z`)/76)0B$N=)/@&S_R4;<P9><'+!)1(JT)X/-@BB.:`!9C&-
MQ0(PDEH80W(-<)8$(`-#%DP'4&\0((4<9`!`P`(7L#'WEG,84V\L``1-N;9I
M6S,`\P$XE&\!@[;[4CD78`*FU3\-<;4$VEB]&+<XM+8&8`(LH+?N%DS/1;<!
M8UU`,)_[\@`F(&\7`+<?L#<?43-9:Y"6NY8IY[B,!;:1HR];:Y"I&#G]UK4H
MUB,FP*D0UE^5]#ST"5'9ZF0M^V$3$`!@`([^^4<`"A8U&US;@[-^P`2FE0!A
MH@`(@%J4,@-KL1;:0K2TXSX$``^;&C"1(P-SZC<RT`(=L*%R(X70Y0$-\(FH
MBB$"VKZI!O]S:$:[E30`2HM:*<M/1#"-+#BG.O8?7/`%&F!K268OPUNH$\8Z
M08*\88``22@#!1`&TT@IH!I9UCL`W4-,T]``CC3!CL42;OH'-G`>B:`!$I"W
M);L;^@*U[KO"IL9!:2:_E?0&(1!=]UM/&E"_.[:[<N8$`1"7`2RH"36S6F&#
M`D:4+K`0R`N*<B`"-A``%X"IE.(%33#%P.$'%=P]$.*$?A`&M_H!;,"FJN,!
M04,CE:*%5S`16E(8#3`Y#ZG"+/S&<*QA,%Q*]>%;-5Q.I^I8+.`%7A`!,R"[
M",C'?(R-SD<$1\"_Z#FG3=+')#-O2)L!G$9A+PL&E"R7=DI%!=S_3,6+6@>P
M!L\S"-/#O:GR`GCX*OI&*:C!E_!WQ=6;0)J0`$$0!,TSPQVL1$T@,\5F+J]6
M-CRP.";J`4E!H.P;Q\1<S+-+30%@CZMUQ^,T!F>90W]``M-2,`J10@=0`=+1
M6)L;?!#L6""`!S:SLK_5EHWE-04@`PYT`=')`A!PS=D<,"$P`#90`5A@80S`
M!5S@NS$;Q$+,!T0<70]'9AX@!9@!G25@DD`K))+%RE:<0&E!!%,\Q8TJ=XXS
M``)PGAY`-\9&*2%`*992DP+AQG!<=I*EOZOE(CS&/B!&TJ>FTDXVQX^4`>^V
MS`^%P]`,,`B``9)!!"0@`BU$!,BKS1;:_U@I)P.D&%Q%]G]Y<`0#PP0/$`=7
M@&`<W`"0S)"&:@%;D,]@H`'!2\#][,^;+%G0Y"K]LB"-!0!=`B?"/':4$@>I
MDBI+P]#DPVX!@'5,<Y8>[%@RD940T"_$D`$:`#"#H`+?,,QO/`AQXP48C1LG
M0"G/'%D%X'E`&]%4@,C"%=%3;',?T)Y-D,<+=PNL%=$(`,B_]00`$KET,0=C
MZ5@F0-F]=:S2U921I0`4&;7&*]L=!M-_-`./[5C,'$[B+%D+X9,&(1GYA@44
M(P/U[%C\@'(!H`-BB=3DS+V.TR\/H`^7V@'WLQ"OIL$O$`%G<&$`L`59O=5=
M_2Z9/,1A[5M(3/^X3=L_;T`%8P"<CA6TEQ`F#!T'K]"!)O`'6-!7;]!O>?U8
MD!)($)HQ,@-#A6W;+(S8.=1\`F%75QM=D1U9`_.H8X`H$$8`L1P$,C'30;`(
M`=/9($8IF'H\1/"H1_`&3DM=O]F5'C`'%F`"DT/+/)?B!2`R5>R<J#4(TZBW
M,1I=W`UBNOU&)GB[!84%)P[-%7"V-%J+PF@"QD.XF$EYA,.L`SE@T]V*+>#D
M0>`4'K!IA?UJ,X"S:6'9U`4!2+`#6BV7_"S$_UQ@A]I80+"G!^8"_;84";KG
M%$,"[O<$`*`O$"`"<0"6!N`"5+`:*%<!)\@A<7`"'LL"B%X!0\8<D1S_;#8`
M`D<``$`0)C*0E;13Q_*$`2NP-`[N`C)``'0#`I>+?OMR`J'(;A<@G!.@?Q8N
MXGY@`14``2Y@`BV`<"R```+PD;Z%![3)O7U%!4,[`02]Z\?S!";PO`2P`F.@
M`"5,._`W7'%C`"4@`"O@YXPP#PH`SI#M>>>!D;V^`CA[`1,@`"70XG'3E3(`
MC/(1X(Y5X1RC%M]0QSR`!U3`:2)3`EDI`7L0`B<D`25<D28P!AB`=Q4`E@7P
M!++7.5L#`050[0"`/95=`G!5``HP`92+6G;UUB1?\F]]PHEP<'EZ4*MM8%6>
M[_!,6BJ`ITPS`UG.+J@-&Y0X",^<U$,=XM]W_P661_,'$`'&?@TX3V$&``7X
MW,.7G$Q?'>?&+&FU.`,D0`52?#R>)P,B?@()>@4?ZN`#\#,N@>K<#3M'<``X
M<`5+(P!S`$2I=^N-!2;9RZY!42=!@!Z<NA!%=PC[P6E-$`$5,`%K$&<*$'UA
M,@,)$`(5`#XT6M@N`AL/X"G30"D@4``<6^Z16P(8.0`6\/;EJ0`\T&(VQY5T
M)P+<H94GA^\CO@M`3P!K()3`80DML*54(`?>!Z-8,`,\0`7(;<7(.ZV##A!;
M>@)>$`)-"JHIP@:P$L^3;Z\9]@PB80&E3\,')=F_19[:;(^*`P`3+I5#)@7B
MW,X`4#T$@`736&0></\0V@R6W=_B+HDJ?B#^%>8!2)#5_PN\`RP2Z0T(?'Q%
M37Z&AXB)BHN,C8Z/D)&2DY25EI>&3RJ'`X4%`X8R7H80#0U/3'X&?QY^`P5^
M,JQ^#7\$M00>$&\'#4P-AE*@B$$!03PE'2P$`PF&*R^&'G@@BAX@`HI!HX9-
M$X8")WX*?Q=^%^6&)'\0#W^&JQX`<H<3A;($L;:(!1%!07@TR'#ES`\T"(:H
M*?KSP`^20H8(_#'`;YBA$W/\;//SX0\)A*K8&:*"!205*GY.T#,T!H>?)BT,
M*4!":Q\Z%H;<04"WPE`%.09:86K$XH]1HW,^5")WM*G3IU"C2IWZY\!02!#_
M$(!4)*/G(HE*KR[*NO72!2@[MH#YLJ:#6ZI_=@B:2[>NW;MW"8G=R[>OW[^`
M'570<>B$IV&B_-C0((($GG?Q7,&2U0J7NQ>87P`($2:?GT^)@FA``J*`4F85
M#"&H]BQ;(A-KS(7F]C+U.'$*V(02>>[/!W?P6`&P4._>+%S\F"!!4D#V`-NK
M#ZUPC8CA9RR':H4U!%I:!)0;_1P(TR%.2)-X#IU,J:#>C)<QQ]%$O@HDN@_H
MA$(`P.2-"<`N-'6"4)0P!=>!",+U7F![@<4@7PY`4087:ZW15@=4R877AAS:
MI=>#((8HXHA#'<"$.1\04<@36"AUPBA4N,8#9+.\_Z)/9;9T1)$?.'WP!@E^
M>#"&18:$=P@SL/@1@A?Y?/"""XHD@)(VV+72A&T*X$:3'P1H\)\'.(3A@2Q*
M%<`*!!F4<$`%$1B'HV?<$6F(C7X`X04P$+P07W4-L=`!#WY`,(.<!8CIP0=2
M!)#/1A[D@L\J8:TW$DHGJ&`.`6'TI$`"$$!@P7RV-,H$`$$60(0'Z!P)@0<%
M:("J#7W-8106@%YB8(*XYFI40R16XF"OE7PP1`T[4/@%6V])I6&'S&[X(;#0
M1BOM7Q`(<,4$8R10"`M>A`&"#J,\\`8``.A`8RLV4E93/A5@(0("8OJ!`!8X
M#"JGD1'128``84PP1Q-P&O]B0@`[)F+`&V>(4)M,6DKG!14E_,(E$P/@D<`L
M!N`A0`5Q'''CNA4I0J<'&&0P`;_;'6*='RZ\@4<31.#$SQM--'%%&%9I-$H#
M+U0@Q:D?M"F%'Y(236D$<_@[@#D/=##&#!'01,`;`MRAT1L0$Q%$;X>T,$,!
M,Z2'A)R8>*#!'W+P:JNN;">805F5--`"`D`D<@`.!1`(P1XX4$1`!3@`R<BO
M7$V`PT"(2!#'$X@0\$0<.!&P`@Y;BY6'%4ZHM98&R4:U;+.@T_7LM*27;CHD
M'H0@P@4M0'2!"$]\P+@?#X@`Q`>PX-X*#\#HSF7>ALA=P%8/M"!#`[4><L'L
MAWC_P#LB3YQ@`H&'F*"V(@U48(X)P(A'T0'7-^!"!5M]8+OO++1"0-(<`4\`
M\-DE?\CSA\C0`@#4'V+:(0:(,#SV!0A@P<XQ._&Y`"0LJ`!%9("X6`S$``<@
MP/B()X(&@,\0%ZA`]SXP/MF\KWD':`'P'B"_H:`C`2FSQ*W:QD*HU*UL*L!#
M!9C00`)@H0`94!L!=*"!K37C!$RPC2((AX@+,`$'+NB`;&)QA1"D`X,"8(@'
MKG"$"71`<$.1P1`D9"S.84A9H0OC7$9WNC*:T8RM.Z,:44<>+W1`!RE<HQQ[
M]0`DY$^%+<SC4SH`-TH8``OF&(,X2*$"'F`!5HCP0A"0_W.`-=R12[Y91`4X
MY0<Y),\`88!-P/S`$%D@A$5[H4`-G,"%`""K<T_YG!B;1<8YNO*5?L$/+&?Y
M@0;$<9:XC"5?5JC'%K*F;%>H6`=^>8``_"$$)%BB'Q0)')`-,9**\)$.9O`'
M4ADB!&[)7L`8$I[(7(4'44##%HQUH2^F<I5A;&4NU\G.=KKSG?`T'2][V39E
M7N(#)"#!%:RYS`!&(`#*5*0-(FD")CR2B(A@P1-X\`9>04`#>Y""!;"PS0<8
MH`/Y",$FQ/(!(PRA#<4"@Q?-Z115HI-#ZHRG2E?*TI:Z=*7SI&>NKK`7$0"@
M`K$YA`6H0((.O"%EBO2`'&80`O\+0.DKT$R$!Z00`B!ZQ@-,$.$?(E!1"'BA
M!"$@`C^O(H0EC'(+IKR0YTX*NI2^]*QH3:M:U_J@F,HT04,3"P#&H(`&*@8#
M"C"!"Q!I"!`,!`)4.((0GWE+#[C@"!A0Y@,4@`$94"%E"@`&`4IPA*U>109&
ML$(-VJ`6+XZ5K,PR*UM'2]K2FI:M;GWK@>PI1X3.D0!)&((5T!)6DC;%I*#U
M$$1.R]O>^O:WZTRM:J="MM8F%98PB,*P)H2LS^;66;L%KG2G2]WJBDBXPXU*
M7&'IVCGRH`I+0`-G1>H6V\;EN2B-KG77R][VNK<1V,WN4RI'"0($X9&1((`!
M$&*#L!#_8)-'.BXC'L!:27B`!>8HA5!L@-]%?,`'1D`!;350SI*B%[KOS;"&
M-SS=^,KW*`"UA#<K<0"C-*``("#"!PA@`?QV-Q%TLH0*_D`%#ZA@`D-[0I(F
M480J1&&4%!JIA2^<%_5R^,A(3C)+/?SA/XRAP8EX0`+88-$_G"`!0`)``A*0
MF@J(H`2_J9G:(%"4!N#@`B!H`!7X2MA%>*`$"4"`*S"@`P7L9%`*P$\33"`"
M`DAA#C56'AX>.P`/G.$"+X#R(LS@@R6@@%BUQ9`Y<4MDT2KYTIC.M!F9_.$]
M00(++3`!"U81`A!@QP`R6,<'J("U"[PA"!((P%8DT@`;@&`"_P`H0"X&)^!K
MXJQN`Q@#$#IP``@<P``"R$,MY&"">O$L!(A8CPM``(0QK+@2/.AQ%&;;60N5
M%T,:@(*XQTWN<IO[W.8&JP+6S>YVN_O=\(ZWO.=-[WK;^][XSK>^]\WO?OO[
MWP`/N,`'3O""&_S@!<="DQ&$14A(0054&#4K@+,'$$CA#VHFS"IP_`>901(8
MAU(`"4C#ZUNRP`(O@+:-M':!"2#@""^H!45>T(03Z,!CZIF284=^!KM"P@U"
M:/06=V!*"E=XX4A/NM*7SO2F._WI4(^ZU*<N]0$^8AEABX=.,`X!C*_G)@1@
M<(!!+H</8,`#*$3J+0GP&]_82)$XJ/]&`6*^#P7@@,QED90,<,"",1!`SI,@
M``P@_.,RF/(+%"XOU1?/^,8[_O&0C[SD)Q]Y`#,"[0%@`@FT_HX76(`!7I]2
M!=X0@/2,W0]X&,@>7E"0-BO"!*0O]-N#``0FZ$``=,_'!>:`!0TH<SU.6I4%
M<%8)&BP@"4N8+3G;8B'*.__YT(^^]*=/_>JSL`.*3@0!$-*H(.7C4(W2Q:P!
MO&LX[5KMC(#`!UJQJD"I+Q>K@M.AX-8I]TO#\H_00M`=70.UG+(#:V!]`CB`
M!%B`!GB`")@@K3=++S9'$C!X'D4L%%).`9B`%GB!&)B!&KB!\F4>N=2`<O0`
M*:!M5M`&Y*3_>!R8@BJX@BS8@@6X8PS8:Z_D!C2P?ULT3O_G@CJX@SS8@SZ(
M="^$2R"X1F[`!Q#X8R'E63^XA$S8A$[XA-?#73+H2BQ@A-I6`V706:CTA%S8
MA5[XA05H=:\TA&IT`3>0`@O@8UC8;5L(AF[XAG`8AU`GAJY$AF?T`3=``X.7
M?*1D="0E`%[P!Q8012R$!QC0=/WR!Q-@3$#0``H'%7C0`!>3($"0(#MU%%*P
M!X0X!T]`!$9QB$=A`0$40`.0*R]``@4P8VR#!P'T$SX8`H^81[!(%7(`BG^`
M!=3T85?0BA9`%5C@1%"QBZ-X<7K0%#.0BWJ4`6:2(&.``')X(-TC_X13.$<?
MH`5ZV&C*AWAM<10XTP\*T`(MU`(G<"`F(%--(`%_<`1O,`<RP`3F910#<S94
M\8U&T1$'$@`R$`1&$4)C8`*/(0$Z4`LNUQ0BQVZ>*!5!<"M'@&Q4,(X*0`54
M,5!-$00NP%@V(`?45W.]U`"!R$*R@'$=*14M\D4`@(Q1,0#NT#9-L`<*4`(/
M("M2<2=1$0#K)@.;\@<2:10#4(J]-`"KD"!4L(QYY)-+B`5><)1(F91*N91,
MV91.^91+Z8DJ`)546956295&H`5&"&$W6"'F%`8/4`!70(\GX`(2@%-'T0$K
M\`1/$`&**``EI@`\$`+1DXY/(`%-\`<%@/\'$G`%1C$!%R`!3'!#$A`"QG04
M(A<""'`&?W!Q>AD`8<"6HW>.C1D`0!"85)"+)^"6?Y!8$A`&<A`"9QF`4H`#
M3W`4QX..'U`!/#`!;=$".A:+?]`!0'`$^A@!Y?@'1(`.$J`,SR&/1D&/1^$%
M=UD!'8`%`/`$+7`B,C`!1X$#P&@4,F``X"@%"Q5%>RD!($``$D"(?Y"01A$"
M430#$L`#AR@'+@``/#`&C_D'<\"8%?`$QND4(F`41X`''8`#$D`">2D"?BD'
M]6D4<K`"R(0!(0`$Y!`@?R``$!F?!4!LV<,$1[$"!4`"+;`&`/J7?Q`'>``$
M<V`!^^F<XE.8;Z#_EVSIB5)0F#,&FP!PF'_0`A^`CB,:`B6*`6S)D_N8EQK@
M(U@0GR3P3R%0`#R``!T``#%*!`JP4(_Q!O$Y/G_`I/)9@7^@D7_`!@7`!'19
M`"4Z!B1@GC(I!\L)%?IH%"RP`CQP<6'3`04@GTUA`:*Y`E3S!"0``AW`H,B$
MHP.0/1*@H"#P!"'P`DW!I9MA)DT@IQ<W!P4```AZB\DY`25J%`D@`1(@`FO0
M9Q)PD#Q8``^PJ9S:J9[ZJ:`:JJ(ZJI]:B4]`JJB:JJJ*JB:@E2,8@?['.4T!
MB']`CP9P,0;`!D>Q!\XY!Q=U`#*@`0(QFS9P`AG@)QK@#@WP`+*9FP9`_TT+
M>11,8`.]1YW?:6)>((]`\#+HN`V4&0:U@`65>!1C:@.R(@4`T''IBIC@R`IN
M*0-LP(I_@`>Y:10B,([ZV(Q'T1$3\``@\`!A$`8$^0`G<`(0^19_N@+.Z9?@
M>11$T``&\#.U"I%_<#9,4&++JG`Y:12T5P$`<`%O))$R,`--\`$=$`;HP)&U
MV@)CD*XX>A0\(+`RH`,@4(Y,<%$/4(I-D))3:K)X\`&<,S4?&9064`MN2:5'
M00`,BP`["X]_(`$V8`$:8`.>B`085P)_L`(54+%.5HD'T`%$T`$B$"!XH*#2
M:6)8J[588``:$`'H<!094(EGL+5<JP,%X`40H/]PMXJ21B&/#V`RSEEHWPD"
M?X`#CCFEXZ@!)<FU%8`'.B`+Y7$G`=``&"FF1P$!<K`&'X`%)S!)[L"9%7L`
MI3@!O;<K+T`%LC`#'_D'`^`I>ND"&?"U<I"3+?(&3!"6&L`M53$#"H`./Z4!
M'OH'3X`#1R&/,C`D/^F#T1B#M^1*U7B&5TATQ_*.]#BF!4"QY5"!F/0`QB1#
M]GH"(/`!!F``'=$`+_L'N5D4]7@4.M"NU8NM8S!J'V`8W>H%E.D15_`$CT&N
M?Z`"T=D1JQN<[6J/UUL`$&L`ZOL')2`*7C`PX;"O1_$$"6`"`-"NM0H`.XF1
M"6`#!G`!"D`P#7`$W\G_2TQ`!:OPD'^P!IMG``-EOD:QL8/K!;N(`"N0!T:!
M``5PORD;B/1X`"Q@BT<A``\PK"3PJ!5P!CD[I3Q+F0.0FQPYM&82!!=P<4AK
M%./Z!CS0M.C[M-3TN$VAL@H0!&\POJ:@EQ?PH"Q,QDWQD6`<!&-P`>-+`*KX
MPA9@`!*:0^,K"K4PPGS[!RX`L1^PLU\D"W!L`!![%`!S`39`O."*P">P`A;L
M!1>P:@AY%!*9LYU+;!>`O3I0KXT)L03PD.0@DSKYD[XZ`:-F`!(1G`H:E.UK
M%+L8QM@*`>.K4$>!!_)+!43Y@W3X6M,H1\]K?$D03B:X%M0+CM:+O3*0ETKD
M_Q]&X07C:@(V]Y%GH[)-D;Y^V2+#66)^#([<_`$-C"$50+_?:;_HR+H/L!@3
M.9LL4*)AL`ICRJ[KJY=4,`'[*Z%&,085L,\L@`=OT,Y_H`,I.0,3,`,M<`6K
M*YQ&842-R11$,%`-:Q0O((_EB,+]N(\@^<).T;!A4`$EL`['A`,ZC'$"BP/M
M&@`VD`%/<0`B<(@NX)SHBP4'8"YXL,3HV,38:@(SYC]]RP-'4,4X><.3]).K
M@)?]^[82VL92\!ARL,=K,#<D@+5<BYK86JM!$)E&@<]'D0<F\)$%0+SX2,H)
MR;=-O2M-0`5!T`%X(!&W.IOF5,4R<#%9\M%9S22S"_^HEJO1##$`G6L4_J'2
M_<O-7H`%ZGL`HOP'I,RZ]E@"6:R@C_H'[VP4`:0"0XL#L@R2OE"QP)F;>Z#+
MR=N#/C>&O[Q&=*`$>7A\R5?,7_".1W!QP+@"4HTVL%9M?U",1F&F(6`"<>#'
M)"`!*_`',H"I^Q@"3"``)B`!)F`N1U$`0!`"00"."P4`+$`$<>#;#Q`'"9"N
M697=1]$`,'T4P%BS$@`$?AF=1E&T3B21L&V9"Q7;31'>QPT$"G<%/:4!A;F_
MZ7BXA>O;!W`$($`"=ZG`UQW$!["?`6(!S:D":U(![A#<1L&:>1F>#R"I!R`'
MBIM/,\3=&/<'_WJ@4M`$``[_&Q+@WD<P-;?8VR30JS(@I^/Z!]P=!K8=W`(@
M`[F]`AG``POU!D1@`"Z@U39PER:0K4#``P`@"UIF%"5@`GX*W)YX!"%P!290
M`070CA+P!"9P!0$`X#S@G1-QF@[NY'H)X'3;%"R@W$<0Y15@`D3PD2%P!),;
M`A'``P6P`K>:GT]`!;40!D'P!,$+J;M]%"#``RM``G&@`2[0VRNPYJS+`RJP
MQ^]-U7\`!&$0!RT0!CA^SI]X`'Q.!"$``'1^!)2EFZL+KFP9!)YXEV?9%`40
M!`?ZV[8SWDP`YDP^!R80`CPPB586`A4@`R5`,)WH@SDCC<T[1Z5]VLA7@L;R
MCH,Y_U5&000N^@<!H`.J"+H=,``3]8AA,`<8D@&V100)@"$J(.U/`9KT^`8Z
M@`7<SKH#@`58H.-3Y5.>Z`4"8`,A:12@&P$Z\*B@>Q1R4(J5Z^RSF0!^"16@
M>P4)((\!H(I$(+#2*INL&P:9]P<&_T5S,/!]FP`#\$5AT(NV%P!NF>X5JP,N
M&@$[&092.@<9_Z0'V8MH,P#+'NYG4P"XG@`3,.8=D``L_P<9,`<!8/'NWK9&
MD>XHAP6>:'N/*`?D0:Y8P$-]>^YN202/;?!GD^Y,X)81</`JS00OP)E,D`#[
MKIN`2O6<&0;G*Z!-@>\=<`4=`-@1(*$1\`(=H`'2'@%OD/\`)R``4O"16)``
MPOT&#B\'<^#WLYGMLPG85\`$#'_V<`O+&H`%,Q;MSZZ;3/]&$=#V$;_VQ9L!
MD'\4`Y#X1S$'FK_RW_X'51_T&++TLMD!+Q`&`+_T[\B"S,.\[,0"IBW,Q)SL
MT#<`NJHK<T`"ROV,JG4"0LETV*N">4`"XPC\;^@5PLY./U#[QW?[QJS\U%_]
MUG_]4Z$;'SC::N0&M2\$R"=>N(_]Y%_^YN^&`>`($/!?V7<D<01^2O4!(*%^
MC="`ZW]^^042\-\74P`(2EHT0DE+:&U<8%\=?XX:%HX5CI25E0*.8WB6G)V6
M'2&3GJ.<>G\(D:2C&42JJJ*NL:[_81.R5U>N8PB<%EZRE"T)G$V_Q<;'R,G*
MR\S-SL_0T=+)'1!^U]C7'E0#`PH-V>'8'B$#5U+6UQ`380H$V#9X&09^!D=7
M)>_B!'\?XM@%NC4Q\2_<!RIR@/BQ,28"G@L%(T9,(XB/$!^'$BUJY,A+`4<R
M8GUPA,77LAD?F]GX4^!%L@I(ELF9-JJ)!%DM3KBBDK)2`2K&@BC@-)*FT:-(
MDRI=RK0IT@XL"GIH$N>"@@00@ER@QR+$@71^9*PQ`.%*$&PR(OBY(@,;`1Q,
M9'A0T>)#&#S_^/DK>*+)A0H:/)BX\``"`1Y[]OHA,$F"GSE4""3`X$&BY7$Y
M!!'"B$@1_R-*,@BPF",#P-9&+B[8T$$)A(<+($JL^&-`Q@<0!CX\^;/F`0NQ
ME4Q?F/&'!0$#E`+(^!T@C($&'T3\`1#GPY$P%R[P<+2R99@G-CX(""_E#Y,&
MVO^<.0`=0[\/(2D))QYBQ84!CEH`_<.#B(D_+[!`V!KR"1,&$'\\40$+++1R
MQ`4L/&$*"R[(P(2`#>"7`(0%W`2"@)M00D)V>?1#0'Q_>,$@"QE0PM,?0&1W
MQA\$$/`?'@P2=X!]E'1@F@$/*.`%A#*\D<=K<:QQ`&%O..7DDU!&*>643W;P
M@%1-5."'"5>,A`4.)JR!0`9'8'.`!N^\(`(V'T2`00#Z7/.!%_\R-$"C'W;&
MZ58_$9V@@!\>].,%$184>00#`2CFQQ\2L!"8'RQT`,YEEA&0F186862%$YX1
MV%%*,K"V@@AS`-`!%BQ44M2+!&#QA@=>=,`E"6/\@0$L(+CP1P`-!(`$+'^$
M0`P#%0SP`8$A2?``%@&PP,0?4NSQ1W<O#"!6`@2L@<4#?S30H@@*(!$FG'_`
M5$FNN_8:Q`.M.&+!2BC]$1]JQ#DB`3$#<,L"<7*DY>@?)W!+0`N--(('"1I\
M$$`'%4C`A`EOK,&""CV:EVI.EFCP1P(`N/B1QEA<P!)0&33000`K&?!$`)0@
ML!L35OW1"`(?%76">V?\1^7.//?L\\__4C*,908*!'#"2#QXH,`)?D#`A`WJ
M8+`&$QJX@`T.6,"(05MRTAF2-2(K>HU>?6*A0`1E>D%9`7-<,X,4V3!J`!9C
MTT:I971<NMD2*$"QA2)K<.012([P%(<)%51P@*J%?[12/XZT]%<%!81`20$M
M_B%"`K]6\D#B%:PP`')__"?!4`G$5_*T+%4[B1=VEDYCX@!(T3GDYEZ>^>9!
M@&`)"?.$(>\?5#RQ`A#[,8HOMR9HW$_JCBBP.`$:SP%$!20<$$9\`D@P@P&)
MFR`\;SP4L,)(&%,R4.A!>/QPXB/]],<8X%<`1``&L'8Y,3`JT`0/]FM?41!'
M.<L![8`(3*`"_Q<XB@Z4`$M'*,`#/#`2?^`!!'[X`,S8Q*`(G.4:`>"!##2@
M@CC-*316\L,),E"9<)"-+Q8H`!#>X04>^.$)+/2#`-:$#49!(``'\$,%PJ"G
MNXGC!WHKQ!(VQ84`@"%PCB#";H9'/+:%H`,=T)\CCE5%UD&N=;3Z@PHBX"+I
MQ$4%MW,$`(X@1@N,SA&F(X8*;,`R*I"`=2T9P.MB]Y\&S"0#3+C=2%90HC*:
M1P8J$(HE=&`"G87$`,)S0?(JX#L\<,L&0\F`A0Q`A2,`87%%$0$F\'``)BB,
M81+`@@E8)@".9.!E(SE!"RI1@4TDH'V->P&WL!"_75C``(%CC0'P0_\)''3L
M0@H8XBD$J+$3;$(%8>A`*AA(S6I:\YI/D4,1M9$E-O'I`0'`P0`>.+8Q8*`)
M<XC3&%Z`@`A@85(9I),?$("/-W#-A7SBRY^PX86S?$`.,\!#&!3%*#^X``L@
M8((-C1B1*63F!C18@"&8N`A/.8(%VM.9;*8C`_!5@@0RF,%&XY.J/XCN#4!J
MP/C@V%$<J&>6E(B``=C3A#`L[@^F`(`P_B``%CS@IB$171AF283XF"("#7A`
M`[!P!IBF:@P7,`4E3-#28+'1$BS`A.P0\```F*`$E%#!!61P``0=X`F^F8D&
M"@``$+2OI`-H@.)N@@<;R$`"'9M`;73F"`/_A(`$*WF7`?^@`_`]8;"RZ8`!
M``#8/S3!!A\Y06TZIKU*=.``,I#!`XY06`E:[@D&P(,]'V``-A"!=-A,K6I7
MR]H&=N">V1`,/"%0@'0P)HC9^$`%0M!"=?"`MP;H+02>L!<95$!L>T(N-F::
MC2=`!%````!8KE&`J-2C`L]EZ#\\D(8<:`&B$HV"%33RF=::%Y>@,9\!M&K>
M]KKWO?!=+197H-WZVA>?RKVO?B^3A>Y^-P5%J$(4T%`&)VJ`(_&]IA8=P00%
MX`$7"8ZPA"=,X:9@40#[S?#=7JCA#D?D!Q3Y;X"C4(,"?\&B%4ZQBE?,XA9'
M&(M,F*Z'9[R8?-+X_\8>F$*(;P!@`9>XHBX.LI"'3.0B1PF+TZFO`5[06X82
MX``B^`!CKN2'&>;%QA)Y`!OJ*]>V?.X=!"`!0R&@XXK`8,0UV$)%$6SD-KOY
MS7".LV4;@>&[0:`R7P,+!-+A@3ZK8[H\\$4#/J0#&QA@!@7A\#_N[(<@>*%I
MV-BS-OI<&0]8PP-,>,."QH,'#T"5H71PJ&9@X`,C#"'-:Y:SJE?-ZE;'%\G5
MH!10-$#5/\P$;BYUK!^HH`-34@&+5L.&R!J`@`/,X0%,3C26PR&=UP:!"9%8
MTVS^@&@%L"$##Q!!(UIPC2S=YP$("$$!&.J!'X@:HJ0VM=]2[>IVN_O=\/_F
M&9)90BDLN""X(;$!8#((I#]<@`H!:.05&F"`#L1IV`20(`)D8`+E*CH;$-#!
M"1J0E3=\``=S,$QMWD"`H>SA`1VP@0U*Z(=N/D#A26VR1+*@8^_R6(E6@`(7
MOJ`!*,;[YCC/N<Z;,>\K4(H'"<!V2#S`+0]@@`VU:``5,"!$(B```7X1=K>N
M08(*2&$%.I!QC?/KAP/H(`(R<+0?`O(!/(SA!&^PB@["TH$XQ.$(4.LFH)IP
M@`10`;>7";5_^0"#!0@8#9RJN<UW3OC"&[[P\Y;499[``BEL[0]$[\=YADT%
M*D"*"`?P:3:&G<$$S`4"Z=S'LL<!!!8\7>P!"<G_!S1H%21DT$J_Z;:6=IU9
M!.B;4N4N,Z;.7(53E^&):QC\X8=/_.++.?%CL(P']L`&*GS`!DCP`/3'?@0`
M($$W3[B&`9#`!MA^X/H>B,,[LDH0T><W*PP`P0<,$`<_/*`%PTW`$Q#P`;9>
MX]]LH/(*@F@#``#*!7BP3?]`!B"61*6&`C6P`T^$16QF?`[X@!"88HFG>#?6
M80]7@?KE`750@/\E44OD-P%0<PQ("4S@*4S`9F3D"1JP4]3@!2[8+G]@`5E3
M"1K@@BRS*Y50@M%`3*H0`"[H/-/`"LF1@RCF"#RX#!W@@C;(!"QH%"K0))80
M`4#(0'/@.Q1&#(`D#?C!_P29XPG\0Q(_Z`IGL&#'0(:[$@93F!0S:`R0``T3
M@($:=H%P6%]94`>BMGLCA@A;$``G-H*V!@#MI$<S\"Q_,`%TY`@9D#PI$CNR
M<`2*.`\&D!TR`P3+H8C7]QS/]@1L`!H4HPPW40GH10I!8``&P`*Y)@VYDR";
M"!*=6`E\M0R_9`/'42RH913<P`DN,!/4)`<?H"L4)C+%(@WMHT>D4!0@08KQ
M0`J*$R+)\#B.T`$K8%<7P(R>H!/.4(N_,#C/P`0".(<;-GK>:$0::&X/M1FF
M5F**(((R$T5=$0`9\!?.PP(24!Y_("Y:!#ON<@0:TP'MD#E>,`8JL`8N8`)D
M2/\$#T!&!4"/-C`'E'`[%3`!34`Z"5"++Y`!8_`&7J``6>."[O('&C`&T70%
M!-`$-_@'01``8Z"+`"(`4XA>!T`,<G`$+!,`T'0%'SD'!2,`":`Q-*D#.X4%
M`M!*Y1(3CA"1CC"1B#@&F?,?6?@&PO,"5S`&-3@&$*8!`J"2EI`O1@A)8W"#
M:&,2'<$$<Y`U8:"/*1(`1V`!'2``^H.6+)DBS^)&4OD'5_`&;Q`!<R"4?V"1
M`>`2/3(`<XF69AD!*G`$?DD)5MD$!=,$`M`D7)@`#)D`;[F78["&IR`#3?`&
MMX`+1`"2[H(%E8D%1X"5+\`1._4"9JD"$.825[`&O>;_"'=I`1<)FP)`3'.@
M`5A8F8YP!0K0+@.`DA`&F*D`C-U`B*6)F`(P/B^0D12CFK?P!Q&@`)DSC)/0
M`4V@`ZY4F<9(16L@,B_`!"ZQEL*#4C@P$Z#I"VMP!1$@!UX@EEGS`I-YGL[8
M1;SA$JDP`,$D`&M`)TW0(DQP!#L5`9V9`5;)@O!)(!'P!@EP!1VSEH=I:Y2@
MBSH@`,\R.'YY!2KPF)$YF19IF9:`0>%87W(8HOQEAQ2A!#SF@3'W-POHAT30
M`FR`!1%P`@.@,3I0`7)P4Q,@`U:XB.42`AAP`420`1,P`S)P!'/0`#,0`BI0
M`#QJ"3*P'PWB""=@C?4H"B*@_Q-S$RSL!7DK@``70`(/<06R!$?%@0<N,`;I
M1`5@V0`2@`'(`R,3``+L0@GH90("T`(%L#4:\`T\0!IX(`5C0`2P<0(AH0`L
M``)/\!$8``)4`(Q$V5=9$P*8T`)`@`$FH!-Q]`=O5'_J1P*X80'X4P(A(!V<
MH)6<"@%20`4A<08\8$E7!3`R$`)74``B4%=$,'%;8P`@``"3<`9X`"8=T!?]
M@`,X8"=Y]`$(4"$F90)+"@&N6`$E8#(*X*@VP#`&@`%01@G81@7&=!X(0`7#
MU`0$``(\8`,((`7_005`*@-@V0*<]`*$,0<8\`!XP%A_4%9!"@0E(`/LM0*;
M\`+(8?\`(E`"%Y"(*1$_X#.#`W`!+F"P5R`'#U`"E-,/-C`!VCH#IM("SBH#
MN]`5&-``-GDS!P`4Q)FE8E12NV(`)1!=_;"G;?*H#S`'Q38#0.!2U*D!G(0#
M0-`!]8H!$K"=*)(J'W``4M`L+0L`S5(!`G`$!S`#F^4%0')VLWH%0#"G[)(`
M-H`!`,`/E&`REH!+#>`%%7`"(``"<J!T"2"U)2!9#-,`&&!7);`'Y?$$<]H`
M3%`!!E``$=`(#T`%MG,YFX`2(8<#XNJ"-1,Y5$"NYHJNZDH\[0J6EO`%7$>B
M5U:YEBL.'D"`NL=W:.8$:M:'?C@*#;"V8?0"/>&C'Q`'5+#_!U2`!5<7`KG8
M`!-`1B]B"1.P![MQ`5"8![Y8CPU0`$]@`F1T!A_QBC3B"-Q2.DL#4_\A`P6`
MG5\$&F34`1<P4)47I79:``7``RL`)Y67J0J`2^5S!!T@!3/R!RX@!0I0'C##
M4RNP`JV2BNIQO!?5)`DC._?"J<BA,,7Q+;(4`E2``%Z;E<L;5XZP.!>PJA)$
M"2?0,<Z1O51P`L2!`Y83<H05.I!$K#<U,7G4,<EK`EEC<)0P!P;4"`E0`2Y@
M%Q40!Q[)5RY@JAT``@:$`P4P$`#"1T1P$';4$^,+(*1C`YG3(`?0)";@'D<P
M12O;`060D@;4!)*4L"-3"0.`2S,P_P'[5WD:1`"X<`0R(`6MH#.R\@;_(@(3
ML`98+`$*7"X#<%E?PHPM(,#TUP\L4P%C(*X7-<*\2YTSH'14T`!-T``:XP5"
MR[TFH"L?0`Q4P`,#/!(/0`P/P,`/0,C/\L!_@+VLVKJ^D+^4(#)AZPAC*P5`
M@`<:HS-B"D?)Y,(T\P=O\``ZX,=*6@$PY0@A$`*KN)6TT0[35@(D,#A%\1,X
M_`(ZS,,DD+J5L`8,D+G?B+G*C`UU6(":<1%\`P4[,',V%WRD@!U/,+PA@;J5
M@(\?D!,G,`?<VP03,`EAL`(&@+"612#6*R]:=<J.@`1`H`!'`(5I!P+31@D#
MY`A"<0*FNO\XX52RTZN\,_@!<_`!53K.=JH`5]$!W+C03:``N[`K5&`"$ZQ5
M$P`N^^'(9R``<T*_^3QMD;)%^HL)`OM%8PLP+;`")%"EM7"J!TPZ_Q$=5>H>
M5(H)2;K0<T"LMRO$#3`&1S!,Q"JV'N$Z)FT"#$D$T.H(.@#"":P``G`?N<-7
M#]DR*4'#-L&__NP%!+#0M1(][?,"(,P",RBR.J-(6TT)!X`'"#('HA`&%4`%
M(!P_$&:$!J0#(E`!#[#0%D<)+Z"W`4<)0/`T5-H"+<"T+<`MQ,D2.&``0.C2
M,/U%+:``=.T(O'M13$"=<;O05U#2O%0),N#0Q,1%"``$D_W(\I+_I3?C!09T
M`CJMT%5J/2.\G21PF$V"(,7A!1J``8<E.S!2+R1P*S%Q._YJ`PLM!Q7`D(@)
M`B8PR_EJ4[9"CS;KR[2\N#?Q1B;IU6#M"6OP!?#4S,K&S,T,`9R[8RD07F@`
M@NK(&T5H"4^@DC(PI,9&"?A(`BX`URKP!"ND(`F``*.3`*1TF&XMX':2.@:.
M8&ET.1`P328-W$+Q#7.P`B-4`0G@`A]!`'-0DBS`-O$K+WB@)JT8BL$B!7/@
M`@TV:Q:.!P5@`1?0!$;:IQW]!P\0!@(``60;J9'3X+3<$BM@.3<"="'0OZ#L
M"[(D4SJ@`+5`!81HA#-MIE(``"\`D0[,_S\D0`5S\`0JX-,I80-R(,1CP`(#
M4-1%GD>B,!(ST'\/L)T/``()T+,/(`<Z0`!Z1)1\11I-VP(J,@8ZX*];K=V.
M)@*BXP(I^`<_[,V%"'1XG-9#L=;NHEL7A0<)T`!S,)$)X!HL(;D#0``ED``L
M$`:IHP-'4`N>;-ES8`-$```K4"JS\3BR5`!Q8`$`P-AL?,DLH-N.@.1L,`E%
M4=FWNUMS(`(?09THPUDGH`'&%-A":PE%$0$7H`.[3N/$<#!S`)':2*P@+N+2
M\P(M4,![^0$84.W_45HS@.,@,`9("01'D`&DD>0VD+?%+0HC9`(AOC+!2`D5
MT`0(\(I3C0FFQ/\&`C"S@Z.D4XW=7+W=@CX`A)X!7>H(WVT%6B?>R27Q$D$&
M&]A=*.JYYU@&Z7C-[]TC.(V(,S$#R?,&0_$'H\Z03!"L&=#&`C`!#+D&):"(
M<R`%(.`\&8`#I%P)5W"$#!;RE(#3^J,#OI``$R#G,8@#,Z`Q1M^*.B`'$Q#6
M:Q"L#FZ&8P#S*>*/"+#S*A`'(-`*7I`Y[C$`[*L`;V`.EL`$0"\`4J!5^J,`
M./`"M8+39F]KPG,%"%`"!,(&4.@(`:!5*.G41RD%L6IKG;@&5SP3<D`Q[.X(
M#&!K$\!9`;#XA!4];S"6`4!,FQ`&SP)VE1``&(`#O@#U"M"5:%_YE$#_!)7W
M+`%`!7'@"RH@#(%/6$WR\DWH!:R!!<S]!S4_`XTP]+#?A/F:.1I0`CB0@K2@
M`^XQ!WW/J17`!E(`85Z```E%;8\PZL+3`4=P`OKS^';O0`@`G];_FW#4BKM)
M_4V"TV$0]KN?`"=P5:R1^>8!`@A@$B\O!T!?^+9""5@`"`@@;W\"*G]_<Q-'
M?V]SB'*'?VMX.!:(BG,,B)P:)1,"B!8X"@IO6"4X`7\1$P-_5SB#?P-7L*]_
MC!IX4K8#JYPJ5"`=G(AXG&]4"+:.?P$X>`D9*@G/8X@ZA`(3UEZXQAWB+G[E
MYN?HZ>KK[.D$?Q_M\O/TZ5EU/U-I2EI\*455_Z)8@;(%S)<U:XH96\BPH<.'
M$"-*G$BQHL6+&#-JW,A1XHPG!4A<ZDBRY!\\(4!HS$#%Y,2/$US*G$FSILV&
MXCI@>5"OIT]T[^+]'-K3`QE\:7+PHP'#1\`:3@IJ0-AAS<VK6+-JW<JUJ]>O
M8,.*':M5G(8$$(BJ;1=TK=MU1_/MTW(CQ0(?2P:6X0)F:D*%9`,+'DRXL.'#
MB!,KOE@5#(BWD,NUC0PYRU%]2OL)<1H%ZA8N!ZE:74RZM.G3J%.K7GVSPY<`
M0"B[G2Q;+82X^OC579#$R!`H._CZ13B:M?'CR),K7\[<Y1HP7%C4)DI[ND^C
M9.0JO<$4;^>]H(D3;_].OKSY\^C3DUWS!4P8H=;K58]/SS+2S/X65!DRI$9P
M@^(AI-Z`!!9HX($%5L5>`"6D1=\\\SW(CGURZ=:=;S40%$!??^6$X(<@ABCB
MB(*)@]`77#PF(5OPK"@/A3\DQ0\?,!21Q!(H0%'&%@$<)`Z)0`8IY)!$,J8@
M>RFZN$Z$2I9#(69:]&/7C0,Y\9^/@!6IY99<=CF@B0AI$,`6)WC0Y#E,*FE9
M7#+21<-FONFX8X]_>6GGG7CF>1J8&H`QY@X5.'AFFBNNB4]N2G!78T!61/49
MAQ[J*>FDE%:*E7CM<;'%%F7<8>:@+9[I)!FX[;,4#'<MT1]X!OWXHZ6PQBK_
MZZP0B=:GGV-"0<&G2A)*GZ':S8BJ4_U%!0:`6=*J[++,ZGGD&AI\T5X`.T"A
M!@%-^FH=L)@EFA]GGO4X5;(0A8$%(@,HI`,B82"`"!;+G%L(%59A\0)$`P#0
M$B),%&,!,A)UH,`$,ZRB`2.<A-(1%83(U&]'3#1,DP8%2+%1!TP@TL),7LP0
MT1482"3O0UX`$!-$#Y]D3!,C,70R(E)DW.S,%>6T(*<U5&%`KZ&ZZ(%]A[;I
M#YP"`<?%AA>%8<(*$;P`Q`1,C"%#''(\\0$B)!10P0,JA/%`!7AT4,`C#SWA
M`C@M'*)`$!*]\00))SP1Q!L=7""O`B&0U(+,+DDA_T='+81<TQEC;Q3&QO#,
M=,6^#S4A@40'1"1"!=9`U$(8B+#-B0+@+&2#,0UX0?/H`9OX&A<[M%&#$0>X
MJ"UEV-41=&:*`A1%?VWP:%#2!H0000(&5,`$`RRT4,P%?U!1`2(BB`#""A2#
M@#@G'2!0@$IAL$`"P!DT4,`1"AQP0@%_KV$]PHC@```G4CSQQQ/[&E#Y'V&,
M84D'.%2`32$%X%#"[Y4[0_*8D`#[60!_%5A7`O!0@19$8'+GPD+^%#B#"JR`
M"!$PP!-*P(DC,'`"*JB`",Z%`T0D(`)_P$$!/-:``S`N%P68`!'^(`<+_FV!
M*V@!%ES`M$9((8&<8((,@/\`@@$H``=S4,;UK(*`&11``&.X'F`JT``7P,.)
M*OF##BH@!8DEH@(3(`06?C@`#EHL%P-000F8(,`_S$`.%EA!`;#AN#]8H`4]
M/((."G`"`A*`<L8H0<6LT@#X<2(,%0`D(KIG2/&1KQ!A8(('D0&"`ISA<YP(
MG<`*0`5_5<`%;$`?Z9B5DP[T25-<*`,:HF`'0<7G=94AU:&ZY:8:42E#//K"
M5!BC`R*(0P=6Z<`,%(*\`RCL#R8(P`%D<(0",.0!2&#"!$B@@0><`1@:>,(<
MF*"`"V0@`Q_H@`1FH`$>,`X(&@@B\I@0.2)$CA-(^``>A#@#)O!@`$U(Y@L(
MT(3_$R#.!'\(W0GD24\A#N`$!@A`'#YP!1VPX`]`J*<,#FJ`J`%A#=\;60&`
M@(45L``+()#!'Y#WAQ,T(0\%>(,"WC>!D6'@"5%3@`5L0(0,&,`++>#:!#Y`
M!#8T(*`Z4&8&$-&!"H``7@3`0`"VUX$XY.T">`A``RI030XBX@A/F.$'D!``
M$\RA"7,[`@\X<84#8"$!/S4!'MY0`)%>[0^<',`#_O!.%@2@IAHP0!/J^``Y
M>.$#%"/!&EQ0@3>PP`L2@QL39O#3)[!A9!%0@0I$BHAL/G:DWPQG!9#P5P>*
MP`5,:!#HO.""`JPA#A/(7F0?X,Q1-JN4IL35%J"`AB$D_V%G]('E6GXF2^W@
MARDVRHN."H(EFB#/!!Y[QE@G80(<A(!KG'AK!ZYF@B88HP"B4P`0$&$#+Q"@
M``4P06O_0`);((((F"2!'$(@2B2X#Q[@Y<$*]B`X&?3SGP'U0MP0\8'X4N$$
MRXO`^A+'`O^>0`2(`&@%.E<`=PG@<1'X*4E-2H0@D&"EG#2&"?A&"D24``$M
MV-@`1#I=^(8WBW]HP4JI`%!D<@((`7@H1(LA@A-PX@6M#6?R%/"$`X"7I']`
M@(\+0-W*NA41<9UK"Q:!8+RMP`!4<)Q/P=N`.13`&AU@&R8Y<0%B!J``]^($
M%0K@T>N&>;M_Z.YFO6``1%Q`9O]`SN\#>`!>&90@;RD<KVN5]:I)1`M%98!"
M#:)0!3/`IS:Z'0IO>TM+NJ3`ED;X3BX[9-R3#)B+B%B!``#0`1"@[P.KP,)Q
MK<L)[/YA;8@('0L2,(!IB+G%'9C<,8!P@>+\`0G+&VD36DV$%9S,!DV8P/*8
M,%>!YOH"NTX`%@#\!R_D^`_V;?6R\;O@Z[:DCE[X*6#AV@0-:&`,'V#K"Z\\
MB0!@P(I_<,$86F!CN?)WI*Q6-B=4G+S6FH`0L-$`)C7'[AL_>\<B`,``6LT)
M-@@<GW0]UX@3]P=SNOL*#9"!+4P@NCU$60(6.,`<!B``MH99RYX;J@8`"V9U
M$N*=2/[_>*J]L.;6&@!S6'A')KW``U<,?``VN((*?+QGTE5E*F#80NI6N80B
M/(!7E$GT=8`5K"@-+;A#0$/N-C2N/KN$I$`(005D0(@])B\$-^4$!F0@`@.L
MJ[K&B)L`4)W?,1C@!`](+B*>\(`6'`#-?YCN]!"!:T0@X`$BD,$E#.`""7R@
M"6&X@-V+K=]<_[T%#;``LYW][@G4/?+^3'#R>``PN%[[<=G^PQY,4`%DX\`$
M+?C<"62`XBM<0`0F$$$'#%```+2YW^Y.W`D.4';1:6S%K06!`2#OL7UKS,;\
M:H"-WTJ%E<K`!0#(-2)HO]$_!%X$R_Q#"$A0>BKD'@"4#8&O_R]P\??QP`4-
M$)O*@;""^3&`[`]P5\DY80`I##3M#VB)YD+7<E'80`0\$&>A`SPM0$2%8``R
M```%0`1QUG/+4A6-$0!<T`:UM01)D`(7@&@]`SN&$C1M<@-#XQ1YD2%'@RPF
M0A,CXP7F]0<C0P3I9`P:(`<*$0"V1D-,(";O4@QK$`8O"(,#P#>(H`(UJ`%\
MPP0'1%1R4$W6I0%AT`&AU@%O4(1-V`@9@S%!R"]3^`8-`PP6``Q_$#&34(7R
M<@5$\`96P028@PB1M1!RX(57@$*-0`A.>(7/T#*(\`;I%(6=,`"C(2_`H(7&
M@`6V(`EXN$@CPPD1,$.($`"70%D9@/\%$3.'?^!MG)`!1!`Q:R`S6#!47SB#
M>1<&MA:##9,RAQ0`7KA(&0,,6(`Q&F"%1&4!&G"(JYAW<D`(;!4`6"`#&-`!
MBNB`,V,6T"%T-3`$1I`$/L`'V!(92B</BR8[^=!H?,`4"U`$2U`T<Q(:'E*#
M7$(%*^B+$/%"!S(&B;0NWC@ZP,@%FJ(Z45",12`$6I"!;[&,Z[!H<2$7,I(H
MBG(727`[-3`G?5%*>4<NY3B0!%F0IE$5F:(I.U`#5K"./K``,'`#;N!*/R&/
MY_`S'?@#]I@9;I("0F`CD68%N-0C6`);!GF2*)F2A0$MTR*!@;9*[+@`*7`#
M,O`!2"<?&[C_=*1R%/BPD4J@&]$X+%50C6@`!5%!)U0!6P*IDDS9E$XY$S\G
M+>W!*4XP:$M@!#Y0!#"0`GR@!6Z0C#AY:/1`C\ZHD5/0+?Q`%_X`:?SH!->H
ME";YE'(YEW2I$7P2C%M`@?QA@0^YE7QP`UJ0`U\)(3DYCQU8EF>I#_<8)2#X
M:'<QE%'G&4=3DG"YE'5YF9B)F3:#*Q.8(5:P!%60!.WHEX"I!4J0!FYP`70`
M`1"`=!'B`1"0!;))!V6ID6:IF#F@%#])%]SAD8]9C0/1!GOA)ZUB(I69F<B9
MG)II%M(2=&6@.@UI!%60E4)`FJ7YDSF0!E/@!C]`!W3P`WS0G=[I_YVU:9N)
MF9AID)ZYN9N\20..Z0.]<3O!N0.YI$L=DI1QJ9SZN9]-R9S'L@.!-HQ1`)I9
M"9$T\)?7B9VYF9WIJ9WG^:"*V:`+^I-I>0,@Z)[#(H("`17"^2A?P)\@&J++
MR1[3DHXU@`8-2:"CF0(I<*`6&B6F2:$+.J,T.J$4FI:\&8V/)@33V!M$"15E
M0)\>VH,B6J1&FI(_]V=^DDI.(&@I.IT%6ITMZJ(O"J,Q>J,4:J6,::$ZNJ/3
MZ!21-@0BF3OHB(X&,2Y'FJ9J.I!@PI)X62TG.@0#*IT^$*4P``,T<*`(:J%\
M6IJ\V:=\$(T8RJ-W`9]#*9\9$A5\<2P`DO\0:_JHD+IG.:&D9?J<3KJ7TFF,
M=KJ5+)JGGAJH@7J@><JBCP8#/%H$==H;1E"-D6F4;7`ENN07EAFIM%JKL2(>
MWH8BFY(Z4"!H*""G5YFI=5J@"U"L0G"LR'JLQ5H$S#JL27"H\HD&&=*AGT%U
M^#FKMIJMVFHI[8&75.FD5B"G`WJ551":27"NPYJJY_JLY6H$JXJH-9`A4/"J
MU7HL/A*0`+FM^KJOE8*02XI*F_*<37JB5O"K47"P2Y"P"KNP!WL[_"&F\=JK
M0LH7TN)MPR$@_)JQ&NLL_KJD$JB092"PO4JP5E"R)GNR)2NM\2JOPKD#]&FF
M]AD@5+&Q-%NS76+_.E)Y+!];IB`;LFWPLT#;!D[PLR$;I)OR&27(J":HE(YJ
MLT[[M$%22F'2G/;*F3Q[M4?+LZ9H$!4;+55'5#8SLU`[MF0;(K!U(E2KM&J[
MLVK+M5+9BI$"MOEY*3-`"&N0`.FT!G4[B7B;8H`S$;#H%2OP!+YW2"&#=S9!
M-CH`CA*!2!=Q%@V!`(?X%024$=)G#,=D#!;P,AV!9\80`>B6%9WC$`BP/S!C
M$0I@3IQ`!!7P!,DE!^!%CLH0`BW@16-&9A'@!6?$@IQ;62X`AW]`:IR06A:1
MN7\@!>!5`)>`!140`KMX7>"%`YN(8EY@NADQ!Z<(`L;;$%>0O((S$UC@_[F'
M(0Y26;ZQ:K'1HK05^[;H"Y=CH0/#MP9L8`(6@P=0%F1`$#)OM1&:$Q&FUA5V
MDRS]Q'`WX8CD6!%-,%<6$7H,\;]A,0!MAA%R9PS[:PPJL+T:857&$``KI17]
M^Q`9EC`6P7D-TP'-)35S@`4-@`?V>P@B0`("4`$#A@CBHP!28`!$P`(R`P(D
MP!`*P`*>VX`2(+P34<%_D`!'=`%$L`8FL`@N9`P$4`I/``!8H&-_```3C!$/
M0,2;)1%-(`,*4`(F\+TNP<"*(;,=(K7G>Y\R*[5B"Q9X(`,2<%H\X#XM(`,K
M\`<5(#Z),P-2(`-F9PQ'8``-0`P6H`=/T`(!P/\##2`%`+54A/<';+`")(!N
M"?`!#8``:X`##2`_QI``)G"_82`#-I!2<X#($W`"$V``#]"-)&`#)C`R(P`!
M!O`"+;8\`US!(V8`+QR\#V``(9-("#A#7VP`C'`";&`#`T!%@C<&!&``(-`$
MRR-7#8`X)!`"+!`3HUS*;Y#`G&`!0'``!H`'/,`"V&,`-N`";$7+86`!#_!_
M;-4"!G!O"Y$'R?4`4?,`C>Q&R'>Y`/`$+#`#`&`#ZS,,FH<!#?```U``M+R"
M!J`'-G!G+.`":X`%!]``$D`(`%4Q#0!C(.`!!C`&VYQ2%I`W6F,#3U`<`D#*
M><P)6E=(9\#*0R52PBS_`T2`!0!%`@#0`"%`!0UP;\N&"'I04F!W`!A@``8`
M#AW`R`?P"I1U`N'[S']`!"90RE9!13S`!"&!U+;@3'D@!1=MO51MU4U``#8P
M`M2#""%0`G&0115$5S)C`YR(3*0F`SH0!W&0=QO&$"1P!BQ0#"!`RZ8[Q&L`
M>22`0B?0R:'`6,;TT2$=B#B<"^\4!BC'<&^P73R`#2-G#&:`U?;[`)CSU(+X
MRSAP!6:-UHA@0?J\4AC5.Q)31[F@9`;``ZM0,0>@3`900G)0U:9UQ0#``BO0
M`5Y0U3R`!6:<&.X+EVD<#H!1F=B*%6D("X=$5'!X-530PSJ`<O!;#!(@!0,`
M_P&/X%6G]CD-,%0BH`!(<`%D@V2B0UB3R`+1?0`S=``OH!`]W03@#5<(Q@;B
M6PPZT-+<U6P_]0=LD\LF%V0&D%=F>``J$`0(=@05,`<'(`XV8`'A)8=_H`)S
M15EK$P!O5E((U@`J4#=78-]1IL"T\`%WRP*$X$T*`3^A%V,9DT0%$#)2,,-W
M^%!R=05[;51CECG&8`"K>'CO,P?]EF9TU8I,`,$+`0%8\`80@$)JE7=!YDR?
M\P#K4@'+1U1J[7T;C@TUW@EJ#0X/@`PAD0ON<S4.G@L5$'KCK'TVYER4!VUP
MY4PX@-T1S.5CL%UO96J:<P$H-`.1,^&U[4P#T,,`U?\"<ZP!+##7@.Y&D8-V
M"^'.6%``<!AA$/5B'4S7B7`!`<`$5S,#RV4,7M##((!\0GQ?--3#Q:`!``5J
M.&C$<-5??S`!"*9YT<4\8Y6+?P`")<0)$E!"*[`^)<#G[&U(Y[+%QK#'>8?/
M)(`-9]!BP?LX7;4,%C/*\&`Q5-`2Y\("@1XY#7`N!B``/_(\Q[TGSJV4Y&'=
M*^4%_2L%+8T!>S```TY23/P'?R3#4H`$>@97HF,""+/6G,`"B<1>5"!^,F!2
M$3Q__9L`\J6`QO`Y#%S@6RX*`PX\<A`\%4`"81`$[5X`)3!5%6`".(8Y<\!]
M%?!0'!X$"8!F-N5B?Z#0![__`@GOS>@R5^X^?0,@!2'@`F\7>@E`6>Q]:A^,
M"#R``0`@!U)PZQG`2:WUP?LG.B9UY)\S!D%@`F'`Y!0<X)[7!#Q0`4``<BW6
M=\R'\"?@;D&078S3O#0OO`I=4HC#-FK^\6[^"B9%]',N4ADVP&9L`:3W7`SG
MYRPH8XDS`4$@`5J]+R*5Z(*C/^]"^-1%Q+%]"2Y0.0D0Z0HA`_-S``<`$IS(
M7D]`Q@DF`P7P!`203JF^!UI3`06`!4$@S'\P!CS``]8EZY/X["#P7CAM#!#P
M!$_04M,'/$`XQ#L6O*_.WEX0`D!@,<K."160!ZE]!A>02`7@N4UP`4\@\)V?
M2)'S_P#IQ`3*+P58T,/OICD>OS:#BUT#GAKIKN[-P>[-UK\K70PFDWOB/0;D
M_3<9P`1]!PA_@G\%5W\5*W]K#0.#!X9S;R8:?R$G30^"!2^"08,A5'\Z!8-_
M-G\!'VL!!G]-)W\?@QT/4D=/!F\R`7]S'4$*?UX%<P<=HFL%7G\B%7\J+'\/
ME`I!T+QQB2:"#P.3E9>9@@.97IY_!@,LQT\G1-$J-DR]`<I_U1T6I1DF#7]A
M)GB)H()G6P09I<XU6'8I#RD+%SH8PE-A0*M2LDQIHE(AS!\$GDYM^X/$&0%!
MWRR1^Q-DF8)0@BZ\J=1D4+<_)UITBL4RV#`O_M+AK%DM@/^,5;(*A'HES)\@
M''C^C,E$X,V;A7^V=;@0P96Q"!H`-%$J".&V%D_6+-+W9VO7)@>RUAPT1H8A
M4=/6D!"0=<:?#+D&F9@[Z(H)($PTR!GTQH""QR3\9APDX14L#6&.9-+UIQ$"
M'G].ED(PK\*,*S:P_)D0`F,I07ADQ"U5^0^58$VV5;WJ)8R&"!>D'2E5`0A*
M+R3&//,HJ(F$4G$F_'DS)ZN@*[\C-G@;]QRP)XU`*'/ZNKSY\^C3JU_/OKW[
M]_#9GRHQG$CK02<:&"C0(8SQ/Z@]$,)S$33P0`-8G*%3*7C8``(3$LC00`D,
M&O"`#&]0(0,`!L21P'\K-%+)(`/_R%"!"8D,@E`E!K:20!P:S5)!"+%]9(!L
ME=27"!4-R`!$!RL0T9F))K3"(QY'M-8@CG_H(0@086C(H8?__6.<?8(<$.4!
M(71HR@-A",#"`T!@$>0?2;[SV@$N"'+"C=LT]L`#SWU2EI`>HB.;#"H`(8,!
M.FA@PR.#1//'BBN4H,-^`A[:I"`*_G&`#$=(V:%_E0AY!(6"G/B$#`D,`N4?
M<4@A2&O1A*`C$0AI26JH2?Y!@H4()?K'BW^P.D@&#51P`&@KV/"`"4+>V$N/
MN81AH0%,V&J=DRWP(.&"@LR![$QZA"I(&`08X.T9?[C@K3/_R/"`#8L-DFUY
M!N#PSRF"_X`0E2!8Q`4`I8,`D,`;!QR(!Q/[F6#,I`9$->EPG?;XP#%'C%EF
M*?"^9H.(^89*WZU.!CLL$6]N2&H#U+:@APPVP"*G`6P,D@``:_[IEY,?]<@R
M`]>.F",;!IP8Y(KQ]>SSST`'+?301!=MM`D@"("RT4P+?06U*@C`<]-45VWU
MU:^U$`S67'?M]==@ARWVV&27[=X;8Y3`EME?!P#"VFS'+??/82PS]]UXYZWW
MWGSW[???@`<N^."$%V[XX8@GKOCBC#?N^..01U[*"<<($@<EK]49]%@%=(['
MRE@#<%<I*Z@&.#131_Y<!4(:C9`4,)ZGZR`K='Z"Z>>-P4*;/_^GGD`(0)PP
M4WJ$`=ULSY$*/<!P<EQ`2M$(I'R>#N=Y45P+\VC^QPPPF1<&I^4!H:U[3&@K
MP?CMO2'%`2W,](8(/"!`%PGVD-AY`<.!@#FI^TN.-PZQ"T/$2C&2H3FG.=JC
M&A8J5XH%!DY>_A,,(>Q6M%.T`!;5(P]/.B"F]!B@.D`;(`C*U`$VF"H]P1&:
M!E+7GI(,S84K`"'14#.9\@RP%`WPA0`64\#IS.,\:_AA>1Y0//98!"5%7$\%
M,/"'%8C@#RQ(0`=.0((_X($$'<@`"RCHP@`\``\XN(\`(Z@W+$3D$!2:@0DD
M<`!];&-4H-L0$)[P!!X80P42>(()9%C_B@.ZH@$`.$`B/O0$(.RO!14`$Q7R
M6`$-Q($$(7B`"#[E%Q`44B=0*L&&#@"+(*TODO(K@0E"4`#0#&(")"`!`#I`
MA4*V:04A"($,^$(O$DC`!'C00`$DP`-G)$!`#ZB`'G5RA#E*`',`VY`H'W"&
M.<SQ`*'B00A(``0`2,``*K#)8L(`F@KP()6./*&34/0`7OSA#`(B@0F80`0>
M/.$`?&%!$,1R@">TZ0PF>&<C+A`"'FQ#`WE\P#*VH8P"1$4#"Q/$&O:@1[X<
MH``DD`$3'OF`.13SG:&RX`F24<=0C*&>(=#@9(+3`%*^@01Z'$,&"'``$!"2
M!P$(PSNI`(00_VAID4]PAA<.(`$`I%`0'S#G.%)T"BJX<P9L@,#Y+,!0$\BO
M!2A]Z*>&<X(\BJ`#B'R``$)5`92"ZTE".L,J!R1-DK!N1:W1S!,>L(*UNNN*
M$KA/*4J2@4'%SHO'D((`!/#,`6`I1T<(I%\&X0+Q;&U%I8H#`<XW@'J:@"\-
M>-`@`,D#(*RA!(F0P8`$.H@PM$`#^21!!FS2!"+D$P@"T`!(IXC2>3%CL40X
MP!P-((<.`."=4;$!`-19BLJ!($3BT$`TA$((^0G"A:1R`1;6@48RZ@V:6!B)
M#?0A`-!LXR8';,`5UD``'F8``*%0EGG\V(0&=(`(F6C`:%O@6E\%@/\(-J`$
M,$[P1!'$10[&>4,"?BF-`5!A,TGQ0@M"<%Y9'"";.N!9=(]1D_*]X`),*(!?
MI"#7";2)"6'`P&QX((`F!*$#8XA(!^+"`B&Y(':V"085+K`8`]3$`@;H@`P6
M$]E#N/8(SEA!$P1`@C=T(`08R`E*#E6`_2%A%X0H00M@)(<J>H!"K-%``%1P
M@&4<X3D04$$')$"]*^C@!&TBJ!<R`!H\G'![;4(-.AKQV!/8()M`>'&,-7J$
MN$CB#URQH@8)L.,6Q(4`\H/=/X+2"/7^00HA(D`C'K"']\:7)>90CAQ$`]37
MO.!YLHA,!WB10@!(YPTLR$`%0@'1OP3!`N;_S4H"W#L(&QSA#;C#@#.>@('J
M=D`#/)A#28"R$P6PK$%_8((Q+A"`#DCX-2ZL2"ED$*@&:(`1O1"H=QZ3YU+$
M!;W'@)>0X763%_CC0P<``"\:,!,;S($*I"#`:$'`N\Y4`#@6",#^B"B"8,R`
M!,")P+C9\`:A'E%2H<`#+%2@`P'H1DA<?@T6/JB`=B/D`[Y-$4E(T`0%N)@0
M->FA<^<FAR?@X'D\"\YU&W'`D62D(@:P@;=F\QKRUFD;$/"6`:33J5#IH%O>
M"G)-T(T2)LB`CL'I!L]YHHP+5GHD(Q[$&<CUAWKM(00$^,D]SB&KX34Q#X)`
M0`&8\F]/>$#FU+J-_VV>$)-6JV`D1+Q']Z"HQ>)6:P5"MHY$YTJN.:R`!/HQ
M0&M$\X807.`$.BB@<4Z.A"88X%[/$?,?>/`.W(6`!=Y"R#FT=@)R%?#-&IW`
M!R+/DS\4J!0$"`(/W-7Y<ZU\S7^(^;@&0*X'V!SG!A``Q`5A**#V[]*5YL<%
M^)+"/3YI#,JN?%G&`'O@HX\<#2C>!]X`F@G0<@83V+53//$25XC#&JHW@'$'
MD6R*]2($"C!.[3]@CDX\YGF#F`$+.L?G&&V[TK0OA12V@?8F\'Q%M""1,V9@
M(0H2\0`RUQH\\B.QU0"#U1D7,1CN9@$LL%L(D4(5@`2EX`4LP`D),!M;\?\'
M#9`N%4!Z)"%/3S!:?R`'!C`&Z+=Q=\,",@!"+-`(;,`RVQ`9.)%X\%<1%:`3
M;\`)(C@(+C=D!L`)%B!$RL8$,M$+3'`)MO$\)I!@;=$*0H=I$V1T/+%;`C`G
MLR`#Q\`&8[`-:T!^]E`-@Q`'9*<!+W`$%W$`<L!U%^$)+*`/<H`[8C=T,N`7
M,&8=TD`4:R<%^S&"!S`3)G`$G]$+K9`Z2-``O"`!,R`%+*,!C9`1$7`,)78`
M77$&K4%XT/0'($"#7V@AI?`[?Z`!U#-Y"A!W)D"'K:!1"7`1U7$!^H``(O4:
M*80'B?`&?"$4/_@'%N`%K,<-C4"$,U$=-'(K$%#_"JRQ!B,H`O6""AX`($W8
M>8@P'1>`!<%'+C+@!1=@C)&@;(.@#PDP-2U08R\08VOP`!90$F^@"AI1?9BP
M$Q\@)&$`:[C3?:]1),N0?+<"!&_P`.7V&-0B"`W`%B_P'#+0%22@$X8B/G]T
M"+S`7_7'<Q[@$0A`<^[&!*-5`6=&1%(@/T0P`.Q$"&Q0'0E00/^F@*PG!3KU
M@)TB@>-P`:T3"Z-%!=M`8=#8DL@%,2Q0'<R!@G(3!W)U!4#0``4P$Z1@%`:P
M`F9`"&5A.?JP`@W@*E54"G-PE+T@E4/)`PWP!%87!VP1!@]@`,(#`M4Q`QC$
M'RNP(<\1`A8@EDEY.U0`_P))R4$E8%I]9`"1I0$BL"$R@`6WXPI,UP$38""<
M<`;ZP41SX)86\)3.$%TE974S4!-J&6PA8`,\H!K/$P+5T00'*`B/]@<8("&A
M\`9/8`,B0`HPPWVB9P/2L0;Y\0"<L")P46,6\)/BYBBDP@9>,"P5<)2DL)<=
MT(:O@0`6PE6"D`=-``(P<061.9G6T9;;DW.Y`H`3T$.I(PXX82#40P+Z$`!6
M^0188`&Q@Y;;TI67\02]HG$@0)?<R0P-B(5(X"V<$`<VT`1O\(TRT`A:B8FQ
MXR0O("$(L`;W.0AZ6%&ET!C#@P?.R08PHGXF`!J8^7V=`B`'`)0=D`=N*0@(
M2O\J<&,;*Z(">/<$O*`[#\`#3=`$6#<(1,!TE6`!<B`SH0``R1<`H4D"JL$&
M!V`#)D"9IS(':KDA-E``QB@(WJD"+BJCGS`':\"4)O`"*A!2+`.<:2<('6"5
MPU`=WHD%)"!)+",.<2`]?P`$*F<`.K%3$BH(?UF?I7"AKQ%X@D!I.MFF?4-A
MB;0UC$,%`("B[U&37#,#@>2F?.H>OO)5>L-".LD$=MJGALHV;W`$()`NC3,'
M)2!4\'$%WH<U%H`'V72HF%H>&-`$#)0W").IH!JJHCJJI%JJIGJJJ)JJJKJJ
MK-JJKKIQ)>`1H,%R04,$%V$><^`,T9F9KW%WM/0'"P+_`H5:'E3P1/%R@LV1
M1$2@/4<`J.LA!4]0`$^P`D+TJM9ZK=B:K:60+K^A"#K0%7]!"6_0DAE`"5@P
M$UB`!5?`"]N0.D3P`L,3`3IPJ1'`!'+`!#&5DTT1`>,C!SHP$Y?&!"S`!BWI
M>3I@C"I0GZ:3"@.@`N@6!A03`7/0/Q7P`8L!$9F@`0E0'1I0`0#`'&%0'>80
M`/_:=%T1`5@0*((`BEA0KX.P":CP`(,U!\S!!"J0`2`$KNF*"CI0K=KZLT`;
MM(]CB%9$`A1H`@Z">GYT"$R44[(B<!E'FX(P!DTI`QH`,"9P`<MP(P5@<0?`
M`N#C!1]P(9DP`S)@`BS`!)<V_P<0(`/=`P(-D+5>@`=C^U4"``%?1`4L4*-/
M5`(&<`"T:AK,0@)WD`DGLB%7T``78!SWHEE>(`-G*P\*H!-->0#76%<F(`,L
M(*<P"UJ<:@(7L@U(("Q[.!(79(T_B3M"N[JLV[I_XVN+IP`2,%IK$!%"L;1$
M0`+M=`H7H`%(V*X8<0PXD`CR2J>Q4!VCV'0_);::*0C^*@)C@'M8`:4V8(QR
M0(.N81NF9`P9(0+;5Q$%T(`KH;%S0&Q"YHF?>)M9,@:3>R@S<0`Z(!9EP;D?
M<`%CFR`IL@("@`0L$QIV>$$Z8`,%Z[H$7,`&3#8=L'P_0AXR>KO:8P,MX`(%
MD`"[&?^U4P,!%9#!,Y`'3Z``NR0I@E!]G=<421D$+G!O"B"]%&2EDV6'@Y`1
M0Q<$6$``&5P!GZIL%1``*_$`)8`!Y"=D4F"LPC!M[3L2E1$"G"`-G)O$5!`"
MMB`(&!`'R"4+I@L+.A!2`WS`6KS%7$PT<!L*=)H!!LH2+6`!`T(Z+2@FG/"[
M4BLI()`!"!`!3_`@'SP2(CP9O.8H$Q-=*4P*TRL(!?-=H:!Q%S``6!##Z'`&
M&1`'0D@Q.YR#40>M&>!%+S``$U!^/5'$@E`9<V`BX<NY>#``<T`"+H!J<["?
M7C#%BX<','8"<X`'$6``"3`#JMO%MGS+N(P>&D``JJ$!+A#_5XN1`7FT9*6@
M`BO0`6M@`L<P`XLA'>W6="&04V_@!=,J`C!"<W-`2V0G"/4@"&WB:RL00QE`
M:I`J!]'L`L8HD8)0`CPP!@(`$Z9R!73D`@R$!Z-S!4\T`0705@$0F\Z@`+8T
M`P%P0E(P!W,`+C07!_=Z!2`0!I<H"%1@2Q*`C$4K`4RD`_/R',X4`B=L`;?5
M2"XP.KD\TB3=Q1&]?25]!+UR`,-:TB[]TC"M'IL6T_32J31]TSB=TSJ]TSS=
MTS[]TT`=U$(]U$1=U$9]U$B=U$J]U$S=U$[]U%`=U5(]U51=U59]U5B=U5J]
MU5S=U5[]U6`=UF(]UF1=UF9]UFB=_]9JO=9`FP`BS1YO()^=,0:06C9,8'5E
MTP0[&!]NW1Y>D$1>$P!RS1X6D,1!TP%>T#_PP01-X+,_,P!RL`9-H`)_;32B
M?#67S31];35R,*GNH0%CD),OD*%D,P>>G1Z"C=?L@05-4-=]<P7H<QWC(]D4
MA#=,H`.U;1Y$X`>\S=LM0`#(:AX&,@@OX`>5[`<>(*=`E1$8X`>?>AZA"31L
M\`&\?0%\Y#71_0=^D$`>Q-L8'!K!?1XGX`=DHP!^<-KF$00U]#/-39WQT01^
M`-BO$08?P$3I82!>X`=4,-[J0=_Z6AX(<`&<H+A70^#F40"W6@HM<$/E`=Q7
M<R`^TP!^4/]`'T!U9G,!&H0>$'P/YPT?2.`'ROTU#X;2YR$''U`3!<"FFD!I
M^=V/[P$$5=(T3>`!+EX>&O`8?K`'"G`%H9=*O'`$_O3<PRT(&2`#_.`'I\9-
MI6@;SBT-!-`!,P`$G`3:03`!!P#+'^`!(1`!)W``)L!$]6`"+7!J?X`##X4[
M`0`!#:``)5`F:X``![`'H3(!.85+@:0<5?Y-U1$!-B4_8Q`$5'``H1"2)/!J
M!7``02``$9#E6RX#,%)=+=4!.E#E+54*!K"Y0.`!3`#<6.`"B!XJ(;`"[K0V
M9NL*0,`#@/KG(H!+J!!(II(-;\XR)X!!VR/E)T#EJQX5`0``)E#_`!W>"7@.
M`F-`R@<@/Q.@T200!"?@"61!%B\0!']X'@<``1ZP#!80!''`21U``DR$!]L<
M+PO:F'Y0`"9@*DUPI07`!%<0!'@0`@#@!P4S`*?NK((``"Z0W_M-WB[@#.W^
M$:/T77[0#2ZP[SJ``R9@`J%@`!X@`R\``$YR!0#P`+<3`,IN`A70`5@0`B9`
M.5#J*SP0#`7@`B$0!$(2Y7[W4V]PZ"+0A1#@"7[&ZC;@`4$0`!TGZ!`M2!!P
M@F9>`%C0<:<1!!8EY1-PV\HNZ"O`PX=0`,`S'!#N!3;UF>1^58-0\U(0`'/@
M`2S0/1(P`1%0\<9J\#P0*G_.ZG^^/@AP__04(HV29'4\QP8S'P0B4$V3V.L?
MX`\Z<$M^@6[Z*P@ZX`$7H#7C?@#N<J2"]*.B4/17]>$*(`=[\`#IWO4N8`)"
M7.8'+S]N/P%2D/)LPD!_WN48Q&,(?P@>D+0GX/@!P.>1+VXKX`=S").V(3"D
M1FE8(`-G,.R>CM(F#`0^FO$/\`170'P$@,2>T/7^M<\",`P',`&&/P"-7P`Z
M3.DK_P:^`@`TWAY^@$$$$'-^$"2;)P,0@#M#_@?%'8[P'F)_2P`JP`0Y?P4>
MD`AF_@!^$&1^T``$\`$\[@%`(,]H^^29#@@'%WY-5`1[!!)_BQA^"HN+.!Z"
M'U@/?@8$'@80!O]_?A`''Q=_!A<\'CHG?BP?'AD7!@<G:S)`'RQ7FD!7?A*Z
M-@\>)51^-A\$D*6>2'X9!`4!/+<?;Q`0,AXAD*M_+`TF`-R8!!]_HD$>1R<0
M"9I8'P60.`>7&*N9YB:3'WX#D'Y.?)+0@I4K+$',7?AP`(*?/Q^"0`QRY8,,
M&1\T*%L4`((+#U+^-/&#RX.%!A=J>5HDP(.,!D]&7KC@`<L,&0<\K'CAAX"!
M)ZRHV``G;F.#!U[\4.F&\D\!`E@@/##P`JB!.0T\0&`0PD16%0TPZ4`9H)4)
M"$^2?K#A#\`'$C(Z0+*U$.(F7[HN"".UJ`4!$@;6?)#Z!X@)%A#>T'S_$,`&
MBWT#CG0RX$?>(D.()&@`<N$E$Q#U/%`IUL!5@W*P/#RX0(#)@P9K3/&`T"0.
M!!(/Y/XA,K-A@98?1$"*.,#/!1;.<&"ST6*.SVP*5IWVP((`!"PA"(3P@`-2
MPC\%DW;R4R$#!!8&/#1X\Z%!PROI(&!@Z>%#!07&!C.I\!>"P,NLR.`'",TH
MD(`,9Q50W''.0-)55F$4!(T$!/!`@'"+2)<>#D00$(P'"A1@7!PG$/`$!!4,
M0(!/2HG8`!Y/_0'``5EE$.,B2;504"LU`;26'T>\80L$0,RP(A#-_%&<`O%A
MD-`3'N`!R0L(>G`"?C\*L(H@?K2PT9<`_6?B_Q]2?02`"W[,M\A14_KQ`GX#
M-%(!.RZ<<\$*'@3P1P(55(#B*AI\],<#$/S1`8PKN`F!/$<08LH))OCQ1B1N
M*F.`)QIXX`*A?X10J`GF^+'"'R#XXX<)[,SI!Q,"$$(3`%=H0$4!^PQ:Z$#9
M+<*"#,5<D<=#D'!"$PM_0,/$K$`-@(TW#XSC#5H9C*-!!1XP<>H)%I&YCY4]
M+L*GGZI.Z\$?.I'J3Y@#M>"!`(T,D%`&`_Z1Z$03Q>&'""=XD,>7`$"@`&MO
MC"2`M4BT:AL(D)"0S"("MRO'"A5<T`!/V_!$Q1]9/1&M44@IQ10I3S$!P0>T
M\/0"QA_(\<<,!0#5A/^Z36!\02-A=`I!4@C,X8B(!CRRR!H(%'#`0Q]XTMX*
M$.CPQTSC-##?=Z060((_,<++`SL\F,#7HL%>`*FD$4!@TIY]0M-K08%ZT`33
M.@#Y&L78FH``)C-`,K<*?WP'C3+$I=EJ$RP<`(G6BWR`JA]I_X&''S,4?4)G
MWID3GA\\3(2#'W@3T$`>VJR"0#H1*+,W?G/,_0(V)V`$23$UL\!"@1%`'$MQ
M&/P-"<LGZABO:B<T0&R&F)?20*)X%]V$!UZR8,,)G*BXC0<I.N)4,BR+&.+"
M?^2H+KOG+M)E+RT$<$(!#11ZZ1])+@DZF3+$#<D5+A1@$7YY]$)%>W\H@#S_
MF&`&M,C>4LE7!:@@A8UAK%F+,!F<9N`'%U`A#G/X@P4\X)+_/4$`?WJ(NFSU
MAS/X`0_X>0%KI'"))IB""@A`P*2R1SE#%:`#,B#%!./`J1A]IX6KZ(4)"#B'
M;HRD"1D`02SR-09J<7`@?L("1';H!R\D*5@DPX.>H(&T,:Q"6<UB$_#^<`40
M&,`<6Z36&T[UP$=DPSWJ@82*+IC!/QB12'^80/<^40$B^`)F<$J("OS'`Z(U
MBP!!*,8)'AB&,*@,$@3P@R+]@(`??@()$"$`7Q;1KS=@004_A!-#!#`4D_W!
M8G^0`QZ^J($7*'%-'5O*0T[3@0<DXP52N(TGV52<_PG,[65JD]D8&)<W`B2%
M"DNZPA&F=@4`A8AH,EA:`R;@@?E($A)8.$((_#"'[XR$"G(<0(SL2(('"L!"
M&@B`!RQ3B@N@4(6-2E,O?F.V)G8#9JSY0R-T\)HP^.$)W@Q`$TB0RS^4H%*K
M*18Y)[*D'S;``);LP!,(H($.'.*=X\+/$=I#P#%X)QE`28HB(E*J`73D17X`
M``'E`#5$R@-.Q7B!3QY8@M41X@V:*Y#$!'#0@A)B$;5$``1TYP5R'>"!:OK#
M*L*`!?3,;0X.-<'QO.28!P)S;]!;TO1ZX8+%70\2VE,;G,*4HP>P0``R,!\S
M_-$J)H&1`+R2@@`@L2L!=/\&/TCX92O^4`PO\6\C_A,HF1Z@@=*@1"-K\L"*
M/J!`?[S!E0:P@6XHL]:E!0YZ$'6C'QIP!M4(Z`5AD,&N_)```6CN`Q-0A@@@
M8!W"*D"2V&AEH6P8*M0V*SN<N((/&=<>0);``X<95P4F:T<),.$T'_B`#HKA
M1&`MXGPF58X)V(+%`XZC`[@HFK.,Z*=,1`M-+F@;.6'Q6%6Y<5QH8LT<;5"?
M.VK5']\AE'C_$"E7!`$+7SPH1";9C`3H2@:[C)D?(#G-)RA##N4@`!`RZ0^4
MF$!SGHP*!"9PG*(5YV*H_.4[>[(B=Y0/!U$AP%B:99Y+$:)1!,#*!32PC^I,
MX)?_ZEL+!/24OU,A!R+)E)@&$',!"$S2+>7S0D$N$`:74&8`I3)'$#1'`!7(
M`1FN(*=G2S.!*]C@`$]I0GMR4@#B0G1M-CZ/!EYCLR]Z07XV($#H_A"`O1#@
M8GL;3A!LVH0Q!+@"$:A.<'NHP8CZ8P*=@``;YB'81&IT(O!`;0/^((//,J&D
MBR`O"5#J)A!`X#1'<&EP(7"$`KGRP`9@\R(ZG!Z>QO'1'Z@;\!8"@1DT)L!S
MR,!@[H`!GQ``!"J2!_14(-@X/"4J!A#057'4)3S.,2`Y`@`!0%4H(*@'"Z5U
M!-20Q@FE+>(!AL,&7'\Y`P\LI$MWW<@)(OB'.,0L#G6[_X(47,#M193@!.B>
M`!9.@`79*C$`.,@N),9@USVMH`1Q2$`/_S"'T`9`!"#0P!E6H(IHSBDG2DR`
M"Z3`8D@<P04G..0+7(`#O,T@#B+!^!@N1IX),-Q0(%A!W?;MA1-X80XM,/D:
MJ.`"-O@;X!HXP5J],`$1J$P.)WB#!?[#B*!VNPEO`($+UH$%</M3U/P6",I/
M4,Q%[#L!H>U`":JZB)VK8`TGJ!DD$G#O?#\]ZE1H01/8_3X71$<`_?:"NS=.
M9BE,8+=<%`$Q+(J%FD>0"@A;!`,FH)LQ("`,)A>J!>8P&Y]!(@PBF$`&2JYV
M=F=`!''`0PG6?4H\B,`"@&<Z//^D9.X9O"'B^U[#!'`@`(S/P(%K4)P(L%`"
M48]A!7@(/(F84`*$O8$**SA"!SXOAW5?P0MQ<$',%M$!*HC@'G2M&PA:BG,J
MU!Z:++?HY[N#AZJRNP-N_X.L7"!JA5]\^-Y:>```'X'/SV$`L&\DSM^P[[1?
MP`8(8/K*6JJ!D.\Y``@8NC+@+>^?*X,*8^![C/<'.B`"4L`$?Y`!)]`"Q=1^
MH>5N'8`!]P98?Q!T8I=S,D=7%F4!(H`'R[<;P:<T;*<,89![[H9S2J0`#J0;
M=/5!9B=!3.<%(H`#)8`!`AAXB_!Z>`!!/;1"&.`"(,""JS`&+F!1V2,%(J!U
M1&@!?R#_`"L0!Y;D;7%D7]4G![7Q!T0X`TQWA8M@?FGG;MPP!^;W!A-P`F>`
M<0\S'T2H"E<P@AJ`!RN``2P8`2V``R`P`[)E`;PG3RTW`>66;8`8B((XB()(
M!?&5=X0XB!\`88G8B([XB)`8B9)X&6`TB1NQ`A=0)Y;(/WGP`"NTB:`8BJ(H
MBC@QBJ9XBIN(`1^`-ZCX?Y78BK`8B[(XB[18B[9XB[B8B[JXB[S8B[[XB\`8
MC,(XC,18C,9XC,B8C,JXC,S8C,X8B%C0<']P!/4&B3,0$HW(!$3P!RK0`I$6
MB6_@!2QX5U3`>8UX!0/TB_]6`)_HB!$`9W<E`'52CE\"`H@X_XW5R#_V^(S\
MV(_^^(\`&9!@<@#^!0DW$HF(-H@M8`-*DF:0B`"K&(A:U(B$4A2].#<&<$J/
M^`*$=5=&1)!?`@1`H`P'>5?()9`HF9(JN9(L*8DKP`,\(`/V%0$2P!QK<`:D
MI0B+4`"+T@`(L!M`P`(2H">]$P+;.`$L$`)*]`(/,!6OZ"XL,`%OD%DB,#R'
MYPHRT`0$,!5#^0<(8`,\H'456`!M58$5()01,`A7(0,8=R8=```L\`!K-9$E
M<`!2P`(N,"DSX!Y*(P$K(`$,,#((T`$@<!1K%0<RT`)2\))P,0,'<!5O0)8R
ML%820"LRH#)SL%Q\%P8\`'_*T`%5"?\$*I,-!8"`H:0U`,`$5R`#%6"5/!!:
M"/``IIE9)0B3,OD'F?4`J"`C+2<#6!`!,L`&?8*;3>E*Y]!2)E`G9/D`_W"2
M+?F<T!F=TNF/`N("/H%K>'85N,"((E(`0:`43+`".(!61X`\%1``3U$"L0!@
M%V`;E:@#G1!+)#`2#R`@SN8%G'`"[A`/`8$`'N!%O[,(*X``7Y0!884#)B`'
ME[`"O:`(;`)Y8>5<B[!;[5,9K2(%!V87'Z"5,X,F+8`*32`!/8$`U:D)H]4L
M`_I%=L$?&8D-$W``@O$`Q6".&'$"PG`%.9%SFS:#PU8<.$%-$F`.;P$)/U2B
M!L`$ZL%,XW+_%'N$`%)0+9<2`=8VGLD`/7L51T(!`1W@G-/9I5[ZI6"*BZKS
M&HUB7W@BH3M9*$P0.$T@`U^TBH-Q`%AP&E[E!_82::`""2+@`1HA"`+#0)"T
MD\F@(N(`/6?A5>.R"%<`!(GE`0Q$3N$Q$`>D`B9@`"\VD=2B$0T@`VCR&G[`
M!L&E)]GR$A8DHA$TI@QY*8O:J#`V*`VP2_8E0:P@#.3$-1;P048T;[GF$\4Q
M`W]S!1XP-XTE$H0PI@W0-I%6`$O:+)=2G\NP2R>3*U8J%1%0J6&!GRL1IMJZ
MK=S:K8]HK,7!;L9Y4#VUDQX@!T=@(D,A`*0$`G2"$?EW`M56`1IP_PRK\Y],
M8`,&0&"!ZA00(`>Q1BX5```@X0*CDB$>,`;;D:Y'*@`=4!`Z,$8&8`$?\``?
MH0#3A*:[=08J8#B7DW(54!')U*JWX`4)L&`BN@C&N@Q$M!VM^AK%$0<!,`-8
MH!I4(`'E9A%$4"I-D*N+,%/ZJFF9``&IQS#%:@ZO<:LK`%_+BH6@("67HC,N
MP`290"9!,`>J\11'``!-="D!0`4&Y*UB.[9D"Z8KVT>@4#>7,&CFZ@$DH0*H
M4#X?X)]N>P0JY;85T`'?"0J5^`9`H$C^PJ^0($?^`%7EH0F3``F+DPEJ4VU^
M$*RMHC9#HQ4/L#AAMDH()%F)E+`!0!-IE/\MK:I2BN0)*4MH2#MHE[*XFO"R
M@W8)/1$`VR$V_V!N#N$'@N.SY[`)FZ!I<K0-1'JTKGH.BK2Z6E0.Q^4)0P,*
MR4`98O,`_ID)79MI2E&VU%N]UIN25Z`R5[`Q$1"QB\`$";"-BT`$84`$+V":
M<R`'1*`R6)``8_8&"7!(N!D&$2"_FZ8#&O$&`_`&3#``IFDH"9`!&E"^N(DW
M'1"_XQ@!"8`%83`I3*`#Y3H`<M`!!ZP"&5!,@T<$_W#!D$`M#]QPYY=Z<M!T
M(TQ\":!U&JRHVALM&1`M"LS`H51,VUMU.J`;7J`#_\L1"=!T*B"6`&P!VZL!
M_JN_;W`$E#%F7;A)O]G+11MC2#V<@$W'P0G8Q.6K=2_@!6%03!GP`@$P`!W0
JPD(LC=<[QF1<QF:LC'4YG0H`!(QXQF[\QG`<QW(\QW1<QW9\QXD8"``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
